Australian Statistics on Medicines 2003

Home , Arginine glutamate, ATC code B01, ATC code C04, ATC code C05, ATC code P03, Chlorphenesin carbamate

Australian Statistics on Medicines

2003 Acknowledgments

Prepared by John Dudley, Maxine Robinson and Penny Main, of the Drug Utilization Sub-Committee Secretariat. We would like to thank the following people for their help in the access and provision of data and information used in this report: • Peter Marlton and Mick Turner, Department of Health and Ageing • Kerri Mackay, TGA • Rebecca Bennetts, Australian Institute of Health and Welfare

ISBN 0 642 82748 6

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the: Commonwealth Copyright Administration, Attorney General’s Department, Robert Garran Offices, National Circuit, Canberra ACT 2600 or posted at http://www.ag.gov.au/cca

Also published on http://www.health.gov.au/internet/wcms/publishing.nsf/ Content/health-pbs-general-pubs-asm.htm

Publications Approval Number: 3712/JN8772

FOREWORD

Comprehensive and valid statistics on use of medicines by Australians in the public domain should be accessible to all interested parties. From the first edition in 1992 until 1999 the Drug Utilization Sub-Committee (DUSC) produced the Australian Statistics on Medicines (ASM) for each calendar year to 1998. In 2002 we presented the annual statistics for 1999 and 2000 and in 2003 we presented the annual statistics for 2001 and 2002. This edition presents the annual statistics for 2003. A continuous data set representing estimates of the aggregate community use (non public hospital) of prescription medicines in Australia is a key tool for Australia’s National Medicines Policy.

The ASM presents dispensing data on most drugs marketed in Australia and is the only current source of data in Australia to cover all prescription medicines dispensed in the community. Drug utilisation data can assist the targeting and evaluation of quality use of medicines initiatives, and the evaluation of changes to the availability of medicines. It is also needed for pharmacosurveillance by regulatory and financing authorities and by the pharmaceutical industry.

Publication of the Australian data also facilitates international comparisons of drug utilisation profiles and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes.

Andrea Mant MBBS, MD, MA, FRACGP Chairman Drug Utilization Sub-Committee

iii

CONTENTS

FOREWORD iii

INTRODUCTION 1

INFORMATION ON THE AUSTRALIAN STATISTICS ON MEDICINES 3

Pharmaceutical Benefits Advisory Committee 4 Drug Utilization Sub-Committee 5 National Medicines Policy 5 Drug classification 6 Measurement unit 8 Health Insurance Commission processing 9 Pharmacy Guild survey data 10 Combined database 11

ADVERSE DRUG EVENT REPORTING IN AUSTRALIA 13

HIGHLY SPECIALISED DRUGS PROGRAM 16

Program overview 16 Highly Specialised Drugs Working Party 16 Criteria for selection of Highly Specialised Drugs 17 Supply of pharmaceutical benefits to remote Aboriginal Health Services 19 Expenditure 20

HEALTH EXPENDITURE TRENDS 21

DRUG UTILISATION TRENDS 23

TABLES IN THE AUSTRALIAN STATISTICS ON MEDICINES 28

References 28

CAVEATS 29

GLOSSARY OF TERMS 30

Weights and measures 31

ANATOMICAL THERAPEUTIC CHEMICAL INDEX (ATC) 32 AND DEFINED DAILY DOSE (DDD) CHANGES 2003

Table 1 Estimates of 2003 community prescription numbers and, 35 for PBS listed drugs, cost (government and patient)

Table 2 Community prescription drug use, in defined daily doses 171 (DDDs) per 1000 population/day, for 2001 to 2003

INDEX BY ATC CODE 255

List of Tables Table A: Prescription numbers by ATC groups 23 Table B: Top 10 drugs by defined daily dose/1000 population/day, 2003 25 Table C: Top 10 drugs by prescription counts, 2003 26 Table D: Top 10 drugs by cost to Government, 2003 26

List of Figures Figure A: Community utilisation of fluoxetine 11 Figure B: Community utilisation of amitriptyline 11 Figure C: Number of prescriptions by type of service 24 Figure D: Top 10 subsidised drugs dispensed in 2003 27 Figure E: Top 10 non-subsidised drugs dispensed in 2003 27

INTRODUCTION

The data contained in the 2003 ASM are drawn from two sources. The first is the Health Insurance Commission records of prescriptions submitted for payment of a subsidy under the Pharmaceutical Benefits and Repatriation Pharmaceutical Benefits Schemes (PBS/RPBS). The second is an ongoing survey of a representative sample of community pharmacies, which provides an estimate of the non-subsidised use of prescription medicines in the Australian community. The usage of prescription medicines dispensed to in-patients in public hospitals is generally not available in this report. The usage of prescription medicines to out-patients and discharged patients in one state of Australia is included. It is planned that all out-patients and discharged patients will receive PBS subsidised prescriptions in the future.

The units of measurement are the prescription and the defined daily dose per 1000 population per day (DDD/1000 population/day). The defined daily dose is established by the WHO Collaborating Centre for Drug Statistics Methodology on the basis of the assumed average dose per day of the drug, used for its main indication by adults. The drugs presented in this publication are arranged using the Anatomical Therapeutic Chemical (ATC) classification system. For more detail on this classification and the unit of measurement, please read the chapter ‘Information on the Australian Statistics on Medicines’.

The data are presented in two major tables. Table 1 includes 2003 community (i.e. subsidised and non-subsidised) prescription numbers, together with the government and patient costs for drugs PBS listed and subsidised by the Australian Government only. Cost information on the dispensing of drugs not listed on the PBS and drugs that are PBS-listed but for which no subsidy is claimed from the Australian Government is not available. Table 2 includes community prescription drug use, in DDDs/1000 population/day, for the year 2003.

INFORMATION ON THE AUSTRALIAN STATISTICS ON MEDICINES

In order to work towards the more rational and cost-effective use of medication in society, it is essential to have accurate information on patterns of drug prescription and use. Where this use is found to be inappropriate, drug utilisation data can monitor the impact of educational or regulatory interventions and can guide the interpretation of pharmacoeconomic analysis.(1)

In Australia community prescriptions (i.e. non public hospital) are dispensed either as private prescriptions or under one of two subsidisation schemes—the Pharmaceutical Benefits Scheme (PBS) and the Repatriation Pharmaceutical Benefits Scheme (RPBS). These schemes were established to provide the general community (PBS) and returned servicemen and women (RPBS) with access to necessary medicinal products, which are affordable, available and of acceptable standards. In 2003 the RPBS was 7.4% of the size of the PBS. However over 90% of the RPBS prescriptions involved PBS listed drugs.

In Australia, a new medicinal drug must gain approval for supply in accord with the requirements of the Therapeutic Goods Act 1989. Approval is also required to extend the indications of an established drug. Applications are dealt with by the Therapeutic Goods Administration (TGA) and, for prescription drugs, advice is sought from an expert committee, the Australian Drug Evaluation Committee (ADEC).

Once a prescription drug is approved for marketing, the company concerned usually applies to have the drug listed on the PBS. This is the national scheme available to the Australian community, for subsidising the cost of pharmaceuticals. Because of the attraction of the scheme to consumers, it is usually necessary for the company to have the drug listed on the scheme for viable marketing to occur.

The Pharmaceutical Benefits Advisory Committee (PBAC) makes recommendations to the Australian Government about what drugs should be listed on the PBS. Whereas the pre-market evaluation addresses the issues of quality, safety and efficacy, the PBAC considers effectiveness and cost-effectiveness of the product relative to other alternatives. Once a drug has been recommended for listing on the PBS by the PBAC, the Pharmaceutical Benefits Pricing Authority (PBPA) negotiates the price paid with the company. The PBPA consists of government, industry and consumer representatives. After agreement is reached, the Australian Government considers the advice of both the PBAC and the PBPA and makes a decision on whether the drug should be listed on the PBS.

Under the PBS, general patients paid the cost of a prescription up to a maximum of $22.40 from February 2002 to February 2003 rising to $23.10 until February 2004. Pensioner and concessional patients paid $3.60 per prescription from February 2002 to February 2003 rising to $3.70 to February 2004.

In addition, there is a safety net to protect people with high medication needs. Once general patients (and their immediate family) incurred $708.40 in 2003 of PBS expenditure (indexed), prescriptions for the remainder of 2003 cost only the concessional copayment amount. Once pensioners and concessionals incurred $192.40 in 2003 of expenditure (indexed) they receive all remaining prescriptions free of charge for the remainder of the calendar year.

Patients may also be required to pay a surcharge where the doctor prescribes a more expensive brand of an item, when there are cheaper, equivalent brands of that item listed on the PBS.

As the general patient copayment rises, the dispensed price of many of the cheaper medications falls under this level. In such cases the patient pays the full price and no claim for payment is transmitted under the PBS. In 2003, under copayment general prescriptions represented around 15% of all community prescribing. There are also many drugs that are not listed on the PBS or RPBS and are available only on private prescription with the patient paying the full cost (7.3% of community prescriptions in 2003).

Pharmaceutical Benefits Advisory Committee The Pharmaceutical Benefits Advisory Committee (PBAC) is an independent statutory body established on 12 May 1954 under section 101 of the National Health Act 1953 to make recommendations and give advice to the Minister about which drugs and medicinal preparations should be made available as pharmaceutical benefits. No new drug may be made available as a pharmaceutical benefit unless the Committee has so recommended.

The Committee is required by the Act to consider the effectiveness and cost of a proposed benefit compared to alternative therapies. In making its recommendations the Committee, on the basis of community usage, recommends maximum quantities and repeats and may also recommend restrictions as to the indications where PBS subsidy is available. When recommending listings, the Committee provides advice to the PBPA regarding comparison with alternatives or their cost-effectiveness.

Drug Utilization Sub-Committee In 1988, PBAC convened the Drug Utilization Sub-Committee (DUSC) to assist it in making recommendations for listings on the PBS. Its terms of reference are:

– To develop and advise on the mechanisms for the collection and analysis of comprehensive data on drug utilisation in Australia and to advise on the interpretation of these data. – To advise PBAC on changes in drug utilisation patterns as a consequence of changes in drug availability or restrictions on drug use and to review the utilisation of drugs or therapeutic groups of drugs, including expenditure impacts within the PBS. – To identify potential health problems and benefits related to patterns of drug utilisation and to evaluate policy and other interventions related to the use of drugs. – To facilitate and promote the dissemination of information on drug utilisation. – To conduct international comparisons of drug utilisation by interaction with appropriate international bodies. – To contribute to educational initiatives which promote the quality use of medicines.

National Medicines Policy In 1992, the Australian Government endorsed a National Medicines Policy to meet medication and related service needs in such a way that optional health outcomes and economic objectives are achieved. Three of the four components of the National Medicinal Drug Policy are strongly linked to the role of DUSC by their common goals and membership. These are:

(1) The availability of medicines which meet appropriate standards of quality, safety and efficacy while allowing the introduction of new products to the Australian market in a timely manner.

This is the primary responsibility of the Therapeutic Goods Adminstration and its advisory committees, the Australian Drug Evaluation Committee (ADEC) and the Adverse Drug Reactions Advisory Committee (ADRAC). ADEC provides independent scientific advice to the Australian Government within the policy framework of the time, whereas ADRAC is responsible for monitoring ongoing drug safety in the post- marketing phase.

(2) The provision of timely access to the medicines that Australians need, at a cost that individuals and the community can afford.

This is the primary role of the PBS and RPBS. The relevant advisory committee, PBAC, makes recommendations on drugs registered for marketing in Australia that are to be subsidised by the Government on the basis of comparative effectiveness and cost-effectiveness.

(3) The achievement of high quality use of medicines by consumers and health care providers. The National Strategy for Quality Use of Medicines set out the approach and principles which promote the concept that doctors, pharmacists, nurses and consumers all have a role to play in ensuring that medicines are used wisely.

The Pharmaceutical Health and Rational Use of Medicines (PHARM) Committee that provides the Australian Government with advice on pharmaceutical education and other aspects of the quality use of medicines. In addition, the National Prescribing Service (NPS) is a non-profit, incorporated organisation independent of government and the pharmaceutical industry that supports national coordinated approaches to quality use of medicines by providing independent information to health professionals and consumers.

(4) The fourth component of the National Medicines Policy is the maintenance of a responsible and viable medicines industry. This is largely carried out through the Pharmaceutical Industry Investment Program which is administered by the Department of Industry, Science and Resources.

The continuing development and implementation of the National Medicinal Drug Policy is coordinated by the Australian Pharmaceutical Advisory Council (APAC), which includes representation from all the major groups involved in pharmaceutical issues in Australia. APAC has a broad charter to develop, promote, influence and assist in the implementation of the National Medicines Policy in Australia.

Historically, the range of ways that prescribing may be effected and the lack of uniformity in drug codes complicated attempts to monitor national trends in this country. (2) DUSC have sought to address these problems through the development of a comprehensive database on community prescription drug use, linked by a uniform structured drug code and an adequate unit of drug utilisation measurement.

Drug Classification DUSC and the Department of Health and Ageing have adopted the Anatomical Therapeutic Chemical (ATC) code as recommended by the World Health Organization (WHO). It has been a goal of WHO to have an internationally accepted classification for presenting and comparing drug usage data. In 1981 the WHO established a central body responsible for coordinating its use—the WHO Collaborating Centre for Drug Statistics Methodology, which is located in Norway.

The ATC code itself is a structured 7 digit alpha-numeric code with 5 levels that classifies drugs according to their site of action and therapeutic and chemical characteristics.

The first level of the code is the anatomical main group (there are 14 anatomical main groups); the second and third levels are for the therapeutic main group and subgroup, with a 4th level being either a chemical or therapeutic subgroup and the 5th level the actual chemical substance.

The five levels thus are:

1 anatomical main group

2 therapeutic main group

3 therapeutic subgroup

4 chemical/therapeutic subgroup

5 generic drug name

Indomethacin, for example, has the following code: M 01 A B 01.

M denotes the musculoskeletal system

01 anti-inflammatory and anti-rheumatic products

A non steroidal

B acetic acid derivative

01 indomethacin

ATC system main groups:

The 14 anatomical main groups of the ATC code are listed below.

A Alimentary tract and metabolism

B Blood and blood forming organs

C Cardiovascular system

D Dermatologicals

G Genitourinary system and sex hormones

H Systemic hormonal preparations, excl. sex hormones

J General anti-infectives for systemic use

L Antineoplastic and immunomodulating agents

M Musculoskeletal system

N Central nervous system

P Antiparasitic products

R Respiratory system

S Sensory organs

V Various

Regular revisions of the ATC system are undertaken by the WHO centre together with the Nordic Council on Medicines. They receive expert advice from an advisory board and an established procedure exists to manage requests for new classifications and to regularly review the current structure.

Although the ATC code extends to the generic drug level it does not identify dosage forms, pack sizes, strengths or brands.

Measurement Unit The international unit of drug utilisation adopted by the DUSC to accompany this coding system is the defined daily dose (DDD) per thousand of the population per day. The defined daily dose is established by the Nordic Council on Medicines and the WHO Drug Utilisation Research Group on the basis of the assumed average dose per day of the drug, used for its main indication by adults. (3)

Use of the DDD allows for comparisons of drug utilisation independent of differences in price, preparation and quantity per prescription. It also allows comparison of the use of drugs in different therapeutic groups and between regions and countries. Expressing drug use in DDDs/1000/day allows the aggregation of data for those drugs which have differing daily doses. However the DDD is only a technical unit of use and does not necessarily reflect the recommended or average prescribed dose in Australia.

The DDD/1000/day figure is calculated from prescription data. All prescriptions submitted in Australia each year to the Health Insurance Commission for payment of a subsidy are surveyed and the actual average quantities dispensed are computed for each strength and dose form of a preparation. The DDD/1000 population/day for each of these items is then calculated as:

N x M x Q x 1000

DDD x P x D

Where:

N is the number of prescriptions dispensed in the year. M is the mass of each dose (e.g. in milligrams or grams and needs to be expressed in the same unit as DDD). Q is the average dispensed quantity per prescription. P is the mid year Australian population for the year of data collection. D is the number of days in the year.

The DDD/1000/ can be calculated over other time periods such as monthly or quarterly.

For PBS items the mass amount (M) is the amount of active drug contained in an individual dose unit e.g. tablet, capsule, suppository etc. Non-PBS items are estimated from a Pharmacy Guild/Amfac survey (see below). Because the data from the survey does not include quantity information, the mass amount for non-subsidised items is the total amount of active drug contained in the pack.

For prescriptions forwarded for subsidy, the average quantity dispensed (Q) is available from the HIC data. For prescriptions that are priced under the general copayment, this quantity is assumed to be the average quantity of the subsidised prescriptions for that drug (i.e. as concessional, safety net and Veterans' Affairs prescriptions). For private prescriptions the quantity dispensed is assumed to be the retail pack size.

For a chronically administered drug, the DDD/1000 population/day figure indicates how many people per 1000 of the population may, in theory, have received a standard dose (as defined by the DDD) daily.

For drugs used intermittently e.g. anti infectives, usage expressed in DDD/1000 population/day may similarly give a rough estimate of the average proportion of the population using these drugs every day. To estimate the number of patients treated during the year, supplementary information, such as the average duration of treatment, is necessary.(3)

The ATC/DDD methodology has a number of limitations. All drugs dispensed are not necessarily consumed and the DDD/1000 population/day is calculated for the total population, while drug use may be concentrated in certain age groups or a particular sex.

It is difficult to assign a DDD, and on occasions an ATC code, to some preparations that have multiple active ingredients. For some drug groups, such as the dermatological and antineoplastic drugs, highly individualised use and wide dose ranges, as well as the experimental nature of some of the therapy, make it difficult to define a daily dose. Consequently there may be a delay between the marketing of a drug and the availability of an ATC code and its associated DDD.

Generally agreed indications for use of the drug may be re-evaluated in light of experience with adverse reactions and other pharmacological effects. Drugs may have multiple indications and it may be difficult to determine what a preparation is used for. Also the DDD is based on overseas experience and may not reflect the prescribed adult dose in Australia.

Health Insurance Commission processing In 1990 the processing of prescriptions submitted for payment of a subsidy under the PBS/RPBS was taken over by the Health Insurance Commission (HIC). Daily tapes containing prescription records, that do not allow the identification of an individual patient, are provided by the HIC to the Department of Health and Ageing for summarisation.

Nevertheless, significant gaps in the data result from the inability to estimate both the level of use for PBS drugs priced under the patient copayment and the level of private prescription drug use.(1)

Pharmacy Guild Survey data Since 1989 DUSC has commissioned the Pharmacy Guild of Australia to conduct an annual survey to estimate the prescription volumes for drugs in the non-subsidised categories i.e. private prescriptions and PBS prescriptions priced under the general patient copayment. Total dispensing information is collected each month from approximately 150 pharmacies, which are members of the Pharmacy Guild.

A major pharmacy computer software supplier (Amfac) was commissioned to administer the collection of the data. Under the joint direction of DUSC and the Guild, Amfac contracted a firm of statisticians specialising in survey design and analysis to design a stratified random sample, using the Guild membership (which represents approximately 80% of pharmacies in Australia) as the population base. In 1993 the survey sample was reviewed and augmented with the assistance of the Statistical Services Section within the Department. A review of the representativeness, sample size, design and risks for the survey was carried out by the Australian Bureau of Statistics (ABS) in February 2002. It found that the relative standard error for a sample size of 150 pharmacies is 4.3%.

In the original form of the survey dispensing records from the participating pharmacies were sent to Amfac’s Canberra premises. These several hundred diskettes were summarised by drug code and category and then a single disk was forwarded to the Department. Details of the dispensing of individual participating pharmacies are not available on these data.

The Survey data was not supplied by the Guild from September 1999 to February 2001. When data collection recommenced data for this period was retrieved retrospectively using an internet connection between each participating pharmacy and Amfac. A total of 142 pharmacies participated in this data collection. Monthly data collection recommenced in February 2001. A new agreement between the software provider, the Guild and Department is being developed to ensure continuation of the Survey.

Following reinstatement of the Survey, data is now transmitted electronically from the Pharmacy Dispensary to the software provider. Data is forwarded to the Guild and thence to DUSC. The data continues to be de-indentified with respect to individual pharmacies.

The pharmacies in the survey are selected to be representative of the population of operational pharmacies on PBS dispensing volume and geographical location and similarly stratified. All pharmacies in Australia are stratified into four equal dispensing volume ranges, based on their annual average PBS dispensing from the previous year. A weighting factor is calculated for each of the volume strata by comparing the number of pharmacies in the survey with the total number of pharmacies in Australia. Volumes of non-subsidised drug use are calculated by multiplying the survey estimate by the weighting factor, which is assumed to apply equally to the subsidised and non-subsidised prescription volumes.

Combined database A Departmental database combines the prescription estimates for the non-subsidised sector (under the general copayment and private prescriptions) from the Pharmacy Guild survey with the actual counts of those prescription categories submitted to the HIC for payment of a subsidy. Information on drugs prescribed in public hospitals and on the use of highly specialised drugs available for out-patients through public hospital pharmacies under Section 100 of the National Health Act 1953 are not included in this database. The advantages of the expanded database can be illustrated by using an example involving utilisation data on two drugs—fluoxetine and amitriptyline. Fluoxetine has a price per prescription, as a general benefit, above the patient copayment and as a consequence, 99.17% of community use is captured on the PBS/RPBS claims database. By contrast, 79.80% of the community use of amitriptyline, which has a price per prescription below the general patient copayment, is captured on the PBS/RPBS. Figures A and B show the time trends for dispensing of fluoxetine and amitriptyline, by the subsidised and non-subsidised components.

Figure A: Community utilisation of fluoxetine

3 SUBSIDISED 2 NON-SUBSIDISED 1

DDDs/1000/population/day 0 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003

Time (years)

Figure B: Community utilisation of amitriplyline

3.0

2.5

2.0 SUBSIDISED 1.5 NON-SUBSIDISED 1.0

DDDs/1000/population/day 0.5 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003

Time (years)

The dispensing trend for amitriptyline, a drug whose dispensed price is below the general copayment, shows the large component of use identified through the Pharmacy Guild survey.

A pattern involving PBS drug utilisation that shows a higher level of usage leading up to the end of a year has been previously reported.(4) It is due to the safety net provisions introduced into the PBS in November 1986. Once the cash-based safety net level is reached, subsequent prescriptions on the scheme are either free or available at a greatly reduced copayment. The safety net period is the calendar year, and the highs and lows are due to stockpiling of medication once this safety net level is reached.

The safety net provisions were introduced into the PBS from November 1986 to ensure that patients with multiple medical conditions who genuinely need a number of medicines are not prevented financially from obtaining them.

The stockpiling of medication once the safety net level is reached has public health, waste and cost implications. Large quantities of potent medicines in the home can be a hazard for other family members, may exceed their expiry date and have the potential for patient confusion if the dosage or the need for a particular medication is subsequently reviewed by the doctor during this period.

Quantities within the PBS Schedule are designed to provide a normal course of treatment for acute conditions and a month’s treatment at usual doses for chronic conditions.

The National Health (Pharmaceutical Benefits) Regulations have been amended to increase the period for redispensing chronically used drugs (i.e. those with five or more repeats) to not less than 20 days. The exception is eye drops which tend to be used at a higher rate than other medications. The redispensing period here was amended to four rather than the previous three days.

The changes were effective from 1 November 1994.

In both cases, the pharmacist has the discretion to supply earlier than the statutory period if the circumstances warrant e.g. medicine lost or prescribed dosage requires more frequent dispensing of repeats.

Preliminary analyses of the effect of the 20 day re-supply rule suggest a smoothing out of the ‘highs and lows’ traditionally seen at the end and start of a safety net year respectively, although the total number of prescriptions dispensed has remained reasonably constant.

ADVERSE DRUG REACTIONS REPORTING IN AUSTRALIA

In Australia the Adverse Drug Reactions Advisory Committee (ADRAC) is responsible for monitoring ongoing drug safety in the post-marketing phase. The ADRAC reporting system began in the late 1960s with the computerised database dating back to November 1972. At the end of March 2004 there were almost 189,000 reports on the database and the average number of reports per month in 2003 was 960. The graph below shows the distribution and progressive increase of these reports.

7000 Companies Hospitals 6000 GPs Others 5000 ts

4000

3000

Number of repor 2000

1000

0 1993 1994 1995 1996 19973 1998 1999 2000 2001 2002 2003

Time (years)

In 2003, ADRAC received approximately 11,500 reports with 29% from pharmaceutical companies, 24% from general practitioners, 26% from hospitals and the remainder from other sources including including State and Territory Health Departments, members of the public, community pharmacists and specialists. The proportion of reports from pharmaceutical companies has remained steady at approximately 28–29% during 2002–2003.

The sharp drop in reporting of adverse events by pharmaceutical companies in 2001 reflects a change in the guidelines for reporting introduced at that time that required companies to only report minor adverse reactions rather than all adverse reactions. The increase in the category marked ‘others’ in 2003 reflects a requirement for vaccination centres to lodge reports on adverse drug reactions introduced in 2003. ADRAC encourages practitioners to report suspected adverse reactions direct to ADRAC rather than through the manufacturer to make communication simpler.

Reports are received by the ADRAC Secretariat where they are assessed. This involves checking the report for the presence of 'minimum' details, i.e. an individual patient, an adverse reaction, at least one (suspected) drug and (preferably) an identifiable reporting health professional. The specific reaction terms are identified along with the suspected, interacting or bystander ('other') drugs. A causality rating for the reaction(s) is applied, the report is acknowledged and a decision is made as to whether further information (clinical or laboratory) is required in relation to the report. The reports are entered into the database. Selected reports are reviewed by ADRAC, with currently about 30% of reports being reviewed by this committee.

Reports are forwarded to the Uppsala Monitoring Centre in Sweden which administers the WHO Collaborating Centre for International Drug Monitoring. This global database began in 1968 as a pilot program involving 10 nations including Australia and now receives reports from over 70 nations with almost 3.08 million reports on file.

ADRAC encourages the reporting of all suspected adverse reactions to drugs and other medicinal substances, including herbal, traditional or alternative remedies. The reporting of seemingly insignificant or common adverse reactions may highlight a widespread prescribing problem. The Committee particularly requests reports of:

• All suspected reactions to new drugs, especially Drugs of Current Interest; • all suspected drug interactions; • reactions to other drugs which are suspected of significantly affecting a patient’s management, including reactions suspected of causing: – death; – danger to life; – admission to hospital; – prolongation of hospitalisation; – absence from productive activity; – increased investigational or treatment costs; and – birth defects.

Reports of suspected adverse drug reactions are best made by using a prepaid reporting form ('blue card') which is available from the Adverse Drug Reactions Unit (02 62328386) or from the website: http://www.tga.gov.au/adr/bluecard.pdf. Tear out blue cards can also be found at the front of all recent editions of the 'Schedule of Pharmaceutical Benefits', and in the 'Australian Medicines Handbook'. Electronic submission of adverse drug reaction reports can be made by following the link below: http://www.tga.gov.au/problem/ index.htm#medicines

Drugs of Current Interest are newly marketed drugs that may receive widespread use and ADRAC is interested in obtaining a comprehensive safety profile. Examples for the list for 2003 are as follows:

Apomorphine (Uprima) Aripiprazole (Abilify) Esomeprazole (Nexium) Fondaparinux (Arixtra) Galantamine (Reminyl) Gatifloxacin (Tequin) Lercanidipine (Zanidip) Levetiracetam (Keppra) Meloxicam (Mobic) Mirtazapine (Avanza, Mirtazon, Remeron) Moxifloxacin (Avelox) Oxcarbazepine (Trileptal) Pioglitazone (Actos) Pramipexol (Sifrol) Reboxetine (Edronax) Risedronate (Actonel) Rivastigmine (Exelon) Rosiglitazone (Avandia) Sibutramine (Reductil) Tadalafil (Cialis) Tegaserod (Zelmac)

The Australian Adverse Drug Reactions Bulletin was published four times per year in 2001 and 2002, but from 2003 is being published six times per year. Some issues highlighted in 2003 were:

• post-partum NSAIDs may cause hypertension; • rofecoxib, celecoxib and cardiovascular risk; • convulsions and blood dyscrasias with mirtazapine; • anti-epileptic drugs, pregnancy and fetal malformations; • maternal SSRI use and neonatal effects; • ACE inhibitor, diuretic and NSAID: a dangerous combination; • serious gastrointestinal effects with celecoxib and rofecoxib; • Travacalm—your reports make a difference!; • hyponatraemia with SSRIs; • fluticasone and adrenal crisis; • interstitial nephritis with the proton pump inhibitors; • minocycline and not so benign intracranial hypertension; • acute neuropsychiatric events with celecoxib and rofecoxib; and • linezolid and peripheral neuropathy.

THE HIGHLY SPECIALISED DRUGS PROGRAM

Program overview The Australian Government provides funding for certain specialised medications under the Highly Specialised Drugs Program. Highly specialised drugs (HSD) are medicines for the treatment of chronic conditions which, because of their clinical use or other special features, are restricted to supply through public and private hospitals having access to appropriate specialist facilities. To prescribe these drugs as pharmaceutical benefit items, medical practitioners are required to be affiliated with these specialist hospital units. A general practitioner or non-specialist hospital doctor may only prescribe HSDs to provide maintenance therapy under the guidance of the treating specialist.

Subsidy for drugs under this program commences after approval by the Australian Government and the States and Territories agree to the administrative arrangements. For HSDs prescribed through private hospitals, claiming and approval of authority prescriptions is administered by the Health Insurance Commission. For HSDs prescribed through public hospitals, claiming and access to the program is administered by the states/territories Health Departments.

The Australian Government provides funding for the drug to be supplied to community based patients i.e. persons who are admitted on a one-day basis, out-patients and in-patients at discharge.

Highly Specialised Drugs Working Party The Highly Specialised Drugs Working Party (HSDWP) was established by the Australian Health Ministers’ Advisory Council in 1991. It consists of representatives from the Health Departments of each of the states and territories, the Australian Private Hospitals Association and the Australian Government as chair. The main purpose of the HSDWP is to identify, and refer for consideration by the PBAC, those drugs which meet the selection criteria for HSDs.

Criteria for selection of Highly Specialised Drugs Drugs recommended for inclusion in the program must satisfy the following criteria:

(1) Ongoing specialised medical supervision required. (2) Treatment of longer term medical conditions not episodes of in-patient treatment or treatment of acute conditions. (3) Drug highly specialised and an identifiable patient target group. (4) Subject to marketing approval by the TGA and specific therapeutic indications covered by the terms of the marketing letter from TGA. (5) High unit cost.

Highly Specialised Drugs, national usage in public hospitals in 2003

Drug Expenditure Packs Patient numbers ABACAVIR SULFATE 4,520,766 16,057 8,712 ABACAVIR SULFATE WITH 6,642,342 7,796 4,154 LAMIVUDINE AND ZIDOVUDINE AMPRENAVIR 404,597 1,778 577 APOMORPHNE HYDROCHLORIDE 765,626 27,620 296 AZITHROMYCIN 156,241 2,304 809 BACLOFEN 578,794 4,134 669 CIDOFOVIR 1,800 2 2 CLARITHROMYCIN 200,076 1,470 1,339 CLOZAPINE 27,669,310 118,670 35,194 CYCLOSPORIN 26,382,482 246,456 29,176 DARBEPOETIN ALFA 41,755,878 65,853 29,324 DELAVIRDINE MESYLATE 108,724 400 220 DESFERRIOXAMINE MESYLATE 4,151,793 66,625 2,807 DIDANOSIDE 3,789,835 13,987 4,999 DISODIUM PAMIDRONATE 8,431,723 21,913 10,235 DORNASE ALFA 7,281,070 6,359 2,673 DOXOBUBICIN HYDROCHLORIDE 119,128 184 26 EFAVIRENZ 4,272,716 15,809 5,665 EPOETIN 33,964,998 52,592 18,582 ETANERCEPT 71,924 88 16 FILGRASTIM 19,742,512 11,306 6,199 FOSCARNET SODIUM 37,982 96 20 GANCICLOVIR 2,593,975 3,623 980 INDINAVIR SULFATE 1,689,750 3,727 1,933 INTERFERON ALFA-2A 154,854 3,777 139 INTERFERON ALFA-2B 1,450,004 4,641 853

Drug Expenditure Packs Patient numbers INTERFERON GAMMA-1B 361,892 344 65 LAMIVUDINE 9,775,694 42,847 15,285 LAMIVUDINE AND ZIDOVUDINE 11,722,594 20,260 7,572 LANREOTIDE ACETATE 275,250 367 89 LENOGRASTIM 397,973 407 322 LOPINAVIR WITH RITONAVIR 9,482,692 29,539 5,606 MYCOPHENOLATE MOFETIL 13,139,497 23,692 19,474 MYCOPHENOLATE SODIUM 74,804 186 87 NELFINAVIR MESYLATE 2,368,243 4,802 2,604 NEVIRAPINE 7,087,737 26,098 9,246 OCTREOTIDE 1,259,561 9,321 629 OCTREOTIDE ACETATE 9,228,908 4,586 1,481 PEGFILGRASTIM 15,854,300 8,236 6,871 PEGINTERFERONE ALFA-2B 261,568 172 62 RIBABIRIN & INTERFERON ALFA-2B 10,156,869 6,509 2,988 RIBRAVIRIN & PEGINTERFERON 2,148,760 1,193 572 ALFA-2A RIBAVIRIN & PEGINTERFERON 298,159 148 501 ALFA-2B RIFABUTIN 90,273 614 176 RITONAVIR 832,780 7,765 2,786 SAQUINAVIR MESYLATE 1,887,325 6,025 2,561 STAVUDINE 6,155,505 14,859 7,717 TACROLIMUS 11,198,189 26,211 10,766 TENOFOVIR DISOPROXIL 9,566,573 18,222 6,797 FUMARATE VALACICLOVIR HYDROCHLORIDE 1,041,446 2,038 1,357 VALGANCICLOVIR HYDROCHLORIDE 527,568 235 279 ZALCITABINE 65,640 272 184 ZIDOVUDINE 914,930 3,458 2,059 ZOLEDRONIC ACID 1,069,455 2,268 5,989 GRAND TOTAL 324,183,086 957,942 279,724

The program expenditure by the Australian Government has grown from less than $20 million in 1991–1992 to almost $376.4 million in 2003. Of this $324.2 million was expenditure in public hospitals and $52.2 million in private hospitals.

Initially there were two drugs subsidised; however, that number has risen to 54 in 2003. Of the nine new inclusions for this financial year, three were for chronic hepatitis C, two were arthritis, one was an immuno-supressive agent, one was for acute myeloid leukemia, one was an HIV/AIDS antiretroviral agent and one was for cytomegalovirus.

Supply of pharmaceutical benefits to remote area Aboriginal Health Services (AHSs) under Section 100 of National Health Act Special arrangements were introduced in 1999 to improve access to the PBS by clients of remote area Aboriginal health services (AHSs) under Section 100 of the National Health Act 1953. Under these arrangements, clients of participating AHSs are able to receive PBS medicines directly from the AHS at the point of consultation, without the need for a normal prescription form, and without charge. Participating AHSs order the required PBS pharmaceuticals from pharmacies, which then transmit claims to the Health Insurance Commission for reimbursement. The eligibility criteria for participation in the program are given below.

Eligibility criteria

1. The health service must have a primary function of meeting the health care needs of Aboriginal and Torres Strait Islander peoples. 2. The clinic or other health care facility operated by the AHS from which pharmaceuticals are supplied to patients must be in a remote zone as defined in the Rural, Remote and Metropolitan Areas Classification 1991 Census Edition. 3. The AHS must not be a party to an arrangement, such as a coordinated care trial, for which funds from the PBS have already been provided. 4. The AHS must employ or be in a contractual relationship with health professionals who are suitably qualified under relevant State/Territory legislation to supply all medications covered by the Section 100 arrangements and undertake that all supply of benefit items will be under the direction of such qualified persons. 5. The clinic or other health care facility operated by the AHS from which pharmaceuticals are supplied must have storage facilities that will: • prevent access by unauthorised persons; • maintain the quality (e.g. chemical and biological stability and sterility) of the pharmaceutical; and • comply with any special conditions specified by the manufacturer of the pharmaceutical.

Expenditure The number of participating remote area AHSs has grown to 142 since the program was introduced in 1999. PBS expenditure via these arrangements for 2003 (including GST) by State/Territory was:

STATE $ NSW $223,561 NT $9,785,730 QLD $3,155,659 SA $397,129 TAS $35,272 WA $3,656,129 GRAND TOTAL $17,253,480

HEALTH EXPENDITURE TRENDS

(a) Pharmaceutical expenditure as % total health expenditure

1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 Australia 10.3 10.8 11.1 11.3 11.6 11.7 12.3 13.1 13.6 13.9 14.0 Canada 13.0 13.1 13.8 14.0 14.8 15.2 15.5 15.9 16.3 16.8 16.9 France 17.5 17.4 17.6 17.6 18.0 18.6 19.5 20.3 20.9 20.8 20.9 Germany 13.2 12.9 12.7 12.8 12.9 13.4 13.5 13.6 14.3 14.5 14.6 New Zealand 14.9 15.8 14.8 14.5 14.4 n.a. n.a. n.a. n.a. n.a. n.a. United Kingdom 14.8 15.1 15.3 15.6 15.8 n.a. n.a. n.a. n.a. n.a. n.a. United States 8.6 8.6 8.9 9.2 9.6 10.2 11.2 11.9 12.3 12.7 12.9

(a) Per person expenditure on pharmaceuticals , $AUS (GDP purchasing power parity)

1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 Australia 214 236 256 278 300 318 338 419 459 506 n.a. Canada 343 348 377 381 419 456 484 533 604 639 684 France 428 430 450 454 476 512 559 642 720 771 818 Germany 335 355 372 390 415 444 459 500 539 565 589 New Zealand 217 245 236 238 254 n.a. n.a. n.a. n.a. n.a. n.a. United Kingdom 242 257 262 293 312 n.a. n.a. n.a. n.a. n.a. n.a. United States 387 402 418 455 494 550 628 714 811 898 983

Total expenditure on health as % GDP

1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 Australia 8.3 8.3 8.4 8.5 8.6 8.7 8.9 9.2 9.3 9.5 9.3 Canada 9.9 9.5 9.2 9.0 8.9 9.2 9.0 8.9 9.4 9.6 9.9 France 9.4 9.4 9.5 9.5 9.4 9.3 9.3 9.3 9.4 9.7 10.1 Germany 9.9 10.2 10.6 10.9 10.7 10.6 10.6 10.6 10.8 10.9 11.1 New Zealand 7.2 7.2 7.2 7.2 7.4 7.8 7.7 7.8 7.9 8.2 8.1 United Kingdom 6.9 7.0 7.0 7.0 6.8 6.9 7.2 7.3 7.5 7.7 7.7 United States 13.2 13.1 13.3 13.2 13.0 13.0 13.0 13.1 13.9 14.6 15.0

(a) See note below for definition: 'Pharmaceuticals' defined. n.a. not available (data not provided to the OECD by these countries for these years) Sources: AIHW health expenditure database, OECD Health Data 2005

‘Pharmaceuticals’ defined For countries other than Australia, the OECD definition of pharmaceuticals has been used, as described in its System of Health Accounts (SHA). The OECD defines pharmaceuticals as ‘pharmaceuticals and other medical non-durables dispensed to out-patients’, which comprises prescription medicines, over-the-counter medicines and other medical non-durables.

Broadly speaking, these include medicinal preparations, branded and generic medicines, drugs, patent medicines, serums and vaccines, vitamins and minerals, and oral contraceptives and a wide range of medical non-durable goods, which are either single use items, for example bandaids and condoms, or have limited re-usage, for example, bandages.

Prescribed medicines are medicines exclusively sold to customers with a medical voucher, irrespective of whether it is covered by public or private funding and include branded and generic products. In the SHA, this includes the full price with a breakdown for cost-sharing.

Over-the-counter medicines (OTC medicines) are classified as private households’ pharmaceutical expenditure of non-prescription medicines.

Other medical non-durables comprise items such as bandages, elastic stockings, incontinence articles, condoms and other mechanical contraceptive devices.

In terms of Australian pharmaceutical expenditure, the Australian Institute of Health and Welfare (AIHW) splits expenditure into two categories, ‘benefit paid pharmaceuticals’ and ‘all other pharmaceuticals’.

‘Benefit paid pharmaceuticals’ are pharmaceuticals in the Pharmaceutical Benefits Scheme (PBS) and the Repatriation Pharmaceutical Benefits Scheme (RPBS) for which the Australian Government paid a benefit.

‘All other pharmaceuticals’ are pharmaceuticals for which no PBS or RPBS benefit was paid and includes the following:

• pharmaceuticals listed in the PBS or RPBS, where the total costs are equal to, or less than, the statutory patient contribution for the class of patient concerned (under co–payment drugs); • medicines dispensed through private prescriptions for items not listed in the PBS or RPBS; and • over–the–counter medicines such as aspirin, cough and cold medicines, vitamins and minerals, some herbal and other complementary medicines and medical non-durables goods, as listed above.

DRUG UTILISATION TRENDS

Listed below in Table A are the prescription counts for 2001, 2002 and 2003 by ATC anatomical main group. The data from the two sources are enumerated separately i.e. subsidised prescriptions (PBS/RPBS) and the estimate of non-subsidised prescriptions (survey).

Table A Prescription numbers by ATC groups (i) Subsidised prescriptions (PBS/RPBS)

ATC GROUP 2001 2002 2003 (A) Alimentary tract 19,377,530 21,520,117 22,740,681 (B) Blood and blood forming 4,407,802 5,279,172 6,055,450 (C) Cardiovascular system 49,300,928 52,756,536 55,636,426 (D) Dermatologicals 3,377,463 3,307,135 3,197,626 (G) Genitourinary system 6,443,505 5,783,534 4,757,566 (H) Hormonal preparations 2,453,513 2,552,152 2,598,634 (J) Antiinfectives 13,190,129 12,833,584 12,630,126 (L) Antineoplastic 1,007,024 1,106,179 1,200,722 (M) Musculoskeletal 10,490,476 12,346,379 13,069,777 (N) Nervous system 33,251,028 34,236,817 35,150,181 (P) Antiparasitic products 1,141,511 1,150,432 1,129,459 (R) Respiratory system 11,382,688 11,154,201 10,847,119 (S) Sensory organs 7,615,186 7,891,125 8,034,352 (V) Various 693,188 721,603 691,238 Other 348,730 333,107 318,233 TOTAL 164,480,701 172,972,073 178,057,590

(ii) Estimated non-subsidised prescriptions (Survey)

ATC GROUP 2001 2002 2003 (A) Alimentary tract 3,221,742 3,068,909 2,850,999 (B) Blood and blood forming 586,114 566,430 571,578 (C) Cardiovascular system 3,420,028 3,362,802 3,550,849 (D) Dermatologicals 2,442,141 2,252,786 2,174,243 (G) Genitourinary system 7,298,700 6,586,493 6,230,972 (H) Hormonal preparations 949,593 905,409 918,520 (J) Antiinfectives 10,990,671 10,012,415 9,184,888 (L) Antineoplastic 97,130 79,600 81,618 (M) Musculoskeletal 2,057,786 1,946,815 2,038,056 (N) Nervous system 7,648,118 7,463,102 7,214,871 (P) Antiparasitic products 465,874 405,574 372,692 (R) Respiratory system 3,187,972 3,465,675 3,315,126 (S) Sensory organs 1,976,125 1,757,452 1,700,054 (V) Various 26,611 64,107 18,639 Other 1,631,437 1,692,031 1,778,849 TOTAL 46,000,042 43,629,600 42,001,954

The estimated changes 1994 to 2003 in the number of prescriptions dispensed under the PBS (concessional and general), RPBS, under copayment and private categories are presented in Figure C.

Figure C: Number of prescriptions by type of service

A number of tables and figures describing the most commonly used drugs in 2003 are included below. Table B shows the top 10 drugs dispensed in the Australian community by DDDs/1000 population/day, which adjusts for the quantity dispensed per prescription. This DDD/1000/day information is presented both as a total community use and split between the subsidised (PBS/RPBS) and non-subsidised (Guild survey) components.

Table B: Top 10 drugs by defined daily dose/thousand population/day, 2003

Drug PBS/RPBS Guild Survey Total community use 1 Atorvastatin 72.100 0.115 72.215 2 Simvastatin 46.946 0.044 46.990 3 Diltiazem hydrochloride 38.170 0.196 38.366 4 Rampril 29.038 0.559 29.597 5 Salbutamol 20.009 7.584 27.593 6 Omeprazole 21.667 0.054 21.721 7 Frusemide 19.210 1.170 20.380 8 Irbesartan with hydrochlorothiazide 19.243 0.036 19.279 9 Irbesartan 18.846 0.171 19.017 10 Aspirin 16.655 1.087 17.742

Changes from 2002:

UP: simvastatin (3 ➝ 2), ramipril (5 ➝ 4) DOWN: diltiazem hydrochloride (2 ➝ 3), salbutamol (4 ➝ 5), irbestartan (8 ➝ 9) IN: irbesartan with hydrochlorothiazide, aspirin OUT: celecoxib (9 ➝ 13), amlodipine besylate (10 ➝ 12)

Table C shows the top 10 drugs dispensed in the Australian community ranked by prescription count for 2003. Table D ranks the top 10 drugs by cost to Government i.e. subsidised prescriptions only for 2003.

Table C: Top 10 drugs by prescription counts—2003

Drug PBS/RPBS Guild Survey Total community use 1 Atorvastatin 6,600,486 12,126 6,612,612 2 Simvastatin 5,708,918 5,554 5,714,472 3 Paracetamol 4,632,689 91,443 4,724,132 4 Omeprazole 4,546,226 11,579 4,557,805 5 Amoxycillin 2,332,539 2,061,114 4,393,653 6 Salbutamol 3,266,510 1,095,182 4,361,692 7 Atenolol 3,053,699 792,539 3,846,238 8 Codeine with paracetamol 2,700,004 1,089,944 3,789,948 9 Celecoxib 3,373,017 31,905 3,404,922 10 Irbesartan 3,212,053 72,731 3,284,784 Changes from 2002: UP: amoxycillin (6 ➝ 5), atenolol (9 ➝ 7)) DOWN: salbutamol (5 ➝ 6), codeine with paracetamol (7 ➝ 8), celecoxib (8 ➝ 9) IN: ibesartan OUT: temazipam (10 ➝ 14)

Table D: Top 10 drugs by cost to Government—2003

Drug PBS/RPBS PBS/RPBS COST TO DDD/1000/DAY SCRIPTS GOVERNMENT ($A) 1 Atorvastatin 72.1 6,600,486 364,401,893 2 Simvastatin 46.946 5,708,918 341,921,246 3 Omeprazole 21.667 4,546,226 200,414,114 4 Salmeterol and fluticasone . 2,582,663 159,025,432 5 Olanzapine 2.879 706,957 148,197,152 6 Pravastatin 13.299 2,046,610 120,218,644 7 Clopidogrel 5.671 1,430,564 113,929,506 8 Rofecoxib 10.763 3,032,135 94,804,356 9 Alendronic acid 7.43 1,801,286 93,266,001 10 Esomeprazole 7.351 1,833,287 92,174,906 Changes from 2002: UP: clopidogrel (10 ➝ 7) DOWN: celecoxib (7 ➝ 11) IN: alendronic acid (alendronate), esomeprazole OUT: pantoprazole (9 ➝ 12)

Figure D presents the top 10 subsidised drugs dispensed in 2003.

Figure D: Top 10 subsidised drugs dispensed in 2003

Rampril

Rofecoxib

Atenolol

Irbestartan

Salbutamol

Celecoxib

Omeprazole

Paracetamol

Simvastatin

Atorvastatin

0 1 2 3 4 5 6 7 8

Number of Scripts (millions)

Figure E presents the top 10 non-subsidised drugs for 2003.

Figure E: Top 10 non-subsidised drugs dispensed in 2003

Dextropropoxyphene with paracetamol

Paracetamol with codeine

Roxithromycin

Atenolol

Codeine with paracetamol

Salbutamol

Amoxycillin with claculanic acid

Cefalexin

Levonorgestrel with ethinyloestradiol

Amoxycillin

0.0 0.5 1.0 1.5 2.0 2.5

Number of Scripts (millions)

TABLES IN THE AUSTRALIAN STATISTICS ON MEDICINES

The data are presented in two major tables. Table 1 is an estimate of the 2003 community (i.e. subsidised and non-subsidised) prescription numbers, together with the costs for PBS listed drugs, which include an estimate of the cost of under copayment PBS prescriptions. Cost information on the dispensing of private prescriptions is not available. The defined daily doses (DDDs), where available, are also included for the drugs covered in the report.

Table 2 includes community prescription drug use, in DDDs/1000 population/day, for the years 2001 to 2003.

References (1) Edmonds DJ, Dumbrell DM, Primrose JG, McManus P, Birkett DJ, Demirian V. Development of an Australian drug utilisation database: a report from the Drug Utilisation Subcommittee of the Pharmaceutical Benefits Advisory Committee PharmacoEconomics 1993; 3(6): 427 432. (2) Hurley SF, McNeil JJ. Drug coding systems: why so many? Med J Aust 1989; 151: 308.

(3) Nordic Council on Medicines. Nordic Statistics on Medicines 1987–1989. NLN publication number 3, Uppsala, Sweden, 1990.

(4) McManus P. Drug utilisation (letter) Med J Aust 1993; 158: 724.

CAVEATS

It needs to be borne in mind that these utilisation data do not include over-the-counter purchase (except for S3 Recordable), public hospital drug usage or the supply of highly specialised drugs to out-patients through public hospitals under Section 100 of the National Health Act 1953. Some extemporaneously prepared items may also not be included.

Comments on classifications, omissions or errata appearing in this edition of the Australian Statistics on Medicines may be sent to:

Maxine Robinson Secretary Drug Utilization Sub-Commitee (DUSC) Department of Health and Aged Care GPO Box 9848 CANBERRA ACT 2601 e-mail: [email protected]

GLOSSARY OF TERMS

Actu Actuated Drp Drops Adhes Adhesive Ds Doses Admin Administration Dust Dusting Aero Aerosol Efferv Effervescent Amp(s) Ampoule(s) Elx Elixir Applic Applicator Enter Enteric Aqu Aqueous Emulsif Emulsifying Breth Breath Equiv Equivalent Calc Calcium Extend Extended Cap(s) Capsule(s) Ferr Ferrous Cart Cartridge Gran Granules CD Controlled delivery Inf Infusion Chew Chewable Inhal Inhalation Clean Cleansing Inj(s) Injection(s) Coat Coated Inrt Inert Co Compound Ins Insert Conc Concentrated Intracav Intracavernosal Cont Contained Intranas Intranasal CR Controlled release Insuff Insufflator Crm Cream Irrig Irrigation Crush Crushable Jel Jelly D Dose Linct Linctus Dev Device Lin Liniment Diag Diagnostic Liq Liquid Dil Diluted Loz Lozenge Disp Dispersable Ltn Lotion Dres Dressing Metronid Metronidazole

Mixt Mixture Sng Single Nas Nasal Sod Sodium Nebu Nebuliser Sol Soluble Not< Not less than Soln Solution Oint Ointment Solv Solvent Ophth Ophthalmic Spr Spray Paed Paediatric Ster Sterile Pdr Powder Sulph Sulphate Pell(s) Pellet(s) Suppl Supplement Pess Pessary Suppos Suppository Phos Phosphorus Supres Suppression Pot Potassium Susp Suspension Prep Preparation Sust Sustained Press Pressurised Syrp Syrup Prot Protective Syrng Syringe Pst Paste Tab(s) Tablet(s) Reag Reagent Td Transdermal Rel Release Tinct Tincture Requ Required Top Topical Sach(s) Sachet(s) Unt(s) Unit(s) SF Sugar free wps Wipes

Weights and Measures cm centimetre(s) ME million units E unit(s) mm millimetre(s) g gram(s) mg milligram(s) kg kilogram(s) mL millilitre(s) iu international unit mmol millimole L litre(s) TE thousand units m metre(s) ug micrograms(s)

ATC & DDD CHANGES 2003

The tables are structured using the 2003 ATC index, but use the DDD relevant to the data year contained in the book, in this edition the calendar year 2003. A number of changes apply from the previous edition of the ASM and include:

(1) Alterations in ATC classification in 2003

Drug/drug group Previous ATC code New ATC code Chondroitin sulfate M09AX02 M01AX25 Levocetirizine R06AE08 R06AE09

New levels established in 2003

H05A Parathyroid hormones and analogues H05AA Parathyroid hormones and analogues J05AF Nucleoside and nucleotide reverse transcriptase inhibitors

(2) Alterations in DDDs for 2003

Previous DDD New DDD B03BB01 Folic acid 0.3* mg O 0.4 mg O 10** mg O deleted R01AD05 Budesonide 0.3 mg N 0.2 mg N

* prophylactic dose ** therapeutic dose Parenteral therapeutic dose unchanged

(3) New DDDs assigned in 2003

A08AA10 Sibutramide 10 mg O A16AB03 Agalsidase alfa 1 mg P A16AB04 Agalsidase beta 5 mg P G01AD03 Ascorbic acid 0.25 g V G03CA03 Estradiol 0.3 mg N J01XX08 Linezolid 1.2 g O,P J02AX04 Caspofungin 50 mg P J05AB14 Valganciclovir 0.9 g O J05AE05 Amprenavir 2.4 g O J05AE06 Lopinavir 0.8g O L04AA10 Sirolimus 6 mg O

M03BX01 Baclofen 0.55 mg P N05AH03 Olanzapine 10 mg P N05AL05 Amisulpride 0.4 g O N06AB10 Escitalopram 10 mg O N07BB04 Naltrexone 50 mg O S01EX04 Unoprostone 0.2 ml

(4) Allocation of ATC codes and DDDs to new products ATC codes assigned to drugs marketed or listed on the PBS since the 2001–2002 edition include:

2003

Famotidine, combinations A02BA53 Tenecteplase B01AD11 Protein C B01AD12 Fondaparinux B01AX05 Ferric sodium gluconate complex B03AC07 Other hypertensives C02KX Bosentan C02KX01 Simvastatin, combination packages C10AA51 Ezetimibe C10AX09 Calcipotriol, combinations D05AX52 Teriparatide H05AA02 Voriconazole J02AC03 Valganciclovir J05AB14 Tenofovir disoproxil J05AF07 MeningococcusC, purified polysaccharides antigen J07AH07 conjugated Diphteria-haemophilus influenzae B-pertussis— J07CA09 poliomyelitis—tetanus—hepatitis B Other plant alkaloids and natural products L01CX Gefitinib L01XX31 Pegfilgrastim L03AA13 Valdecoxib M01AH03 Parecoxib M01AH04 Escitalopram N06AB10 Povidone-iodine S01AX18

Full details on current ATC coding and defined daily doses (DDDs) can be obtained from the DUSC Secretary, Department of Health and Aged Care, GPO Box 9848, Canberra ACT 2601 or direct from the coordinating body, the WHO Collaborating Centre for Drug Statistics Methodology, P.O. Box 100, Veitvet 0518 Oslo Norway.

TABLE 1

2003 COMMUNITY PRESCRIPTION NUMBERS, TOGETHER WITH GOVERNMENT AND PATIENT COSTS FOR PBS-LISTED DRUGS

Table 1 includes an estimate of community (non-public hospital) prescription numbers for the 2003 calendar year, costs (government and patient contribution) for the items with a four digit PBS/RPBS code, together with the defined daily dose (DDD) where assigned. There is no cost information available for items with a five digit Amfac drug code. Table 1 exclude the presentation of information on any item with an estimated community use of less than 110 prescriptions in 2003.

The prescription items are arranged by ATC code on generic name, and by form and strength using either the PBS drug code (4 digit) or, for non-PBS items, the Amfac drug code (5 digit). Consult the index (page 255) by generic drug name to obtain the appropriate ATC code.

An index by 2nd level of the ATC classification follows:

ALIMENTARY TRACT AND METABOLISM PAGE NO

A01 STOMATOLOGICAL PREPARATIONS 39 A02 DRUGS FOR ACID RELATED DISORDERS 40 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 43 A04 ANTIEMETICS AND ANTINAUSEANTS 45 A05 BILE AND LIVER THERAPY 46 A06 LAXATIVES 47 A07 ANTIDIARRHOEALS, INTESTINAL 49 ANTIINFLAMMATORY/ANTIINFECTIVES A08 ANTIOBESITY PREPARATIONS, EXCLUDING DIET PRODUCTS 51 A09 DIGESTIVES, INCLUDING ENZYMES 52 A10 ANTIDIABETIC THERAPY 53 A11 VITAMINS 55 A12 MINERAL SUPPLEMENTS 57 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 58

BLOOD AND BLOOD FORMING ORGANS

B01 ANTITHROMBOTIC AGENTS 59 B02 ANTIHAEMORRHAGICS 61 B03 ANTIANAEMIC PREPARATIONS 62 B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS 63 B06 OTHER HAEMATOLOGICAL AGENTS 64 CARDIOVASCULAR SYSTEM

C01 CARDIAC THERAPY 65 C02 ANTIHYPERTENSIVES 67 C03 DIURETICS 68 C04 PERIPHERAL VASODILATORS 70 C05 VASOPROTECTIVES 71 C07 BETA BLOCKING AGENTS 72 C08 CALCIUM CHANNEL BLOCKERS 73 C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 75 C10 SERUM LIPID REDUCING AGENTS 77 DERMATOLOGICALS

D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 78 D02 EMOLLIENTS AND PROTECTIVES 80 D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS 81 D04 ANTIPRURITICS, INCLUDING ANTIHISTAMINES, ANAESTHETICS ETC 82 D05 ANTIPSORIATICS 83 D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE 84 D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 85 D08 ANTISEPTICS AND DISINFECTANTS 87 D09 MEDICATED DRESSINGS 88 D10 ANTI-ACNE PREPARATIONS 89 D11 OTHER DERMATOLOGICAL PREPARATIONS 90 GENITOURINARY SYSTEM AND SEX HORMONES

G01 GYNAECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 92 G02 OTHER GYNAECOLOGICALS 93 G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 94 G04 UROLOGICALS 99

SYSTEMIC HORMONAL PREPARATIONS, EXCLUDING SEX HORMONES

H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES 100 H02 CORTICOSTEROIDS FOR SYSTEMIC USE 101 H03 THYROID THERAPY 102 H04 PANCREATIC HORMONES 103 H05 CALCIUM HOMEOSTASIS 104 GENERAL ANTIINFECTIVES FOR SYSTEMIC USE

J01 ANTIBACTERIALS FOR SYSTEMIC USE 105 J02 ANTIMYCOTICS FOR SYSTEMIC USE 112 J04 ANTIMYCOBACTERIALS 113 J05 ANTIVIRALS FOR SYSTEMIC USE 114 J07 VACCINES 115 ANTINEOPLASTIC AND IMMUNO-MODULATING AGENTS

L01 ANTINEOPLASTIC AGENTS 117 L02 ENDOCRINE THERAPY 122 L03 IMMUNOSTIMULANTS 123 L04 IMMUNO-SUPPRESSIVE AGENTS 124 MUSCULO-SKELETAL SYSTEM

M01 ANTI-INFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS 125 M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 127 M03 MUSCLE RELAXANTS 128 M04 ANTI-GOUT PREPARATIONS 129 M05 DRUGS FOR TREATMENT OF BONE DISEASES 130 NERVOUS SYSTEM

N01 ANAESTHETICS 131 N02 ANALGESICS 132 N03 ANTI-EPILEPTICS 138 N04 ANTI-PARKINSON DRUGS 140 N05 PSYCHOLEPTICS 141 N06 PSYCHOANALEPTICS 145 N07 OTHER NERVOUS SYSTEM DRUGS 148 ANTI-PARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

P01 ANTI-PROTOZOALS 150 P02 ANTHELMINTICS 151 P03 ECTOPARASITICIDES, INCLUDING SCABICIDES, INSECTICIDES AND REPELLENTS 152

RESPIRATORY SYSTEM

R01 NASAL PREPARATIONS 153 R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 155 R05 COUGH AND COLD PREPARATIONS 158 R06 ANTI-HISTAMINES FOR SYSTEMIC USE 159 SENSORY ORGANS

S01 OPHTHALMOLOGICALS 162 S02 OTOLOGICALS 167 S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS 168 VARIOUS

V01 ALLERGENS 169 V03 ALL OTHER THERAPEUTIC PRODUCTS 170

38 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS

STOMATOLOGICAL PREPARATIONS ANTIINFECTIVES FOR LOCAL ORAL TREATMENT A01AB04 AMPHOTERICIN 2931 Lozenge 10 mg 40.00 MG 154,932 1,210,119 3306 Lozenge 10 mg 40.00 MG 4,299 32,991 A01AB03 CHLORHEXIDINE 4160 Mouth wash 2 mg per ml (0.2%), 250 ml 30.00 MG 258 3,237 4161 Mouth wash 2 mg per ml (0.2%), 250 ml 30.00 MG 4,081 42,744 A01AB09 MICONAZOLE 13832 Oral gel 20 mg per ml (2%), 20 g 0.20 GM 13,612 - 14054 Oral gel 40 mg per ml (2%), 40 g 0.20 GM 6,199 - A01AB11 NYSTATIN 3033 Oral suspension 100,000 units per ml, 24 ml 1500.00 TE 152,706 1,391,866 3343 Oral suspension 100,000 units per ml, 24 ml 1500.00 TE 818 7,366 16261 Pastille 100,000 units 28 - - 570 - A01AB11 POVIDINE IODINE 10359 Gargle 1 - - 313 - CORTICOSTEROIDS FOR LOCAL ORAL TREATMENT A01AC01 TRIAMCINOLONE ACETONIDE with PECTIN 11075 Paste 1% 5gm - - 27,116 - OTHER AGENTS FOR LOCAL ORAL TREATMENT A01AD02 BENZYDAMINE HYDROCHLORIDE 1121 Mouth and throat rinse 22.5mg per 15mL,500mL - - 8,350 142,774 8568 Mouth and throat rinse 22.5g 18mg per 15mL, 500mL - - 852 15,056 13466 Lozenge 3mg 12 - - 213 - 13467 Gel 3% 30g 1 - - 347 - 13655 Gel 5% 30g 1 - - 297 - 13757 Gel 3% 75g 1 - - 806 - 13982 Cream 3% 75g 1 - - 112 - 14683 Solution 0.15% 200 ml - - 458 - A01AD02 BENZYDAMINE with CHLORHEXIDINE 14358 Solution 100 ml - - 161 - 14359 Solution 200 ml - - 249 - A01AD11 CHOLINE SALICYLATE with CETALKONIUM CHLORIDE 12855 Gel 10g 1 - - 1,665 - A01AD11 CHOLINE SALICYLATE with CETALKONIUM CHLORIDE with MENTHOL and GLYCEROL 16097 Jelly 87 mg-100 ug-570 ug-46 mg- - - 232 - A01AD11 LIGNOCAINE HYDROCHLORIDE 15923 Spray 10% 30 ml 1 - - 148 - A01AD11 SALIVA SUBSTITUTE 4568 Solution 25 ml - - 453 4,645 4569 Solution 100 ml - - 837 12,292

39 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS

ANTACIDS MAGNESIUM COMPOUNDS A02AA05 MAGNESIUM TRISILICATE 7342 Mixture 200 mL - - 1,193 14,724 A02AA10 MAGNESIUM TRISILICATE with BELLADONNA 7343 Mixture - - 180 2,027 ALUMINIUM COMPOUNDS A02AB01 ALUMINIUM HYDROXIDE 10038 Tablet 600 mg 100 - - 1,091 - CALCIUM COMPOUNDS A02AC10 CALCIUM CARBONATE with GLYCINE 4055 Tablet 420 mg-180 mg - - 758 13,320 COMBS AND COMPLEXES OF ALUMINIUM,CALCIUM AND MAGNESIUM COMPO A02AD ALUMINIUM HYDROXIDE with MAGNESIUM CARBONATE with SIMETHICONE 11194 Mixture 375ml 1 - - 254 - A02AD ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE 2157 Oral suspension 200 mg-200 mg per 5 ml, 500 ml - - 168,096 2,088,423 2576 Tablet 200 mg-200 mg - - 68,196 838,887 4117 Tablet 400 mg-400 mg-30 mg - - 3,471 77,062 4118 Oral suspension 400 mg-400 mg-30 mg per 5 ml, - - 5,936 105,193 A02AD ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE with SIMETHICONE 11195 Table (chewable) 50 - - 136 - 11196 Mixture 750ml 1 - - 183 - A02AD ALUMINIUM HYDROXIDE with MAGNESIUM TRISILICATE and MAGNESIUM HYDROXIDE 1032 Tablet 250 mg-120 mg-120 mg - - 10,351 127,289 2159 Oral suspension 250 mg-120 mg-120 mg per 5 ml, - - 19,469 241,607 ANTACIDS, OTHER COMBINATIONS A02AX ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE with OXETHAZAINE 16009 Mixture 500ml 1 - - 980 - DRUGS FOR PEPTIC ULCER AND GORD H2-RECEPTOR ANTAGONISTS A02BA01 CIMETIDINE 1156 Effervescent tablet 800 mg (as hydrochloride) 0.80 GM 2,861 78,546 1157 Tablet 200 mg 0.80 GM 5,004 134,985 1158 Tablet 400 mg 0.80 GM 57,392 1,558,949 1159 Tablet 800 mg 0.80 GM 5,613 155,828 8150 Tablet 200mg 0.80 GM 784 20,992 8151 Tablet 400mg 0.80 GM 2,933 79,522 8152 Tablet 800mg 0.80 GM 374 10,168 8153 Tablet 800mg 0.80 GM 448 12,147 8901 Effervescent tablet 800 mg (as hydrochloride) 0.80 GM 426 18,024

40 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS

DRUGS FOR PEPTIC ULCER AND GORD H2-RECEPTOR ANTAGONISTS A02BA03 FAMOTIDINE 2487 Tablet 20 mg 40.00 MG 167,329 3,548,931 2488 Tablet 40 mg 40.00 MG 136,412 3,024,434 4982 Tablet 20 mg 40.00 MG 1,381 37,380 4984 Tablet 40 mg 40.00 MG 1,581 54,616 8154 Tablet 20 mg 40.00 MG 5,240 110,790 8155 Tablet 40 mg 40.00 MG 4,884 105,103 8906 Tablet 20 mg 40.00 MG 295 8,131 8907 Tablet 20 mg 40.00 MG 9,220 250,840 8908 Tablet 40 mg 40.00 MG 433 16,546 8909 Tablet 40 mg 40.00 MG 11,731 434,060 17871 Tablet 20 mg 40.00 MG 130 - 18010 Tablet 40 mg 40.00 MG 137 - A02BA04 NIZATIDINE 1504 Capsules 300mg 30 0.30 GM 17,272 379,733 1505 Capsules 150mg 30 0.30 GM 96,247 2,066,435 4967 Capsules 150mg 60 0.30 GM 849 21,712 4969 Capsules 300mg 30 0.30 GM 236 7,783 8156 Capsules 150mg 30 0.30 GM 3,853 82,605 8157 Capsules 300mg 30 0.30 GM 1,283 28,231 8930 Capsules 150mg 60 0.30 GM 140 3,675 8931 Capsules 150mg 60 0.30 GM 5,494 142,644 8933 Capsules 300mg 30 0.30 GM 1,526 51,513 17883 Capsules 150mg 30 0.30 GM 148 - A02BA02 RANITIDINE HYDROCHLORIDE 1937 Effervescent tablet 150 mg (base) 0.30 GM 63,740 1,393,448 1977 Tablet 300 mg (base) 0.30 GM 385,754 8,701,383 1978 Tablet 150 mg (base) 0.30 GM 1,606,557 35,121,399 4978 Effervescent tablet 150 mg (base) 0.30 GM 384 9,648 4980 Syrup 150 mg (base) per 10 ml, 300 ml 0.30 GM 112 2,704 8158 Tablet 150 mg (base) 0.30 GM 49,275 1,072,027 8159 Effervescent tablet 150 mg (base) 0.30 GM 4,759 104,049 8160 Tablet 300 mg (base) 0.30 GM 13,609 299,850 8161 Syrup 150 mg (base) per 10 ml, 300 ml 0.30 GM 4,743 89,240 8162 Syrup 150 mg (base) per 10 ml, 300 ml 0.30 GM 15,790 309,957 8903 Effervescent tablet 150 mg (base) 0.30 GM 2,036 51,292 8905 Syrup 150 mg (base) per 10 ml, 300 ml 0.30 GM 184 4,962 17164 Tablet 150 mg 14 0.30 GM 280 - 17891 Tablet 150 mg (base) 0.30 GM 337 - 17896 Tablet 150 mg (base) 0.30 GM 165 - 17897 Effervescent tablet 150 mg (base) 0.30 GM 119 - PROSTAGLANDINS A02BB01 MISOPROSTOL 1648 Tablet 200 ug 0.80 MG 3,521 181,570

41 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS

DRUGS FOR PEPTIC ULCER AND GORD PROTON PUMP INHIBITORS A02BC05 ESOMEPRAZOLE 8600 Tablet 20 mg (enteric coated),30 30.00 MG 1,062,589 49,056,360 8601 Tablet 40 mg (enteric coated),30 30.00 MG 775,238 58,398,053 17171 Tablet 20 mg (enteric coated),7 30.00 MG 179 - A02BC03 LANSOPRAZOLE 2240 Capsule 30 mg 30.00 MG 39,423 2,168,655 2241 Capsule 30 mg 30.00 MG 829,275 44,434,056 8198 Capsule 15 mg 30.00 MG 16,280 511,823 8528 Sachet for oral suspension, 30mg 30.00 MG 1,210 57,705 8529 Sachet for oral suspension, 30mg 30.00 MG 8,739 422,260 A02BC01 OMEPRAZOLE 1326 Capsule 20 mg 20.00 MG 15,565 763,903 1327 Capsule 20 mg 20.00 MG 196,503 10,322,172 8331 Tablet 20mg (base) 30 20.00 MG 178,653 9,357,897 8332 Tablet 10 mg 30 20.00 MG 46,429 1,403,794 8333 Tablet 20 mg 30 20.00 MG 4,119,647 211,199,852 18013 Capsule 20 mg 20.00 MG 547 - 18014 Capsule 20 mg 20.00 MG 389 - A02BC02 PANTOPRAZOLE 8007 Tablet (enteric coated) equivalent to 40mg 40.00 MG 131,259 6,585,969 8008 Tablet (enteric coated) equivalent to 40mg 40.00 MG 1,838,143 92,928,628 8399 Tablet (enteric coated) equivalent to 20mg 40.00 MG 123,076 3,791,505 16667 Tablet (enteric coated) equivalent to 40mg 40.00 MG 642 - A02BC04 RABEPRAZOLE 8507 Tablet 10 mg 30 20.00 MG 18,208 510,027 8508 Tablet 20 mg 30 20.00 MG 658,824 31,752,349 8509 Tablet 20 mg 30 20.00 MG 88,628 4,191,416 COMBINATIONS FOR ERADICATION OF HELICOBACTER PYLORI A02BD05 OMEPRAZOLE MAGNESIUM and CLARITHROMYCIN and AMOXYCILLIN 8376 Pack 14 caps 20mg,14 tabs 500mg,28 caps 500mg - - 71,262 6,965,435 A02BD05 OMEPRAZOLE and CLARITHROMYCIN and AMOXYCILLIN 8272 Pack 14 caps 20mg,14 tabs 500mg,28 caps 500mg - - 5,116 500,133 OTHER DRUGS FOR PEPTIC ULCER AND GORD A02BX13 ALGINIC ACID with MAGNESIUM TRISILICATE with ALUMINIUM HYDROXIDE with 10917 Table (chewable) 48 - - 590 - A02BX13 SODIUM ALGINATE with CALCIUM CARBONATE and SODIUM BICARBONATE 2014 Oral liquid 1 gm -320 mg in 20ml, 500ml - - 135,711 1,721,670 A02BX13 SODIUM ALGINATE with CALCIUM CARBONATE with SODIUM BICARBONATE 10916 Mixture pep500m 1 - - 159 - A02BX02 SUCRALFATE 2055 Tablet 1 g 4.00 GM 12,642 287,462 ANTIFLATULENTS ANTIFLATULENTS A02DA PEPPERMINT OIL 13210 Capsule 0.2ml 63 - - 162 -

42 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

DRUGS FOR FUNCTIONAL BOWEL DISORDERS SYNT ANTICHOLIN,ESTERS WITH TERTIARY AMINO GROUP A03AA DICYCLOMINE HYDROCHLORIDE 4185 Tablet 10 mg - - 5,607 128,707 11151 Syrup 5mg/5ml 1 - - 717 - A03AA04 MEBEVERINE HYDROCHLORIDE 4328 Tablet 135 mg 0.30 GM 65,891 1,838,592 12730 Tablet 135 mg 30 0.30 GM 24,730 - 14130 Tablet 135 mg 30 0.30 GM 4,233 - SYNT ANTICHOLINERGICS,ESTERS,QUATER AMMONIUM COMP A03AB05 PROPANTHELINE 1953 Tablet 15 mg 60.00 MG 34,447 610,797 PAPAVERINE AND DERIVATIVES A03AD01 PAPAVERINE 13290 Ampoule 30mg/ml 5 0.10 GM 227 - DRUGS ACTING ON SEROTONIN RECEPTORS A03AE02 TEGASEROD 17465 Tablet 6mg 30 - - 8,796 - 17466 Tablet 6mg 60 - - 7,999 - OTHER DRUGS FOR FUNCTIONAL BOWEL DISORDERS A03AX13 SIMETHICONE 11033 Drop 30ml 1 - - 114 - 13445 Capsule 100mg 30 - - 1,020 - BELLADONNA AND DERIVATIVES, PLAIN BELLADONNA ALKALOIDS, TERTIARY AMINES A03BA01 ATROPINE 1089 Injection 600 ug in 1 ml 1.50 MG 2,285 26,843 3453 Injection 600 ug in 1 ml 1.50 MG 12,685 129,015 15453 Tablet 600 ug 1.50 MG 498 - A03BA04 HYOSCYAMINE HYDROBROMIDE with ATROPINE SULPHATE and HYOSCINE HYDROBROM 15792 Tablet 92.5 ug-13.5 ug 1.00 MG 2,968 - 15793 Tablet 138.7 ug-20.3 ug 1.00 MG 3,639 - A03BA04 HYOSCYAMINE SULPHATE with ATROPINE SULPHATE with HYOSCINE HYDROBROMIDE 10631 Mixture 100ml 1 1.00 MG 626 - 15794 Tablet 103.7 ug-19.4 ug 1.00 MG 985 - A03BA KAOLIN with PECTIN with HYOSCYAMINE SULPHATE with ATROPINE SULPHATE 10629 Suspension 200ml 1 - - 647 - BELLADONNA ALKALOIDS SEMISYNT,QUATER AMMONIUM COMP A03BB01 HYOSCINE BUTYLBROMIDE 4279 Injection 20 mg in 1 ml 60.00 MG 2,850 62,676 12939 Tablet 10mg 100 60.00 MG 14,152 - 15287 Tablet 10mg 60.00 MG 23,055 - A03BB HYOSCINE HYDROBROMIDE 10972 Ampoule 400ug 5 - - 2,003 -

43 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

PROPULSIVES PROPULSIVES A03FA02 CISAPRIDE 1188 Tablet 5 mg 30.00 MG 8,383 185,653 1189 Tablet 10 mg 30.00 MG 42,692 1,635,322 1190 Oral suspension 1 mg per ml, 200 ml 30.00 MG 3,526 192,796 17662 Tablet 20mg 30.00 MG 320 - A03FA03 DOMPERIDONE 1347 Tablet 10 mg 30.00 MG 171,863 1,657,100 11309 Tablet 10mg 100 30.00 MG 5,824 - A03FA01 METOCLOPRAMIDE HYDROCHLORIDE 1205 Syrup 5 mg per 5 ml, 100 ml 30.00 MG 29,858 231,738 1206 Injection 10 mg in 2 ml 30.00 MG 35,431 484,886 1207 Tablet 10 mg 30.00 MG 609,329 3,963,448 3476 Injection 10 mg in 2 ml 30.00 MG 35,510 394,748 5151 Tablet 10 mg 30.00 MG 200 1,241 11138 Tablet 10mg 100 30.00 MG 4,552 -

44 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS

ANTIEMETICS AND ANTINAUSEANTS SEROTONIN (5HT3) ANTAGONISTS A04AA04 DOLASETRON MESYLATE 5923 Tablet 200 mg 0.20 GM 2,685 150,165 5924 I.V. injection 100 mg in 5 ml 0.10 GM 2,343 57,340 8191 Tablet 200 mg 0.20 GM 16,081 1,413,720 8192 I.V. injection 100 mg in 5 ml 0.10 GM 16,080 641,600 A04AA01 ONDANSETRON 1594 Tablet 4 mg 16.00 MG 1,994 278,973 1595 Tablet 8 mg 16.00 MG 5,601 1,402,660 1596 I.V.injection 4mg/2mL 16.00 MG 239 17,728 1597 I.V.injection 8mg/4mL 16.00 MG 1,786 390,334 5967 Tablet 4 mg 16.00 MG 119 6,275 5968 Tablet 8 mg 16.00 MG 4,656 267,032 5969 Wafer 4mg 4 16.00 MG 124 5,919 5970 Wafer 8mg 4 16.00 MG 505 41,991 5971 I.V. injection 4 mg in 2 mL 16.00 MG 113 3,310 5972 I.V. injection 8 mg in 4 mL 16.00 MG 2,886 100,586 8224 Tablet 4 mg 16.00 MG 7,002 390,978 8225 Tablet 8 mg 16.00 MG 33,038 3,011,661 8226 I.V. injection 4 mg in 2 mL 16.00 MG 4,842 146,417 8227 I.V. injection 8 mg in 4 mL 16.00 MG 27,777 1,856,576 8410 Wafer 4mg 4 16.00 MG 2,847 156,138 8411 Wafer 8mg 4 16.00 MG 5,117 540,808 8412 Wafer 4mg 10 16.00 MG 1,420 202,451 8413 Wafer 8mg 10 16.00 MG 1,681 436,316 16286 I.V.injection 4mg/2mL 5 16.00 MG 585 - A04AA03 TROPISETRON 2745 Capsule 5 mg (base) 5.00 MG 21,998 2,100,990 2746 I.V. injection 5mg/5mL 5.00 MG 22,498 1,339,915 5986 Capsule 5 mg (base) 5.00 MG 4,822 276,172 5987 I.V. injection 5mg/5mL 5.00 MG 6,127 238,056

45 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM BILE AND LIVER THERAPY

BILE THERAPY BILE ACID PREPARATIONS A05AA02 URSODEOXYCHOLIC ACID 8448 Capsule 250 mg 100 0.75 GM 18,456 3,414,271

46 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM LAXATIVES

LAXATIVES SOFTENERS, EMOLLIENTS A06AA02 DOCUSATE SODIUM 4200 Tablet 50 mg 0.15 GM 8,805 92,128 16099 Tablet 120 mg 100 0.15 GM 15,055 - A06AA POLOXALKOL 10469 Drop 10% 30ml 1 - - 593 - CONTACT LAXATIVES A06AB02 BISACODYL 1258 Suppositories 10 mg, 12 10.00 MG 1,749 29,733 1259 Tablet 5 mg 10.00 MG 47,285 617,975 1260 Suppositories 10 mg, 10 10.00 MG 55,549 1,134,481 3250 Suppositories 10 mg, 10 10.00 MG 962 42,276 10633 Suppositories 5mg 6 10.00 MG 163 - 10635 Tablet 5mg 200 10.00 MG 329 - 12669 Tablet 5mg 50 10.00 MG 1,962 - A06AB52 DOCUSATE SODIUM with BISACODYL 1125 Suppositories 100 mg-10 mg, 5 10.00 MG 3,336 69,792 3253 Suppositories 100 mg-10 mg, 5 10.00 MG 214 8,496 A06AB56 DOCUSATE SODIUM with SENNA 4198 Tablet 50 mg-8 mg - - 237,697 2,814,094 12753 Tablet 30 - - 7,486 - A06AB04 PHENOLPHTHALEIN with LIQUID PARAFFIN 10107 Mixture 200ml 1 0.20 GM 1,143 - 10108 Mixture 500ml 1 0.20 GM 19,597 - 10119 Mixture 200ml 1 0.20 GM 201 - 10120 Mixture 500ml 1 0.20 GM 3,159 - A06AB20 PLANTAGO OVATA EXTRACT with SENNA FRUIT 10015 Granules 100g 1 - - 134 - 13096 Granules 250g 1 - - 823 - A06AB06 SENNA STANDARDISED 4455 Tablet 7.5 mg - - 24,628 256,932 11880 Granules 150g 1 - - 7,705 - BULK PRODUCERS A06AC51 ISPAGHULA COMBINATIONS 4415 Oral Powder 225 g - - 286 3,828 4416 Oral Powder 440 g - - 3,618 68,202 A06AC01 PSYLLIUM HYDROPHILIC MUCILLOID 4285 Sachets 3.5 g, 30 7.00 GM 8,569 124,270 4419 Oral powder (orange-flavour,sugar free) 315gm 7.00 GM 29,774 563,477 4422 Oral powder (non-flavoured) 375 g 7.00 GM 34,191 647,357 11156 Powder 500g 1 7.00 GM 2,436 - 11273 Powder 500g 1 7.00 GM 792 - A06AC53 STERCULIA with FRANGULA BARK 1102 Granules 473 mg-83 mg per g (47.3%-8.3%), 250 g - - 26,307 599,599 1104 Granules 620 mg-80 mg per g (62%-8), 500 g - - 91,877 2,120,395 3262 Granules 473 mg-83 mg per g (47.3%-8.3%), 250 g - - 162 5,042 3275 Granules 620 mg-80 mg per g (62%-8.%), 500 g - - 505 16,474 4557 Granules 473 mg-83 mg per g (47.3%-8.3%), 250 g - - 5,673 129,259 4558 Granules 620 mg-80 mg per g (62%-8), 500 g - - 15,321 352,827 13098 Granules 200g 1 - - 146 -

47 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM LAXATIVES

LAXATIVES OSMOTICALLY ACTING LAXATIVES A06AD11 LACTULOSE 3064 Mixture 3.34 g per 5 ml, 500 ml 6.70 GM 397,413 5,983,546 A06AD11 LACTULOSE with GALACTOSE with LACTOSE with EPILACTOSE 10693 Syrup 200 ml 1 6.70 GM 943 - A06AD15 MACROGAL 8612 Sachets powder 13.125 g with electrolytes, 30 10.00 GM 44,275 1,016,718 A06AD SORBITOL 14787 Liquid 70% 500 ml - - 11,469 - ENEMAS A06AG02 BISACODYL 1263 Enemas 10 mg in 5 ml, 25 - - 8,721 332,343 3263 Enemas 10 mg in 5 ml, 25 - - 4,330 241,110 A06AG20 COMBINATION (SORBITOL/SODIUM CITRATE/SODIUM LAVRYL SULFOACETATE) 2091 Enemas 3.125 g-450 mg-45 mg in 5ml 12 - - 47,275 1,407,620 3274 Enemas 3.125g-450mg-45mg in 5 ml, 12 - - 3,419 159,936 4462 Enemas 3.125g-450mg-45mg in 5 ml, 4 - - 2,588 25,870 8175 Enemas 3.150g-450 mg-45 mg in 5 ml ,12 - - 293 8,619 A06AG01 SODIUM PHOSPHATE 15629 Laxative Mixt 3.3G/5mL - - 3,758 - OTHER LAXATIVES A06AX01 GLYCEROL 2555 Suppositories 700 mg (for infants), 12 - - 563 7,308 2556 Suppositories 1.4 g (for children), 12 - - 677 9,116 2557 Suppositories 2.8 g (for adults), 12 - - 10,420 146,874 3267 Suppositories 2.8 g (for adults), 12 - - 276 6,774 4246 Suppositories 2.8 g (for adults), 12 - - 933 13,223 13916 Suppositories adult size 2.7 g, 12 - - 140 -

48 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM ANTIDIARR.,INTEST. ANTIINFL./ANTIINFECT. AGENTS

INTESTINAL ANTIINFECTIVES ANTIBIOTICS A07AA01 NEOMYCIN SULPHATE 2325 Tablet 500 mg 5.00 GM 1,169 27,740 A07AA02 NYSTATIN 1696 Tablet 500,000 units 1500.00 TE 26,611 486,436 1699 Capsule 500,000 units 1500.00 TE 34,307 681,357 3345 Capsule 500,000 units 1500.00 TE 117 1,876 A07AA09 VANCOMYCIN 3113 Capsule 125 mg (125,000 i.u.) vancomycin activity 2.00 GM 160 38,379 3114 Capsule 250 mg (250,000 i.u.) vancomycin activity 2.00 GM 910 474,208 INTESTINAL ADSORBENTS CHARCOAL PREPARATIONS A07BA01 CHARCOAL 15944 Tablet 300 mg 500 5.00 GM 266 - OTHER INTESTINAL ADSORBENTS A07BC02 KAOLIN with ALUMINIUM HYDROXIDE 12714 Mixture 200m 1 - - 1,208 - ELECTROLYTES WITH CARBOHYDRATES ORAL REHYDRATION SALT FORMULATIONS A07CA ELECTROLYTE REPLACEMENT (ORAL) 3196 Sachets containing powder for oral sol. 4.87g,10 - - 23,227 335,740 ANTIPROPULSIVES ANTIPROPULSIVES A07DA01 DIPHENOXYLATE HYDROCHLORIDE with ATROPINE SULPHATE 2501 Tablet 2.5 mg-25 ug 15.00 MG 296,767 2,157,091 11123 Tablet 2.5 mg-25 ug 15.00 MG 1,625 - 16260 Tablet 2.5 mg-25 ug 15.00 MG 15,332 - A07DA03 LOPERAMIDE HYDROCHLORIDE 1571 Capsule 2 mg 10.00 MG 289,071 2,982,889 16133 Tablet 2 mg 8 10.00 MG 1,328 - INTESTINAL ANTIINFLAMMATORY AGENTS CORTICOSTEROIDS FOR LOCAL USE A07EA02 HYDROCORTISONE ACETATE 1502 Rectal foam 125 mg per applicator (10%), aerosol - - 16,729 609,478 A07EA01 PREDNISOLONE SODIUM PHOSPHATE 1920 Retention enema equivalent to 20 mg prednisolone - - 9,061 824,127 2554 Suppositories equivalent to 5 mg prednisolone, 10 - - 11,980 323,188

49 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM ANTIDIARR.,INTEST. ANTIINFL./ANTIINFECT. AGENTS

INTESTINAL ANTIINFLAMMATORY AGENTS AMINOSALICYLIC ACID AND SIMILAR AGENTS A07EC02 MESALAZINE 1611 Tablet 250 mg 1.50 GM 103,981 13,658,747 8598 Oral granules 500mg per sachet, 100 1.50 GM 2,936 449,944 8599 Oral granules 1 mg per sachet, 100 1.50 GM 14,458 3,755,138 8616 Enemas 2 g in 60 mL, 7 1.50 GM 2,159 738,610 8617 Enemas 4 g in 60 mL, 7 1.50 GM 4,881 2,245,903 A07EC03 OLSALAZINE SODIUM 1728 Capsule 250 mg 1.00 GM 12,590 1,011,126 8086 Capsule 500 mg 1.00 GM 21,304 2,560,582 A07EC01 SULPHASALAZINE 2093 Tablet 500 mg 2.00 GM 24,106 1,129,564 2096 Tablet 500 mg (enteric coated) 2.00 GM 187,246 9,690,561 11849 Suppositories 10 2.00 GM 499 -

50 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL DIET PRODUCTS

ANTIOBESITY PREPARATIONS, EXCL DIET PRODUCTS CENTRALLY ACTING ANTIOBESITY PRODUCTS A08AA03 DIETHYLPROPION 12053 Tablet 25 mg 50 75.00 MG 2,567 - 12054 Tablet 75 mg 30 75.00 MG 37,336 - 12055 Tablet 75 mg 100 75.00 MG 2,439 - A08AA01 PHENTERMINE 10636 Capsule 15mg 30 15.00 MG 11,323 - 10637 Capsule 30mg 30 15.00 MG 52,666 - 10638 Capsule 40mg 30 15.00 MG 71,005 - A08AA10 SIBUTRAMINE 17447 Capsule 10mg 30 10.00 MG 85,110 - 17448 Capsule 15mg 30 10.00 MG 73,966 - PERIPHERALLY ACTING ANTIOBESITY PRODUCTS A08AB01 ORLISTAT 16722 Capsule 120mg 84 0.36 GM 127,014 -

51 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM DIGESTIVES, INCL ENZYMES

DIGESTIVES, INCL ENZYMES ENZYME PREPARATIONS A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) 2495 Capsule providing not less than 10,000 BP units of - - 7,323 1,319,256 2496 Capsule providing not less than 5,000 BP units of - - 19,755 2,437,484 8020 Capsule (containing enteric coated microspheres) - - 7,440 1,283,964 8021 Capsule (containing enteric coated microspheres) - - 14,521 2,504,757 8366 Capsule providing not less than 25,000 BP units of - - 770 108,999 8556 Capsule (containing enteric coated microspheres) - - 2,681 321,652

52 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM ANTIDIABETIC THERAPY

INSULINS AND ANALOGUES INSULINS AND ANALOGUES, FAST-ACTING A10AB02 INSULIN (BEEF) 1713 Injection 100 units per ml, 10 ml 40.00 IE 1,045 141,169 A10AB01 INSULIN (HUMAN) 1531 Injection 100 units per ml, 10 ml 40.00 IE 33,275 4,378,726 1762 Injection 100 units per ml, 3 ml,5 40.00 IE 42,407 9,586,469 A10AB05 INSULIN ASPART 8435 Injection (human) 100 units per mL, 3mL, 5 40.00 IE 31,971 8,562,704 8571 Injection (human) 100 units per mL,10mL, 5 40.00 IE 3,099 491,649 18110 Injection (human) 100 units per mL, 3mL, 5 40.00 IE 183 - A10AB04 INSULIN LISPRO 8084 Injection 100 units per ml, 10ml 40.00 IE 12,527 2,024,778 8085 Injection 100 units per ml, 1.5 ml,5 40.00 IE 1,139 303,991 8212 Injection 100 units per ml, 3 ml,5 40.00 IE 31,561 8,508,477 INSULINS AND ANALOGUES, INTERMEDIATE-ACTING A10AC02 INSULIN (BEEF) 1711 Injection 100 units per ml, 10 ml 40.00 IE 1,773 239,799 A10AC01 INSULIN (HUMAN) 1533 Injection 100 units per ml, 10 ml 40.00 IE 52,344 7,069,500 1718 Injection 100 units per ml, 10 ml 40.00 IE 15,073 2,042,217 1761 Injection 100 units per ml, 3ml,5 40.00 IE 97,611 22,176,151 INSULINS AND ANALOGUES, INTERMEDIATE ACTING COMBINED WITH FAST-ACTING A10AD01 INSULIN (HUMAN) 1425 Injection 100 units (50 units-50 units) 40.00 IE 2,748 371,566 1426 Injection 100 units (30 units-70 units) 40.00 IE 32,697 4,402,028 1763 Injection 100 units (30 units-70 units) 40.00 IE 123,163 27,983,001 2062 Injection 100u/ml (50 units-50 units) 40.00 IE 9,163 2,072,980 8006 Injection 100u/ml (20 units-80 units) 40.00 IE 9,858 2,241,421 18112 Injection 100u/ml (20 units-80 units) 40.00 IE 230 - 18113 Injection 100 units (30 units-70 units) 40.00 IE 210 - A10AD30 INSULIN ASPART/PROTAMINE ASPART 8609 Injection (human) 30/70 units per mL 40.00 IE 23,300 6,235,315 A10AD04 INSULIN LISPRO 8390 Inj (human analogue) 100 units(25/75)per mL, 3mL 5 40.00 IE 16,904 4,568,457 INSULINS AND ANALOGUES, LONG-ACTING A10AE01 INSULIN (HUMAN) 1722 Injection 100 units per ml, 10 ml 40.00 IE 9,437 1,283,844 ORAL BLOOD GLUCOSE LOWERING DRUGS BIGUANIDES A10BA02 METFORMIN HYDROCHLORIDE 1801 Tablet 850 mg 2.00 GM 491,745 7,631,478 2430 Tablet 500 mg 2.00 GM 2,241,675 34,188,942 8607 Tablet 100 mg 2.00 GM 297,384 5,351,848

53 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM ANTIDIABETIC THERAPY

ORAL BLOOD GLUCOSE LOWERING DRUGS SULFONAMIDES, UREA DERIVATIVES A10BB01 GLIBENCLAMIDE 2939 Tablet 5 mg 10.00 MG 300,703 3,004,281 A10BB09 GLICLAZIDE 2449 Tablet 80 mg 0.16 GM 875,596 13,511,176 8535 Tablet 30 mg (modified release) 0.16 GM 313,511 4,896,095 A10BB12 GLIMEPIRIDE 8450 Tablet 1 mg 30 2.00 MG 138,086 1,195,648 8451 Tablet 2 mg 30 2.00 MG 163,260 2,017,027 8452 Tablet 4 mg 30 2.00 MG 267,627 4,606,718 8533 Tablet 3 mg 30 2.00 MG 37,530 548,236 A10BB07 GLIPIZIDE 2440 Tablet 5 mg, 100 10.00 MG 141,655 1,614,865 A10BB03 TOLBUTAMIDE 17566 Tablet 1 g 1.50 GM 116 - ALPHA GLUCOSIDASE INHIBITORS A10BF01 ACARBOSE 8188 Tablet 50 mg 0.30 GM 41,887 1,248,022 8189 Tablet 100 mg 0.30 GM 35,114 1,487,895 THIAZOLIDINEDIONES A10BG03 PIOGLITAZONE HYDROCHLORIDE 8691 Tablet 15 mg (base) 28 30.00 MG 2,048 134,759 8692 Tablet 30 mg (base) 28 30.00 MG 2,748 270,749 8693 Tablet 45 mg (base) 28 30.00 MG 422 51,931 8694 Tablet 15 mg (base) 28 30.00 MG 252 16,711 8695 Tablet 30 mg (base) 28 30.00 MG 297 29,401 17191 Tablet 15 mg 28 30.00 MG 644 - 17192 Tablet 30 mg 28 30.00 MG 561 - A10BG02 ROSIGLITAZONE 8687 Tablet 4 mg (base) 28 6.00 MG 5,276 326,446 8688 Tablet 8 mg (base) 28 6.00 MG 2,370 218,676 8689 Tablet 4 mg (base) 28 6.00 MG 614 38,704 8690 Tablet 8 mg (base) 28 6.00 MG 322 30,098 16906 Tablet 4 mg 28 6.00 MG 2,803 - 16907 Tablet 8 mg 28 6.00 MG 731 - OTHER OTHER BLOOD GLUCOSE LOWERING DRUGS A10BX02 REPAGLINIDE 16645 Tablet 0.5mg 90 6.00 MG 467 - 16646 Tablet 1mg 90 6.00 MG 2,198 - 16647 Tablet 2mg 90 6.00 MG 1,224 -

54 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM VITAMINS

MULTIVITAMINS, COMBINATIONS MULTIVITAMINS WITH MINERALS A11AA03 VITAMINS 11956 Dispersable tablet 20 - - 171 - 16530 Tablet 60 - - 388 - A11AA01 VITAMINS with IRON 11030 Syrup 100m 1 - - 129 - 11031 Syrup 200m 1 - - 212 - MULTIVITAMINS, PLAIN MULTIVITAMINS, PLAIN A11BA VITAMIN A with B with C 12853 Ampoule 2ml 10 - - 2,256 - VIT A AND D, INCL COMBINATIONS OF THE TWO VITAMIN A, PLAIN A11CA01 VITAMIN A 12182 Capsule 50 000 units 100 50.00 TE 950 - VITAMIN D AND ANALOGUES A11CC04 CALCITRIOL 2502 Capsule 0.25 ug 1.00 UG 235,646 14,454,374 A11CC01 ERGOCALCIFEROL 16060 Capsule 25ug 60 - - 67,122 - VIT B1,PLAIN AND IN COMB WITH VITAMIN B6 AND B12 THIAMINE (VIT B1), PLAIN A11DA01 THIAMINE HYDROCHLORIDE 1065 Injection 100 mg in 1 ml 50.00 MG 9,929 126,302 4043 Tablet 100 mg 50.00 MG 57,638 508,070 VITAMIN B-COMPLEX, INCL COMBINATIONS VITAMIN B-COMPLEX, PLAIN A11EA VITAMIN B GROUP COMPLEX 4493 Oral liquid 200 ml - - 24,536 277,367 VITAMIN B-COMPLEX WITH VITAMIN C A11EB VITAMIN B with C 14139 Tablet 90 - - 1,874 - 14140 Tablet 100 - - 253 - ASCORBIC ACID (VIT C), INCL COMBINATIONS ASCORBIC ACID (VIT C), PLAIN A11GA01 ASCORBIC ACID 4565 Tablet 250 mg (sugar free) 100 200.00 MG 329 2,439 11775 Dispersable tablet orange 20 200.00 MG 193 - OTHER PLAIN VITAMIN PREPARATIONS OTHER PLAIN VITAMIN PREPARATIONS A11HA02 PYRIDOXINE HYDROCHLORIDE 1965 Tablet 25 mg 160.00 MG 14,178 137,918 11646 Ampoule 50mg/ml 5 160.00 MG 345 - 11648 Tablet 25mg 100 160.00 MG 1,107 - 11649 Tablet 100mg 50 160.00 MG 1,804 - 15255 Injection 50 mg in 1 ml 160.00 MG 324 -

55 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM VITAMINS

OTHER VITAMIN PRODUCTS, COMBINATIONS VITAMINS WITH MINERALS A11JB VITAMINS with MINERALS 10099 Capsule 30 - - 635 - 12946 Capsule 100 - - 1,505 - 12947 Capsule 100 - - 976 - 12948 Capsule 100 - - 177 -

56 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM MINERAL SUPPLEMENTS

CALCIUM CALCIUM A12AA20 CALCIUM (DIFFERENT SALTS IN COMBINATION) 15690 Compound effervescent tablet equivalent to 1 g 0.50 GM 1,355 - A12AA04 CALCIUM CARBONATE 3116 Tablet (chewable) 500 mg (as carbonate) 3.00 GM 24,616 328,754 3117 Tablet 600 mg (as carbonate) 3.00 GM 750,064 9,363,867 A12AA CALCIUM CITRATE 8560 Tablet 250mg (as citrate) - - 63,543 789,143 CALCIUM, COMBINATIONS WITH OTHER DRUGS A12AX CALCIUM CARBONATE with CHOLECALCIFEROL 10600 Tablet 600mg 60 3.00 4,786 - POTASSIUM POTASSIUM A12BA01 POTASSIUM CHLORIDE 2642 Tablet 600 mg (sustained release) 3.00 GM 366,469 3,820,307 3012 Effervescent tabs 14 mmol K, 8 mmol CL IONS 3.00 GM 32,189 358,319 17928 Tablet 600 mg (sustained release) 3.00 GM 889 - OTHER MINERAL SUPPLEMENTS ZINC A12CB01 ZINC SULPHATE 12264 Capsule 50mg 100 0.60 GM 1,646 - MAGNESIUM A12CC05 MAGNESIUM ASPARTATE 4321 Tablet 500 mg - - 11,268 146,591 11226 Tablet 100 - - 3,044 - SELENIUM A12CE01 SELENIUM 12016 Tablet 50ug 100 0.20 MG 561 - 16226 Drop 50 mL 0.8mg/mL 0.20 MG 1,468 - 16524 Tablet 60 0.20 MG 128 -

57 A

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ALIMENTARY TRACT AND METABOLISM ANABOLIC AGENTS FOR SYSTEMIC USE

ANABOLIC STEROIDS ANDROSTAN DERIVATIVES A14AA08 OXANDROLONE 2545 Tablet 2.5 mg - - 574 442,721 ESTREN DERIVATIVES A14AB01 NANDROLONE DECANOATE 1671 Injection 50 mg in 1 ml, disposable syringe 2.00 MG 42,959 831,765 10649 Ampoule 50mg/ml 3 2.00 MG 1,614 -

58 B

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS

ANTITHROMBOTIC AGENTS VITAMIN K ANTAGONISTS B01AA02 PHENINDIONE 14975 Tablet 10 mg 0.10 GM 361 - B01AA03 WARFARIN 2209 Tablet 2 mg 7.50 MG 714,889 5,463,599 2211 Tablet 5 mg 7.50 MG 453,438 3,796,109 2843 Tablet 1 mg 7.50 MG 795,853 5,948,543 2844 Tablet 3 mg 7.50 MG 240,066 1,892,393 HEPARIN GROUP B01AB04 DALTEPARIN 2816 Inj 5,000 units (anti-Xa) in 0.2mL syringe 2.50 TE 9,558 749,932 8269 Inj 10,000 units (anti-Xa) in 1 mL syringe 2.50 TE 1,241 239,236 8271 Inj 7,500 units (anti-Xa) in 0.75 mL syringe 2.50 TE 1,464 202,813 8603 Inj 2,500 units (anti-Xa) in 0.2 mL syringe 2.50 TE 6,361 385,972 8641 Inj 2,500 units (anti-Xa) in 0.2 mL syringe 2.50 TE 303 25,020 8642 Inj 5,000 units (anti-Xa) in 0.2 mL syringe 2.50 TE 724 83,037 8643 Inj 7,500 units (anti-Xa) in 0.75 mL syringe 2.50 TE 118 25,484 B01AB05 ENOXAPARIN 8262 Inj 60mg (6000u anti-Xa) in 0.6mL syringe 2.00 TE 19,061 2,221,418 8263 Inj 80mg (8000u anti-Xa) in 0.8mL syringe 2.00 TE 22,986 3,076,400 8264 Inj 100mg (10000u anti-Xa) in 1 mL syringe 2.00 TE 16,831 2,792,221 8510 Inj 40mg (4000u anti-Xa) in 0.4 mL syringe 2.00 TE 50,811 3,627,344 8558 Inj 20mg (2000u anti-Xa) in 0.2mL syringe 2.00 TE 21,910 1,391,393 8639 Inj 40mg (4000u anti-Xa) in 0.4mL syringe 2.00 TE 3,793 438,315 8640 Inj 60mg (6000u anti-Xa) in 0.6mL syringe 2.00 TE 2,396 430,617 B01AB01 HEPARIN CALCIUM 1234 Injection 5,000 units in 0.2 mL 10.00 TE 33,938 383,151 B01AB01 HEPARIN SODIUM 1076 Injection 35,000 units in 35 ml, 12 10.00 TE 1,840 155,814 1463 Injection 5,000 units in 5 ml 10.00 TE 2,568 131,562 1466 Injection 5,000 units in 0.2 ml 10.00 TE 18,146 219,393 1467 Injection 5,000 units in 1 ml 10.00 TE 1,691 20,742 B01AB01 HEPARINISED SALINE 13825 Ampoule 50u/5ml 50 10.00 TE 198 -

59 B

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS

ANTITHROMBOTIC AGENTS PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN B01AC13 ABCIXIMAB 8048 I.V.injection 10 mg in 5 ml 25.00 MG 3,730 6,089,656 B01AC06 ASPIRIN 4076 Tablet 100mg (enteric coated) 0.10 GM 39,179 472,107 4077 Tablet 100mg (enteric coated) 0.10 GM 77,837 859,598 4078 Capsule 100mg (enteric coated pellets) 0.10 GM 22,843 256,109 8202 Tablet 100mg 0.10 GM 1,001,588 6,107,362 10544 Tablet 100mg 30 0.10 GM 11,414 - 10599 Tablet 100mg 28 0.10 GM 8,922 - 13020 Capsule 100mg 28 0.10 GM 1,638 - B01AC04 CLOPIDOGREL 4179 Tablet 75mg (base) 28 75.00 MG 92,147 7,742,968 8358 Tablet 75mg 75.00 MG 1,341,527 112,708,029 B01AC07 DIPYRIDAMOLE 8335 Capsule 200 mg (sustained release) 0.40 GM 93,992 3,160,959 11571 Tablet 25mg 100 0.40 GM 684 - 13040 Tablet 100mg 100 0.40 GM 1,503 - B01AC30 DIPYRIDAMOLE with ASPRIN 8382 Capsule 200 mg (sustained release) 25 mg 0.40 MG 390,579 13,101,902 B01AC05 TICLOPIDINE HYDROCHLORIDE 2095 Tablet 250mg 0.50 GM 6,780 1,036,755 B01AC17 TIROFIBAN 8350 Solution concentrate I.V. infusion 12.5mg in 50mL 10.00 MG 2,131 910,337 ENZYMES B01AD07 RETEPLASE 8253 Pack 2 vials powder 10 units, 2 single use prefill 20.00 IE 224 502,615 B01AD11 TENECTEPLASE 8527 Powder for injection 50mg with solvent 40.00 MG 256 568,625

60 B

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

BLOOD AND BLOOD FORMING ORGANS ANTIHAEMORRHAGICS

ANTIFIBRINOLYTICS AMINO ACIDS B02AA02 TRANEXAMIC ACID 2180 Tablet 500 mg 2.00 GM 23,253 1,177,033 VITAMIN K AND OTHER HAEMOSTATICS VITAMIN K B02BA02 MENAPHTHONE 11082 Tablet 10mg 100 10.00 MG 676 - B02BA01 PHYTOMENADIONE 11080 Tablet 10mg 100 20.00 MG 599 - 13637 Ampoule 10mg/ml 10 20.00 MG 116 - 16049 Ampoule 10mg/mL 5 20.00 MG 243 - 16648 Ampoule 2mg/0.2mL 5 20.00 MG 149 -

61 B

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

BLOOD AND BLOOD FORMING ORGANS ANTIANAEMIC PREPARATIONS

IRON PREPARATIONS IRON BIVALENT, ORAL PREPARATIONS B03AA03 FERROUS GLUCONATE 2726 Paediatric elixir 300 mg per 5 ml (6%), 100 ml 0.20 GM 35,148 358,815 B03AA07 FERROUS SULPHATE DRIED 16996 Tablet 0.20 GM 105,720 - IRON TRIVALENT, PARENTERAL PREPARATIONS B03AC03 IRON POLYMALTOSE COMPLEX 2593 Injection 100 mg (iron) in 2 ml 0.10 GM 32,763 1,792,224 IRON IN COMBINATION WITH FOLIC ACID B03AD03 FERROUS SULPHATE DRIED with FOLIC ACID 3160 Tablet 270 mg-300 ug (sustained release) - - 334,562 2,365,048 14528 Capsule 270 mg-300 ug (delayed release) - - 16,203 - VITAMIN B12 AND FOLIC ACID VITAMIN B12 (CYANOCOBALAMIN AND DERIVATIVES) B03BA01 CYANOCOBALAMIN 12782 Ampoule 1000ug/ 5 20.00 UG 2,735 - B03BA03 HYDROXOCOBALAMIN 1508 Injection 1 mg in 1 ml 20.00 UG 339,438 3,832,981 FOLIC ACID AND DERIVATIVES B03BB01 FOLIC ACID 1437 Tablet 5 mg - - 104,998 777,526 2958 Tablet 500 ug - - 37,515 279,918 18012 Tablet 5 mg 10.00 MG 2,059 - OTHER ANTIANAEMIC PREPARATIONS OTHER ANTIANAEMIC PREPARATIONS B03XA02 DARBEPOETIN ALPHA 6320 Injection 10ug in 0.4mL syringe 4.50 UG 215 46,607 6321 Injection 20ug in 0.5mL syringe 4.50 UG 1,568 641,805 6322 Injection 30ug in 0.3mL syringe 4.50 UG 1,266 746,207 6323 Injection 40ug in 0.4mL syringe 4.50 UG 3,788 2,871,293 6324 Injection 50ug in 0.5mL syringe 4.50 UG 589 532,140 6325 Injection 60ug in 0.3mL syringe 4.50 UG 1,267 1,391,386 6326 Injection 100ug in 0.5mL syringe 4.50 UG 657 1,388,076 B03XA01 ERYTHROPOIETIN 6204 Injection 2,000 units in 0.5 mL syringe 1.00 TE 173 103,818 6205 Injection 3,000 units in 0.3 mL syringe 1.00 TE 173 96,078 6206 Injection 4,000 units in 0.4 mL syringe 1.00 TE 1,905 1,551,386 6207 Injection 10,000 units in 1 mL syringe 1.00 TE 1,032 1,811,511 6302 Injection 5,000 units in 0.5 mL syringe 1.00 TE 134 135,087 6303 Injection 6,000 units in 0.6 mL syringe 1.00 TE 561 582,682 6305 Injection 8,000 units in 0.8 mL syringe 1.00 TE 546 713,762 6339 Injection 40,000 units in 1 mL syringe 1.00 TE 189 513,586

62 B

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

BLOOD AND RELATED PRODUCTS BLOOD SUBSTITUTES AND PLASMA PROTEIN FRACTIONS B05AA06 GELATIN SUCCINYLATED 8444 I.V. infusion 20 g per 500 ml, 500 mL - - 7,099 277,104 B05AA06 POLYGELINE 2334 I.V. infusion 17.5 g per 500 ml (3.5%) with - - 1,989 75,397 I.V. SOLUTIONS SOLUTIONS FOR PARENTERAL NUTRITION B05BA03 GLUCOSE 2245 I.V. infusion 278 mmol per l (5%), 1 l - - 1,965 41,568 SOLUTIONS AFFECTING THE ELECTROLYTE BALANCE B05BB01 ELECTROLYTE REPLACEMENT SOLUTION 3199 I.V. infusion 1 l - - 150 2,906 B05BB01 SODIUM CHLORIDE 2260 I.V. infusion 513 mmol per l (3%), 1 l - - 400 37,487 2264 I.V. infusion 154 mmol per l (0.9%), 1 l - - 26,829 870,365 11906 Vial 0.9%500m 1 - - 1,020 - B05BB02 SODIUM CHLORIDE with GLUCOSE 2281 I.V. infusion 31 mmol-222 mmol per l (0.18%-4%), - - 5,140 109,818 B05BB01 SODIUM LACTATE COMPOUND 2286 I.V. infusion 1 l - - 11,495 235,446 IRRIGATING SOLUTIONS SALT SOLUTIONS B05CB01 SODIUM CHLORIDE 4460 Irrigation solution 9 mg per ml (0.9%), 500 ml - - 1,306 11,038 4461 Irrigation solution 9 mg per ml (0.9%), 1 L - - 636 5,603

63 B

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

BLOOD AND BLOOD FORMING ORGANS OTHER HAEMATOLOGICAL AGENTS

OTHER HAEMATOLOGICAL AGENTS ENZYMES B06AA03 HYALURONIDASE 10985 Ampoule 1500u 5 - - 390 -

64 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM CARDIAC THERAPY

CARDIAC GLYCOSIDES DIGITALIS GLYCOSIDES C01AA05 DIGOXIN 1322 Tablet 250 ug 0.25 MG 247,685 2,149,819 2605 Tablet 62.5 ug 0.25 MG 313,308 2,626,454 3164 Oral solution for children 50 ug per ml, 0.25 MG 1,101 28,530 ANTIARRHYTHMICS, CLASS I AND III ANTIARRHYTHMICS, CLASS IA C01BA03 DISOPYRAMIDE 2923 Capsule 100 mg 0.40 GM 9,118 232,894 2924 Capsule 150 mg 0.40 GM 5,373 184,403 C01BA02 PROCAINAMIDE HYDROCHLORIDE 2653 Capsule 250 mg 3.00 GM 152 9,190 C01BA01 QUINIDINE 2623 Tablet 250 mg (sustained release) 1.20 GM 15,000 487,300 ANTIARRHYTHMICS, CLASS IB C01BB01 LIGNOCAINE HYDROCHLORIDE 2875 Injection 100 mg in 5 ml 3.00 GM 739 12,885 2876 Infusion 500 mg in 5 ml 3.00 GM 1,913 79,566 3474 Injection 100 mg in 5 ml 3.00 GM 9,028 207,259 C01BB02 MEXILETINE HYDROCHLORIDE 1682 Capsule 50 mg 0.80 GM 5,911 176,324 1683 Capsule 200 mg 0.80 GM 4,217 238,989 ANTIARRHYTHMICS, CLASS IC C01BC04 FLECAINIDE ACETATE 1088 Tablet 50 mg 60 0.20 GM 39,685 1,542,543 1090 Tablet 100 mg 0.20 GM 75,392 3,602,728 ANTIARRHYTHMICS, CLASS III C01BD01 AMIODARONE HYDROCHLORIDE 2343 Tablet 200 mg 0.20 GM 328,299 8,261,957 2344 Tablet 100 mg 0.20 GM 107,296 1,731,018 CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES ADRENERGIC AGENTS C01CA24 ADRENALINE 1016 Injection 1 mg in 1 ml (1 in 1,000) 0.50 MG 3,342 36,788 3451 Injection 1 mg in 1 ml (1 in 1,000) 0.50 MG 22,859 213,233 8697 I.M. injection 150mg in 0.3mL syringe 0.50 MG 2,182 335,147 8698 I.M. injection 300mg in 0.3mL syringe 0.50 MG 2,533 296,114 13436 Syrng 1/1000 1 0.50 MG 466 - 13437 Syrng 1/10000 1 0.50 MG 322 - 14814 Injection 2 ml 0.15 mg/2ml 0.50 MG 2,555 - 14815 Injection 2 ml 0.3 mg/2ml 0.50 MG 4,812 -

65 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM CARDIAC THERAPY

VASODILATORS USED IN CARDIC DISEASES ORGANIC NITRATES C01DA02 GLYCERYL TRINITRATE 1459 Tablets 600 ug, 100 2.50 MG 113,288 866,941 1515 Td pad releasing approximately 5 mg per hour 5.00 MG 289,289 7,801,985 1516 Td pad releasing approximately 10 mg per hour 5.00 MG 202,092 6,872,881 3475 Buccal/sublingual spray (pump pack) 400 ug per dos 2.50 MG 21,923 390,274 8010 Td patch releasing approximately 5 mg per 5.00 MG 78,675 2,120,918 8011 Td patch releasing approximately 10 mg per hour 5.00 MG 57,515 1,953,248 8026 Td patch releasing approx 15 mg/24 hrs 5.00 MG 19,313 657,904 8027 Td patch releasing approx 5 mg/24 hrs 5.00 MG 16,146 436,183 8028 Td patch releasing approx 10 mg/24 hrs 5.00 MG 11,543 392,869 8119 Td patch releasing approx 15 mg/24 hrs 5.00 MG 5,708 195,711 8171 Buccal/sublingual spray (pump pack) 400 ug per dos 2.50 MG 298,870 5,312,237 C01DA08 ISOSORBIDE DINITRATE 2586 Tablet 20 mg 100 60.00 MG 6,059 73,472 2587 Tablet 10 mg 60.00 MG 30,584 358,505 2588 Sublingual tablet 5 mg 20.00 MG 16,783 213,314 C01DA14 ISOSORBIDE MONONITRATE 1558 Tablets sustained release 60mg, 30 40.00 MG 951,185 12,613,781 8273 Tablets sustained release 120mg, 30 40.00 MG 325,999 8,135,673 OTHER VASODILATORS USED IN CARDIAC DISEASES C01DX16 NICORANDIL 8228 Tablet 10 mg 40.00 MG 106,683 2,234,983 8229 Tablet 20 mg 40.00 MG 48,797 1,357,629

66 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES

ANTIADRENERGIC AGENTS, CENTRALLY ACTING METHYLDOPA C02AB01 METHYLDOPA 1629 Tablet 250 mg 1.00 GM 166,134 1,736,788 IMIDAZOLINE RECEPTOR AGONISTS C02AC01 CLONIDINE 3141 Tablet 150 ug 0.45 MG 37,224 1,271,109 3145 Tablet 100 ug 0.45 MG 97,310 2,521,141 12786 Ampoule 150ug/ml 5 0.45 MG 713 - ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING ALPHA - ADRENOCEPTOR BLOCKING AGENTS C02CA01 PRAZOSIN HYDROCHLORIDE 1478 Tablet 5 mg (base) 5.00 MG 149,028 3,555,807 1479 Tablet 1 mg (base) 5.00 MG 234,386 2,997,604 1480 Tablet 2 mg (base) 5.00 MG 159,085 2,525,483 ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON HYDRAZINOPHTHALAZINE DERIVATIVES C02DB02 HYDRALAZINE HYDROCHLORIDE 1639 Tablet 50 mg 0.10 GM 16,593 218,921 1640 Tablet 25 mg 0.10 GM 19,088 202,330 PYRIMIDINE DERIVATIVES C02DC01 MINOXIDIL 2313 Tablet 10 mg 20.00 MG 4,179 231,016 NITROFERRICYANIDE DERIVATIVES C02DD01 SODIUM NITROPRUSSIDE 1100 I.V. infusion 50 mg 0.05 GM 274 6,359

67 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM DIURETICS

LOW-CEILING DIURETICS, THIAZIDES THIAZIDES, PLAIN C03AA01 BENDROFLUAZIDE 1106 Tablet 5 mg 2.50 MG 118,636 1,054,547 C03AA03 HYDROCHLOROTHIAZIDE 1484 Tablet 25 mg 25.00 MG 16,976 325,073 17666 Tablet 25 mg 25.00 MG 3,334 - 17667 Tablet 50 mg 25.00 MG 1,160 - LOW-CEILING DIURETICS, EXCL THIAZIDES SULFONAMIDES, PLAIN C03BA04 CHLORTHALIDONE 1585 Tablet 25 mg 25.00 MG 41,485 448,521 C03BA11 INDAPAMIDE 2436 Tablet 2.5 mg, 90 2.50 MG 419,477 8,065,936 8532 Tablet 1.5 mg (sustained release) 2.50 MG 309,224 6,070,056 16435 Tablet 1.5 mg, 30 2.50 MG 875 - HIGH-CEILING DIURETICS SULFONAMIDES, PLAIN C03CA02 BUMETANIDE 1130 Tablet 1 mg 1.00 MG 13,948 147,561 17855 Tablet 1 mg 1.00 MG 13,382 - C03CA01 FRUSEMIDE 2411 Oral solution 10 mg per ml, 30 ml 40.00 MG 2,819 46,091 2412 Tablet 40 mg 40.00 MG 1,260,425 9,794,336 2413 Injection 20 mg in 2 ml 40.00 MG 6,465 80,959 2414 Tablet 20 mg 40.00 MG 170,872 1,373,585 2415 Tablet 500 mg 40.00 MG 19,232 399,518 3466 Injection 20 mg in 2 ml 40.00 MG 10,782 115,998 ARYLOXYACETIC ACID DERIVATIVES C03CC01 ETHACRYNIC ACID 2511 Tablet 50 mg 50.00 MG 3,524 204,278 POTASSIUM-SPARING AGENTS ALDOSTERONE ANTAGONISTS C03DA01 SPIRONOLACTONE 2339 Tablet 25 mg 75.00 MG 249,289 3,139,974 2340 Tablet 100 mg 75.00 MG 60,819 2,193,695 OTHER POTASSIUM-SPARING AGENTS C03DB01 AMILORIDE HYDROCHLORIDE 3109 Tablet 5 mg 10.00 MG 41,718 344,579

68 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM DIURETICS

DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB LOW-CEILING DIURETICS AND POTASSIUM-SPARING AGENTS C03EA01 HYDROCHLOROTHIAZIDE with AMILORIDE HYDROCHLORIDE 1486 Tablet 50 mg-5 mg 25.00 MG 236,631 2,598,692 C03EA01 HYDROCHLOROTHIAZIDE with TRIAMTERENE 1280 Tablet 25 mg-50 mg, 100 25.00 MG 82,207 907,322

69 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM PERIPHERAL VASODILATORS

PERIPHERAL VASODILATORS IMIDAZOLINE DERIVATIVES C04AB01 PHENTOLAMINE MESYLATE 11776 Ampoule 10mg/ml 5 10.00 MG 143 - PURINE DERIVATIVES C04AD03 OXPENTIFYLLINE 12650 Tablet 400mg 90 1.00 GM 342 - 17632 Tablet 400mg 50 1.00 GM 2,595 - OTHER PERIPHERAL VASODILATORS C04AX02 PHENOXYBENZAMINE HYDROCHLORIDE 1862 Capsule 10 mg 30.00 MG 3,275 177,506

70 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM VASOPROTECTIVES

ANTIHAEMORRHOIDALS FOR TOPICAL USE PRODUCTS CONTAINING CORTICOSTEROIDS C05AA08 FLUOCORTOLONE PIVALATE, FLUOCORTOLONE HEXANOATE, CLEMIZOLE UNDECYLENAT 14650 Ointment 920 ug -950 ug -10 mg-5 mg - - 2,518 - 14651 Ointment 920 ug -950 ug -10 mg-5 mg - - 1,972 - 14652 Suppositories 610 ug -630 ug-5 mg- - - 625 - C05AA01 HYDROCORTISONE with CINCHOCAINE HYDROCHLORIDE 4036 Ointment 5 mg-5 mg per g (0.5%-).5%), 30g - - 31,102 545,986 C05AA01 HYDROCORTISONE, CINCHOCAINE HYDROCHLORIDE 4038 Suppositories-5 mg-5 mg, 12 - - 21,105 363,991 14345 Ointment 5 mg-5 mg-10 mg per g (0.5%-0.5%-1%), - - 18,968 - C05AA01 HYDROCORTISONE, LIGNOCAINE BASE, ALUMINIUM SUBACETATE and ZINC OXIDE 14653 Ointment 2.5 mg-50 mg-35 mg-180 mg per g - - 3,490 - C05AA04 PREDNISOLONE HEXANOATE, CINCHOCAINE HYDROCHLORIDE and CLEMIZOLE UNDECY 14656 Ointment 1.9 mg-5 mg-10 mg per g (0.19%-0.5%-1%) - - 6,607 - 14657 Ointment 1.9 mg-5 mg-10 mg per g (0.195-0.5%-1%) - - 5,035 - 14658 Suppositories 1.3 mg-1 mg-5 mg, 12 - - 5,682 - PRODUCTS CONTAINING LOCAL ANESTHETICS C05AD03 ADRENALINE EPHEDRINE BENZOCAINE 13135 Suppositories 12 1 - - 1,538 - C05AD03 ADRENALINE EPHEDRINE BENZOCAINE ZINC OXIDE 13134 Ointment 50g 1 - - 4,961 - OTHER ANTIHAEMORRHOIDALS FOR TOPICAL USE C05AX04 ZINC OXIDE 4039 Compound ointment 50 g - - 3,677 45,421 4040 Compound suppositories, 12 - - 2,269 26,468 ANTIVARICOSE THERAPY HEPARINS OR HEPARINOIDS FOR TOPICAL USE C05BA01 HEPARINOID 12829 Cream 0.3%40g 1 - - 495 - 13774 Cream 0.3% 20g 1 - - 1,657 - C05BA01 HEPARINOID with HYALURONIDASE 12830 Ointment 14g 1 - - 827 - 12831 Ointment 40g 1 - - 356 - SCLEROSING AGENTS FOR LOCAL INJECTION C05BB SODIUM TETRADECYL SULPHATE 13702 Ampoule 3% 2ml 5 - - 178 - CAPILLARY STABILIZING AGENTS BIOFLAVONOIDS C05CA02 HYDROXYETHYLRUTOSIDES 13500 Capsule 250mg 50 - - 837 - 16101 Capsule 250 mg 100 - - 1,670 -

71 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS

BETA BLOCKING AGENTS, PLAIN BETA BLOCKING AGENTS, PLAIN, NON-SELECTIVE C07AA02 OXPRENOLOL HYDROCHLORIDE 2942 Tablet 20 mg 0.16 GM 2,255 18,457 2961 Tablet 40 mg 0.16 GM 14,433 146,329 C07AA03 PINDOLOL 3062 Tablet 5 mg 15.00 MG 41,243 466,945 3065 Tablet 15 mg 15.00 MG 36,147 521,713 C07AA05 PROPRANOLOL HYDROCHLORIDE 2565 Tablet 10 mg 0.16 GM 102,346 614,412 2566 Tablet 40 mg 0.16 GM 322,792 2,364,365 2899 Tablet 160 mg 0.16 GM 43,986 386,631 C07AA07 SOTALOL HYDROCHLORIDE 2043 Tablet 160 mg 0.16 GM 175,224 5,499,180 8398 Tablet 80mg 60 0.16 GM 202,062 3,440,763 BETA BLOCKING AGENTS, PLAIN, SELECTIVE C07AB03 ATENOLOL 1081 Tablet 50 mg 0.08 GM 3,846,222 38,881,929 C07AB07 BISOPROLOL 8604 Tablet 2.5 mg 10.00 MG 13,353 779,217 8605 Tablet 5 mg 10.00 MG 9,197 661,802 8606 Tablet 10 mg 10.00 MG 4,822 406,949 C07AB02 METOPROLOL TARTRATE 1324 Tablet 50 mg 150.00 MG 746,989 7,775,418 1325 Tablet 100 mg 150.00 MG 480,867 5,851,199 ALPHA- AND BETA- ADRENOCEPTOR BLOCKING AGENTS C07AG02 CARVEDILOL 8255 Tablet 3.125 mg 30 37.50 MG 30,732 904,696 8256 Tablet 6.25 mg 37.50 MG 113,014 8,898,846 8257 Tablet 12.5 mg 37.50 MG 99,221 9,590,236 8258 Tablet 25 mg 37.50 MG 144,760 17,442,467 16540 Tablet 6.25 mg 30 37.50 MG 139 - C07AG01 LABETALOL HYDROCHLORIDE 1566 Tablet 100 mg 0.60 GM 14,992 202,872 1567 Tablet 200 mg 0.60 GM 23,699 495,750

72 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS

SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS DIHYDROPYRIDINE DERIVATIVES C08CA01 AMLODIPINE BESYLATE 2751 Tablet 5 mg (base), 30 5.00 MG 1,213,617 26,501,616 2752 Tablet 10 mg (base), 30 5.00 MG 844,087 28,730,281 4985 Tablet 5 mg (base), 30 5.00 MG 25,388 676,602 4986 Tablet 10 mg (base), 30 5.00 MG 18,843 755,691 8923 Tablet 5 mg (base), 30 5.00 MG 230,114 6,144,323 8924 Tablet 10 mg (base), 30 5.00 MG 243,648 9,888,724 C08CA02 FELODIPINE 2361 Tablet 2.5 mg (extended release) 5.00 MG 229,977 3,531,885 2366 Tablet 5 mg (extended release) 5.00 MG 662,410 12,890,407 2367 Tablet 10 mg (extended release) 5.00 MG 722,930 23,403,945 C08CA13 LERCANIPIDINE 4960 Tablet 10 mg 30 10.00 GM 3,334 114,333 8534 Tablet 10 mg 30 10.00 GM 522,581 12,829,064 8679 Tablet 20 mg 30 10.00 GM 5,092 190,353 8939 Tablet 10 mg 30 10.00 GM 29,462 1,015,178 8940 Tablet 20 mg 30 10.00 GM 423 17,791 C08CA05 NIFEDIPINE 1694 Tablet 10 mg 60 30.00 MG 43,530 846,758 1695 Tablet 20 mg 30.00 MG 74,323 1,748,165 1906 Tablet 30 mg (controlled release) 30.00 MG 506,645 12,442,109 1907 Tablet 60 mg (controlled release) 30.00 MG 354,751 10,707,791 4961 Tablet 20 mg (controlled release) 30 30.00 MG 352 8,521 4973 Tablet 30 mg (controlled release) 30 30.00 MG 1,535 43,137 4974 Tablet 60 mg (controlled release) 30 30.00 MG 1,043 38,712 8610 Tablet 20 mg (controlled release) 30 30.00 MG 40,504 843,784 8925 Tablet 30 mg (controlled release) 30 30.00 MG 11,734 337,517 8926 Tablet 60 mg (controlled release) 30 30.00 MG 10,906 408,373 8938 Tablet 20 mg (controlled release) 30 30.00 MG 2,695 74,865 17913 Tablet 30 mg (controlled release) 30 30.00 MG 217 - 17914 Tablet 60 mg (controlled release) 30 30.00 MG 138 - SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS PHENYLALKYLAMINE DERIVATIVES C08DA01 VERAPAMIL HYDROCHLORIDE 1241 Tablet 240 mg (sustained release) 0.24 GM 852,488 15,439,038 1248 Tablet 40 mg 0.24 GM 48,664 552,446 1250 Tablet 80 mg 0.24 GM 57,399 949,462 1253 Tablet 160 mg 0.24 GM 28,168 583,980 1254 Tablet 120 mg 0.24 GM 6,867 150,334 2206 Capsule 160 mg (sustained release) 0.24 GM 59,062 771,970 2207 Capsule 240 mg (sustained release) 0.24 GM 83,683 1,527,107 2208 Capsule 180 mg (sustained release) 0.24 GM 205,276 3,033,554 3494 Injection 5 mg in 2 ml 0.24 GM 4,053 42,841

73 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS

SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECT BENZOTHIAZEPINE DERIVATIVES C08DB01 DILTIAZEM HYDROCHLORIDE 1312 Capsule 180 mg controlled delivery 0.24 GM 596,163 14,015,572 1313 Capsule 240 mg controlled delivery 0.24 GM 620,993 18,467,146 1335 Tablet 60 mg 0.24 GM 100,027 2,349,785 8480 Capsule 360 mg controlled delivery 30 0.24 GM 203,684 7,173,729 NON-SELECTIVE CALCIUM CHANNEL BLOCKERS OTHER NON-SELECTIVE CALCIUM CHANNEL BLOCKERS C08EX02 PERHEXILINE MALEATE 1822 Tablet 100 mg 0.20 GM 35,181 1,870,623

74 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM

ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, PLAIN CONVERTING ENZYME BLOCKERS C09AA01 CAPTOPRIL 1147 Tablet 12.5 mg 50.00 MG 46,402 930,187 1148 Tablet 25 mg 50.00 MG 92,633 2,499,945 1149 Tablet 50 mg 50.00 MG 138,417 6,840,574 C09AA02 ENALAPRIL MALEATE 1368 Tablet 10 mg 10.00 MG 399,183 9,072,963 1369 Tablet 20 mg 10.00 MG 698,361 21,274,998 1370 Tablet 5 mg 10.00 MG 207,843 3,198,516 C09AA09 FOSINOPRIL 1182 Tablet 10 mg 30 15.00 MG 241,104 4,851,857 1183 Tablet 20 mg 15.00 MG 319,746 9,478,743 C09AA03 LISINOPRIL 2456 Tablet 5 mg 30 10.00 MG 243,007 4,404,240 2457 Tablet 10 mg 30 10.00 MG 418,046 10,333,930 2458 Tablet 20 mg 30 10.00 MG 568,667 17,873,297 C09AA04 PERINDOPRIL 3050 Tablet 2 mg 30 4.00 MG 961,154 18,728,567 3051 Tablet 4 mg 30 4.00 MG 1,691,008 45,512,256 C09AA06 QUINAPRIL 1968 Tablet 5 mg 30 15.00 MG 102,130 1,789,559 1969 Tablet 10 mg 30 15.00 MG 255,681 5,869,678 1970 Tablet 20 mg 30 15.00 MG 385,847 11,318,117 C09AA05 RAMIPRIL 1944 Capsule 1.25 mg 28 2.50 MG 181,382 2,925,562 1945 Capsule 2.5 mg 28 2.50 MG 553,584 11,598,190 1946 Capsule 5.0 mg 28 2.50 MG 1,183,569 30,502,998 4962 Capsule 10 mg 30 2.50 MG 13,285 527,924 8470 Capsule 10 mg 30 2.50 MG 781,591 27,397,830 8668 Pack 7 Tabs 2.5mg, 21 tabs 5mg and 10 caps 10mg 2.50 MG 450 14,591 8937 Capsule 10 mg 30 2.50 MG 138,499 5,588,324 17037 Capsule 10 mg 30 2.50 MG 132 - C09AA10 TRANDOLAPRIL 2791 Capsule 500 ug 2.00 MG 65,507 951,414 2792 Capsule 1 mg 2.00 MG 190,404 3,900,238 2793 Capsule 2 mg 2.00 MG 478,926 12,423,984 ACE INHIBITORS, COMBINATIONS ANGIOTENSIN-CONVERTING ENZYME BLOCKERS AND DIURETICS C09BA02 ENALAPRIL and HYDROCHLOROTHIAZIDE 8477 Tablet 20 mg-6 mg 10.00 MG 156,526 4,859,996 C09BA09 FOSINOPRIL with HYDROCHLOROTHIAZIDE 8400 Tablet 10 mg-12.5 mg 15.00 MG 119,475 2,736,924 8401 Tablet 20 mg-12.5 mg 15.00 MG 481,414 15,327,013 C09BA04 PERINDOPRIL and INDAPAMIDE 8449 Tablet 4 mg-1.25 mg 4.00 MG 1,355,065 44,826,214 C09BA06 QUINAPRIL and HYDROCHLOROTHIAZIDE 8589 Tablet 10mg(base) / 12.5mg, 30 - - 12,093 285,440 8590 Tablet 20mg(base) / 12.5mg, 30 - - 40,333 1,121,682

75 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM

ANGIOTENSIN II ANTAGONISTS ANGIOTENSIN II ANTAGONISTS, PLAIN C09CA06 CANDESARTAN 8295 Tablet 4 mg 30 8.00 MG 122,188 2,339,755 8296 Tablet 8 mg 30 8.00 MG 421,696 9,693,834 8297 Tablet 16 mg 30 8.00 MG 445,475 12,464,486 C09CA02 EPROSARTAN 8397 Tablet 400 mg (base) 56 0.60 GM 26,585 868,938 8447 Tablet 600 mg (base) 28 0.60 GM 87,530 2,701,648 C09CA04 IRBESARTAN 8246 Tablet 75 mg 150.00 MG 350,374 7,936,219 8247 Tablet 150 mg 150.00 MG 1,651,934 45,188,372 8248 Tablet 300 mg 150.00 MG 1,282,476 42,876,907 C09CA01 LOSARTAN 16073 Tablet 50 mg 30 0.05 GM 4,730 - C09CA07 TELMISARTAN 8355 Tablet 40mg 40.00 MG 468,067 10,958,945 8356 Tablet 80mg 40.00 MG 454,932 12,964,271 ANGIOTENSIN II ANTAGONISTS, COMBINATIONS ANGIOTENSIN II ANTAGONISTS AND DIURETICS C09DA06 CANDESARTAN with HYDROCHLOROTHIAZIDE 8504 Tablet 16 mg-12.5 mg 8.00 MG 506,279 14,455,405 C09DA02 EPROSARTAN and DIURETICS 8624 Tablet 600 mg (base) -12.5 mg 28 - - 20,846 650,045 C09DA04 IRBESARTAN with HYDROCHLOROTHIAZIDE 8404 Tablet 150 mg-12.5 mg 150.00 MG 771,861 21,682,097 8405 Tablet 300 mg-12.5 mg 150.00 MG 1,844,610 62,887,955 C09DA02 TELMISARTAN and DIURETICS 8622 Tablet 40 mg-12.5 mg 28 - - 19,839 478,261 8623 Tablet 80 mg-12.5 mg 28 - - 93,228 2,707,709

76 C

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

CARDIOVASCULAR SYSTEM SERUM LIPID REDUCING AGENTS

CHOLESTEROL- AND TRIGLYCERIDE REDUCERS HMG COA REDUCTASE INHIBITORS C10AA05 ATORVASTATIN 8213 Tablet 10 mg 10.00 MG 2,058,438 88,671,484 8214 Tablet 20 mg 10.00 MG 2,621,144 156,232,155 8215 Tablet 40 mg 10.00 MG 1,547,025 129,646,975 8521 Tablet 80 mg 10.00 MG 386,005 45,355,078 C10AA04 FLUVASTATIN 8023 Capsule 20mg (base) 40.00 MG 66,930 1,945,373 8024 Capsule 40mg (base) 40.00 MG 82,970 3,003,022 C10AA03 PRAVASTATIN 2833 Tablet 10 mg, 30 20.00 MG 195,655 6,863,889 2834 Tablet 20 mg, 30 20.00 MG 743,648 39,080,489 8197 Tablet 40 mg, 30 20.00 MG 1,111,468 88,713,149 C10AA01 SIMVASTATIN 2011 Tablet 10 mg 15.00 MG 1,039,221 44,002,657 2012 Tablet 20 mg 15.00 MG 2,447,097 142,915,602 2013 Tablet 5 mg 15.00 MG 52,268 1,621,921 8173 Tablet 40 mg 15.00 MG 1,754,105 143,151,090 8313 Tablet 80 mg 15.00 MG 421,781 48,474,211 FIBRATES C10AB04 GEMFIBROZIL 1453 Tablet 600 mg 1.20 GM 433,206 17,254,938 BILE ACID SEQUESTRANTS C10AC01 CHOLESTYRAMINE 2967 Sachets 4.7g(equiv to 4 g cholestyramine) 14.00 GM 33,389 1,863,688 2978 Sachets 9.4g equiv to 8 g cholestyramine) 14.00 GM 16,330 909,946 C10AC02 COLESTIPOL HYDROCHLORIDE 1224 Sachets 5 g, 120 20.00 GM 2,204 150,224 NICOTINIC ACID AND DERIVATIVES C10AD02 NICOTINIC ACID 1687 Tablet 250 mg 2.00 GM 15,134 299,010 OTHER CHOLESTEROL- AND TRIGLYCERIDE REDUCERS C10AX09 EZETIMIBE 18038 Tablet 10mg 30 10.00 MG 819 -

77 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE

ANTIFUNGALS FOR TOPICAL USE ANTIBIOTICS D01AA01 NYSTATIN 4001 Cream 100,000 units per g, 15 g - - 4,200 41,219 4002 Ointment 100,000 units per g, 15 g - - 625 6,882 IMIDAZOLE DERIVATIVES D01AC10 BIFONAZOLE 4003 Cream 10 mg per g (1%), 15 g - - 9,405 122,705 D01AC01 CLOTRIMAZOLE 4004 Cream 10 mg per g (1%), 20 g - - 26,258 186,040 4005 Lotion 10 mg per ml (1%), 20 ml - - 3,792 36,992 15576 Cream 10 mg per g (1%), 50 g - - 4,776 - 15786 Cream 10 mg per g (1%), 50 g - - 26,321 - 16585 Cream 10 mg per g (1%), 20 g - - 5,948 - 17061 Cream (vaginal) 100 mg per g (10%) - - 2,652 - D01AC03 ECONAZOLE NITRATE 4555 Cream 10 mg per g (1%), 25 g - - 2,014 21,586 15470 Cream 10 mg per g (1%), 20 g - - 1,840 - D01AC08 KETOCONAZOLE 4007 Shampoo 20 mg per ml (2%),100 ml - - 276 5,009 4008 Shampoo 20 mg per ml (2%), 60 ml - - 5,910 98,915 13472 Cream 2% 30g 1 - - 4,160 - D01AC02 MICONAZOLE 4341 Tincture 20 mg per ml (2%), 20 ml - - 3,487 56,380 14846 Ointment 15 g - - 366 - 17964 Cream 10mg per g (1%) 40g - - 3,043 - D01AC02 MICONAZOLE NITRATE 4009 Cream 20 mg per g (2%), 20 g - - 2,396 20,628 14052 Cream 30 mg per g (2%), 30 g - - 3,589 - 14053 Lotion 30 mg per ml (2%), 30 g - - 366 - 14055 Powder 2%30g 1 - - 183 - D01AC20 MICONAZOLE and DIMETHICONE 16259 Cream 2% 25g - - 175 - D01AC52 MICONAZOLE and HYDROCORTISONE 17203 Cream 1% 1g/100g 30g - - 2,477 - 17966 Cream 1% 1g/100g 30g - - 7,546 - OTHER ANTIFUNGALS FOR TOPICAL USE D01AE16 AMOROLFINE 4010 Nail treatment kit containing 50 mg (base) per ml - - 7,492 673,202 D01AE15 TERBINAFINE 4463 Gel 10 mg per g (1%), 15 g - - 981 19,901 4473 Cream 10mg per g (1%), 15g - - 20,437 393,718 D01AE18 TOLNAFTATE 4481 Spray aerosol 10 mg per g (1%), 100 g - - 1,230 20,853 12864 Cream 1%20g 1 - - 133 - 12866 Soln 1%10ml 1 - - 254 -

78 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE

ANTIFUNGALS FOR SYSTEMIC USE ANTIFUNGALS FOR SYSTEMIC USE D01BA01 GRISEOFULVIN 1460 Tablet 125 mg 0.50 GM 4,396 75,308 2982 Tablet 500 mg 0.50 GM 96,689 1,725,225 2983 Tablet 330 mg 0.50 GM 1,935 34,556 17009 Tablet 500 mg 28 0.50 GM 233 - D01BA02 TERBINAFINE 2804 Tablet 250 mg (base) 0.25 GM 99,727 15,596,978 4011 Tablet 250 mg (base) 0.25 GM 4,329 677,158

79 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS EMOLLIENTS AND PROTECTIVES

EMOLLIENTS AND PROTECTIVES SILICONE PRODUCTS D02AA DIMETHICONE and GLYCEROL 4551 Cream 150 mg-20 mg per g (15%-2%), 600 g - - 399 7,889 4556 Cream 150 mg-20 mg per g (15%-2%), 75 g - - 641 5,963 SOFT PARAFFIN AND FAT PRODUCTS D02AC DEWAXED OIL with SOLUBLE KERATIN with LANOLIN with MINERAL OIL with PG 10147 Ltn 250ml 1 - - 168 - D02AC MINERAL OIL 10982 Oil 250ml 1 - - 123 - D02AC PARAFFIN 4041 Ointment 100g - - 1,284 13,378 CARBAMIDE PRODUCTS D02AE01 UREA 4042 Cream 100 mg per g (10%), 100 g - - 39,810 403,649 OTHER EMOLLIENTS AND PROTECTIVES D02AX BATH EMOLLIENT 4122 Bath oil 500 ml - - 14,125 231,746 D02AX CARMELLOSE SODIUM with PECTIN and GELATIN 4518 Paste 167 mg-167 mg-167 mg per g (16.7%-16.7%- - - 480 4,366 D02AX CETOMACROGOL 15823 Sorbolene crm 100g - - 1,036 - D02AX CETOMACROGOL with GLYCERINE 11020 Cream 100g 1 - - 410 - D02AX DEWAXED OIL with LANOLIN 4107 Lotion 500 mL - - 2,726 41,151 PROTECTIVES AGAINST UV-RADIATION PROTECTIVES AGAINST UV-RADIATION FOR TOPICAL USE D02BA SUNSCREENS 4209 Solid stick 5 g - - 2,134 19,273 4544 Cream 100 g - - 18,427 248,591 4546 Lotion (non-alcoholic) 125 ml - - 6,172 86,436 D02BA SUNSCREENS DIBENZOYL METHANE AND AMERSCREEN P 4476 Lotion (alcoholic) 100 ml - - 239 3,112

80 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS PREPARATIONS FOR TREATMENT OF WOUNDS & ULCERS

CICATRIZANTS OTHER CICATRIZANTS D03AX07 GLYCERYL TRINITRATE 16349 Ointment 0.2% 30g 1 - - 5,771 - D03AX VITAMIN A 16106 Ointment 50 g - - 3,277 -

81 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS ANTIPRURITICS,INCL ANTIHIST,ANESTHET,ETC.

ANTIPRURITICS,INCL ANTIHIST,ANESTHET,ETC. ANAESTHETICS FOR TOPICAL USE D04AB01 LIGNOCAINE 11553 Cream 75g 1 - - 157 - 12234 Jel 2%15ml 1 - - 1,830 - 12239 Ointment 5%15g 1 - - 1,041 - 12240 Ointment 5% 35g 1 - - 354 - D04AB01 LIGNOCAINE HYDROCHLORIDE and CARBOXYMETHYLCELLULOSE 4308 Mucilage 20 mg-25 mg per ml (2%-2.5%), 200 ml - - 2,214 141,722 D04AB01 LIGNOCAINE with PRILOCAINE 13084 Cream 5%5g 5 - - 313 - 13085 Cream 5% 30g 1 - - 249 - OTHER ANTIPRURITICS D04AX CROTAMITON 12933 Cream 10%20g 1 - - 304 - 12934 Ltn 10%50ml1 - - 161 - D04AX PINE TAR and TRIETHANOLAMINE 4408 Solution 23 mg-60 mg per ml (2.3%-6%), 500 ml - - 4,106 70,328

82 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS ANTIPSORIATICS

ANTIPSORIATICS FOR TOPICAL USE TARS D05AA ALLANTOIN, SULPHUR, PHENOL, COAL TAR SOLUTION and MENTHOL 4506 Gel 25 mg-5 mg-5 mg-0.05 ml-7.5 mg per g (2.5%- - - 269 4,831 D05AA PINE TAR with GLYCEROL 12682 Gel 100g 1 - - 139 - ANTRACEN DERIVATIVES D05AC01 DITHRANOL 13299 Cream 0.25% 50 1 - - 111 - 13301 Cream 1% 50 1 - - 213 - 13302 Cream 2% 50 1 - - 119 - OTHER ANTIPSORIATICS FOR TOPICAL USE D05AX02 CALCIPOTRIOL 8291 Ointment 0.005%, 30gm - - 89,315 4,090,776 14883 Ointment 100 gm - - 1,098 - 15867 Cream 30g - - 2,760 - 15868 Cream 100g - - 1,217 - 16979 Scalp Solution 30mL 50ug/mL - - 2,154 - 16980 Scalp Solution 60mL 50ug/mL - - 229 - ANTIPSORIATICS FOR SYTEMIC USE RETINOIDS FOR TREATMENT OF PSORIASIS D05BB02 ACITRETIN 2019 Capsule 10 mg 35.00 MG 4,954 1,002,327 2020 Capsule 25 mg 35.00 MG 7,422 2,887,470

83 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHER. FOR DERMATOLOGICAL USE

ANTIBIOTICS FOR TOPICAL USE TETRACYCLINE AND DERIVATIVES D06AA02 CHLORTETRACYCLINE HYDROCHLORIDE 16096 Ointment 3% , 15 g 1 - - 189 - OTHER ANTIBIOTICS FOR TOPICAL USE D06AX FRAMYCETIN SULPHATE with GRAMICIDIN 12003 Ointment 1.5%15g 1 - - 1,157 - D06AX01 FUSIDIC ACID 13926 Ointment 2% 15mg 1 - - 15,936 - D06AX09 MUPIROCIN 4348 Cream 20mg (as calcium) per g (2%), 15g - - 87,839 1,226,917 4350 Ointment 20mg per g(2%), 15g - - 115,353 1,634,202 13705 Ointment nasal 3g 1 - - 26,100 - D06AX04 NEOMYCIN 11888 Ointment 30g 1 - - 985 - D06AX NEOMYCIN with BACITRACIN 10457 Powder 15g 1 - - 5,184 - D06AX POLYMIXIN B SULPHATE with NEOMYCIN with BACITRACIN 11330 Ointment 15g 1 - - 24,209 - CHEMOTHERAPEUTICS FOR TOPICAL USE SULFONAMIDES D06BA51 SILVER SULPHADIAZINE with CHLORHEXIDINE GLUCONATE 1996 Cream 10 mg-2 mg per g (1%-0.2%), 50 g - - 21,781 309,919 1997 Cream 10 mg-2 mg per g (1%-0.2%), 100 g - - 44,648 866,760 13610 Cream 1%500g 1 - - 418 - ANTIVIRALS D06BB01 IDOXURIDINE with LIGNOCAINE with BENZALKONIUM CHLORIDE 12214 Cream 5g 1 - - 140 - D06BB10 IMIQUIMOD 16216 Cream 5% sachets 12 - - 23,448 - 17990 Cream 5% sachets 6 - - 4,831 - D06BB04 PODOPHYLLOTOXIN 4566 Paint 5mg per ml (0.5%), 3.5 ml (with 30 swabs) - - 4,761 104,037 17402 Paint 5mg per ml (0.5%), 3 ml (with applicators) - - 1,178 - 17933 Cream 1.5mg per gram (0.15%) 5g - - 587 - OTHER CHEMOTHERAPEUTICS D06BX01 METRONIDAZOLE 4336 Gel 7.5 mg per g (0.75%) 15 g - - 20,674 258,782 4340 Cream 7.5 mg per g (0.75%), 30g - - 7,281 131,757 16445 Gel 0.75% 50 g - - 9,176 - 17694 Gel 0.75% 30g 1 - - 26,559 -

84 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

CORTICOSTEROIDS, PLAIN CORTICOSTEROIDS, WEAK (GROUP I) D07AA02 HYDROCORTISONE 1495 Cream 10 mg per g (1%), 50 g - - 120,387 843,882 2881 Cream 10 mg per g (1%), 50 g - - 282,458 1,970,579 2882 Topical ointment 10 mg per g (1%), 50 g - - 64,578 454,042 2887 Cream 10 mg per g (1%), 30 g - - 105,365 683,050 2888 Topical ointment 10 mg per g (1%), 30 g - - 27,100 175,433 10542 Cream 0.5% 30g 1 - - 205 - 10719 Cream 0.5% 30g 1 - - 1,789 - 16165 Cream 10 mg per g (1%), 30 g - - 556 - 16625 Cream 1%30g 1 - - 24,105 - 16626 Cream 0.5%30g 1 - - 743 - 16627 Cream 1%30g 1 - - 7,516 - CORTICOSTEROIDS, MODERATELY POTENT (GROUP II) D07AB09 TRIAMCINOLONE ACETONIDE 2117 Cream 200 ug per g (0.02%), 100 g - - 355,372 4,706,904 2118 Ointment 200 ug per g (0.02%), 100 g - - 57,853 765,719 CORTICOSTEROIDS, POTENT (GROUP III) D07AC01 BETAMETHASONE 1115 Cream 500 ug per g (0.05%), 15 g - - 309,784 2,532,018 1119 Ointment 500 ug per g (0.05%), 15 g - - 185,701 1,711,664 2812 Cream 200 ug per g (0.02%), 100 g - - 394,467 5,244,231 2813 Cream 500 ug per g (0.05%), 15 g - - 136,474 1,010,500 2815 Ointment 500 ug per g (0.05%), 15 g - - 46,419 356,129 2820 Ointment 200 ug per g (0.02%), 100 g - - 62,824 840,639 4131 Cream 1 mg per g (0.1%), 30 g - - 13,088 279,684 4132 Ointment 1 mg per g (0.1%), 30 g - - 7,979 178,153 4133 Scalp application 1 mg per g (0.1%), 30 g - - 10,077 174,944 4511 Cream 500 ug per g (0.05%), 30 g - - 10,702 114,318 4513 Ointment 500 ug per g (0.05%), 30 g - - 4,956 53,689 10627 Ointment 30g 1 - - 21,555 - 12881 Cream 30g 1 - - 21,606 - 15271 Cream 500 ug per g (0.05%), 50 g - - 10,918 - 15272 Ointment 500 ug per g (0.05%), 50 g - - 9,996 - 15275 Cream 1 mg per g (0.1%), 30 g - - 2,776 - 15276 Ointment 1 mg per g (0.1%), 30 g - - 2,182 - 17216 Scalp lotion 500 ug per ml (0.05%), 30 ml - - 16,742 - 17217 Scalp lotion 500 ug per ml (0.05%), 30 ml - - 18,375 - D07AC14 METHYLPREDNISOLONE ACEPONATE 8054 Cream 1 mg per g (0.1%), 15 g - - 202,042 3,067,328 8055 Ointment 1 mg per g (0.1%) 15 g - - 118,590 2,016,260 8128 Ointment 1 mg per g (0.1%) 15 g - - 118,753 2,186,287 8618 Lotion 1 mg per g (0.1%), 20 g - - 15,847 247,614 15990 Cream 0.1% 30gm 1 - - 7,814 - 15991 Ointment 0.1% 30gm 1 - - 4,501 -

85 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

CORTICOSTEROIDS, PLAIN CORTICOSTEROIDS, POTENT (GROUP III) D07AC13 MOMETASONE 1913 Cream 1 mg per g (0.1%), 15 g - - 470,122 6,546,558 1915 Ointment 1 mg per g (0.1%), 15 g - - 235,808 4,065,246 4342 Cream 1 mg per g (0.1%), 45 g - - 26,052 788,748 4343 Ointment 1 mg per g (0.1%), 45 g - - 18,327 582,568 8043 Lotion 1 mg per g (0.1% w/w),30 ml - - 190,557 3,910,683 16061 Lotion 0.1%50mL 1 - - 906 - CORTICOSTEROIDS, COMB WITH ANTISEPTICS CORTICOSTEROIDS, WEAK, COMB WITH ANTISEPTICS D07BA04 HYDROCORTISONE and CLIOQUINOL 16100 Cream 1%-1% 30gm - - 12,699 - 17035 Cream 1%-1% 60gm - - 4,053 - CORTICOSTEROIDS, COMB WITH ANTIBIOTICS CORTICOSTEROIDS, WEAK, COMB WITH ANTIBIOTICS D07CA01 HYDROCORTISONE and CLOTRIMAZOLE 13540 Cream 1%30g 1 - - 44,802 - CORTICOSTEROIDS, MODERAT. POTENT, COMB W/ANTIBIOT. D07CB01 TRIAMCINOLONE ACETONIDE with NEOMYCIN with GRAMICIDIN with NYSTATIN 4482 Ointment 1 mg-2.5 mg (base)-250 ug- - - 48,635 722,096 11072 Ointment 30g 1 - - 13,445 - CORTICOSTEROIDS, POTENT, COMB WITH ANTIBIOTICS D07CC01 BETAMETHASONE VALERATE with GENTAMICIN SULPHATE 10505 Cream 0.1%30 1 - - 1,071 - 10506 Ointment .1%30 1 - - 291 - CORTICOSTEROIDS, OTHER COMBINATIONS CORTICOSTEROIDS, WEAK, OTHER COMBINATIONS D07XA01 HYDROCORTISONE with CLOTRIMAZOLE 16834 Cream 1% 50g 1 - - 18,987 -

86 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS ANTISEPTICS AND DISINFECTANTS

ANTISEPTICS AND DISINFECTANTS BIGUANIDES AND AMIDINES D08AC52 CHLORHEXIDINE with CETRIMIDE 11860 Cream 75g 1 - - 339 - PHENOL AND DERIVATIVES D08AE04 TRICLOSAN 11855 Skin-cl 250ml 1 - - 197 - D08AE04 TRICLOSAN with ENTSUFON 11586 Ltn 200ml 1 - - 190 - 11587 Ltn 500ml 1 - - 124 - IODINE PRODUCTS D08AG02 POVIDONE IODINE 4411 Solution 100 mg per ml (10%), 100 ml - - 7,907 138,773 10226 Ointment 25g 1 - - 1,114 - 10230 Soln 15ml 1 - - 1,357 - 16104 Powder 20g 1 - - 196 -

87 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS MEDICATED DRESSINGS

MEDICATED DRESSINGS OINTMENT DRESSINGS WITH ANTIINFECTIVES D09AA CADEXOMER IODINE 4932 Tube 10 g, 4 - - 444 37,150 D09AA01 FRAMYCETIN SULPHATE 11975 Dressing 10x10 10 - - 196 - D09AA09 POVIDONE-IODINE 4779 Sterile sachets 22.5 cm x 7.5 cm, 12 - - 212 6,838 ZINC BANDAGES D09AB01 BANDAGE ZINC PASTE 4750 Bandage 7.5 cm x 6 m - - 833 67,983 SOFT PARAFFIN DRESSINGS D09AX SOFT PARAFFIN DRESSING 4759 Sterile sachets 10 cm x 10 cm, 10 - - 3,106 46,905 4845 Sterile sachets 10 cm x 10 cm, 10 - - 2,049 39,862

88 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS ANTI-ACNE PREPARATIONS

ANTI-ACNE PREPARATIONS FOR TOPICAL USE CORTICOSTEROIDS,COMBINATIONS FOR TREATMENT OF ACNE D10AA02 NEOMYCIN with METHYLPREDNISOLONE 11325 Ltn 30ml 1 - - 3,753 - 11326 Ltn 75ml 1 - - 1,639 - RETINOIDS FOR TOPICAL USE IN ACNE D10AD03 ADAPALENE 15680 Gel 0.1% 30G 1 - - 38,598 - 16348 Cream 0.1% 30g 1 - - 23,409 - D10AD04 ISOTRETINOIN 14786 Gel 0.05% 30g - - 10,951 - D10AD01 TRETINOIN 11780 Cream 0.05%20g 1 - - 14,834 - 14354 Cream .025% 25g 1 - - 4,148 - 14355 Cream 0.05% 25g 1 - - 4,299 - 14356 Cream 0.1% 25g 1 - - 2,366 - 14512 Cream 0.05% 50g 1 - - 8,385 - 17039 Gel 0.01%30g 1 - - 5,660 - PEROXIDES D10AE01 BENZOYL PEROXIDE 11523 Gel 5%40g 1 - - 229 - 11524 Gel 10%40g 1 - - 138 - ANTIINFECTIVES FOR TREATMENT OF ACNE D10AF01 CLINDAMYCIN 13816 Topical solution 1% 100mL 1 - - 18,429 - 16422 Topical solution 1% 50mL 1 - - 10,768 - 16520 Ltn 10 mg /mL 60 mL - - 3,783 - D10AF02 ERYTHROMYCIN 15129 Gel 2% 30 g 1 - - 72,429 - OTHER ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AX01 ALUMINIUM CHLORIDE 10734 Roll-on 20%50ml 1 - - 255 - D10AX03 AZELAIC ACID 14704 Cream 20 % 30 mg - - 491 - ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE RETINOIDS FOR TREATMENT OF ACNE D10BA01 ISOTRETINOIN 2591 Capsule 10 mg 30.00 MG 3,885 379,441 2592 Capsule 20 mg 30.00 MG 129,086 19,334,076

89 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS

OTHER DERMATOLOGICAL PREPARATIONS ANTIHIDROTICS D11AA DIPHEMANIL METHYLSULPHATE 4191 Dusting powder 20 mg per g (2%), 50 g - - 10,331 170,069

MEDICATED SHAMPOOS D11AC30 PINE TAR, CADE OIL, COAL TAR SOLUTION, ARACHIS OIL EXTRACT OF CRUDE COAL 4409 Scalp cleanser 3 mg-3 mg-1 mg-3 mg-10 mg per ml - - 1,194 21,914 D11AC30 SALICYLIC ACID BENZALKONIUM CHLORIDE ALCOHOL and POLYOXYETHYLENE ETHER 4445 Scalp cleanser 20 mg-2 mg-130 mg-216 mg per ml - - 739 11,413 D11AC SALICYLIC ACID with BENZALKONIUM CHLORIDE with COAL TAR with ALCOHOL 13661 Shampoo 125ml 1 - - 260 - 11048 Shampoo 500ml 1 - - 170 - D11AC30 SALICYLIC ACID, BENZALKONIUM CHLORIDE, ALCOHOL, COAL TAR and POLYOXYET 4560 Scalp cleanser 20 mg-2 mg-130 mg-50 mg-216 mg - - 5,622 89,930 D11AC30 SALICYLIC ACID, COAL TAR SOLUTION, PINE TAR and UNDECYLENAMIDE 4447 Scalp cleanser 20 mg-10 mg-10 mg-10 mg per ml - - 1,853 27,917 D11AC03 SELENIUM SULFIDE 4452 Shampoo 25 mg per ml (2.5%), 125 ml - - 1,364 16,672

WART AND ANTI-CORN PREPARATIONS D11AF LACTIC ACID with SALICYLIC ACID 10706 Paint 15ml 1 - - 354 - D11AF PODOPHYLLUM RESIN with SALICYLIC ACID 4450 Paint 100 mg-200 mg per ml (10%-20%), 6 ml - - 2,012 26,435 11612 Ointment 10g 1 - - 3,152 - OTHER DERMATOLOGICALS D11AX ALLANTOIN, GLYCEROL and ICHTHAMMOL 4280 Ointment 5mg-10 mg per g(0.5%-1%-1%), 50g - - 353 4,852 4281 Cream 5mg-10mg-10mg per g(0.5%-1%-1%),50g - - 785 12,431 D11AX CATIONIC CONDITIONER with PANTHENOL 4519 Solution 250 ml - - 638 7,111 D11AX HYDROLYZED COLLAGEN PROTEINS 4271 Hair conditioner 250 ml - - 1,529 16,333 D11AX05 MAGNESIUM SULFATE 12530 Pst 100g 1 - - 397 - 18065 Cream 1% (1gm/100gm) 15gm - - 4,508 - D11AX01 MINOXIDIL 14182 Application 2% 60 ml 1 - - 114 - 16036 Application 5% 60 ml 1 - - 282 - 17460 Solution 5% 60 ml - - 200 - D11AX SALICYLIC ACID COMPOUND 16407 Cream 15mL 1 - - 201 - D11AX SKIN CLEANSER 4549 Lotion 500 ml - - 14,688 259,014

90 D

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS

OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICALS D11AX ZINC OXIDE, STARCH and CHLORPHENESIN 4497 Dusting powder 100 g - - 1,493 15,088 D11AX12 ZINC PYRITHIONE 4498 Shampoo 10 mg per ml (1%), 200 ml - - 310 3,150

91 G

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENITO URINARY SYSTEM AND SEX HORMONES GYNAECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS

ANTIINFECTIVES/ANTISEPT.,EXCL COMB WITH CORTICOST. ANTIBIOTICS G01AA10 CLINDAMYCIN 15081 Vaginal cream 2% 40 gm 0.10 GM 11,359 - G01AA01 NYSTATIN 4012 Cream pessaries 100,000 units, 15 100.00 TE 9,491 109,014 4013 Vaginal cream 100,000 units per dose, 15 doses, 100.00 TE 21,049 242,540 ORGANIC ACIDS G01AD02 RICINOLEIC ACID, ACETIC ACID and HYDROXYQUINOLINE SULPHATE 4434 Vaginal jelly 7 mg-9.4 mg-250 ug per g - - 1,402 36,555 IMIDAZOLE DERIVATIVES G01AF02 CLOTRIMAZOLE 4014 Pessaries 100 mg, 6 0.10 GM 18,483 250,960 4015 Pessary 500 mg 0.10 GM 18,299 255,818 4016 Vaginal cream 50 mg per 5 g (1%), 35 g 0.10 GM 107,798 1,455,506 4017 Vaginal cream 100 mg per 5 g (2%), 20 g 0.10 GM 50,297 693,380 15913 Pessary 500 mg 0.10 GM 4,935 - G01AF05 ECONAZOLE NITRATE 12661 Foam-sol 1%10g 3 0.10 GM 2,011 - 15473 Pessaries 150 mg, 3 0.10 GM 4,567 - G01AF04 MICONAZOLE NITRATE 4020 Pessaries 100 mg, 7 0.10 GM 2,037 23,035 4021 Vaginal cream 100 mg per 5 g (2%), 40 g 0.10 GM 4,853 57,155 15486 Vaginal cream 100 mg per 5 g (2%), 40 g 0.10 GM 1,416 - OTHER ANTIINFECTIVES AND ANTISEPTICS G01AX11 POVIDONE 12904 Pess 2g 14 - - 416 -

92 G

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNAECOLOGICALS

CONTRACEPTIVES FOR TOPICAL USE INTRAUTERINE CONTRACEPTIVES G02BA03 PLASTIC IUD with PROGASTERONE 8633 Intrauerine drug delivery 52 mg (rel 20 ug per 24) - - 22,281 4,899,699 G02BA02 POLYETHYLENE COPPER 13296 IUD 1 - - 688 - OTHER GYNAECOLOGICALS PROLACTIN INHIBITORS G02CB01 BROMOCRIPTINE MESYLATE 1444 Tablet 2.5 mg 5.00 MG 4,300 94,411 G02CB03 CABERGOLINE 8114 Tablet 0.5 mg 0.50 MG 23,814 2,075,920 8115 Tablet 0.5 mg 0.50 MG 3,147 90,137

93 G

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE PROGESTOGENS AND ESTROGENS, FIXED COMBINATIONS G03AA09 DESOGESTREL with ETHINYLOESTRADIOL 14249 Tablet 28 1 150 ug/30ug - - 101,133 - G03AA12 ETHINYLOESTRADIOL with DROSPIRENONE 17645 Tablet 30mg/ 3mg, 7 inert 28 - - 70,536 - 17646 Tablet 30mg/ 3mg, 7 inert 28X3 - - 122,745 - G03AA10 ETHINYLOESTRADIOL with GESTODENE 15082 Tablet 28, 2 - - 24,959 - 15084 Tablet 28, 2 - - 21,926 - G03AA07 LEVONORGESTREL with ETHINYLOESTRADIOL 1393 Tablets 150 ug - 30 ug, 21 - - 20,209 301,270 1394 Pack containing 21 tablets 150 ug - - 1,307,689 19,679,645 1456 Tablets 125 ug - 50 ug, 21 7 inert - - 108,521 1,631,633 16212 Tablets 100 ug - 50 ug, 28 - - 101,078 - 16217 Tablets 100 ug 20 ug and 7 inert, 28 - - 58,327 - 16970 Tablets 100 ug - 20 ug, 21 7 inert - - 111,009 - 17485 Tablets 250 ug - 50 ug, 21 - - 481 - 17499 Tablets 150 ug - 30 ug, 21 - - 476 - 17562 Tablets 125 ug - 50 ug, 21 - - 794 - 17583 Tablets 125 ug - 50 ug, 21 7 inert - - 301 - 17668 Pack containing 21 tablets 250 ug - - 621 - 17707 Tablets 100 ug 20 ug and 7 inert, 28 - - 550 - 17708 Tablets 100 ug 20 ug and 7 inert, 28X3 - - 2,013 - G03AA05 NORETHISTERONE with ETHINYLOESTRADIOL 2772 Tablets 500 ug - 35 ug, 21 - - 3,591 54,056 2773 Tablets 1 mg-35 ug, 21 - - 3,673 55,339 2774 Pack containing 21 tablets 500 ug - - 155,252 2,336,863 2775 Pack containing 21 tablets 1 mg-35 ug - - 90,982 1,369,887 G03AA05 NORETHISTERONE with MESTRANOL 3176 Tablets 1 mg-50 ug, 21 - - 3,503 52,554 3179 Pack containing 21 tablets 1 mg-50 ug - - 19,199 288,985 PROGESTOGENS AND ESTROGENS,SEQUENTIAL PREPARATIONS G03AB06 ETHINYLOESTRADIOL WITH GESTODENE 15087 Tablet 28, 2 - - 4,602 - 15088 Tablet 28, 2 - - 3,508 - G03AB03 LEVONORGESTREL with ETHINYLOESTRADIOL 1391 Pack containing 6 tablets 50 ug- - - 1,212 18,241 1392 Pack containing 6 tablets 50 ug- - - 858,689 12,930,117 1458 Pack containing 11 tablets 50 ug - - 13,083 197,016 17584 Pack containing 11 tablets 50 ug - - 110 - 17685 Pack containing 6 tablets 50 ug- - - 1,354 - G03AB04 NORETHISTERONE with ETHINYLOESTRADIOL 2776 Pack containing 12 tablets 500 ug - - 14,442 217,293

94 G

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE PROGESTOGENS G03AC08 ETONOGESTREL 8487 Subcutaneous implant 68 mg 0.07 MG 55,570 12,231,880 G03AC03 LEVONORGESTREL 2913 Tablets 30 ug, 28 0.03 MG 122,449 1,829,028 17047 IUD 1 - - 293 - 17548 Tablet 0.75mg 2 - - 79,735 - G03AC06 MEDROXYPROGESTERONE 3118 Injection 150 mg in 1 ml 1.67 MG 222,416 2,882,606 15290 Injection 150 mg in 1 ml 1.67 MG 332 - G03AC01 NORETHISTERONE 1967 Tablets 350 ug, 28 - - 29,838 448,738 ANDROGENS 3-OXOANDROSTEN (4) DERIVATIVES G03BA03 TESTOSTERONE 2101 Injection 250 mg 18.00 MG 43,531 1,371,165 2114 Injection 250 mg in 1 ml 18.00 MG 14,130 445,337 2115 Capsule 40 mg 120.00 MG 38,356 1,934,062 2670 Injection 100 mg 18.00 MG 9,412 170,619 8098 Subcutaneous implant 100 mg 18.00 MG 3,240 558,534 8099 Subcutaneous implant 200 mg 18.00 MG 5,483 1,365,196 8460 Transdermal patch 12.2 mg (2.5 mg per 24 hr),60 3.00 MG 9,758 996,872 8619 Transdermal patch 24.3 mg (5 mg per 24 hr),30 3.00 MG 10,539 1,073,808 16153 Cream 2%, 50g - - 1,586 - 16326 Cream 1%, 50g - - 2,399 - 17178 Cream 5%, 50g - - 1,771 - 5-ANDROSTANON (3) DERIVATIVES G03BB01 MESTEROLONE 11642 Tablet 25mg 50 50.00 MG 531 -

95 G

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

ESTROGENS NATURAL AND SEMISYNTHETIC ESTROGENS, PLAIN G03CA03 OESTRADIOL 1742 Vaginal tablets 25 ug 0.03 MG 334,706 6,462,085 1743 Transdermal patches 2 mg, 8 0.05 MG 99,427 1,598,736 1744 Transdermal patches 4 mg, 8 0.05 MG 174,908 2,811,803 1745 Transdermal patches 8 mg, 8 0.05 MG 42,509 784,366 8012 Transdermal patches 3.28 mg 0.05 MG 41,479 666,227 8013 Transdermal patches 4.33mg(rel 50ug/24 hours) 0.05 MG 54,292 872,818 8014 Transdermal patches 6.57 mg (rel 50ug/24 hours) 0.05 MG 34,657 636,255 8041 Transdermal patches 8.66 mg (rel 100ug/24 hours) 0.05 MG 18,108 337,168 8082 Transdermal patches 4 mg (rel 50 ug/24 hours) 0.05 MG 13,405 216,445 8125 Transdermal patches 3.9 mg (rel 50 ug/24 hours) 0.05 MG 93,115 1,494,631 8126 Transdermal patches 7.8 mg (rel 100 ug/24 hours) 0.05 MG 30,285 566,513 8140 Transdermal patches 1.5 mg (rel 50 ug/24 hours) 0.05 MG 26,531 426,954 8194 Transdermal patches 2 mg (releasing approx 25ug 0.05 MG 5,143 82,554 8195 Transdermal patches 8 mg (releasing approx 100ug 0.05 MG 4,584 85,354 8286 Transdermal gel 1 mg in 1g sachet, 28 1.00 MG 122,377 2,160,856 8311 Transdermal pat 750ug (rel 25ug/24 hrs) 0.05 MG 11,077 177,854 8312 Transdermal patch 3mg (rel 100ug/24 hrs) 0.05 MG 9,805 181,382 8485 Transdermal patches 2 mg (rel 25 ug/24 hours) 0.05 MG 18,679 300,095 8486 Transdermal patches 5.7 mg (rel 75 ug/24 hours) 0.05 MG 16,127 295,476 8645 Nasal spray 150 ug per actuation, 60 actuat, 4.2mL 0.30 MG 5,571 110,535 16209 Tablet 1mg 28 2.00 MG 3,912 - 16210 Tablet 2mg 28 2.00 MG 5,912 - 16211 Tablet 4mg 28 2.00 MG 2,067 - 17847 Nasal spray 150 ug per actuation, 60 actuat, 4.2mL 0.30 MG 1,061 - G03CA03 OESTRADIOL VALERATE 1061 Injection 10 mg in 1 ml 1.00 MG 5,960 376,907 1663 Tablets 1 mg, 28 2.00 MG 45,735 468,466 1664 Tablets 2 mg, 28 2.00 MG 81,223 1,001,739 4365 Implant 50mg 1 - - 3,066 177,989 4366 Implant 100mg 1 - - 7,130 777,847 8274 Tablets 2 mg, 56 2.00 MG 4,922 60,147 G03CA04 OESTRIOL 1771 Pessaries 500 ug, 15 0.20 MG 55,936 1,079,311 1776 Tablets 1 mg, 30 2.00 MG 8,718 93,290 1781 Vaginal cream 1 mg per g (0.1%), 15 g 0.20 MG 263,981 4,247,514 G03CA57 OESTROGENS CONJUGATED 1733 Tablets 300 ug, 28 0.63 MG 217,979 2,233,938 1734 Tablets 625 ug, 28 0.63 MG 507,916 6,238,784 15325 Tablet 1.25 mg 28 0.63 MG 20,968 - G03CA07 OESTRONE 1777 Tablet 730 ug 1.00 MG 106,181 1,088,849 1778 Tablet 1.46 mg 1.00 MG 154,225 1,896,263 11413 Tablet 625ug 100 1.00 MG 238 - 11414 Tablet 1.25mg 100 1.00 MG 727 - 16519 Tablet 2.5mg 100 1.00 MG 2,748 -

96 G

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

PROGESTOGENS PREGNEN (4) DERIVATIVES G03DA02 MEDROXYPROGESTERONE 2319 Injection 50 mg in 1 ml 7.00 MG 674 7,190 2321 Tablet 10 mg 5.00 MG 63,114 924,192 2323 Tablet 5 mg, 56 5.00 MG 222,928 3,011,263 2722 Tablet 10 mg 5.00 MG 19,625 600,826 14247 Tablet 2.5 mg 5.00 MG 1,811 - G03DA04 PROGESTERONE 6366 Gel Vaginal (prolonged release) 90mg single dose 90.00 MG 113 - 15327 Cream 1.6% 50 g - - 1,243 - 15328 Cream 3.2% 50 g - - 4,393 - 16638 Cream 10% 50 g - - 337 - PREGNADIEN DERIVATIVES G03DB01 DYDROGESTERONE 1350 Tablet 10 mg 10.00 MG 16,976 254,943 ESTREN DERIVATIVES G03DC02 NORETHISTERONE 2993 Tablet 5 mg 5.00 MG 187,681 5,730,845 G03DC05 TIBOLONE 16835 Tablet 2.5mg 28 2.50 MG 312,611 - PROGESTOGENS AND ESTROGENS IN COMBINATION PROGESTOGENS AND ESTROGENS, FIXED COMBINATIONS G03FA12 MEDROXYPROGESTERONE AND ESTROGEN 1813 Tablet 28 oestrogens 625 ug 28 tablets meddroxypr 0.63 MG 32,644 521,407 8168 Tablet 625 ug 2.5mg, 28 0.63 MG 110,183 1,761,265 8169 Tablet 625 ug 5mg, 28 0.63 MG 381,903 6,113,319 8680 Tablet 450 ug 1.5mg, 28 0.63 MG 1,603 25,534 15086 Tablet 28 oestrogens 625 ug 28 tablets meddroxypr 0.63 MG 411 - 17687 Tablet 28 oestrogens 625 ug 28 tablets meddroxypr 0.63 MG 2,210 - G03FA01 NORETHISTERONE AND ESTROGEN 8081 Pack containing 28 tablets 2 mg-1 mg 2.00 MG 158,280 2,534,071 8353 Tablets 1mg-500ug, 28 - - 150,131 2,396,296 PROGESTOGENS AND ESTROGENS,SEQUENTIAL PREPARATIONS G03FB08 DYDROGESTERONE AND ESTROGEN 8244 Pack 14 tab oestradiol 2mg+14 tab oest 2mg 2.00 MG 7,216 115,155 G03FB06 MEDROXYPROGESTERONE AND ESTROGEN 8210 Pack 14 tablets oestrogens 625 ug 0.63 MG 59,779 955,336 8538 Pack 14 tab oestrogens 625ug,14 tab medroxypr 0.63 MG 13,104 209,196 17673 Tab 28 oestrog 625 ug, 14 medroxy 10mg 0.63 MG 917 - G03FB05 OESTRADIOL with NORETHISTERONE ACETATE 1764 Tablets sequential pack 2 mg - 1mg 2.00 MG 138,020 2,200,562 1765 Tablets sequential pack 4 mg - 1mg 2.00 MG 33,205 529,676 8029 Pack containing 4 transdermal patches oestradiol 0.05 MG 18,356 336,522 8425 Transdermal patch 4 4.33mg, 4 620ug/2.7mg 0.05 MG 24,969 456,272 8426 Transdermal patch 4 4.33mg, 4 510ug/4.8mg 0.05 MG 19,218 351,108 8427 Transdermal patch 620ug/2.7mg, 8 0.05 MG 106,272 1,941,903 8428 Transdermal patch 510ug/4.8mg, 8 0.05 MG 49,089 895,906

97 G

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

GONADOTROPHINS AND OTHER OVULATION STIMULANTS GONADOTROPHINS G03GA05 FOLLITROPIN ALFA 8251 Injection set containing 10 ampoules powder for 75.00 IE 1,194 589,669 8252 Injection set containing 10 ampoules powder for 75.00 IE 617 683,884 8602 Injection set 1 vial pwd for inj 1,200 iu 2mL solv 75.00 IE 682 471,855 G03GA06 FOLLITROPIN BETA 8436 Soln for injection 50 iu in 0.5mL, 10 75.00 IE 224 82,579 8437 Soln for injection 100 iu in 0.5mL, 10 75.00 IE 252 178,072 8438 Soln for injection 150 iu in 0.5mL, 10 75.00 IE 256 324,647 8565 Soln for injection 300iu in 0.36mL mulit-dose cart 75.00 IE 776 426,464 8566 Soln for injection 600iu in 0.75mL mulit-dose cart 75.00 IE 1,517 1,118,683 G03GA01 HUMAN CHORIONIC GONADOTROPHIN 1477 Injection set containing 1 ampoule powder for 250.00 IE 4,708 123,514 1579 Injection set containing 3 ampoules powder for 250.00 IE 1,001 30,407 1581 Injection set containing 3 ampoules powder for 250.00 IE 2,148 109,696 1582 Injection set containing 3 ampoules powder for 250.00 IE 2,893 144,580 6180 Injection set containing 3 ampoules powder for 250.00 IE 113 - 6181 Injection set containing 3 ampoules powder for 250.00 IE 217 - OVULATION STIMULANTS, SYNTHETIC G03GB02 CLOMIPHENE CITRATE 1211 Tablet 50 mg 9.00 MG 39,170 1,563,472 ANTIANDROGENS ANTIANDROGENS, PLAIN PREPARATIONS G03HA01 CYPROTERONE ACETATE 1269 Tablet 50 mg 0.10 GM 24,104 1,930,506 1270 Tablet 50 mg 0.10 GM 15,344 4,254,560 8019 Tablet 100 mg 0.10 GM 44,954 13,434,676 12897 Tablet 10 mg 15 0.10 GM 1,582 - ANTIANDROGENS AND ESTROGENS G03HB01 CYPROTERONE and OESTROGEN 8062 Tablet 2 mg 11 / 2 mg + 1 mg 10 - - 5,843 93,158 8429 Tablet 2 mg 16 / 2 mg + 1 mg 12 - - 7,920 127,032 14126 Tablet 35 ug/2mg 28 1 - - 76,999 - 14127 Tablet 35 ug/2mg 28 3 - - 213,852 - 15418 Tablet 28 1 - - 41,814 - 15419 Tablet 28 3 - - 91,177 - 17090 Tablet 28 1 - - 20,376 - 17091 Tablet 28 3 - - 58,780 - 18070 Tablet 35 ug/2mg 28 1 - - 227 - 18071 Tablet 35 ug/2mg 28 3 - - 1,059 - OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM ANTIGONADOTROPINS AND SIMILAR AGENTS G03XA01 DANAZOL 1285 Capsule 100 mg 0.60 GM 891 52,646 1287 Capsule 200 mg 0.60 GM 3,747 330,403 G03XA02 GESTRINONE 8015 Capsule 2.5 mg 0.70 MG 721 56,980 G03XC01 RALOXIFENE 8363 Tablet 60mg 28 60.00 MG 364,511 22,087,784

98 G

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS

OTHER UROLOGICALS, INCL ANTISPASMODICS ACIDIFIERS G04BA01 AMMONIUM CHLORIDE 1044 Tablet 500 mg 8.50 GM 4,113 78,879 URINARY ANTISPASMODICS G04BD04 OXYBUTYNIN 8039 Tablet 5 mg 15.00 MG 196,581 3,067,214 DRUGS USED IN ERECTILE DYSFUNCTION G04BE01 ALPROSTADIL 4579 Intracavernosal injection 10 ug in single syringe 0.02 MG 2,646 206,980 4580 Intracavernosal injection 20 ug in single syringe 0.02 MG 6,980 699,977 4582 Injection set containing five ampoules 10 ug in 0.02 MG 6,978 473,536 4583 Injection set containing five ampoules 20 ug in 0.02 MG 11,141 953,044 17540 Intracavernosal injection 20 ug in 1 ml 0.02 MG 607 - 17934 Intracavernosal injection 10 ug per syringe 2 0.02 MG 395 - 17935 Intracavernosal injection 20 ug per syringe 2 0.02 MG 1,561 - G04BE03 SILDENAFIL 4584 Tablet 25mg 4 50.00 MG 3,396 173,176 4585 Tablet 50mg 4 50.00 MG 78,605 5,001,126 4586 Tablet 100mg 4 50.00 MG 261,140 17,853,454 G04BE08 TADALAFIL 17825 Tablet 10mg 4 - - 16,120 - 17826 Tablet 20mg 4 - - 127,397 - G04BE09 VARDENAFIL 17959 Tablet 5mg 4 - - 241 - 17960 Tablet 10mg 2 - - 419 - 17961 Tablet 10mg 4 - - 5,213 - 17962 Tablet 20mg 2 - - 577 - 17963 Tablet 20mg 2 - - 11,172 - OTHER UROLOGICALS G04BX SODIUM BICARBONATE 4458 Capsule 840 mg - - 12,278 142,275 G04BX SODIUM CITRO-TARTRATE 4047 Sachets cont. oral effervescent powder 4 g, 25 - - 477 5,182 4048 Sachets cont. oral effervescent powder 4 g, 28 - - 3,607 41,406 4049 Sachets cont. oral effervescent powder 4 g, 28 - - 45,036 497,512 DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY ALPHA-ADRENORECEPTOR ANTAGONISTS G04CA02 TAMSULOSIN 4464 Capsule 400 ug (modified release) 0.40 MG 76,346 4,062,446 G04CA03 TERAZOSIN 4397 Tablet 2 mg 5.00 MG 3,811 163,938 4398 Tablet 5 mg 5.00 MG 3,479 203,038 4399 Tablet 10 mg 5.00 MG 1,374 116,968 TESTOSTERONE-5-ALPHA REDUCTASE INHIBITORS G04CB01 FINASTERIDE 4233 Tablet 5mg 5.00 MG 29,749 2,894,318 16113 Tablet 1mg 28 - - 59,599 -

99 H

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

SYSTEMIC HORMONAL PREP,EXCL SEX HORMONES PITUITARY, HYPOTHALAMIC HORMONES AND ANALOGUES

ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES ACTH H01AA02 TETRACOSACTRIN 2832 Injection 1 mg in 1 ml 0.25 MG 391 27,071 POSTERIOR PITUITARY LOBE HORMONES VASOPRESSIN AND ANALOGUES H01BA02 DESMOPRESSIN 2129 Intranasal solution 100 ug per ml, 2.5 ml 25.00 UG 5,044 863,536 8031 Nasal spray (pump pack) 10 ug per ml 5 25.00 UG 42,707 3,331,386 8032 Nasal spray (pump pack) 10 ug per ml 5 25.00 UG 19,986 2,767,541 8662 Tablet 200 mg 90 400.00 UG 211 31,532 8663 Tablet 200 mg 30 400.00 UG 1,284 81,535 HYPOTHALAMIC HORMONES GONADOTROPHIN-RELEASING HORMONES H01CA02 NAFARELIN 2962 Nasal spray (pump pack) 200 ug base per dose 60 0.40 MG 4,087 399,759 ANTIGROWTH HORMONE H01CB02 OCTREOTIDE 6228 Injection 100 ug in 1 mL ampoule 5 0.70 MG 255 313,524 6268 Inj (modified release) 20 mg vial - - 570 1,414,824 6269 Inj (modified release) 30 mg vial - - 506 1,612,476

100 H

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

SYSTEMIC HORMONAL PREP,EXCL SEX HORMONES CORTICOSTEROIDS FOR SYSTEMIC USE

CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN MINERALOCORTICOIDS H02AA02 FLUDROCORTISONE ACETATE 1433 Tablet 100 ug 0.10 MG 21,515 319,845 GLUCOCORTICOIDS H02AB01 BETAMETHASONE 2694 Injection 3 mg-3.9 mg (equivalent to 5.7 mg 1.50 MG 66,182 1,618,856 H02AB16 BUDESONIDE 16038 Capsule 3mg 90 9.00 MG 1,617 - H02AB10 CORTISONE 1246 Tablet 5 mg 37.50 MG 7,314 128,508 1247 Tablet 25 mg 37.50 MG 32,783 441,552 H02AB02 DEXAMETHASONE 1291 Injection 8 mg in 2 ml 1.50 MG 6,233 143,470 1292 Tablet 500 ug 1.50 MG 22,878 159,235 2507 Tablet 4 mg 1.50 MG 74,800 757,065 2509 Injection 4 mg in 1 ml 1.50 MG 7,445 115,901 3472 Injection 4 mg in 1 ml 1.50 MG 8,564 115,322 H02AB09 HYDROCORTISONE 1499 Tablet 4 mg 30.00 MG 13,095 163,644 1500 Tablet 20 mg 30.00 MG 12,212 162,288 1501 Injection set containing equivalent of 100 mg 30.00 MG 1,909 28,588 1510 Injection set containing equivalent of 100 mg 30.00 MG 11,090 340,518 1511 Injection set containing equivalent of 250 mg 30.00 MG 688 30,661 3096 Injection set containing equivalent of 250 mg 30.00 MG 714 8,807 3470 Injection set containing equivalent of 100 mg 30.00 MG 12,077 152,701 3471 Injection set containing equivalent of 250 mg 30.00 MG 9,769 111,078 H02AB04 METHYLPREDNISOLONE 1928 Injection 40 mg in 1 ml 20.00 MG 50,534 1,144,363 2981 Injection equiv to 40 mg methylprednisolone 20.00 MG 5,683 393,763 H02AB06 PREDNISOLONE 1916 Tablet 25 mg 10.00 MG 372,729 3,502,144 1917 Tablet 5 mg 10.00 MG 608,758 4,448,176 3152 Tablet 1 mg 10.00 MG 174,529 1,205,300 8285 Oral solution equival to 5 mg prednisolone per mL 10.00 MG 203,223 2,601,471 H02AB07 PREDNISONE 1934 Tablet 1 mg 10.00 MG 94,884 655,699 1935 Tablet 5 mg 10.00 MG 322,763 2,360,907 1936 Tablet 25 mg 10.00 MG 192,434 1,818,489 H02AB08 TRIAMCINOLONE ACETONIDE 2990 Injection 10 mg in 1 ml 7.50 MG 32,590 799,026 11073 Ampoule 40mg/m 5 7.50 MG 923 -

101 H

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

SYSTEMIC HORMONAL PREP,EXCL SEX HORMONES THYROID THERAPY

THYROID PREPARATIONS THYROID HORMONES H03AA02 LIOTHYRONINE 2318 Tablet 20 ug 60.00 UG 9,834 731,956 H03AA01 THYROXINE SODIUM 2173 Tablet equivalent to 200 ug anhydrous 0.15 MG 63,296 724,080 2174 Tablet equivalent to 50 ug anhydrous 0.15 MG 421,884 3,405,822 2175 Tablet equivalent to 100 ug anhydrous 0.15 MG 460,653 4,219,902 ANTITHYROID PREPARATIONS THIOURACILS H03BA02 PROPYLTHIOURACIL 1955 Tablet 50 mg 0.10 GM 14,888 467,237 SULPHUR-CONTAINING IMIDAZOLE DERIVATIVES H03BB01 CARBIMAZOLE 1153 Tablet 5 mg 15.00 MG 62,129 1,755,581

102 H

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

SYSTEMIC HORMONAL PREP,EXCL SEX HORMONES PANCREATIC HORMONES

GLYCOGENOLYTIC HORMONES GLYCOGENOLYTIC HORMONES H04AA01 GLUCAGON HYDROCHLORIDE 1449 Injection set containing 1 mg (1 i.u.) 1.00 MG 21,125 791,523 3467 Injection set containing 1 mg (1 i.u.) 1.00 MG 16,693 615,991

103 H

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

SYSTEMIC HORMONAL PREP,EXCL SEX HORMONES CALCIUM HOMEOSTASIS

ANTI-PARATHYROID HORMONES CALCITONIN PREPARATIONS H05BA01 CALCITONIN (SALMON SYNTHETIC) 2995 Injection (salmon) 50 i.u. in 1 ml ampoule 100.00 IE 253 52,214 2997 Injection (salmon) 100 i.u. in 1 ml ampoule 100.00 IE 677 132,067

104 J

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE

TETRACYCLINES TETRACYCLINES J01AA01 DEMECLOCYCLINE HYDROCHLORIDE 2854 Capsule 150 mg 0.60 GM 2,527 112,551 J01AA02 DOXYCYCLINE 2702 Tablet 100 mg 0.10 GM 50,867 780,044 2703 Capsule 100 mg 0.10 GM 46,798 720,350 2707 Capsule 50 mg 0.10 GM 213,832 2,044,631 2708 Capsule 100 mg 0.10 GM 279,856 2,111,589 2709 Tablet 100 mg 0.10 GM 328,402 2,457,443 2711 Tablet 50 mg 0.10 GM 368,279 3,515,656 2714 Tablet 100 mg 0.10 GM 49,863 620,557 2715 Capsule 100 mg 0.10 GM 48,786 618,422 3321 Tablet 100 mg 0.10 GM 3,853 28,241 3322 Capsule 100 mg 0.10 GM 1,602 11,744 J01AA08 MINOCYCLINE 1616 Tablet 50 mg 0.20 GM 372,816 6,187,426 3037 Capsule 100 mg 0.20 GM 7,808 70,855 J01AA07 TETRACYCLINE 2134 Capsule 250 mg 1.00 GM 12,795 96,633 2135 Capsule 250 mg 1.00 GM 16,098 160,647 2145 Capsule 250 mg 1.00 GM 27,771 209,446 2146 Capsule 250 mg 1.00 GM 82,673 824,839 3383 Capsule 250 mg 1.00 GM 1,669 12,190 3386 Capsule 250 mg 1.00 GM 2,018 14,722 AMPHENICOLS AMPHENICOLS J01BA01 CHLORAMPHENICOL 1174 Capsule 250 mg 3.00 GM 326 13,364 BETA-LACTAM ANTIBACTERIALS,PENICILLINS PENICILLINS WITH EXTENDED SPECTRUM J01CA04 AMOXYCILLIN 1878 Sachet containing oral powder 3 g 1.00 GM 16,729 174,722 1883 Chewable tablet 250 mg 1.00 GM 76,745 682,006 1884 Capsule 250 mg 1.00 GM 427,574 3,370,362 1886 Powder for syrup 125 mg per 5 ml, 100 ml 1.00 GM 458,511 4,497,708 1887 Powder for syrup 250 mg per 5 ml, 100 ml 1.00 GM 665,418 7,376,174 1888 Powder for paediatric oral drops 100 mg per ml, 1.00 GM 128,419 1,508,307 1889 Capsule 500 mg 1.00 GM 1,935,249 21,682,522 3300 Capsule 500 mg 1.00 GM 339,904 3,714,487 3301 Capsule 250 mg 1.00 GM 92,410 724,693 3302 Powder for syrup 125 mg per 5 mL, 100 ml 1.00 GM 12,449 122,039 3303 Chewable tablet 250 mg 1.00 GM 2,163 19,089 3309 Sachet containing oral powder 3 g 1.00 GM 35,257 306,806 3393 Powder for syrup 250 mg per 5 mL, 100 ml 1.00 GM 5,600 61,638 8581 Tablet 1g 14 1.00 GM 196,344 2,209,645 10116 Vial 1g 5 1.00 GM 597 - 17565 Capsule 250 mg 1.00 GM 139 -

105 J

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE

BETA-LACTAM ANTIBACTERIALS,PENICILLINS PENICILLINS WITH EXTENDED SPECTRUM J01CA01 AMPICILLIN 1048 Capsule 250 mg 2.00 GM 851 9,617 2390 Injection 500 mg (solvent required) 2.00 GM 397 4,384 2671 Capsule 500 mg 2.00 GM 3,924 49,521 2977 Injection 1 g (solvent required) 2.00 GM 9,517 174,041 6533 Injection 1 g and 10mL WFI 2.00 GM 982 35,482 6536 Injection 1 g and 10mL NS 2.00 GM 165 7,021 BETA-LACTAMASE SENSITIVE PENICILLINS J01CE08 BENZATHINE PENICILLIN 1766 Injection 1.8 g in 4 ml, disposable syringe 3.60 GM 1,778 81,048 8167 Injection 900 mg in 2 ml cartridge-needle unit 3.60 GM 988 23,400 J01CE01 BENZYLPENICILLIN 1775 Injection 600 mg (solvent required) 3.60 GM 5,353 189,797 2647 Injection 3 g (solvent required) 3.60 GM 796 58,561 3486 Injection 600 mg (with sterilised Water for 3.60 GM 4,782 148,959 3487 Injection 3g (solvent supplied) 3.60 GM 3,985 53,445 6561 Injection 600 mg and 2mL WFI 3.60 GM 255 13,837 6563 Injection 600 mg and 10mL WFI 3.60 GM 686 90,383 J01CE02 PHENOXYMETHYLPENICILLIN 1702 Tablet 125 mg 2.00 GM 1,044 11,637 1703 Tablet 250 mg 2.00 GM 15,059 168,759 1705 Capsule 250 mg 2.00 GM 25,291 280,717 1786 Tablet 125 mg 2.00 GM 573 6,038 1787 Tablet 250 mg 2.00 GM 21,861 230,948 1789 Capsule 250 mg 2.00 GM 37,069 395,293 2965 Capsule 500 mg 2.00 GM 205,704 2,897,494 3028 Tablet 500 mg 2.00 GM 93,818 1,289,767 3360 Tablet 250 mg 2.00 GM 3,082 26,099 3361 Tablet 500 mg 2.00 GM 4,070 41,422 3363 Capsule 250 mg 2.00 GM 3,779 34,833 3364 Capsule 500 mg 2.00 GM 6,428 73,836 18005 Tablet 125 mg 2.00 GM 122 - J01CE09 PROCAINE PENICILLIN 1794 Injection 1.5 g 3.60 GM 10,650 557,910 3485 Injection 1.5 g 3.60 GM 26,081 1,365,633 BETA-LACTAMASE RESISTANT PENICILLINS J01CF01 DICLOXACILLIN 5097 Capsule 500 mg 2.00 GM 115 2,128 7064 Injection 1 gm 10mL and WFI 2.00 GM 534 24,170 8121 Capsule 250 mg 2.00 GM 58,467 673,888 8122 Capsule 500 mg 2.00 GM 322,116 6,769,350 8123 Injection 500 mg (solvent required) 2.00 GM 393 10,739 8124 Injection 1 gm (solvent required) 2.00 GM 7,242 269,476

106 J

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE

BETA-LACTAM ANTIBACTERIALS,PENICILLINS BETA-LACTAMASE RESISTANT PENICILLINS J01CF05 FLUCLOXACILLIN 1524 Injection 500 mg (solvent required) 2.00 GM 467 8,467 1525 Injection 1 g (solvent required) 2.00 GM 21,232 826,458 1526 Capsule 250 mg 2.00 GM 53,244 623,759 1527 Capsule 500 mg 2.00 GM 233,881 4,999,721 1528 Powder for syrup 125 mg per 5 ml, 100 ml 2.00 GM 28,398 373,088 1529 Powder for syrup 250 mg per 5 ml, 100 ml 2.00 GM 47,867 878,270 5090 Capsule 250 mg 2.00 GM 114 1,227 5091 Capsule 500 mg 2.00 GM 336 6,116 6731 Injection 1 g 10mL WFI 2.00 GM 724 42,042 6734 Injection 1 g 10mL NS 2.00 GM 202 13,748 COMBINATIONS OF PENICILLINS, INCL.BETA-LACTAMASE INHIBITORS J01CR02 AMOXYCILLIN with CLAVULANIC ACID 1891 Tablet 500 mg-125 mg 1.00 GM 312,430 4,223,401 1892 Powder for syrup 125mg-31.25mg per 5ml, 75ml 1.00 GM 48,954 602,650 5006 Tablet 875 mg-125 mg 1.00 GM 21,579 365,571 5008 Tablet 500 mg-125 mg 1.00 GM 6,008 79,804 5009 Powder for syrup 125mg-31.25mg per 5ml, 75ml 1.00 GM 176 2,157 5011 Powder for syrup 400mg-57mg per 5ml, 50ml 1.00 GM 424 6,157 8254 Tablet 875 mg-125 mg 1.00 GM 1,771,296 30,945,899 8319 Powder for syrup 400mg-57mg per 5ml, 50ml 1.00 GM 336,028 4,957,796 16246 Tablet 500 mg-125 mg 1.00 GM 149 - 16447 Powder for syrup 250mg-62.5mg per 5ml, 75ml 1.00 GM 194 - J01CR03 TICARCILLIN with CLAVULANIC ACID 2179 Injection 3 g-100 mg (solvent required) 15.00 GM 14,606 2,542,686 6881 Injection 3 g-100 mg 10mL and WFI 15.00 GM 546 117,384 OTHER BETA-LACTAM ANTIBACTERIALS FIRST-GENERATION CEPHALOSPORINS J01DB01 CEFALEXIN 3058 Capsule 250 mg 2.00 GM 320,588 2,710,643 3094 Granules for syrup 125 mg per 5 ml, 100 ml 2.00 GM 98,173 1,111,304 3095 Granules for syrup 250 mg per 5 ml, 100 ml 2.00 GM 250,594 3,433,246 3119 Capsule 500 mg 2.00 GM 2,354,580 27,091,508 3317 Capsule 250 mg 2.00 GM 4,675 38,788 3318 Capsule 500 mg 2.00 GM 13,714 152,404 3319 Granules for syrup 125 mg per 5 ml, 100 ml 2.00 GM 201 2,269 3320 Granules for syrup 250 mg per 5 ml, 100 ml 2.00 GM 261 3,441 17604 Capsule 500 mg 2.00 GM 207 - J01DB03 CEPHALOTHIN 2964 Injection 1 g (solvent required) 4.00 GM 62,587 2,445,417 6609 Injection 1 g and 2mL WFI 4.00 GM 131 6,260 6611 Injection 1 g and 10mL WFI 4.00 GM 2,671 149,058 6614 Injection 1 g and 10mL NS 4.00 GM 690 42,687 J01DB04 CEPHAZOLIN 1257 Injection 1 g (solvent required) 3.00 GM 12,154 784,242 6635 Injection 1 g and 10mL WFI 3.00 GM 278 24,337 6638 Injection 1 g and 10mL NS 3.00 GM 145 19,124

107 J

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE

OTHER BETA-LACTAM ANTIBACTERIALS SECOND-GENERATION CEPHALOSPORINS J01DC04 CEFACLOR 1169 Tablet 375 mg (sustained release) 1.00 GM 718,206 10,533,570 2460 Powder for oral susp 125 mg per 5 ml, 100 ml 1.00 GM 142,882 1,973,794 2461 Powder for oral susp 250 mg per 5 ml, 75 ml 1.00 GM 300,469 4,314,108 5045 Tablet 375mg (sustained release) 1.00 GM 1,264 18,213 J01DC05 CEFOTETAN 1772 Injection 1 g (solvent required) 4.00 GM 2,444 307,193 1773 Injection 2 g (solvent required) 4.00 GM 301 47,595 6641 Injection 1 g 10mL and WFI 4.00 GM 163 21,277 J01DC02 CEFUROXIME 8292 Tablet 250mg 14 0.50 GM 92,573 1,398,851 THIRD-GENERATION CEPHALOSPORINS J01DD01 CEFOTAXIME 1085 Injection 1 g (solvent required) 4.00 GM 4,705 269,753 1086 Injection 2 g (solvent required) 4.00 GM 659 68,754 6593 Injection 1 g 10mL and WFI 4.00 GM 143 10,076 6596 Injection 1 g 10mL and NS 4.00 GM 137 10,211 J01DD02 CEFTAZIDIME 12747 Vial 1g 1 6.00 GM 288 - J01DD04 CEFTRIAXONE 1782 Injection 250 mg (solvent required) 2.00 GM 619 7,201 1783 Injection 500 mg (solvent required) 2.00 GM 532 28,820 1784 Injection 1 g (solvent required) 2.00 GM 39,085 3,322,562 1785 Injection 2 g (solvent required) 2.00 GM 5,775 881,482 1790 Injection 250 mg (solvent required) 2.00 GM 154 5,618 6867 Injection 1 g 2mL and WFI 2.00 GM 297 29,852 6868 Injection 1g (solvent supplied) 2.00 GM 203 19,046 6869 Injection 1 g 10mL and WFI 2.00 GM 1,752 162,710 6872 Injection 1 g 10mL and NS 2.00 GM 369 35,246 6875 Injection 2 g and 10mL WFI 2.00 GM 249 41,271 FOUTH-GENERATION CEPHALOSPORINS J01DE01 CEFEPIME 8315 Injection 1 g (solvent required) 2.00 GM 899 197,615 8316 Injection 2 g (solvent required) 2.00 GM 563 311,148

108 J

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE

SULFONAMIDES AND TRIMETHOPRIM TRIMETHOPRIM AND DERIVATIVES J01EA01 TRIMETHOPRIM 2922 Tablet 300 mg 0.40 GM 601,500 4,645,333 COMBINATIONS OF SULFONAMIDES AND TRIMETHOPRIM, INCL. DERIVATIVES J01EE01 TRIMETHOPRIM with SULPHAMETHOXAZOLE 2949 Tablet 80 mg-400 mg 320.00 MG 8,413 83,287 2951 Tablet 160 mg-800 mg 320.00 MG 315,151 3,490,820 3103 Oral suspension 40 mg-200 mg per 5 ml, 100 ml 320.00 MG 118,237 983,490 3390 Tablet 160 mg-800 mg 320.00 MG 2,123 18,167 3391 Oral suspension 40 mg-200 mg per 5 ml, 100 ml 320.00 MG 177 1,440 MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS MACROLIDES J01FA10 AZITHROMYCIN 4115 Tablet 500 mg 0.30 GM 1,130 37,636 8200 Tablet 500 mg 0.30 GM 28,643 626,645 8201 Powder for oral suspension 200 mg per 5 ml, 15 ml 0.30 GM 376 7,144 8336 Tablet 500 mg 2 0.30 GM 12,978 284,401 J01FA09 CLARITHROMYCIN 6152 Tablet 500 mg 100 0.50 GM 476 85,400 8318 Tablet 250mg 14 0.50 GM 511,663 10,390,222 16432 Liquid 250 mg/5 mL 1 0.50 GM 4,217 - J01FA01 ERYTHROMYCIN 1397 I.V. infusion 1 g (base) 1.00 GM 208 13,279 1398 I.V. infusion 300 mg (base) 1.00 GM 1,152 84,191 1400 Capsule 175 mg 1.00 GM 5,652 46,016 1401 Tablet 250 mg (base) 1.00 GM 10,855 89,921 1404 Capsule 250 mg 1.00 GM 123,616 1,232,590 2424 Granules for paediatric oral susp 200 mg 1.00 GM 120,041 1,286,396 2425 Paediatric oral susp 125 mg (base) per 5 ml 1.00 GM 4,505 39,905 2428 Granules for oral susp 400mg (base)per 5ml,10 1.00 GM 125,525 1,591,633 2610 Oral suspension 250 mg (base) per 5 ml, 100 ml 1.00 GM 5,402 62,432 2750 Tablet 400 mg (base) 1.00 GM 298,522 2,817,758 3325 Capsule 250 mg 1.00 GM 18,827 172,147 3328 Tablet 250 mg (base) 1.00 GM 2,145 16,883 3332 Paediatric oral suspension 125 mg (base) per 5 ml, 1.00 GM 152 1,340 3334 Granules for paediatric oral suspension 200 mg 1.00 GM 617 6,608 3336 Tablet 400 mg (base) 1.00 GM 6,078 53,257 3337 Granules for oral suspension 400mg(base) per 5 ml, 1.00 GM 205 2,583 17994 Tablet 250 mg (base) 1.00 GM 514 - J01FA06 ROXITHROMYCIN 1760 Tablet 150 mg 0.30 GM 749,115 9,617,382 8016 Tablet 300 mg 0.30 GM 1,078,742 14,054,055 8129 Tablet for oral suspension 50 mg 0.30 GM 64,148 726,489

109 J

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE

MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS LINCOSAMIDES J01FF01 CLINDAMYCIN 3138 Capsule 150 mg 1.20 GM 44,999 1,428,355 5057 Capsule 150 mg 1.20 GM 14,602 233,832 14057 Ampoule 600 m in 4ml 10 1.80 GM 366 - 16644 Capsule 150 mg 100 1.20 GM 200 - J01FF02 LINCOMYCIN 2530 Injection 600 mg in 2 ml 1.80 GM 2,430 60,411 AMINOGLYCOSIDE ANTIBACTERIALS OTHER AMINOGLYCOSIDES J01GB03 GENTAMICIN SULPHATE 1068 Injection 40 mg (base) in 1 ml 0.24 GM 804 21,274 1168 Injection 60 mg (base) in 1.5 ml 0.24 GM 1,564 52,083 2824 Injection 80 mg (base) in 2 ml 0.24 GM 26,108 498,291 J01GB01 TOBRAMYCIN 1356 Injection 80 mg (base) 0.24 GM 3,180 408,659 QUINOLONE ANTIBACTERIALS FLUOROQUINOLONES J01MA02 CIPROFLOXACIN 1208 Tablet 250 mg 1.00 GM 10,901 525,037 1209 Tablet 500 mg 1.00 GM 91,973 8,068,374 1210 Tablet 750 mg 1.00 GM 35,830 5,401,351 1311 Tablet 250 mg 1.00 GM 5,328 65,301 J01MA14 MOXIFLOXACIN 4329 Tablet 400mg 5 0.40 GM 1,871 106,961 8635 Solution for I.V. infusion 400mg (base)in 250mL - - 137 39,646 8636 Tablet 400mg (base) 5 0.40 GM 4,635 251,245 J01MA06 NORFLOXACIN 3010 Tablet 400 mg 0.80 GM 163,857 3,834,268 13660 Tablet 400mg 6 0.80 GM 24,669 - OTHER ANTIBACTERIALS GLYCOPEPTIDE ANTIBACTERIALS J01XA01 VANCOMYCIN 3130 Injection 500mg(500,000iu) (solvent required) 2.00 GM 1,316 98,695 3131 Injection 500mg(500,000iu) (solvent required) 2.00 GM 18,478 3,594,006 6837 Injection 500mg(500,000iu) and 2mL WFI 2.00 GM 169 29,512 6839 Injection 500mg(500,000iu) and 10mL WFI 2.00 GM 664 106,165 6842 Injection 500mg(500,000iu) and 10mL NS 2.00 GM 308 71,294 STEROID ANTIBACTERIALS J01XC01 FUSIDIC ACID 2311 Oral suspension 50 mg per ml, 90 ml 1.50 GM 336 31,720 2312 Tablet (sodium salt) 250 mg (enteric coated) 1.50 GM 18,627 2,595,462

110 J

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE

OTHER ANTIBACTERIALS IMIDAZOLE DERIVATIVES J01XD01 METRONIDAZOLE 1638 I.V. infusion 500 mg in 100 ml 1.50 GM 33,498 1,291,930 NITROFURAN DERIVATIVES J01XE01 NITROFURANTOIN 1691 Paediatric oral suspension 25 mg per 5 ml, 200 ml 0.20 GM 2,014 34,793 1692 Capsule 50 mg 0.20 GM 71,416 956,379 1693 Capsule 100 mg 0.20 GM 88,729 1,355,385 17927 Capsule 50 mg 0.20 GM 586 - 18116 Capsule 100 mg 0.20 GM 442 - 18315 Paediatric oral suspension 25 mg per 5 ml, 200 ml 0.20 GM 136 - OTHER ANTIBACTERIALS J01XX05 METHENAMINE 3124 Tablet 1 g 2.00 GM 66,317 2,145,800

111 J

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE

ANTIMYCOTICS FOR SYSTEMIC USE ANTIBIOTICS J02AA01 AMPHOTERICIN 1047 Injection 50mg (solvent required) 35.00 MG 458 36,886 IMIDAZOLE DERIVATIVES J02AB02 KETOCONAZOLE 1572 Tablet 200 mg 0.20 GM 25,972 976,582 1573 Tablet 200 mg 0.20 GM 34,171 606,992 TRIAZOLE DERIVATIVES J02AC01 FLUCONAZOLE 1471 Capsule 50 mg, 28 0.20 GM 2,417 434,847 1472 Capsule 100 mg, 28 0.20 GM 7,501 2,660,823 1474 Solution for IV infusion 200 mg in 100 ml, 7 0.20 GM 542 303,021 1475 Capsule 200 mg 0.20 GM 5,481 4,230,219 14171 Capsule 150 mg 0.20 GM 43,037 - J02AC02 ITRACONAZOLE 8196 Capsule 100mg 0.20 GM 4,476 1,192,578 14810 Capsule 100mg 0.20 GM 1,199 - 16227 Capsule 100mg 28 0.20 GM 649 -

112 J

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS

DRUGS FOR TREATMENT OF TUBERCULOSIS ANTIBIOTICS J04AB04 RIFABUTIN 6195 Capsule 150 mg 0.15 GM 761 334,397 J04AB02 RIFAMPICIN 1981 Capsule 150 mg 0.60 GM 1,282 12,833 1982 Capsule 150 mg 0.60 GM 201 6,816 1983 Capsule 300 mg 0.60 GM 1,155 71,032 1984 Capsule 300 mg 0.60 GM 6,647 87,517 8025 Syrup 100 mg per 5 ml, 60 ml 0.60 GM 598 15,030 HYDRAZIDES J04AC01 ISONIAZID 1554 Tablet 100 mg 0.30 GM 1,331 11,338 OTHER DRUGS FOR TREATMENT OF TUBERCULOSIS J04AK02 ETHAMBUTOL HYDROCHLORIDE 16028 Tablet 400 mg 100 1.20 GM 282 - DRUGS FOR TREATMENT OF LEPRA DRUGS FOR TREATMENT OF LEPRA J04BA01 CLOFAZIMINE 14752 Capsule 50 mg 0.10 GM 614 -

113 J

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE

DIRECT ACTING ANTIVIRALS NUCLEOSIDES AND NUCLEOTIDES EXCL. REVERSE TRANSCRIPTASE INHIBITORS J05AB01 ACICLOVIR 1003 Tablet 200 mg 4.00 GM 3,712 408,971 1007 Tablets 200 mg, 90 4.00 GM 42,609 8,015,704 1052 Tablets 800 mg, 35 4.00 GM 6,980 1,574,883 8234 Tablets 800 mg, 120 4.00 GM 377 261,633 J05AB09 FAMCICLOVIR 8002 Tablet 250 mg 0.75 GM 36,378 6,122,472 8092 Tablet 125 mg 0.75 GM 11,047 1,760,317 8217 Tablet 250 mg 0.75 GM 50,418 21,235,531 J05AB54 RIBAVIRIN, COMBINATIONS 6262 140 cap ribavirin 200mg and 2 cart interf alfa-2b - - 509 769,921 6263 168 cap ribavirin 200mg and 2 cart interf alfa-2b - - 459 807,880 J05AB11 VALACICLOVIR 8064 Tablet 500 mg 3.00 GM 29,199 7,206,106 8133 Tablet 500 mg 3.00 GM 12,718 1,588,730 8134 Tablet 500 mg 3.00 GM 174,731 34,011,016 NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS J05AF05 LAMIVUDINE 6257 Tablet 100 mg 0.30 GM 6,412 880,539 NEURAMINIDASE INHIBITORS J05AH01 ZANAMIVIR 16327 Rotadisk 5mg 20 20.00 MG 2,560 -

114 J

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE VACCINES

BACTERIAL VACCINES CHOLERA VACCINES J07AE02 CHOLERA, LIVE ATTENUATED 16761 Oral Vaccine - - 538 - HEMOPHILUS INFLUENZA B VACCINES J07AG01 HAEMOPHILUS INFLUENZA B VACCINE 14180 Injection 0.5ml 1 - - 224 - MENINGOCOCCAL VACCINES J07AH04 MENINGOCOCCAL 14507 Vial 0.5 ml 1 - - 6,109 - 15130 Vial 0.5 ml 1 - - 269 - J07AH07 MENINGOCOCCAL C 17391 Vial 0.5 ml 1 - - 7,727 - 17637 Syringe 10ug per 0.5mL conjugated 1 - - 41,040 - 17650 Vial 0.5 ml 1 - - 10,355 - PERTUSSIS VACCINES J07AJ52 DIPHTERIA WITH TETANUS WITH PERTUSSIS PURIFIED ANTIGEN 17092 Injection 0.5mL 1 - - 1,312 - PNEUMOCOCCAL VACCINES J07AL01 PNEUMOCOCCAL 1903 Injection 0.5 ml (23 valent) - - 330,881 12,267,164 17156 Injection 0.5 ml (7 valent) - - 19,177 - TETANUS VACCINES J07AM51 DIPHTHERIA and TETANUS VACCINE, ADSORBED 1341 Injection 0.5 mL - - 204 2,830 J07AM51 DIPHTHERIA and TETANUS VACCINE, ADSORBED, DILUTED FOR ADULT USE 3019 Injection 0.5 mL - - 3,309 46,436 3462 Injection 0.5 mL - - 27,105 1,809,487 J07AM01 TETANUS 2127 Injection 0.5 ml - - 2,339 29,110 3493 Injection 0.5 ml - - 14,771 369,199 TYPHOID,VACCINES J07AP01 TYPHOID ORAL LIVE ATTENUATED 13158 Cap-ec 3 1 - - 547 - J07AP03 TYPHOID PURIFIED POLYSACCHARIDE ANTIGEN 14718 Syringe 0.5 ml - - 41,772 - 16719 Injection 25ug - - 9,090 - OTHER BACTERIAL VACCINES J07AX Q FEVER 15417 Vaccine 0.5 ml - - 254 - VIRAL VACCINES ENCEPHALITIS VACCINES J07BA02 JAPANESE ENCEPHALITIS VACCINE 16423 Vaccine 1 mL vial 3 - - 418 -

115 J

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE VACCINES

VIRAL VACCINES INFLUENZA VACCINES J07BB02 INFLUENZA VACCINE 2852 Injection (trivalent) 0.5 ml - - 912,134 16,137,126 HEPATITIS VACCINES J07BC02 HEPATITIS A 15374 Vaccine 1 ml 1440u - - 1,143 - 15677 Syrng 720u/0.5mL - - 4,742 - 15687 Syrng 144u 1 - - 38,459 - 15771 Syrng 50u 1 - - 597 - J07BC20 HEPATITIS A\HEPATITIS B 15760 Syrng 1mL - - 85,816 - 15917 Syrng 0.5mL - - 6,099 - 17055 Syrng 0.5mL - - 212 - J07BC01 HEPATITIS B 12913 Vial 1ml 1 - - 8,000 - 12914 Vial 0.5ml 1 - - 1,500 - 13026 Ampoule 20ug/ml 1 - - 26,141 - 13473 Ampoule 10 mc/0.5 mL 1 - - 3,186 - 15783 Vial 40ug/mL 1 - - 260 - 17629 Vial 10ug/0.5mL (adult) 10 - - 112 - J07BC20 SALMONELLA and HEPATITIS A 17818 Prefilled syringe 25ug / 160 Elisa units - - 3,215 - MEASLES VACCINES J07BD52 MEASLES with MUMPS with RUBELLA 13288 Injection 0.5ml 1 - - 783 - POLIOMYELITIS VACCINES J07BF03 POLIOMYELITIS 16235 Injection 0.5mL - - 771 - RABIES VACCINES J07BG01 RABIES INACTIVATED 14107 Injection 1 ml 1 - - 976 - RUBELLA VACCINES J07BJ01 RUBELLA 11227 Injection 0.5ml - - 793 - VARICELLA VACCINES J07BK01 VARICELLA LIVE ATTENUATED 16723 Vaccine 0.5mL - - 55,129 - 16892 Vaccine 0.5mL - - 777 - 17821 Vaccine 0.5mL - - 1,077 -

116 L

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS

ALKYLATING AGENTS NITROGEN MUSTARD ANALOGUES L01AA02 CHLORAMBUCIL 1163 Tablet 2 mg - - 5,632 430,194 L01AA01 CYCLOPHOSPHAMIDE 1031 Injection 2 g (solvent required) - - 7,441 314,507 1079 Injection 500 mg (solvent required) - - 2,829 71,341 1080 Injection 1 g (solvent required) - - 11,214 288,396 1266 Tablet 50 mg - - 12,603 369,180 5914 Injection 500 mg (solvent required) - - 1,042 11,347 5915 Injection 1 g (solvent required) - - 1,702 29,638 5916 Injection 2 g (solvent required) - - 619 18,395 6707 Injection 1 g 10mL and WFI - - 263 8,009 7052 Injection 2 g 10mL and WFI - - 124 5,538 L01AA06 IFOSFAMIDE 8076 Powder for I.V. injection 1g - - 360 96,737 8077 Powder for I.V. injection 2g - - 694 347,954 L01AA03 MELPHALAN 2547 Tablet 2 mg - - 2,806 77,827 ALKYL SULPHONATES L01AB01 BUSULPHAN 1128 Tablet 2 mg - - 460 21,480 ETHYLENE IMINES L01AC01 THIOTEPA 2345 Injection 15 mg (solvent required) - - 131 14,956 NITROSOUREAS L01AD01 CARMUSTINE 14118 Vial 100 mg 1 - - 144 - OTHER ALKYLATING AGENTS L01AX04 DACARBAZINE 16833 Injection 200mg - - 296 - L01AX03 TEMOZOLOMIDE 8379 Capsule 20mg 5 - - 391 194,500 8380 Capsule 100mg 5 - - 2,296 5,292,770 8381 Capsule 250mg 5 - - 1,406 3,203,485 ANTIMETABOLITES FOLIC ACID ANALOGUES L01BA01 METHOTREXATE 1622 Tablet 2.5 mg - - 110,820 1,307,168 1623 Tablet 10 mg - - 52,055 2,436,798 2395 Injection 50 mg in 2 ml - - 17,304 930,732 2396 Injection 5 mg in 2 ml - - 1,274 57,824 5962 Injection 5 mg in 2 ml - - 266 5,230 5963 Injection 50 mg in 2 ml - - 598 10,586 L01BA03 RALTITREXED 8284 Powder for I.V. infusion 2 mg - - 135 115,092

117 L

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS

ANTIMETABOLITES PURINE ANALOGUES L01BB02 MERCAPTOPURINE 1598 Tablet 50 mg - - 6,488 643,644 L01BB03 THIOGUANINE 1233 Tablet 40 mg - - 614 68,525 PYRIMIDINE ANALOGUES L01BC06 CAPECITABINE 8361 Tablet 150 mg - - 1,081 141,103 8362 Tablet 500 mg 120 - - 12,867 9,196,372 L01BC01 CYTARABINE 2884 Injection set containing 100 mg and 5 ml solvent - - 161 9,074 2885 Injection set containing 500 mg and 25 ml solvent - - 300 134,937 5917 Injection set containing 100 mg and 1 ml solvent - - 159 3,485 8033 Injection set containing 100 mg and 1 ml solvent - - 128 7,352 8034 Injection set containing 500 mg and 5 ml solvent - - 495 207,961 L01BC02 FLUOROURACIL 2521 Injection 250 mg in 10 mL - - 3,016 192,441 2528 Injection 500 mg in 10 mL - - 25,345 1,565,286 4222 Cream 50 mg per g (5%), 20 g - - 44,340 1,620,532 5934 Injection 250 mg in 10 mL - - 150 3,419 5935 Injection 500 mg in 10 mL - - 5,419 190,895 L01BC05 GEMCITABINE 5936 Powder for I.V. infusion 200 mg (base) - - 736 133,399 5937 Powder for I.V. infusion 1 gm (base) - - 1,386 708,290 8049 Powder for I.V. infusion 200 mg (base) - - 5,249 1,900,940 8050 Powder for I.V. infusion 1 gm (base) - - 11,517 8,121,907 PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS VINCA ALKALOIDS AND ANALOGUES L01CA01 VINBLASTINE SULPHATE 2198 Injection 10 mg (solvent required) - - 171 11,907 2199 Injection set containing 10 mg and 10 ml solvent - - 740 57,094 5988 Injection 10 mg (solvent required) - - 138 4,312 5989 Injection set containing 10 mg and 10 ml solvent - - 377 9,817 L01CA02 VINCRISTINE SULPHATE 2371 Injection 1mg (solvent required) - - 239 34,109 2374 Injection set containing 1 mg and 1 ml solvent - - 3,843 448,959 5990 Injection set containing 1 mg and 10 ml solvent - - 183 7,406 5991 Injection set containing 1 mg and 1 ml solvent - - 1,440 58,354 L01CA04 VINORELBINE 5992 Solution for I.V. infusion 10 mg (base) in 1 mL - - 128 49,611 5993 Solution for I.V. infusion 50 mg (base) in 5 mL - - 578 335,135 8280 Solution for I.V. infusion 10 mg (base) in 1 mL - - 741 748,710 8281 Solution for I.V. infusion 50 mg (base) in 5 mL - - 1,921 2,599,031

118 L

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS

PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS PODOPHYLLOTOXIN DERIVATIVES L01CB01 ETOPOSIDE 1389 Capsule 100 mg - - 697 299,596 1390 Solution for I.V. infusion 100 mg in 5 ml - - 1,889 397,732 1396 Capsule 50 mg - - 776 388,327 5931 Solution for I.V. infusion 100 mg in 5 ml - - 426 48,301 5932 Powder for I.V. infusion 113.6 mg - - 489 71,611 8120 Powder for I.V. infusion 113.6 mg - - 2,509 546,580 8515 Powder for I.V. infusion 1136 mg - - 436 176,110 TAXANES L01CD02 DOCETAXEL 5921 Injection set containing I.V. infusion 20 mg - - 684 669,435 5922 Injection set containing I.V. infusion 80 mg - - 645 1,192,994 8071 Injection set containing I.V. infusion 20 mg - - 5,341 8,015,196 8074 Injection set containing I.V. infusion 80 mg - - 5,121 13,014,989 L01CD01 PACLITAXEL 3017 Solution for I.V. infusion 150 mg in 25 ml - - 831 1,930,387 3026 Solution for I.V. infusion 30 mg in 5 ml - - 2,389 2,386,606 5973 Solution for I.V. infusion 30 mg in 5 ml - - 466 233,349 5974 Solution for I.V. infusion 100 mg in 16.7 ml - - 447 490,061 5975 Solution for I.V. infusion 150 mg in 25 ml - - 161 218,072 5976 Solution for I.V. infusion 300 mg in 50 ml - - 666 1,370,372 8018 Solution for I.V. infusion 100 mg in 16.7 ml - - 3,128 5,866,042 8360 Solution for I.V. infusion 300 mg in 50 ml - - 4,146 10,229,993 CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES ACTINOMYCINES L01DA01 DACTINOMYCIN 17555 Injection 0.5mg - - 366 - ANTHRACYCLINES AND RELATED SUBSTANCES L01DB01 DOXORUBICIN HYDROCHLORIDE 1336 Solution for I.V. or intravesical 10mg - - 526 60,898 1340 Solution for I.V. or intravesical 20mg - - 1,689 428,168 1342 Solution for I.V. or intravesical 50mg - - 11,531 5,027,763 5891 Solution for I.V. infusion 20mg in 10mL - - 129 170,214 5892 Suspn for IV infusion 50mg in 25 mL - - 165 357,821 5925 Solution for I.V. or intravesical 10mg - - 348 17,656 5926 Solution for I.V. or intravesical 20mg - - 490 55,940 5927 Solution for I.V. or intravesical 50mg - - 2,888 731,619 8569 Suspn for IV infusion 20mg in 10 mL - - 827 1,594,661 8570 Suspn for IV infusion 50mg in 25 mL - - 875 2,321,674 L01DB03 EPIRUBICIN HYDROCHLORIDE 1375 Solution for I.V. injection 10mg in 5 ml, 4 - - 437 73,008 1376 Solution for I.V. injection 20mg in 10 ml, 4 - - 762 256,035 1377 Solution for I.V. injection 50mg in 25 ml, 3 - - 6,943 5,243,234 5928 Solution for I.V. injection 10mg in 5 ml, 4 - - 273 17,057 5929 Solution for I.V. injection 20mg in 10 ml, 4 - - 466 66,379 5930 Solution for I.V. injection 50mg in 25 ml, 3 - - 1,308 764,536

119 L

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS

CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES ANTHRACYCLINES AND RELATED SUBSTANCES L01DB07 MITOZANTRONE 1929 Injection 20 mg in 10 ml - - 1,977 712,785 1930 Injection 25 mg in 12.5 ml - - 917 408,569 1932 Injection 10 mg in 5 ml - - 456 88,209 5965 Injection 20 mg in 10 ml - - 308 92,264 5966 Injection 25 mg in 12.5 ml - - 128 47,900 OTHER CYTOTOXIC ANTIBIOTICS L01DC01 BLEOMYCIN 2315 Injection 15,000 units (solvent required) - - 759 215,023 5903 Injection 15,000 units (solvent required) - - 501 57,937 L01DC03 MITOMYCIN 13990 Vial 2mg 10 - - 236 - 13992 Vial 20mg 5 - - 172 - OTHER ANTINEOPLASTIC AGENTS PLATINUM COMPOUNDS L01XA02 CARBOPLATIN 1160 Solution for I.V. injection 50 mg in 5 ml - - 661 45,228 1161 Solution for I.V. injection 150 mg in 15 ml - - 6,247 2,756,409 1162 Solution for I.V. injection 450 mg in 45 ml - - 5,602 1,654,080 5906 Solution for I.V. injection 50 mg in 5 ml - - 650 29,290 5907 Solution for I.V. injection 150 mg in 15 ml - - 1,599 287,902 5908 Solution for I.V. injection 450 mg in 45 ml - - 1,934 333,536 L01XA01 CISPLATIN 2578 I.V. injection 10 mg in 10 ml - - 274 6,470 2579 I.V. injection 50 mg in 50 ml - - 3,186 139,735 2580 I.V. injection 100 mg in 100 ml - - 4,567 347,968 5910 I.V. injection 50 mg in 50 ml - - 419 12,003 5911 I.V. injection 100 mg in 100 ml - - 829 54,751 L01XA03 OXALIPLATIN 5994 Powder for I.V. infusion 50 mg - - 470 197,174 5995 Powder for I.V. infusion 100 mg - - 869 874,167 8539 Powder for I.V. infusion 50 mg - - 3,618 2,859,031 8540 Powder for I.V. infusion 100 mg - - 7,006 11,367,811 MONOCLONAL ANTIBODIES L01XC02 RITUXIMAB 5896 Soln for IV infusion 100mg\10ml 0.10 GM 112 87,827 5978 Soln for IV infusion 100mg\10ml - - 1,355 1,220,108 5979 Soln for IV infusion 500mg\50ml - - 1,387 3,365,460 8293 Soln for IV infusion 100mg\10ml - - 7,735 9,055,930 8294 Soln for IV infusion 500mg\50ml - - 8,340 22,335,141 8665 Soln for IV infusion 100mg\10ml - - 1,286 1,383,159 8666 Soln for IV infusion 500mg\50ml - - 1,331 3,316,347 L01XC03 TRASTUZUMAB 16961 Vial 150 mg IV - - 1,598 -

120 L

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS

OTHER ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS L01XX05 HYDROXYUREA 3093 Capsule 500 mg - - 25,726 1,985,989 L01XX28 IMATINIB 6359 Capsule 100 mg (base) 120 - - 2,506 10,009,622 6360 Capsule 100 mg (base) 180 - - 618 3,629,537 6361 Capsule 100 mg (base) 120 - - 642 2,870,513 6362 Capsule 100 mg (base) 180 - - 704 4,131,182 L01XX19 IRINOTECAN 5958 I V injection 40 mg in 2 mL - - 376 93,163 5959 I V injection 100 mg in 5 mL - - 857 841,888 8414 I V injection 40 mg in 2 mL - - 2,105 880,838 8415 I V injection 100 mg in 5 mL - - 5,959 8,357,768 L01XX17 TOPOTECAN 8199 Powder for I.V. infusion 4 mg (base) - - 259 588,574

121 L

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY

HORMONES AND RELATED AGENTS ESTROGENS L02AA04 FOSFESTROL 1353 Tablet 120 mg 250.00 MG 138 10,886 PROGESTOGENS L02AB02 MEDROXYPROGESTERONE 2316 Tablet 200 mg 1000.00 MG 1,876 206,790 2725 Tablet 100 mg 1000.00 MG 2,536 245,019 2727 Tablet 250 mg 1000.00 MG 365 49,286 2728 Tablet 500 mg 1000.00 MG 1,843 240,436 L02AB01 MEGESTROL 2731 Tablet 40 mg 160.00 MG 351 20,702 2734 Tablet 160 mg 160.00 MG 2,542 188,016 GONADOTROPHIN RELEASING HORMONE ANALOGUES L02AE03 GOSERELIN 1454 Subcutaneous implant 3.6 mg 0.13 MG 29,403 10,038,657 8093 Subcutaneous implant 10.8 mg (base) in prefilled 0.13 MG 38,307 43,885,041 L02AE02 LEUPRORELIN ACETATE 1565 Injection 7.5 0.13 MG 9,422 4,066,896 8211 Injection 7.5 0.13 MG 12,496 14,353,741 8484 I.M. injection (modified release) 0.13 MG 6,326 9,672,325 14727 Injection 5 mg 0.13 MG 278 - HORMONE ANTAGONISTS AND RELATED AGENTS ANTI-ESTROGENS L02BA01 TAMOXIFEN 2109 Tablet 10 mg (base), 60 20.00 MG 9,762 459,625 2110 Tablet 20 mg (base), 60 20.00 MG 197,066 15,483,000 L02BA02 TOREMIFENE 8216 Tablet 60 mg (base) 60.00 MG 9,453 656,217 ANTI-ANDROGENS L02BB03 BICALUTAMIDE 8094 Tablet 50 mg 50.00 MG 34,680 8,146,402 L02BB01 FLUTAMIDE 1417 Tablet 250 mg 750.00 MG 7,991 1,771,988 L02BB02 NILUTAMIDE 8131 Tablet 150 mg 30.00 MG 3,262 769,945 ENZYME INHIBITORS L02BG01 AMINOGLUTETHIMIDE 1036 Tablet 250 mg 1000.00 MG 549 87,883 L02BG03 ANASTROZOLE 8179 Tablet 1 mg 1.00 MG 32,499 7,073,541 L02BG06 EXEMESTANE 8506 Tablet 25 mg 30 25.00 MG 6,869 1,540,286 L02BG04 LETROZOLE 8245 Tablet 2.5 mg 2.50 MG 33,778 7,323,800

122 L

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS

CYTOKINES AND IMMUNOMODULATORS COLONY STIMULATING FACTORS L03AA02 FILGRASTIM 6126 Injection 300 ug in 1 ml vial 0.35 MG 127 240,195 6291 Injection 300 microgram in 0.5 mL syringe 0.35 MG 4,692 9,027,114 6292 Injection 480 microgram in 0.5 mL syringe 0.35 MG 1,078 4,285,307 L03AA13 PEGFILGRASTIM 6363 Injection 6 mg in 0.6 mL single use syringe 0.30 MG 6,300 13,887,903 INTERFERONS L03AB07 INTERFERON BETA-1a 8289 Injection set 1 vial powder dose 30ug(6m i.u.) 4.30 UG 14,047 15,310,630 8403 Injection 44 ug (12m i.u.)in 0.5 mL single syringe 4.30 UG 12,689 16,916,389 L03AB08 INTERFERON BETA-1b 8101 Injection set 1 vial powder dose 8,000,000 i.u. 4.00 ME 32,968 38,828,460 L03AB04 INTERFERON-ALFA-2a 8180 Solution for injection 3,000,000iu in 0.5 mL 2.00 ME 1,361 704,552 8181 Solution for injection 3,000,000iu in 0.5 mL 2.00 ME 490 277,684 8551 Injection 4,5000,000iu in 0.5mL syringe 2.00 ME 113 51,227 8552 Injection 6,0000,000iu in 0.5mL syringe 2.00 ME 110 68,090 L03AB05 INTERFERON-ALFA-2b 6253 Solution for injection 18,000,000iu in 1.2 mL mult 2.00 ME 130 95,864 6255 Solution for injection 60,000,000iu in 1.2 mL mult 2.00 ME 229 439,536 8348 Solution for injection 18,000,000iu in 1.2 mL mult 2.00 ME 938 576,828 8476 Solution for injection 30,000,000iu solvent 2mL 2.00 ME 141 152,627 8572 Solution for injection 18,000,000iu in 1.2 mL mult 2.00 ME 184 104,725 OTHER CYTOKINES AND IMMUNOMODULATORS L03AX03 BCG VACCINE 1131 mpoule containing powder 5x10<^> 8CFU - - 927 469,232 1140 Injection set 1 vial Powder - - 1,114 480,113 L03AX13 GLATIRAMER ACETATE 8352 Pdr for s\c inj 20mg single use vial + diluent 20.00 MG 12,892 14,053,984

123 L

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSIVE AGENTS

IMMUNOSUPPRESSIVE AGENTS SELECTIVE IMMUNOSUPPRESSIVE AGENTS L04AA01 CYCLOSPORIN 6111 Capsule 25 mg (cont microemulsion pre-concentrate) 0.25 GM 178 26,969 6112 Capsule 50 mg (cont microemulsion pre-concentrate) 0.25 GM 224 55,887 6114 Capsule 100mg (cont microemulsion pre-concentrate) 0.25 GM 378 185,302 6232 Capsule 10 mg (cont microemulsion pre-concentrate) 0.25 GM 261 19,608 6352 Capsule 25 mg 30 0.25 GM 1,772 331,611 6353 Capsule 50 mg 30 0.25 GM 1,810 444,656 6354 Capsule 25 mg 30 0.25 GM 4,862 2,380,196 8658 Capsule 25 mg 60 0.25 GM 415 75,568 8659 Capsule 50 mg 60 0.25 GM 388 97,662 8660 Capsule 100 mg 60 0.25 GM 668 318,714 L04AA11 ETANERCEPT 6367 Injection set 4 vials pdr 25mg and 4 syringe solv 7.00 MG 158 266,883 8637 Injection set 4 vials pdr 25mg and 4 syringe solv 7.00 MG 1,843 3,465,530 8638 Injection set 4 vials pdr 25mg and 4 syringe solv 7.00 MG 516 970,958 L04AA13 LEFLUNOMIDE 8373 Pack 3 Tablets 100 mg and 30 tablets 20 mg 20.00 MG 633 190,404 8374 Tablet 10mg 30 20.00 MG 18,849 2,685,324 8375 Tablet 20mg 30 20.00 MG 79,416 16,562,762 L04AA06 MYCOPHENOLIC ACID 6208 Capsule 250 mg 2.00 GM 138 65,779 6209 Tablet 500 mg 2.00 GM 884 543,439 8650 Capsule 500 mg 150 2.00 GM 207 133,754 L04AA05 TACROLIMUS 6216 Capsule 1 mg 5.00 MG 389 318,053 8647 Capsule 1 mg 100 5.00 MG 175 102,045 OTHER IMMUNOSUPPRESSIVE AGENTS L04AX01 AZATHIOPRINE 2687 Tablet 50 mg 0.15 GM 88,530 6,535,395 2688 Tablet 25 mg 0.15 GM 11,588 522,312

124 M

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS ACETIC ACID DERIVATIVES AND RELATED SUBSTANCES M01AB05 DICLOFENAC 1299 Tablet 25 mg (enteric coated) 0.10 GM 69,822 895,466 1300 Tablet 50 mg (enteric coated), 50 0.10 GM 1,179,509 12,672,048 1302 Suppository 100 mg,40 0.10 GM 22,918 504,061 1332 Tablet 50 mg, 20 0.10 GM 211,575 1,639,462 5075 Tablet 50 mg, 20 0.10 GM 1,360 10,264 5076 Tablet 25 mg (enteric coated) 0.10 GM 209 1,907 5077 Tablet 50 mg (enteric coated) 0.10 GM 1,668 14,742 16918 Tablet 25 mg, 20 0.10 GM 20,441 - 16971 Tablet 25 mg, 10 0.10 GM 4,716 - 17454 Tablet 25mg 30 0.10 GM 9,100 - M01AB55 DICLOFENAC WITH MISOPROSTOL 4190 Tablet 50mg 200ug 0.10 MG 4,261 151,536 M01AB01 INDOMETHACIN 2454 Capsule 25 mg 0.10 GM 297,085 2,289,198 2757 Suppository 100 mg 0.10 GM 72,832 1,386,586 M01AB15 KETOROLAC 13986 Ampoule 30 mg/1 ml 5 30.00 MG 3,296 - 14188 Tablet 10 mg 30 30.00 MG 3,211 - M01AB02 SULINDAC 2047 Tablet 100 mg 0.40 GM 6,805 96,550 2048 Tablet 200 mg 0.40 GM 25,491 342,193 17800 Tablet 100 mg 0.40 GM 1,409 - OXICAMS M01AC06 MELOXICAM 8561 Tablet 7.5 mg 15.00 MG 360,889 8,938,445 8562 Tablet 15 mg 15.00 MG 586,984 19,952,477 M01AC01 PIROXICAM 1895 Dispersible tablet 10 mg,50 20.00 MG 15,537 196,523 1896 Dispersible tablet 20 mg,25 20.00 MG 136,174 1,670,240 1897 Capsule 10 mg 20.00 MG 38,057 481,133 1898 Capsule 20 mg 20.00 MG 213,582 2,621,122 5202 Dispersible tablet 20 mg 20.00 MG 121 1,306 5203 Capsule 10 mg 20.00 MG 863 10,230 M01AC02 TENOXICAM 17675 Tablet 10 mg 20.00 MG 1,911 - PROPIONIC ACID DERIVATIVES M01AE01 IBUPROFEN 3190 Tablet 400 mg 1.20 GM 294,107 3,443,170 3192 Tablet 400 mg 20 1.20 GM 85,191 560,942 3198 Tablet 200 mg 1.20 GM 25,707 221,903 5121 Tablet 200 mg 1.20 GM 883 6,246 5123 Tablet 400 mg 1.20 GM 2,104 17,567 5124 Tablet 400 mg 20 1.20 GM 2,811 18,508 13267 Tablet 200mg 12 1.20 GM 137 - 13268 Tablet 200mg 24 1.20 GM 5,913 - 13372 Tablet 200mg 48 1.20 GM 4,381 - 15401 Susp 0.1/5 ml 100 ml 1.20 GM 3,952 - M01AE01 IBUPROFEN with CODEINE 17716 Tablet 200 mg 12.8mg 48 1.20 GM 113,844 -

125 M

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS PROPIONIC ACID DERIVATIVES M01AE03 KETOPROFEN 1588 Suppository 100 mg 0.15 GM 4,809 95,125 1589 Capsule 100 mg (sustained release), 50 0.15 GM 2,179 30,647 1590 Capsules 200 mg (sustained release), 28 0.15 GM 279,394 4,265,747 5136 Capsule 200 mg (sustained release) 0.15 GM 317 4,642 17683 Capsule 100 mg (sustained release), 50 0.15 GM 596 - 17743 Capsule 50 mg 0.15 GM 125 - 17745 Capsule 100 mg (sustained release), 50 0.15 GM 2,252 - M01AE02 NAPROXEN 1614 Tablets 750 mg (sustained release), 28 0.50 GM 73,401 915,418 1615 Tablets 1 g (sustained release), 28 0.50 GM 243,978 3,682,713 1659 Tablet 500 mg 0.50 GM 219,937 2,896,728 1674 Tablet 250 mg 0.50 GM 46,044 605,400 1795 Tablet 550 mg, 50 0.50 GM 52,223 700,556 5176 Tablet 250 mg 0.50 GM 365 3,326 5177 Tablet 500 mg 0.50 GM 260 2,955 5179 Tablet 1 g (sustained release) 0.50 GM 181 2,201 11401 Tablet 275mg 12 0.50 GM 575 - 17669 Suppository 500 mg 0.50 GM 999 - 17671 Oral suspension 125 mg per 5 ml, 500 ml 0.50 GM 144 - M01AE11 TIAPROFENIC ACID 2102 Tablet 200 mg 600.00 MG 4,706 48,910 2103 Tablet 300 mg 600.00 MG 37,115 521,895 FENAMATES M01AG01 MEFENAMIC ACID 1824 Capsule 250 mg 1.00 GM 43,831 708,620 11611 Capsule 250 mg 20 1.00 GM 660 - COXIBS M01AH01 CELECOXIB 8439 Capsule 100 mg 60 0.20 GM 326,545 10,448,987 8440 Capsule 200 mg 60 0.20 GM 3,076,148 103,394,595 17093 Capsule 200 mg 10 0.20 GM 2,229 - M01AH02 ROFECOXIB 8471 Tablet 12.5 mg 30 25.00 MG 965,625 28,536,997 8472 Tablet 25 mg 30 25.00 MG 2,081,079 89,309,237 8473 Oral suspension 12.5 mg per 5 mL, 150 mL 25.00 MG 2,286 67,600 8474 Oral suspension 25 mg per 5 mL, 150 mL 25.00 MG 1,827 78,662 OTHER ANTIINFL./ANTIRHEUMATIC AGENTS, NON-STEROIDS M01AX12 PENTOSAN-POLY SULFATE SODIUM 14955 Capsule 100 mg 100 - - 625 - SPECIFIC ANTIRHEUMATIC AGENTS GOLD PREPARATIONS M01CB03 AURANOFIN 1095 Tablet 3 mg 6.00 MG 5,229 335,043 M01CB01 SODIUM AUROTHIOMALATE 2016 Injection 10 mg 2.40 MG 254 13,812 2017 Injection 20 mg 2.40 MG 572 46,227 2018 Injection 50 mg 2.40 MG 3,731 472,759 PENICILLAMINE M01CC01 PENICILLAMINE 2721 Tablet 125 mg 0.50 GM 1,737 69,530 2838 Tablet 250 mg 0.50 GM 5,650 248,953

126 M

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

MUSCULO-SKELETAL SYSTEM TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN

TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN ANTIINFL. PREP., NON-STEROIDS FOR TOPICAL USE M02AA05 BENZYDAMINE HYDROCHLORIDE 12729 Cream 30g 1 - - 323 - M02AA15 DICLOFENAC 14860 Gel 50 g 1 - - 7,193 - 14861 Gel 100 g 1 - - 11,768 - 14979 Gel 20 g 1 - - 3,226 - M02AA19 FLURBIPROFEN 17040 Lozenge 8.75mg - - 2,430 - M02AA10 KETOPROFEN 14948 Gel 2.5% 30g 1 - - 1,421 - 14949 Gel 2.5% 60g 1 - - 3,107 - M02AA07 PIROXICAM 15090 Gel 0.5% 25g 1 - - 1,524 - 15091 Gel 0.5% 50g 1 - - 2,812 - CAPSICUM PREPARATIONS M02AB CAPSAICIN 15579 Cream 0.025% 45g - - 1,100 - PREPARATIONS WITH SALICYLIC ACID DERIVATIVES M02AC METHYL SALICYLATE 4022 Compound Cream APF, 100gm - - 4,796 54,024 4023 Ointment BP, 100gm - - 5,420 50,958 4024 Compound ointment BPC 1973, 100gm - - 235 2,535 4025 Compound ointment APF 1934, 100gm - - 1,717 14,557 4026 Liniment APF, 100gm - - 5,607 42,324 4027 Compound liniment APF, 100gm - - 955 8,491 10653 Cream 50g 1 - - 128 - 12931 Cream 100g 1 - - 2,249 - 15805 Liniment APF, 100 mL - - 1,146 - 18022 Compound ointment APF 1934, 100gm - - 119 - M02AC METHYL SALICYLATE with MENTHOL with EUCALYPTUS OIL 11224 Cream 125g 1 - - 1,308 - 12943 Cream 50g 1 - - 1,308 - OTHER TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN M02AX10 NONYLVANILLAMIDE with BUTOXYETHYL NICOTINATE 10868 Cream 50g 1 - - 286 -

127 M

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS

MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS ETHERS, CHEMICALLY CLOSE TO ANTIHISTAMINES M03BC01 ORPHENADRINE CITRATE 11353 Tablet 100mg 100 0.12 GM 5,170 - M03BC51 ORPHENADRINE CITRATE with PARACETAMOL 11354 Tablet 100 0.12 GM 1,991 - OTHER CENTRALLY ACTING AGENTS M03BX01 BACLOFEN 2729 Tablet 10 mg 50.00 MG 74,498 3,003,978 2730 Tablet 25 mg 50.00 MG 41,341 3,387,355 6284 Intrathecal injection 10 mg in 5 mL 55.00 MG 687 251,889 MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS DANTROLENE AND DERIVATIVES M03CA01 DANTROLENE SODIUM 1779 Capsule 25 mg 0.10 GM 4,609 133,896 1780 Capsule 50 mg 0.10 GM 2,353 112,770

128 M

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

MUSCULO-SKELETAL SYSTEM ANTIGOUT PREPARATIONS

ANTIGOUT PREPARATIONS PREPARATIONS INHIBITING URIC ACID PRODUCTION M04AA01 ALLOPURINOL 2600 Tablet 100 mg 0.40 GM 197,064 2,617,332 2603 Capsule 300 mg 0.40 GM 6,657 69,997 2604 Tablet 300 mg 0.40 GM 892,102 8,844,570 PREPARATIONS INCREASING URIC ACID EXCRETION M04AB01 PROBENECID 1940 Tablet 500 mg 1.00 GM 17,619 787,310 PREPARATIONS WITH NO EFFECT ON URIC ACID METABOLISM M04AC01 COLCHICINE 1227 Tablet 500 ug 1.00 MG 220,411 1,854,615

129 M

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES

DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION BISPHOSPHONATES M05BA04 ALENDRONIC ACID 8090 Tablet 40 mg 10.00 MG 22,698 2,515,598 8102 Tablet 10 mg 10.00 MG 59,358 3,548,734 8511 Tablet 70 mg alendronic acid 10.00 MG 1,789,424 99,977,324 M05BA02 CLODRONIC ACID 8132 Capsule equivalent to 400 mg sodium clodronate 1.60 GM 1,067 367,757 8265 Capsule equivalent to 800 mg sodium clodronate 1.60 GM 19,191 7,550,398 M05BA01 DISODIUM ETIDRONATE 2920 Tablet 200 mg 0.40 GM 1,172 150,916 M05BA03 DISODIUM PAMIDRONATE 6223 Inj set 1 vials pdr for iv infuse 90mg,1 amp10ml 60.00 MG 10,760 5,142,403 6279 Inj set 2 vials pdr for iv infuse 30 mg 60.00 MG 174 49,772 6289 Concentrated injection 90 mg in 10 mL 60.00 MG 2,677 1,188,388 8208 Inj set 4 vials pdr for iv infuse 15mg,4 amp 5ml 60.00 MG 118 35,414 8209 Inj set 2 vials pdr for iv infuse 30mg,2 amp10ml 60.00 MG 919 288,932 8463 Concentrated injection 60 mg in 10 mL 60.00 MG 350 99,075 M05BA07 RISEDRONIC ACID 4444 Tablet 35 mg 4 5.00 MG 1,065 59,461 8481 Tablet 5 mg 28 5.00 MG 85,833 4,798,358 8482 Tablet 30 mg 28 5.00 MG 4,367 1,361,819 8621 Tablet 35 mg 5.00 MG 228,165 12,745,080 M05BA05 TILUDRONIC ACID 8267 Tablet 200 mg 0.40 MG 1,575 340,101 M05BA08 ZOLEDRONIC ACID 6343 Powder for I.V. infusion 4 mg vial with diluent 4.00 MG 2,054 1,249,858 6371 Injection concentrate I.V. infusion 4mg in 5 mL 4.00 MG 770 463,969 18344 Powder for I.V. infusion 4 mg vial with diluent 4.00 MG 200 - BISPHOSPHONATES AND CALCIUM M05BB01 ETIDRONIC ACID AND CALCIUM 8056 Pack containing 28 tablets 200 mg and 76 calcium - - 33,430 2,693,400

130 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM ANAESTHETICS

ANAESTHETICS, GENERAL OPIOID ANAESTHETICS N01AH01 FENTANYL 14186 Ampoule 100ug/2 5 - - 201 - OTHER GENERAL ANAESTHETICS N01AX03 KETAMINE HYDROCHLORIDE 11084 Ampoule 200mg/2m 5 - - 274 - ANAESTHETICS, LOCAL ESTERS OF AMINO BENZOIC ACID N01BA02 PROCAINE HYDROCHLORIDE 11631 Ampoule 2%2ml 5 - - 125 - 11632 Ampoule 2%5ml 5 - - 215 - AMIDES N01BB01 BUPIVACAINE 11219 Vial 0.5% 20mL 5 - - 157 - 13777 Ampoule 0.5% 10 mL 5 - - 247 - N01BB02 LIGNOCAINE HYDROCHLORIDE 13643 Ampoule 2% 5ml 10 - - 162 - 15896 Ampoule 1%2mL 50 - - 235 - 17544 Ampoule 1%5mL 50 - - 146 - N01BB52 LIGNOCAINE with ADRENALINE 15905 Vial 2%20mL 5 - - 359 - N01BB52 PRILOCAINE with LIGNOCAINE 14984 Patch 1 g - - 337 - N01BB09 ROPIVACAINE 15645 Inj 10mL 10mg/mL 5 - - 357 -

131 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM ANALGESICS

OPIOIDS NATURAL OPIUM ALKALOIDS N02AA59 CODEINE with ASPIRIN 10521 Tablet 50 100.00 MG 658 - 16916 Tablet 30 mg-325 mg 100.00 MG 2,264 - N02AA59 CODEINE with PARACETAMOL 1215 Tablet 30 mg-500 mg 100.00 MG 3,490,680 37,301,692 3316 Tablet 30 mg-500 mg 100.00 MG 94,437 690,727 12736 Tablet 30mg - 500mg, 50 100.00 MG 7,452 - 17267 Caplet 8mg/500mg 48 100.00 MG 9,295 - 17702 Tablet 8mg/500mg 48 100.00 MG 117 - 17703 Tablet 8mg/500mg 96 100.00 MG 193 - 17819 Tablet 8mg/500mg 24 100.00 MG 5,430 - 17820 Tablet 8mg/500mg 48 100.00 MG 1,838 - N02AA08 DIHYDROCODEINE 11535 Linct 200ml 1 - - 280 - 11785 Linct 200ml 1 - - 42,593 - 12824 Linct 100ml 1 - - 161 - 12825 Linct 100ml 1 - - 18,775 - N02AA03 HYDROMORPHONE 8420 Injection 2 mg in 1 mL 5 4.00 MG 914 15,892 8421 Injection 10 mg in 1 mL 5 4.00 MG 1,160 57,306 8422 Injection 50 mg in 5 mL 5 4.00 MG 1,579 176,935 8423 Injection 500 mg in 50 mL 4.00 MG 335 74,069 8424 Oral liquid 1 mg per mL, 473 mL 20.00 MG 1,168 31,810 8541 Tablet 2mg 20 20.00 MG 636 11,628 8542 Tablet 4mg 20.00 MG 610 19,002 8543 Tablet 8mg 20.00 MG 1,161 57,429

132 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM ANALGESICS

OPIOIDS NATURAL OPIUM ALKALOIDS N02AA01 MORPHINE 1607 Injection 120 mg in 1.5 ml 30.00 MG 4,809 332,424 1644 Injection 10 mg in 1 mL 30.00 MG 35,963 538,795 1645 Injection 15 mg in 1 mL 30.00 MG 20,613 342,961 1646 Tablet 30 mg 100.00 MG 17,917 313,319 1647 Injection 30 mg in 1 mL 30.00 MG 33,651 924,113 1653 Tablet 10 mg (controlled release) 100.00 MG 121,538 2,817,660 1654 Tablet 30 mg (controlled release) 100.00 MG 114,625 4,812,251 1655 Tablet 60 mg (controlled release) 100.00 MG 77,348 5,297,591 1656 Tablet 100 mg (controlled release) 100.00 MG 67,931 7,477,726 2122 Oral solution 2 mg per ml, 200 ml 100.00 MG 27,474 423,518 2123 Oral solution 5 mg per ml, 200 ml 100.00 MG 41,459 793,807 2124 Oral solution 10 mg per ml, 200 ml 100.00 MG 43,976 1,108,520 2839 Capsule 20mg (sustained release) 100.00 MG 82,679 2,740,586 2840 Capsule 50 mg (sustained release) 100.00 MG 59,322 3,279,219 2841 Capsule 100 mg (sustained release) 100.00 MG 45,389 5,310,262 3479 Injection 15 mg in 1 ml 30.00 MG 11,399 134,787 3480 Injection 30 mg in 1 ml 30.00 MG 6,109 80,107 4349 Tablet 200 mg (controlled release) 100.00 MG 276 53,237 8035 Tablet 5 mg (controlled release) 100.00 MG 41,519 578,309 8146 Sachet 30 mg (controlled release) 100.00 MG 1,762 66,699 8305 Sachet 60mg, granules for oral suspn 100.00 MG 1,032 61,544 8306 Sachet 100mg, granules for oral suspn 100.00 MG 564 62,050 8349 Capsule 10 mg (sustained release) 20 100.00 MG 33,375 651,832 8453 Tablet 200 mg (controlled release) 100.00 MG 2,551 987,890 8489 Tablet 15 mg (controlled release) 20 100.00 MG 35,094 841,024 8490 Sachet 20mg, granules for oral suspn 20 100.00 MG 2,941 76,282 8491 Capsule 30 mg (controlled release) 10 100.00 MG 1,720 43,195 8492 Capsule 60 mg (controlled release) 10 100.00 MG 2,051 84,732 8493 Capsule 90 mg (controlled release) 10 100.00 MG 1,554 93,045 8494 Capsule 120 mg (controlled release) 10 100.00 MG 2,724 253,632 14258 Tablet 10 mg (controlled release) 60 100.00 MG 451 - 14259 Tablet 30 mg (controlled release) 60 100.00 MG 254 - 14260 Tablet 60 mg (controlled release) 60 100.00 MG 394 - 14931 Capsule 20 mg (sustained release) 100.00 MG 517 - 14933 Capsule 50 mg (sustained release) 100.00 MG 411 - 15415 Mixture 200 ml 1mg/ml 100.00 MG 666 - 16362 Capsule 10 mg (sustained release) 60 100.00 MG 130 - N02AA05 OXYCODONE 2481 Suppository 30 mg 30.00 MG 23,985 758,151 2622 Tablet 5 mg 75.00 MG 340,459 4,371,652 5195 Tablet 5 mg 75.00 MG 215 2,227 8385 Tablet 10 mg (controlled release) 20 75.00 MG 114,534 3,004,323 8386 Tablet 20 mg (controlled release) 20 75.00 MG 140,088 5,488,656 8387 Tablet 40 mg (controlled release) 20 75.00 MG 87,947 5,535,450 8388 Tablet 80 mg (controlled release) 20 75.00 MG 45,047 5,804,118 8464 Capsule 5 mg 20 75.00 MG 10,339 122,881 8501 Capsule 10 mg 20 75.00 MG 17,143 274,550 8502 Capsule 20 mg 20 75.00 MG 16,806 454,069 8644 Oral solution 5mg per 5mL, 250mL 75.00 MG 390 6,123 8681 Tablet 5 mg (controlled release) 20 75.00 MG 1,026 17,683 16414 Tablet 10 mg (controlled release) 60 30.00 MG 352 - 16418 Tablet 40 mg (controlled release) 60 30.00 MG 450 - 16420 Tablet 80 mg (controlled release) 60 30.00 MG 138 -

133 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM ANALGESICS

OPIOIDS PHENYLPIPERIDINE DERIVATIVES N02AB03 FENTANYL 8337 Transdermal patch 2.5mg (25 ug per hour) 1.20 MG 31,130 2,028,528 8338 Transdermal patch 5mg (50 ug per hour) 1.20 MG 23,871 2,770,769 8339 Transdermal patch 7.5mg (75 ug per hour) 1.20 MG 11,754 1,919,653 8340 Transdermal patch 10 mg (100 ug per hour) 1.20 MG 15,958 3,955,819 N02AB02 PETHIDINE HYDROCHLORIDE 1828 Injection 50 mg in 1 mL 0.40 GM 2,421 25,986 1829 Injection 100 mg in 2 mL 0.40 GM 60,672 667,962 3483 Injection 100 mg in 2 ml 0.40 GM 29,003 324,743 11572 Tablet 50mg 100 0.40 GM 2,020 - 13605 Tablet 50mg 20 0.40 GM 2,709 - 15888 Injection 100 mg in 2 mL 10 0.40 GM 1,312 - DIPHENYLPROPYLAMINE DERIVATIVES N02AC01 DEXTROMORAMIDE 12515 Tablet 5mg 20 20.00 MG 1,039 - N02AC04 DEXTROPROPOXYPHENE NAPSYLATE 4081 Capsule 100 mg 300.00 MG 37,758 636,993 N02AC54 DEXTROPROPOXYPHENE with PARACETAMOL 16347 Capsule 20 0.20 GM 180,820 - 16444 Tablet 20 0.20 GM 401,626 - 16650 Tablet 20 0.20 GM 72,368 - BENZOMORPHAN DERIVATIVES N02AD01 PENTAZOCINE 12845 Tablet 25mg 50 0.20 GM 278 - 12886 Tablet 50mg 50 0.20 GM 1,859 - 15196 Injection 60 mg 2 ml 10 0.20 GM 861 - ORIPAVINE DERIVATIVES N02AE01 BUPRENORPHINE 15207 Tablets .2 mg (slow release) 1.20 MG 1,001 - OTHER OPIOIDS N02AX02 TRAMADOL 3484 Injection 100mg in 2mL 5 0.30 GM 12,098 133,062 5232 Capsule 50mg 20 0.30 GM 1,531 12,620 5234 Tablet 100mg (sustained release) 20 0.30 GM 243 3,642 8455 Capsule 50mg 20 0.30 GM 395,636 3,298,725 8523 Tablet 100mg (sustained release) 20 0.30 GM 491,921 10,153,622 8524 Tablet 150mg (sustained release) 20 0.30 GM 221,383 5,765,410 8525 Tablet 200mg (sustained release) 20 0.30 GM 298,059 10,251,287 8582 Injection 100mg in 2mL 5 0.30 GM 15,037 166,344 8611 Capsule 50mg 20 0.30 GM 610,260 5,088,306 16145 Capsule 50mg 30 0.30 GM 1,190 - 17988 Capsule 50mg 50 0.30 GM 331 -

134 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM ANALGESICS

OTHER ANALGESICS AND ANTIPYRETICS SALICYLIC ACID DERIVATIVES N02BA01 ASPIRIN 1008 Tablet 300 mg 3.00 GM 7,155 49,595 1010 Tablet 300 mg (dispersible) 3.00 GM 347,087 2,378,249 10669 Tab-sol 24 3.00 GM 128 - N02BA51 CODEINE with ASPIRIN 4061 Tablet soluble 8 mg-300 mg 100.00 MG 13,658 149,776 10090 Tab-sol 20 100.00 MG 1,350 - 10091 Tab-sol 100 100.00 MG 14,698 - 10465 Tab-sol 50 100.00 MG 4,118 - 10556 Tablet 96 100.00 MG 288 - 12168 Tablet 50 100.00 MG 1,461 - 12169 Tablet 100 100.00 MG 4,291 - N02BA11 DIFLUNISAL 1319 Tablet 250 mg 750.00 MG 6,908 100,820 1320 Tablet 500 mg 750.00 MG 28,297 421,604 5080 Tablet 250 mg 750.00 MG 1,088 9,556 5081 Tablet 500 mg 750.00 MG 428 5,313 ANILIDES N02BE51 CODEINE with PARACETAMOL 4170 Tablet 15 mg - 500 mg - - 21,424 180,415 4171 Tablet 8 mg-500 mg 100.00 MG 53,462 555,470 10526 Tablet 50 100.00 MG 427 - 10527 Tablet 100 100.00 MG 1,201 - 11705 Tablet 50 100.00 MG 29,659 - 11706 Tablet 100 100.00 MG 51,565 - 11755 Tab-sol 24 100.00 MG 877 - 12670 Tablet 20 100.00 MG 307 - 12692 Tablet 100 100.00 MG 1,809 - 14215 Tablet 8 mg - 500 mg 50 100.00 MG 1,780 - 14788 Tablet 100 100.00 MG 7,110 - 14978 Caplet 50 100.00 MG 3,110 - 15994 Tablet 50 100.00 MG 1,086 - 16901 Tablet 24 100.00 MG 405 - 17212 Tablet 9.6 mg - 500 mg 48 - - 5,722 - 17275 Tablet 48 - - 138 - 17276 Tablet 96 - - 190 -

135 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM ANALGESICS

OTHER ANALGESICS AND ANTIPYRETICS ANILIDES N02BE01 PARACETAMOL 1746 Tablet 500 mg 3.00 GM 4,435,227 34,115,298 1747 Mixture 120 mg per 5 ml, 100 ml 3.00 GM 59,781 432,777 1770 Elixir 240 mg per 5 ml, 200 ml 3.00 GM 210,332 2,087,070 5196 Tablet 500 mg 3.00 GM 612 4,617 11511 Elx 120mg/5 1 3.00 GM 602 - 11512 Elx 200ml 1 3.00 GM 682 - 11515 Tablet 500mg 50 3.00 GM 724 - 11516 Tablet 500mg 100 3.00 GM 2,135 - 11517 Tab-sol 500mg 24 3.00 GM 8,741 - 11519 Drop 20ml 1 3.00 GM 1,625 - 11698 Suppositories 125mg 20 3.00 GM 254 - 11699 Suppositories 250mg 20 3.00 GM 188 - 11721 Suppositories 500mg 24 3.00 GM 1,779 - 13129 Tablet 500mg 50 3.00 GM 369 - 13759 Tablet 500mg 100 3.00 GM 160 - 16574 Tablet 500 mg 3.00 GM 145 - 17787 Tablet 500 mg 3.00 GM 562 - N02BE51 PARACETAMOL with CODEINE with DOXYLAMINE 10870 Tablet 24 - - 45,450 - 12600 Tablet 20 - - 358,465 - 12932 Capsule 24 - - 26,685 - 13102 Tablet 20 - - 135,768 - 13200 Capsule 20 - - 9,636 - 13823 Capsule 20 - - 8,947 - 15227 Tablet 24 - - 15,456 - 15286 Tablet 24 - - 12,552 - 15650 Caplet 500mg 8mg 5mg - - 26,036 - 15684 Tablet 24 - - 32,260 - 16284 Capsule 24 - - 4,386 - 16896 Tablet 20 - - 13,144 - 17268 Tablet 500mg 9.6mg 5.1mg, 20 - - 24,556 - 17291 Tablet 24 - - 478 - 17388 Tablet 24 - - 618 - N02BE51 PARACETAMOL with PROMETHAZINE 11525 Suspension 100ml 1 - - 2,705 - 11526 Suspension 200ml 1 - - 1,325 - N02BE51 PARACETAMOL with PROMETHAZINE with CODEINE 14779 Syrup 200 ml 1 - - 27,181 -

136 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM ANALGESICS

ANTIMIGRAINE PREPARATIONS ERGOT ALKALOIDS N02CA01 DIHYDROERGOTAMINE 1323 Injection 1 mg in 1 ml 4.00 MG 2,378 49,270 3460 Injection 1 mg in 1 ml 4.00 MG 7,920 119,996 N02CA02 ERGOTAMINE 17561 Capsule 1 mg 4.00 MG 206 - N02CA52 ERGOTAMINE TARTRATE with CAFFEINE 1386 Suppositories 2 mg-100 mg, 5 - - 27,965 290,376 N02CA52 ERGOTAMINE with CAFFEINE 13550 Tablet 20 - - 55,347 - N02CA52 ERGOTAMINE with CAFFEINE with DIPHENHYDRAMINE 13142 Capsule 50 - - 12,686 - N02CA04 METHYSERGIDE 2826 Tablet 1 mg 4.00 MG 12,903 566,867

SELECTIVE 5HT RECEPTOR AGONISTS N02CC02 NARATRIPTAN 8298 Tablet 2.5 mg (base) 2 2.50 MG 98,761 1,515,548 16135 Tablet 2.5 mg 4 2.50 MG 3,421 - N02CC01 SUMATRIPTAN 8144 Tablet 50 mg (base) 50.00 MG 258,011 3,985,246 8341 Nasal Spray 20mg/dose 2 20.00 MG 75,012 1,160,627 14181 Tablet 100 mg 50.00 MG 28,633 - 15210 Tablet 50 mg 50.00 MG 11,660 - 15987 Nasal Spray 10mg/dose 2 20.00 MG 1,656 - 16720 Injection 6mg in 0.5ml refill 6.00 MG 1,829 - 16730 Injection 6mg in 0.5ml 6.00 MG 317 - 17455 Tablet 50 mg (base) 4 50.00 MG 9,342 - 17456 Tablet 100 mg 2 50.00 MG 3,130 - N02CC03 ZOLMITRIPTAN 8266 Tablet 2.5 mg 2.50 MG 152,455 2,341,479 17273 Tablet 2.5 mg 2.50 MG 393 - OTHER ANTIMIGRAINE PREPARATIONS N02CX01 PIZOTIFEN MALATE 3074 Tablet 500 ug (base) 1.50 MG 131,241 2,672,505

137 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM ANTIEPILEPTICS

ANTIEPILEPTICS BARBITURATES AND DERIVATIVES N03AA01 METHYLPHENOBARBITONE 1634 Tablet 60 mg 0.50 GM 600 13,837 17746 Tablet 60 mg 0.50 GM 1,690 - N03AA02 PHENOBARBITONE 1850 Tablet 30 mg 0.10 GM 19,997 182,412 1853 Injection 200 mg in 1 ml 0.10 GM 176 5,647 N03AA03 PRIMIDONE 1939 Tablet 250 mg 1.25 GM 18,922 446,856 HYDANTOIN DERIVATIVES N03AB02 PHENYTOIN 1249 Tablet 50 mg 0.30 GM 8,673 243,506 1873 Capsule 30 mg 0.30 GM 22,260 602,819 1874 Capsule 100 mg 0.30 GM 193,057 5,405,723 2692 Paediatric oral suspension 30 mg per 5 ml, 500 ml 0.30 GM 8,521 210,958 10623 Syrup 100mg/ 1 0.30 GM 492 - SUCCINIMIDE DERIVATIVES N03AD01 ETHOSUXIMIDE 1413 Capsule 250 mg 1.25 GM 1,545 79,307 1414 Paediatric syrup 250 mg per 5 ml, 250 ml 1.25 GM 5,315 168,401 BENZODIAZEPINE DERIVATIVES N03AE01 CLONAZEPAM 1805 Tablet 500 ug 8.00 MG 59,978 1,349,658 1806 Tablet 2 mg 8.00 MG 35,215 1,341,026 1807 Injection 1 mg in 2 ml (set containing solution 8.00 MG 2,302 54,674 1808 Paediatric oral drops 2.5 mg in 1 ml, 10 ml 8.00 MG 4,616 69,028 CARBOXAMIDE DERIVATIVES N03AF01 CARBAMAZEPINE 2419 Tablet 200 mg 1.00 GM 171,395 6,168,494 2422 Tablet 100 mg 1.00 GM 57,192 1,216,531 2426 Tablet 200 mg (controlled release) 1.00 GM 60,920 2,225,530 2427 Oral suspension 100 mg per 5 ml, 300 ml 1.00 GM 28,458 708,606 2431 Tablet 400 mg (controlled release) 1.00 GM 47,911 3,124,640 5039 Tablet 100 mg 1.00 GM 147 2,844 N03AF02 OXCARBAZEPINE 8584 Tablet 150 mg 100 1.00 GM 1,510 143,283 8585 Tablet 300 mg 100 1.00 GM 3,061 468,133 8586 Tablet 600 mg 100 1.00 GM 1,498 356,858 8588 Oral suspension 60mg/mL 250mL 1.00 GM 261 44,613

138 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM ANTIEPILEPTICS

ANTIEPILEPTICS FATTY ACID DERIVATIVES N03AG01 SODIUM VALPROATE 2289 Tablet 200 mg (enteric coated), 200 1.50 GM 220,044 7,880,315 2290 Tablet 500 mg (enteric coated), 200 1.50 GM 245,304 16,174,045 2293 Oral liquid 200 mg per 5 ml, 300 ml 1.50 GM 40,874 1,473,655 2294 Crushable tablet 100 mg 1.50 GM 38,551 1,166,817 2295 Syrup 200 mg per 5 ml, 300 ml 1.50 GM 17,071 611,637 N03AG06 TIAGABINE 8221 Tablet 5 mg (base) 30.00 MG 1,636 177,834 8222 Tablet 10 mg (base) 30.00 MG 1,782 339,686 8223 Tablet 15 mg (base) 30.00 MG 804 201,866 N03AG04 VIGABATRIN 2667 Tablet 500mg, 120 2.00 GM 13,081 2,111,858 2668 Oral powder, sachet 500 mg 2.00 GM 2,403 250,892 OTHER ANTIEPILEPTICS N03AX12 GABAPENTIN 1834 Capsule 300 mg 100 1.80 GM 51,924 6,382,571 1835 Capsule 400 mg 100 1.80 GM 23,391 4,213,350 4591 Capsule 100 mg 100 1.80 GM 2,784 119,577 4592 Capsule 300 mg 100 1.80 GM 14,366 1,613,041 4593 Capsule 400 mg 100 1.80 GM 1,774 271,964 4594 Tablet 600 mg 100 1.80 GM 1,017 218,362 4595 Tablet 800 mg 100 1.80 GM 884 253,151 8389 Tablet 800 mg 100 1.80 GM 12,744 3,718,753 8505 Capsule 100 mg 100 1.80 GM 6,610 280,127 8559 Tablet 600 mg 100 1.80 GM 5,121 1,153,178 N03AX09 LAMOTRIGINE 2848 Tablet 25 mg 0.30 GM 32,319 1,856,525 2849 Tablet 50 mg 0.30 GM 48,558 3,993,160 2850 Tablet 100 mg 0.30 GM 75,707 10,239,656 2851 Tablet 200 mg 0.30 GM 51,225 10,599,244 8063 Tablet 5 mg 0.30 GM 5,509 196,607 N03AX14 LEVETIRACETAM 8654 Tablet 250 mg 60 1.50 GM 1,216 101,352 8655 Tablet 500 mg 60 1.50 GM 5,342 876,327 8656 Tablet 1 gm 60 1.50 GM 1,304 266,740 N03AX03 SULTHIAME 2099 Tablet 50 mg 0.40 GM 1,343 43,297 2100 Tablet 200 mg 0.40 GM 1,754 132,903 N03AX11 TOPIRAMATE 8163 Tablet 25 mg 0.30 GM 16,691 1,069,682 8164 Tablet 50 mg 0.30 GM 18,741 1,652,697 8165 Tablet 100 mg 0.30 GM 23,226 3,207,720 8166 Tablet 200 mg 0.30 GM 15,026 3,575,188 8371 Capsule 15 mg 0.30 GM 1,076 58,968 8372 Capsule 25 mg 0.30 GM 1,427 103,284 8520 Capsule 50 mg 0.30 GM 985 99,996

139 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM ANTI-PARKINSON DRUGS

ANTICHOLINERGIC AGENTS TERTIARY AMINES WITH CARBON CHAIN N04AA01 BENZHEXOL HYDROCHLORIDE 1109 Tablet 2 mg 10.00 MG 15,022 175,109 1110 Tablet 5 mg 10.00 MG 7,439 102,369 N04AA02 BIPERIDEN HYDROCHLORIDE 2544 Tablet 2 mg 10.00 MG 8,710 158,164 ETHERS OF TROPINE OR TROPINE DERIVATIVES N04AC01 BENZTROPINE MESYLATE 2362 Tablet 2 mg 60 2.00 MG 65,095 626,655 3038 Injection 2 mg in 2 ml 2.00 MG 1,383 31,942 3457 Injection 2 mg in 2 ml 2.00 MG 6,797 126,961 17440 Tablet 2 mg 60 2.00 MG 528 - DOPAMINERGIC AGENTS DOPA AND DOPA DERIVATIVES N04BA02 LEVODOPA with BENSERAZIDE 2225 Capsule 100 mg-25 mg 0.60 GM 36,423 1,397,832 2226 Capsule 200 mg-50 mg 0.60 GM 17,397 888,510 2227 Capsule 50 mg-12.5 mg 0.60 GM 22,109 476,508 2228 Tablet 200 mg-50 mg 0.60 GM 32,619 1,710,715 2229 Tablet 100 mg-25 mg 0.60 GM 36,246 1,399,055 2231 Capsule 100 mg-25 mg (sustained release) 0.60 GM 12,338 519,697 8218 Dispersible tablet 50 mg 12.5 mg 0.60 GM 4,880 108,546 8219 Dispersible tablet 100 mg 12.5 mg 0.60 GM 6,443 266,560 N04BA02 LEVODOPA with CARBIDOPA 1242 Tablet 100 mg-25 mg 0.60 GM 170,239 7,126,650 1245 Tablet 250 mg-25 mg 0.60 GM 46,844 2,416,832 1255 Tablet 200 mg-50 mg,100 0.60 GM 31,052 2,235,080 ADAMANTANE DERIVATIVES N04BB01 AMANTADINE HYDROCHLORIDE 3016 Capsule 100 mg 0.20 GM 13,774 585,608 DOPAMINE AGONISTS N04BC01 BROMOCRIPTINE MESYLATE 1443 Capsule 2.5 mg (base) 40.00 MG 19,066 706,963 1445 Capsule 10 mg 40.00 MG 2,590 545,737 1446 Capsule 5 mg 40.00 MG 8,995 644,467 N04BC06 CABERGOLINE 8393 Tablet 1 mg, 30 3.00 MG 27,946 2,100,048 8394 Tablet 2 mg, 30 3.00 MG 24,138 2,380,761 8395 Tablet 4 mg, 30 3.00 MG 16,587 1,865,184 N04BC02 PERGOLIDE 2808 Tablet 50 ug (base) 3.00 MG 2,962 171,567 2809 Tablet 250 ug (base) 3.00 MG 8,223 586,018 2810 Tablet 1 mg (base) 3.00 MG 4,379 1,122,737 MONOAMINE OXIDASE TYPE B INHIBITORS N04BD01 SELEGILINE HYDROCHLORIDE 1973 Tablet 5 mg 100 5.00 MG 9,491 536,243 OTHER DOPAMINERGIC AGENTS N04BX02 ENTACAPONE 8367 Tablet 200 mg 1.00 GM 19,141 5,507,643

140 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM PSYCHOLEPTICS

ANTIPSYCHOTICS PHENOTHIAZINE WITH DIMETHYLAMINOPROPYL GROUP N05AA01 CHLORPROMAZINE HYDROCHLORIDE 1195 Injection 50 mg in 2 mL 0.10 GM 1,174 16,117 1196 Tablet 10 mg 0.30 GM 12,578 97,334 1197 Tablet 25 mg 0.30 GM 54,115 498,968 1199 Tablet 100 mg 0.30 GM 30,819 403,946 1201 Mixture 25 mg per 5 mL, 100 mL 0.30 GM 6,396 86,107 3455 Injection 50 mg in 2 mL 0.10 GM 4,766 65,895 PHENOTHIAZINE WITH PIPERAZINE STRUCTURE N05AB02 FLUPHENAZINE DECANOATE 1001 Injection 50 mg in 2 mL 1.00 MG 5,989 213,985 1046 Injection 12.5 mg in 0.5 mL 1.00 MG 3,584 61,887 3098 Injection 25 mg in 1 mL 1.00 MG 7,237 176,311 N05AB02 FLUPHENAZINE HYDROCHLORIDE 16328 Elixir 480mL 0.5mg/mL 10.00 MG 152 - N05AB04 PROCHLORPERAZINE 2369 Injection 12.5 mg in 1 mL 50.00 MG 10,146 151,351 2893 Tablet 5 mg 100.00 MG 812,590 6,195,926 2894 Suppositories 5 mg, 5 100.00 MG 6,137 100,567 2895 Suppositories 25 mg, 5 100.00 MG 25,662 554,967 3477 Injection 12.5 mg in 1 ml 50.00 MG 16,572 232,490 5205 Tablet 5 mg 100.00 MG 223 1,616 N05AB06 TRIFLUOPERAZINE HYDROCHLORIDE 2185 Tablet 1 mg (base) 20.00 MG 17,287 134,953 2186 Tablet 5 mg (base) 20.00 MG 25,713 251,438 2386 Tablet 2 mg (base) 20.00 MG 17,206 149,562 PHENOTHIAZINE WITH PIPERIDINE STRUCTURE N05AC01 PERICYAZINE 3052 Tablet 2.5 mg 50.00 MG 57,804 484,608 3053 Tablet 10 mg 50.00 MG 19,148 241,399 N05AC02 THIORIDAZINE HYDROCHLORIDE 2163 Tablet 10 mg 0.30 GM 8,670 68,021 2164 Tablet 50 mg 0.30 GM 9,384 91,659 2165 Tablet 100 mg 0.30 GM 9,593 130,603 2359 Tablet 25 mg 0.30 GM 11,084 103,061 8096 Oral suspension 10 mg per ml, 500 ml 0.30 GM 410 12,553 18136 Tablet 10 mg 0.30 GM 522 - 18137 Tablet 25 mg 0.30 GM 1,060 - 18138 Tablet 50 mg 0.30 GM 870 - 18139 Tablet 100 mg 0.30 GM 204 - BUTYROPHENONE DERIVATIVES N05AD01 HALOPERIDOL 2761 Tablet 500 ug 100 8.00 MG 60,507 497,640 2763 Oral liquid 2 mg per ml, 100 ml 8.00 MG 2,843 43,041 2765 I.M. injection equivalent to 50 mg haloperidol 3.30 MG 2,952 71,891 2766 I.M. injection equivalent to 150 mg haloperidol 3.30 MG 2,552 110,433 2767 Tablet 1.5 mg 8.00 MG 22,101 191,928 2768 Injection 5 mg in 1 ml 8.00 MG 6,488 101,912 2770 Tablet 5 mg 8.00 MG 31,757 295,877 3456 Injection 5 mg in 1 ml 8.00 MG 4,803 69,399 11883 Tablet 5mg 100 8.00 MG 115 -

141 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM PSYCHOLEPTICS

ANTIPSYCHOTICS THIOXANTHENE DERIVATIVES N05AF01 FLUPENTHIXOL 2255 Injection oily I.M. 20 mg in 1 ml 4.00 MG 6,589 113,880 2256 Injection oily I.M. 40 mg in 1 ml 4.00 MG 3,601 87,184 2257 Injection oily I.M. 100 mg in 1 ml 4.00 MG 5,783 250,275 N05AF05 ZUCLOPENTHIXOL 8097 Oily I.M. injection 200 mg in 1 ml 15.00 MG 23,630 555,846 15616 Tablet 10mg 100 30.00 MG 337 - DIPHENYLBUTYLPIPERIDINE DERIVATIVES N05AG02 PIMOZIDE 11421 Tablet 2mg 50 4.00 MG 3,783 - DIAZEPINES, OXAZEPINES AND THIAZEPINES N05AH02 CLOZAPINE 6101 Tablet 25 mg 0.30 GM 5,251 324,362 6102 Tablet 100 mg 0.30 GM 18,190 5,809,035 N05AH03 OLANZAPINE 8170 Tablet 2.5 mg 30 10.00 MG 125,378 8,917,576 8185 Tablet 5 mg 30 10.00 MG 215,399 29,874,355 8186 Tablet 7.5 mg 30 10.00 MG 56,074 13,099,440 8187 Tablet 10 mg 30 10.00 MG 254,458 86,768,796 8433 Wafer 5 mg 28 10.00 MG 32,629 4,254,537 8434 Wafer 10 mg 28 10.00 MG 33,214 10,893,456 N05AH04 QUETIAPINE 8456 Tablet 25 mg (base) 60 0.40 GM 32,894 2,219,285 8457 Tablet 100 mg (base) 90 0.40 GM 30,153 4,821,173 8458 Tablet 200 mg (base) 60 0.40 GM 49,056 13,751,685 8580 Tablet 300 mg (base) 60 0.40 GM 15,828 5,627,211 NEUROLEPTICS, IN TARDIVE DYSKINESIA N05AK01 TETRABENAZINE 1330 Tablet 25 mg 0.10 GM 3,821 1,036,220 BENZAMIDES N05AL05 AMISULPRIDE 8594 Tablet 100 mg 30 0.40 GM 12,540 708,682 8595 Tablet 200 mg 60 0.40 GM 21,270 3,492,803 8596 Tablet 400 mg 60 0.40 GM 21,572 6,158,248

142 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM PSYCHOLEPTICS

ANTIPSYCHOTICS LITHIUM N05AN01 LITHIUM CARBONATE 3059 Tablet 250 mg 889.00 MG 102,758 1,213,652 8290 Tablet 450 mg (slow release) 889.00 MG 21,376 543,702 OTHER ANTIPSYCHOTICS N05AX08 RISPERIDONE 3169 Tablet 1 mg 5.00 MG 111,821 8,694,885 3170 Tablet 2 mg 5.00 MG 68,842 10,485,810 3171 Tablet 3 mg 5.00 MG 30,143 6,556,508 3172 Tablet 4 mg 5.00 MG 24,546 7,054,562 8100 Oral solution 1 mg per ml, 100 ml 5.00 MG 5,702 747,622 ANXIOLYTICS BENZODIAZEPINE DERIVATIVES N05BA12 ALPRAZOLAM 2130 Tablet 250 ug 1.00 MG 57,252 552,576 2131 Tablet 500 ug 1.00 MG 142,847 1,862,174 2132 Tablet 1mg 1.00 MG 186,821 3,891,575 8118 Tablet 2 mg 1.00 MG 67,207 1,991,283 N05BA08 BROMAZEPAM 4150 Tablet 3 mg 10.00 MG 13,099 314,694 4151 Tablet 6 mg 10.00 MG 27,720 858,836 N05BA09 CLOBAZAM 10898 Tablet 10mg 50 20.00 MG 22,601 - N05BA01 DIAZEPAM 2558 Injection 10 mg in 2 ml 10.00 MG 7,064 71,828 3161 Tablet 2 mg 10.00 MG 219,851 1,468,172 3162 Tablet 5 mg 10.00 MG 1,713,443 11,860,524 3458 Injection 10 mg in 2 ml 10.00 MG 16,300 156,104 5071 Tablet 2 mg 10.00 MG 884 5,551 5072 Tablet 5 mg 10.00 MG 2,544 15,924 13803 Injection 10 mg in 2 ml 10.00 MG 1,216 - 15450 Elixir 0.1% 100ml 10.00 MG 308 - N05BA06 LORAZEPAM 13807 Tablet 1mg 50 2.50 MG 58,094 - 13808 Tablet 2.5mg 50 2.50 MG 29,538 - N05BA04 OXAZEPAM 3132 Tablet 15 mg 50.00 MG 180,969 1,078,199 3133 Tablet 30 mg 50.00 MG 1,326,788 8,160,773 3134 Tablet 15 mg 50.00 MG 4,980 37,056 3135 Tablet 30 mg 50.00 MG 11,657 92,953 5193 Tablet 30 mg 50.00 MG 173 1,049 17343 Tablet 15 mg 50.00 MG 598 -

143 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM PSYCHOLEPTICS

ANXIOLYTICS AZASPIRODECANEDIONE DERIVATIVES N05BE01 BUSPIRONE HYDROCHLORIDE 4144 Tablet 5mg 50 30.00 MG 1,806 78,990 4145 Tablet 10mg 50 30.00 MG 2,674 210,581 HYPNOTICS AND SEDATIVES BARBITURATES, PLAIN N05CA02 AMYLOBARBITONE SODIUM 11346 Tablet 50mg 100 0.10 GM 900 - BENZODIAZEPINE DERIVATIVES N05CD03 FLUNITRAZEPAM 4216 Tablet 1 mg 30 1.00 MG 71,831 1,176,264 16529 Tablet 1 mg 30 1.00 MG 122 - N05CD08 MIDAZOLAM 11021 Ampoule 15mg/3ml 5 15.00 MG 1,078 - 12645 Ampoule 5mg/ml 10 15.00 MG 4,895 - 13771 Ampoule 5mg/ml 10 15.00 MG 228 - 16838 Ampoule 5mg/5ml 5 15.00 MG 221 - 17973 Ampoule 5mg/ml 5 15.00 MG 414 - N05CD02 NITRAZEPAM 2723 Tablet 5 mg 5.00 MG 743,552 4,905,688 2732 Tablet 5 mg 5.00 MG 9,556 83,851 11167 Tablet 5 mg 100 5.00 MG 3,829 - N05CD07 TEMAZEPAM 2088 Tablet 10 mg 20.00 MG 41,005 350,522 2089 Tablet 10 mg 25 20.00 MG 2,664,926 17,594,506 2105 Capsule 10 mg 20.00 MG 16,554 139,839 2108 Capsule 10 mg 20.00 MG 104,377 724,428 5221 Tablet 10 mg 20.00 MG 1,296 8,221 10800 Capsule 10 mg 100 20.00 MG 1,425 - 10815 Capsule 20 mg 25 20.00 MG 13,827 - 10816 Capsule 20 mg 100 20.00 MG 4,245 - 11356 Capsule 20mg 25 20.00 MG 51,192 - 12893 Capsule 20mg 50 20.00 MG 2,893 - 17494 Capsule 10 mg 20.00 MG 419 - 18340 Capsule 10 mg 20.00 MG 871 - N05CD05 TRIAZOLAM 13374 Tablet 0.125 mg 50 0.25 MG 7,738 - BENZODIAZEPINE RELATED DRUGS N05CF02 ZOLPIDEM 16809 Tablet 10 mg 7 10.00 MG 45,031 - 16810 Tablet 10 mg 28 10.00 MG 40,264 - 17644 Tablet 10 mg 20 10.00 MG 340,897 - N05CF01 ZOPICLONE 4522 Tablet 7.5 mg 7.50 MG 48,698 1,006,228 14925 Tablet 7.5 mg 10 7.50 MG 5,729 - OTHER HYPNOTICS AND SEDATIVES N05CM02 CHLORMETHIAZOLE EDISYLATE 13706 Capsule 192mg 1.50 GM 1,269 -

144 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM PSYCHOANALEPTICS

ANTIDEPRESSANTS NON SELECTIVE MONOAMINE REUPTAKE INHIBITORS N06AA09 AMITRIPTYLINE HYDROCHLORIDE 2417 Tablet 10 mg 75.00 MG 232,588 1,338,960 2418 Tablet 25 mg 75.00 MG 554,151 3,516,813 2429 Tablet 50 mg 75.00 MG 324,812 2,501,938 N06AA04 CLOMIPRAMINE HYDROCHLORIDE 1561 Tablet 25 mg 100.00 MG 74,285 2,418,167 N06AA16 DOTHIEPIN HYDROCHLORIDE 1357 Capsule 25 mg 150.00 MG 340,922 2,496,252 1358 Tablet 75 mg 150.00 MG 434,504 3,658,924 N06AA12 DOXEPIN HYDROCHLORIDE 1011 Capsule 10 mg (base) 100.00 MG 81,142 519,213 1012 Tablet 50 mg (base) 100.00 MG 173,341 1,461,777 1013 Capsule 25 mg (base) 100.00 MG 240,996 1,656,107 14246 Tablet 75mg 30 100.00 MG 1,508 - N06AA02 IMIPRAMINE HYDROCHLORIDE 2420 Tablet 10 mg 100.00 MG 59,383 413,731 2421 Tablet 25 mg 100.00 MG 174,848 1,349,554 N06AA10 NORTRIPTYLINE HYDROCHLORIDE 2522 Tablet 10 mg (base) 50 75.00 MG 30,953 470,619 2523 Tablet 25 mg (base) 75.00 MG 37,852 580,860 N06AA06 TRIMIPRAMINE MALEATE 14531 Tablet 25 mg (base) 150.00 MG 3,192 - 16468 Capsule 50 mg 50 150.00 MG 12,539 - SELECTIVE SEROTONIN REUPTAKE INHIBITORS N06AB04 CITALOPRAM 8220 Tablet 20 mg (base) 20.00 MG 1,785,220 65,945,223 N06AB03 FLUOXETINE HYDROCHLORIDE 1434 Capsule 20 mg (base) 20.00 MG 704,403 30,755,627 1809 Oral solution 20 mg (base) per 5 ml, 140ml 20.00 MG 10,349 505,292 8270 Tablet 20 mg (base) (dispersible) 20.00 MG 162,736 6,489,477 N06AB08 FLUVOXAMINE 8174 Tablet 100 mg 0.10 GM 280,385 12,718,934 8512 Tablet 50 mg 30 0.10 GM 79,751 2,098,074 N06AB05 PAROXETINE 2242 Tablet 20 mg (base) 20.00 MG 1,338,501 55,967,399 N06AB06 SERTRALINE 2236 Tablet 50 mg (base) 50.00 MG 1,368,834 51,289,385 2237 Tablet 100 mg (base) 50.00 MG 1,180,230 49,124,288 MONOAMINE OXIDASE INHIBITORS, NON-SELECTIVE N06AF03 PHENELZINE SULPHATE 2856 Tablet 15 mg (base) 100 60.00 MG 2,375 269,036 6355 Tablet 15 mg (base) 60.00 MG 1,612 - N06AF04 TRANYLCYPROMINE SULPHATE 2444 Tablet 10 mg (base) 10.00 MG 20,751 457,277 MONOAMINE OXIDASE TYPE A INHIBITORS N06AG02 MOCLOBEMIDE 1900 Tablet 150 mg 300.00 MG 79,494 2,134,003 8003 Tablet 300 mg 300.00 MG 208,601 10,726,832

145 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM PSYCHOANALEPTICS

ANTIDEPRESSANTS OTHER ANTIDEPRESSANTS N06AX03 MIANSERIN HYDROCHLORIDE 1627 Tablet 10 mg 60.00 MG 29,356 429,704 1628 Tablet 20 mg 60.00 MG 65,938 2,105,161 N06AX11 MIRTAZAPINE 8513 Tablet 30 mg 30.00 MG 544,350 22,134,846 N06AX06 NEFAZODONE 8137 Tablet 100 mg 0.40 GM 26,974 558,732 8138 Tablet 200 mg 0.40 GM 32,569 1,332,049 8139 Tablet 300 mg 0.40 GM 22,061 1,345,215 N06AX18 REBOXETINE 8583 Tablet 4 mg (base) 60 8.00 MG 22,525 974,529 N06AX16 VENLAFAXINE 8068 Tablet 37.5 mg (base) 0.10 GM 92,234 4,021,281 8069 Tablet 75 mg (base) 0.10 GM 69,203 4,008,544 8301 Capsule 75 mg (base) modified release 0.10 GM 663,926 31,327,664 8302 Capsule 150 mg (base)modified release 0.10 GM 761,210 48,794,348 PSYCHOSTIMULANTS AND NOOTROPICS CENTRALLY ACTING SYMPATHOMIMETICS N06BA02 DEXAMPHETAMINE SULPHATE 1165 Tablet 5 mg 15.00 MG 306,208 6,683,721 N06BA04 METHYLPHENIDATE 11791 Tablet 10mg 100 30.00 MG 57,805 - 16747 Tablet 10mg 100 30.00 MG 23,797 - 17636 Tablet 10mg 100 30.00 MG 1,246 - 17704 Capsule C R 20mg 30.00 MG 34,894 - 17705 Capsule C R 30mg 30.00 MG 28,432 - 17706 Capsule C R 40mg 30.00 MG 22,846 - 17931 Tablet 10mg 100 30.00 MG 377 - 17932 Tablet 10mg 100 30.00 MG 209 - 18284 Tablet C R 18mg 30 30.00 MG 329 - 18285 Tablet C R 36mg 30 30.00 MG 605 - N06BA07 MODAFINIL 17624 Tablet 100mg 30 0.30 GM 156 - 17625 Tablet 100mg 60 0.30 GM 542 - OTHER PSYCHOSTIMULANTS AND NOOTROPICS N06BX15 PIPRADROL AND VITAMINS 10023 Mixture 375ml 1 - - 12,346 -

146 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM PSYCHOANALEPTICS

ANTI-DEMENTIA DRUGS ANTICHOLINESTERASES N06DA02 DONEPEZIL 8495 Tablet 5mg 28 7.50 MG 53,893 8,772,591 8496 Tablet 10mg 28 7.50 MG 128,939 20,505,082 N06DA04 GALANTAMINE 8536 Tablet 4 mg (base) 56 16.00 MG 13,587 2,169,038 8537 Tablet 8 mg (base) 56 16.00 MG 33,012 5,245,311 N06DA03 RIVASTIGMINE 8497 Capsule 1.5 mg 56 9.00 MG 5,540 926,268 8498 Capsule 3 mg 56 9.00 MG 9,400 1,519,830 8499 Capsule 4.5 mg 56 9.00 MG 4,421 702,544 8500 Capsule 6 mg 56 9.00 MG 6,138 973,230 8563 Oral solution 2mg (base) per mL, 120mL 9.00 MG 501 85,484 OTHER ANTI-DEMENTIA DRUGS N06DX01 MEMANTINE HYDROCHLORIDE 18031 Tablet 10mg 56 - - 2,084 - 18032 Solution 10mg/mL - - 252 -

147 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS

PARASYMPATHOMIMETICS ANTICHOLINESTERASES N07AA02 PYRIDOSTIGMINE BROMIDE 1959 Tablet 60 mg 180.00 MG 9,773 582,402 2608 Tablet 180 mg (sustained release) 180.00 MG 1,277 151,132 2724 Tablet 10 mg 180.00 MG 2,523 64,874 CHOLINE ESTERS N07AB02 BETHANECHOL CHLORIDE 1062 Tablet 10 mg 45.00 MG 9,500 167,858 DRUGS USED IN ADDICTIVE DISORDERS DRUGS USED IN NICOTINE DEPENDENCE N07BA02 BUPROPION 8465 Tablet 150 mg (sustained release) 0.30 GM 67,629 16,154,759 16946 Tablet 150 mg (sustained release) 30 0.30 GM 495 - 16947 Tablet 150 mg (sustained release) 60 0.30 GM 522 - N07BA01 NICOTINE 4571 Transdermal patch 7 cm ,7 (release 7mg/24hr) 14.00 MG 683 39,302 4572 Transdermal patch 14 cm,7 (release 14mg/24hr) 14.00 MG 1,131 71,385 4573 Transdermal patch 21 cm,7 (release 21mg/24hr) 14.00 MG 3,734 261,880 4576 Transdermal patch 7 (releasing 5mg/16hr) 14.00 MG 143 6,682 4577 Transdermal patch 7 (releasing 10mg/16hr) 14.00 MG 288 14,474 4578 Transdermal patch 7 (releasing 15mg/16hr) 14.00 MG 908 50,086 16841 Inhaler cartridge 10mg 6 60.00 MG 238 - 16842 Inhaler cartridge refill 10mg 42 60.00 MG 165 - DRUGS USED IN ALCOHOL DEPENDENCE N07BB03 ACAMPROSATE 8357 Tablet 333 mg (enteric coated) 2.00 GM 21,928 3,727,297 N07BB01 DISULFIRAM 16345 Effervescent Tablet 200 mg 30 - - 1,050 - N07BB04 NALTREXONE 8370 Tablet 50mg 30 50.00 MG 13,138 2,198,913 DRUGS USED IN OPIOID DEPENDENCE N07BC01 BUPRENORPHINE 6307 Sublingual tablet 0.4 mg (base) 8.00 MG 515 - 6308 Sublingual tablet 2 mg (base) 8.00 MG 8,113 - 6309 Sublingual tablet 8 mg (base) 8.00 MG 9,909 - N07BC02 METHADONE HYDROCHLORIDE 1606 Injection 10 mg in 1 ml 25.00 MG 589 27,204 1609 Tablet 10 mg 25.00 MG 97,902 1,934,321 6171 Syrup 25 mg per 5 ml, 200 ml 25.00 MG 11,657 - 6172 Syrup 25 mg per 5 ml, 1 L 25.00 MG 1,068 - 17513 Syrup 25 mg per 5 ml, 200 ml 25.00 MG 138,053 -

148 N

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS

ANTIVERTIGO PREPARATIONS ANTIVERTIGO PREPARATIONS N07CA01 BETAHISTINE 16064 Tablet 16mg 25 24.00 MG 138,719 - 18064 Tablet 16mg 10 24.00 MG 134 - OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS N07XX02 RILUZOLE 8664 Tablet 50 mg 56 0.10 MG 1,487 1,007,453

149 P

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLANTS ANTIPROTOZOALS

AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES NITROIMIDAZOLE DERIVATIVES P01AB01 METRONIDAZOLE 1621 Tablet 400 mg 2.00 GM 261,028 2,451,242 1626 Tablet 400 mg 2.00 GM 2,297 15,772 1630 Oral suspension 320 mg per 5 ml 2.00 GM 31,644 457,987 1636 Tablet 200 mg 2.00 GM 124,000 828,364 1642 Suppositories 500 mg, 10 2.00 GM 2,013 45,766 3339 Tablet 200 mg 2.00 GM 56,323 375,061 3341 Oral suspension 320 mg per 5 ml 2.00 GM 416 5,933 5155 Tablet 400 mg 2.00 GM 31,044 289,895 5159 Tablet 400 mg 2.00 GM 263 1,725 P01AB02 TINIDAZOLE 1465 Tablet 500 mg 2.00 GM 120,458 927,403 ANTIMALARIALS QUINOLINE DERIVATIVES P01BA01 CHLOROQUINE 15137 Tablet equivalent to 150 mg (approx.) 0.50 GM 4,904 - P01BA02 HYDROXYCHLOROQUINE SULPHATE 1512 Tablet 200 mg 0.52 GM 102,672 3,633,878 P01BA03 PRIMAQUINE PHOSPHATE 17824 Tablet 7.5mg 60 15.00 MG 145 - BIGUANIDES P01BB51 ATOVAQUONE with PROGUANIL 16050 Tablet 12 - - 2,156 - P01BB01 PROGUANIL 15224 Tablet 100mg 0.20 GM 1,376 - METHANOLQUINOLINES P01BC02 MEFLOQUINE 14495 Tablet 250mg 8 1.00 GM 7,449 - P01BC01 QUININE BISULPHATE 1972 Tablet 300 mg 1.50 GM 254,416 2,494,972 18131 Tablet 300 mg 1.50 GM 2,261 - P01BC01 QUININE SULPHATE 1975 Tablet 300 mg 1.50 GM 434,971 4,264,760 DIAMINOPYRIMIDINES P01BD01 PYRIMETHAMINE 1966 Tablet 25 mg - - 539 6,605 P01BD51 PYRIMETHAMINE with SULFADOXINE 14791 Tablet 3 75.00 MG 239 - ARTEMISININ AND DERIVATIVES P01BE52 ARTEMETHER with LUMEFANTRINE 17720 Tablet 20mg/120mg 24 - - 143 -

150 P

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLANTS ANTHELMINTICS

ANTITREMATODALS QUINOLINE DERIVATIVES P02BA01 PRAZIQUANTEL 13814 Tablet 600mg 8 3.00 GM 137 - ANTINEMATODAL AGENTS BENZIMIDAZOLE DERIVATIVES P02CA03 ALBENDAZOLE 8459 Tablet 400 mg 4.00 GM 330 52,506 8503 Tablet 200 mg 6 0.40 GM 714 22,066 P02CA01 MEBENDAZOLE 4325 Tablet 100 mg 0.20 GM 677 10,504 TETRAHYDROPYRIMIDINE DERIVATIVES P02CC01 PYRANTEL EMBONATE 3047 Tablet 125 mg (base) 0.75 GM 1,042 6,511 3048 Tablet 250 mg (base) 0.75 GM 4,144 31,725 10472 suspension 15ml 50mg/ml 1 0.75 GM 295 - IMIDAZOTHIAZOLE DERIVATIVES P02CE01 LEVAMISOLE 8065 Tablet 50 mg (base) 0.15 GM 173 36,436 AVERMECTINES P02CF01 IVERMECTIN 8359 Tablet 3 mg 4 12.00 MG 923 28,901

151 P

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLANTS ECTOPARASITICIDES, INCL SCABICIDES, INSECTICIDES AND REPELLANTS

ECTOPARASITICIDES, INCL SCABICIDES CHLORINE CONTAINING PRODUCTS P03AB02 LINDANE 11763 Ltn 100ml 1 - - 153 - PYRETHRINES, INCL SYNTHETIC COMPOUNDS P03AC04 PERMETHRIN 3054 Cream 50 mg per g (5%), 30 g - - 48,554 723,881 OTHER ECTOPARASITICIDES, INCL SCABICIDES P03AX01 BENZYL BENZOATE 1114 Application 50 g in 200 ml (25%) - - 3,436 24,325 13227 Ltn 25%200ml 1 - - 467 -

152 R

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

RESPIRATORY SYSTEM NASAL PREPARATIONS

DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE SYMPATHOMIMETICS, PLAIN R01AA03 EPHEDRINE 15957 Ephedrine nas drop 15ml - - 1,695 - R01AA05 OXYMETAZOLINE 4377 Nasal drops 500 ug per ml (0.05%), 15 ml 0.40 MG 1,675 24,354 4378 Nasal spray 500 ug per ml (0.05%), 15 ml 0.40 MG 3,047 44,435 4379 Nasal spray 500 ug per ml (0.05%), 18 ml 0.40 MG 395 5,579 10688 Nas-drop inf15ml 1 0.40 MG 1,112 - 10690 Nas spray pmp15ml 1 0.40 MG 360 - R01AA07 XYLOMETAZOLINE 11434 Nas-mst ad 1 0.80 MG 222 - 11435 Nas-drop ad15ml 1 0.80 MG 191 - 11436 Nas spray ad15ml 1 0.80 MG 822 - 11437 Nas-drop ch 1 0.80 MG 285 - ANTIALLERGIC AGENTS, EXCL CORTICOSTEROIDS R01AC02 LEVOCABASTINE 4311 Nasal spray 500 ug per ml (0.05), 10 ml 0.60 MG 4,493 63,668 R01AC01 SODIUM CROMOGLYCATE 4468 Nasal spray metered dose pump 20 mg per ml (2%), 40.00 MG 1,175 21,106 CORTICOSTEROIDS R01AD01 BECLOMETHASONE DIPROPIONATE 4086 Nas spray 50 ug per dose 0.40 MG 1,779 25,457 4087 Aqueous nasal spray 50 ug per dose,set 0.40 MG 15,636 380,104 4088 Aqueous nasal spray 50 ug per dose, 400 dose 0.40 MG 1,368 31,932 16475 Nas spray 50 ug per dose 0.40 MG 2,479 - 17056 Aqueous nasal spray 50 ug per dose, 200 dose 0.40 MG 63,697 - 17089 Aqueous nasal spray 50 ug per dose, 200 dose 0.40 MG 3,783 - 17808 Aqueous nasal spray 50 ug per dose, 200 dose 0.40 MG 10,498 - 17809 Aqueous nasal spray 50 ug per dose, 400 dose 0.40 MG 2,163 - R01AD05 BUDESONIDE 4092 Nasal spray aqueous(pump)64ug per dose (120 doses) 0.30 MG 137,203 2,912,601 17198 Nasal spray aqueous(pump)64ug per dose (60 doses) 0.30 MG 347 - 17200 Nasal spray aqueous(pump)32ug per dose (60 doses) 0.30 MG 38,052 - 17201 Nasal spray aqueous(pump)32ug per dose (120 doses) 0.30 MG 29,922 - 17850 Nasal spray aqueous(pump)64ug per dose (240 doses) 0.30 MG 20,375 - 17952 Nasal spray aqueous(pump)64ug per dose (120 doses) 0.30 MG 226,354 - R01AD09 MOMETASONE FUROATE 16441 Aqueous Nasal spray 50 ug per dose 0.20 MG 257,731 - 17215 Aqueous Nasal spray 50 ug per dose (65 doses) 0.20 MG 1,658 - 18043 Aqueous Nasal spray 50 ug per dose (65 doses) 0.20 MG 6,508 - OTHER NASAL PREPARATIONS R01AX03 IPRATROPIUM BROMIDE 4089 Aqueous nasal spray(pump pack)21ug per dose 0.24 MG 13,910 264,283 4090 Aqueous nasal spray(pump pack)42ug per dose 0.24 MG 13,484 333,430 16829 Aqueous nasal spray(pump pack)42ug per dose 10mL 0.24 MG 2,094 - R01AX10 SODIUM CHLORIDE 16067 Aqueous nasal spray (pump pack) - - 2,947 -

153 R

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

RESPIRATORY SYSTEM NASAL PREPARATIONS

NASAL DECONGESTANTS FOR SYSTEMIC USE SYMPATHOMIMETICS R01BA52 PARACETAMOL with PSEUDOEPHEDRINE 11895 Tablet 30 - - 135 - R01BA52 PARACETAMOL with PSEUDOEPHEDRINE with CHLORPHENIRAMINE 11897 Tablet 10 - - 110 - R01BA02 PSEUDOEPHEDRINE 4418 Tablet 60 mg 0.24 GM 8,007 105,926 4420 Tablet 60 mg 0.24 GM 213,769 2,949,879 10746 Tablet repetabs 18 0.24 GM 1,091 - 11948 Elx 30mg/5ml 1 0.24 GM 914 - 12612 Tablet 60mg 60 0.24 GM 1,265 - 12614 Capsule 120mg 10 0.24 GM 8,042 - 17457 Capsule 60mg 30 0.24 GM 2,072 - 17458 Tablet 60mg 60 0.24 GM 13,541 - R01BA52 TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDE 10013 Tablet 30 - - 42,879 -

154 R

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

ADRENERGICS, INHALANTS NON-SELECTIVE BETA-ADRENOCEPTOR AGONISTS R03AB03 ORCIPRENALINE 13440 Inhaler compl 1 6.00 MG 1,411 - SELECTIVE BETA-2-ADRENOCEPTOR AGONISTS R03AC13 EFORMOTEROL 8136 Capsule contain powder oral inhalation 12ug 24.00 UG 42,471 1,557,177 8239 Powder oral inhalation breath actuated 6ug 24.00 UG 15,785 385,491 8240 Powder oral inhalation breath actuated 12ug 24.00 UG 180,836 6,456,527 R03AC02 SALBUTAMOL 1099 Capsule 200 ug (base) (oral inhalation) 0.80 MG 5,454 110,479 2000 Nebuliser solution single dose 2.5mg(base) 10.00 MG 142,006 3,320,991 2001 Nebuliser solution single dose 5mg(base) 10.00 MG 689,131 17,152,483 2003 Nebuliser solution 5mg (base) per ml(0.5%) 10.00 MG 853 10,623 3495 Oral pressurised inhal 100 ug (base) CFC-free 0.80 MG 12,753 137,204 3496 Nebuliser solution single dose 2.5mg(base) 10.00 MG 8,760 129,002 3497 Nebuliser solution single dose 5mg(base) 10.00 MG 12,598 192,548 8288 Oral pressurised inhal 100 ug (base) CFC-free 0.80 MG 3,282,201 53,101,432 8354 Oral press inhal,breth actu dev 100ug, 200 0.80 MG 130,902 4,694,359 13815 Oral pressurised inhalation 100 ug 0.80 MG 6,510 - 16298 Oral pressurised inhalation 100 ug per 0.80 MG 7,060 - 17489 Powder for oral inhalation refill disks 200ug 0.80 MG 130 - R03AC12 SALMETEROL 3027 Oral pressurised inhalation 25 ug (base) 0.10 MG 150,204 5,175,545 8141 Powder oral inhalation breath actuated 50ug 0.10 MG 49,815 1,749,519 R03AC03 TERBUTALINE SULPHATE 1243 Nebuliser solution 10mg per ml(1%),50ml 20.00 MG 491 6,030 1251 Nebuliser solution single dose 5mg in 2ml 20.00 MG 5,958 163,212 1252 Powder for oral inhalation in breath actuated 2.00 MG 468,004 7,441,279 17236 Elixir 0.3mg/mL 300 mL 2.00 MG 41,479 - ADRENERGICS AND OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES R03AK07 EFORMOTEROL with BUDESONIDE 8625 Pdr oral inhal breth actv dev 200ug/6ug per dose - - 202,752 11,361,262 17812 Oral Press inhal 6ug/200ug 60 - - 259 - R03AK04 SALBUTAMOL with IPRATROPIUM BROMIDE 4283 Oral press inhal 20ug (anhydrous)-100 ug per dose 0.80 MG 7,617 347,451 R03AK06 SALMETEROL and FLUTICASONE 8430 Pdr oral inhal breth actu dev 50ug/100ug - - 108,246 4,970,183 8431 Pdr oral inhal breth actu dev 50ug/250ug - - 668,262 39,717,553 8432 Pdr oral inhal breth actu dev 50ug/500ug - - 872,298 70,287,289 8517 Oral Press inhal 25ug/50ug - - 64,636 2,964,526 8518 Oral Press inhal 25ug/125ug - - 190,032 11,267,129 8519 Oral Press inhal 25ug/250ug - - 683,907 54,432,968

155 R

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,INHALANTS GLUCOCORTICOIDS R03BA01 BECLOMETHASONE DIPROPIONATE 8406 Oral press inhal 50 ug per dose(200 dose)CFC free 0.80 MG 23,771 412,334 8407 Oral press inhal 100 ug per dose(200 dose)CFC free 0.80 MG 131,395 4,120,739 8408 Oral press inhal in breath actu 50 ug CFC free 0.80 MG 8,561 221,103 8409 Oral press inhal in breath actu 100ug CFC free 0.80 MG 66,707 2,466,321 17496 Oral pressurised inhalation 100 ug per dose 0.80 MG 187 - 17572 Oral pressurised inhalation 250 ug per dose 0.80 MG 331 - 17655 Oral pressurised inhalation 100 ug per dose 0.80 MG 541 - 17656 Oral pressurised inhalation 250 ug per dose 0.80 MG 115 - 17659 Oral pressurised inhalation 250 ug per dose 0.80 MG 166 - R03BA02 BUDESONIDE 2065 Nebuliser suspension single dose units 1.50 MG 10,089 574,682 2066 Nebuliser suspension single dose units 1 mg 1.50 MG 23,297 1,894,057 2070 Powder for oral inhalation in breath actuated 0.80 MG 16,067 343,076 2071 Powder for oral inhalation in breath actuated 0.80 MG 107,556 3,118,300 2072 Powder for oral inhalation in breath actuated 0.80 MG 360,310 15,965,240 17660 Oral pressurised inhalation 100 ug per 0.80 MG 1,126 - 17661 Oral pressurised inhalation 200 ug per 0.80 MG 1,102 - R03BA05 FLUTICASONE 8147 Powder for oral inhalation 100ug per dose(60) 0.60 MG 25,042 380,719 8148 Powder for oral inhalation 250ug per dose(60) 0.60 MG 92,671 2,654,036 8149 Powder for oral inhalation 500ug per dose(60) 0.60 MG 94,196 4,721,129 8345 Oral press inhal 125ug\dose cfc-free 0.60 MG 155,225 4,438,287 8346 Oral press inhal 250ug\dose cfc-free 0.60 MG 434,871 21,292,652 8516 Oral press inhal 50ug\dose cfc-free 0.60 MG 113,630 1,723,397 16949 Oral press inhal 50ug\dose 60 dose 0.60 MG 688 - 16950 Oral press inhal 125ug\dose cfc-free 60 dose 0.60 MG 175 - 16952 Oral press inhal 250ug\dose cfc-free 60 dose 0.60 MG 138 - ANTICHOLINERGICS R03BB01 IPRATROPIUM BROMIDE 1540 Oral pressurised inhalation 20 ug per dose 0.12 MG 114,762 4,018,445 1541 Nebuliser solution 250 ug per ml (0.025%) 0.30 MG 2,862 61,475 1542 Neb soln single dose 250ug/mL 30 0.30 MG 82,004 4,182,519 8135 Oral pressurised inhalation 40 ug per dose 0.12 MG 275,481 6,967,097 8238 Nebuliser solution single dose 500 ug 1 mL 0.30 MG 455,718 27,554,804 8279 Oral pressurised inhalation 20 ug per dose 0.12 MG 35,756 1,838,312 8671 Oral pressurised inhalation 21 ug per dose (200) 0.12 MG 1,002 37,648 R03BB04 TIOTROPIUM BROMIDE 8626 Capsule 18ug (base)(oral inhalation) 30 18.00 UG 482,474 37,373,024 ANTIALLERGIC AGENTS, EXCL CORTICOSTEROIDS R03BC03 NEDOCROMIL 8365 Oral pressurised inhalation 2mg CFC-free 8.00 MG 90,577 3,063,456 17486 Oral pressurised inhalation 2mg (112 doses) 8.00 MG 265 - R03BC01 SODIUM CROMOGLYCATE 1124 Nebuliser solution 20 mg per 2 ml, ampoule 80.00 MG 13,957 792,842 2872 Oral pressurised inhalation 1 mg per dose 40.00 MG 11,458 313,168 2878 Capsule 20 mg (oral inhalation) 80.00 MG 4,189 129,337 8334 Oral press inhal 5mg\dose cfc-free 40.00 MG 91,256 3,093,034 17111 Oral pressurised inhalation 5 mg per dose - - 269 -

156 R

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

ADRENERGICS FOR SYSTEMIC USE ALPHA- AND BETA-ADRENOCEPTOR AGONISTS R03CA02 EPHEDRINE 10792 Tablet 30mg 100 50.00 MG 788 - SELECTIVE BETA-2-ADRENOCEPTOR AGONISTS R03CC02 SALBUTAMOL 1103 Syrup 2 mg (base) per 5 ml, 300 ml 12.00 MG 62,341 729,205 17979 Syrup 2 mg (base) per 5 ml, 300 ml 12.00 MG 751 - R03CC03 TERBUTALINE SULPHATE 1034 Injection 500 ug in 1 ml 15.00 MG 346 5,446 3490 Injection 100 ug in 1 ml 15.00 MG 2,037 19,777 3491 Injection 500 ug in 1 ml 15.00 MG 3,165 31,077 OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES XANTHINES R03DA02 CHOLINE THEOPHYLLINATE 16083 Elixir 50 mg per 5 ml, 500 ml 0.60 GM 20,330 - R03DA54 CHOLINE THEOPHYLLINATE with GUAIPHENESIN 10362 Exp 500ml 1 - - 29,400 - R03DA04 THEOPHYLLINE 1143 Tablet 125 mg 0.40 GM 4,166 35,542 2614 Syrup 80 mg per 15 ml, 500 ml 0.40 GM 23,318 210,081 2634 Tablet 250 mg (sustained release) 0.40 GM 35,018 400,719 8230 Tablet 200 mg (sustained release) 0.20 GM 20,843 214,374 8231 Tablet 300 mg (sustained release) 0.40 GM 29,834 381,740 LEUKOTRIENERECEPTOR ANTAGONISTS R03DC03 MONTELUKAST 8627 Chewable tablet 4mg (base) 28 10.00 MG 19,455 908,221 8628 Chewable tablet 5mg (base) 28 10.00 MG 31,317 1,464,120 16114 Chewable tablet 5mg 28 10.00 MG 404 - 16115 Chewable tablet 10mg 28 10.00 MG 34,056 - 17211 Tablet 4mg 28 10.00 MG 128 - R03DC01 ZAFIRLUKAST 16282 Tablet 20mg 56 40.00 MG 1,617 -

157 R

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

RESPIRATORY SYSTEM COUGH AND COLD PREPARATIONS

EXPECTORANTS,EXCL COMBINATIONS WITH ANTITUSSIVES EXPECTORANTS R05CA CAMPHOR COMPOUND 15831 Linct 100ml - - 2,930 - R05CA10 SENEGA and AMMONIA 4074 Mixture 200 ml - - 20,858 144,491 13810 Mixture 200 ml - - 13,149 - MUCOLYTICS R05CB01 ACETYLCYSTEINE 2630 Solution inhalation 200mg per mL(20%),10mL 1.60 GM 6,438 401,005 R05CB02 BROMHEXINE HYDROCHLORIDE 10212 Elx 4mg/5ml 1 24.00 MG 9,406 - 13662 Tablet 8mg 100 24.00 MG 5,428 - COUGH SUPPRESSANTS, EXCL.COMBINATIONS WITH EXPECTORANTS OPIUM ALKALOIDS AND DERIVATIVES R05DA04 CODEINE 1214 Tablet 30 mg 100.00 MG 80,141 1,287,822 10550 Tablet 30mg 100 100.00 MG 734 - 12817 Linct 0.5%100m 1 100.00 MG 952 - 16517 Tablet 30mg 100 100.00 MG 914 - R05DA20 CODEINE with PARACETAMOL with PSEUDOEPHEDRINE 10584 Tablet 24 - - 334 - 14778 Tablet 48 - - 10,120 - R05DA20 CODEINE with PSEUDOEPHEDRINE 11364 Mixture 200ml 100.00 MG 1,519 - 12608 Linct 100ml 1 100.00 MG 389 - R05DA20 DEXTROMETHORPHAN with BROMPHENIRAMINE with PHENYLEPHRINE 14751 Elixir sugar free 200 ml - - 168 - 14785 Elixir sugar free 100 ml - - 344 - 17186 Elixir sugar and colour free 50 ml - - 4,387 - R05DA08 PHOLCODINE 4071 Linctus 1 mg per ml (0.1%), 100 ml 50.00 MG 13,488 132,709 10170 Linct 0.1%200m 1 50.00 MG 591 - 10723 Linct 200ml 1 50.00 MG 1,674 - 12611 Linct ft200ml 1 50.00 MG 1,099 - 12921 Exp 200ml 1 50.00 MG 1,151 - 13187 Linct 0.1% 1 50.00 MG 3,242 - 13809 Linctus 1 mg per ml (0.1%), 100 ml 50.00 MG 118 - R05DA20 PHOLCODINE with PSEUDOEPHEDRINE 13367 Mixture 200ml 1 50.00 MG 607 -

158 R

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE

ANTIHISTAMINES FOR SYSTEMIC USE AMINOALKYL ETHERS R06AA02 DIMENHYDRINATE 10683 Tablet 50mg 10 300.00 MG 1,101 - 10684 Syrup 2.5mg/ml 50ml 300.00 MG 1,284 - R06AA02 DIPHENHYDRAMINE 15912 Capsule 50 mg 8 200.00 MG 7,824 - R06AA52 DIPHENHYDRAMINE with AMMONIUM CHLORIDE 10194 Mixture 100ml 1 - - 262 - 13099 Mixture 200ml 1 - - 423 - R06AA52 DIPHENHYDRAMINE with PHENYLEPH 11693 100ml 1 - - 1,029 - 11694 200ml 1 - - 4,649 - R06AA09 DOXYLAMINE 13003 Tablet 25mg 20 - - 25,051 - 14123 Capsule 25 mg 20 - - 36,844 - SUBSTITUTED ALKYLAMINES R06AB01 BROMPHENIRAMINE 16130 Drops 50mL 1 - - 18,730 - R06AB51 BROMPHENIRAMINE COMBINATIONS 10663 Elx 100ml 1 24.00 MG 770 - 10665 Drop 30ml 1 24.00 MG 19,244 - 10713 Elx 200ml 1 24.00 MG 387 - 14816 Drop 50 ml - - 5,569 - R06AB54 CHLORPHENIRAMINE with PHENYLEPHRINE 10604 Syrup 100mL 1 - - 722 - 10605 Syrup 200mL 1 - - 655 - 16069 Syrup 100mL 1 - - 852 - 16070 Syrup Infant 50mL 1 - - 30,718 - R06AB54 CHLORPHENIRAMINE with PSEUDOEPHEDRINE 10606 Tablet 30 - - 4,415 - 13477 Syrup infant 50mL 1 - - 27,730 - R06AB54 CHLORPHENIRAMINE with PSEUDOEPHREDINE with PARACETAMOL 14784 Tablet 14 - - 230 - R06AB02 DEXCHLORPHENIRAMINE 11600 Tablet 6mg 50 6.00 MG 10,639 - 11602 Syrup 2mg/5ml 1 6.00 MG 22,449 - 11603 Tablet 2mg 30 6.00 MG 45,742 - 12592 Tablet 6mg 20 6.00 MG 23,078 - 12822 Tablet 2mg 50 6.00 MG 58,283 - R06AB52 DEXCHLORPHENIRAMINE with PHENYLEPHRINE 10608 Tablet 18 - - 1,874 - R06AB05 PHENIRAMINE 10065 Syrp100m 15mg/5ml 1 75.00 MG 660 - 10066 Tablet 50mg 10 75.00 MG 2,002 - 10067 Tablet 75mg 50 75.00 MG 3,311 - 12531 Syrup 15mg/5ml 1 75.00 MG 1,628 - 13917 Tablet 50 mg 75.00 MG 10,361 -

159 R

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE

ANTIHISTAMINES FOR SYSTEMIC USE SUBSTITUTED ETHYLENE DIAMINES R06AC01 MEPYRAMINE 11839 Tablet 20 25 mg 0.20 GM 1,635 - PHENOTHIAZINE DERIVATIVES R06AD04 METHDILAZINE HYDROCHLORIDE 16167 Tablet 4 mg 100 16.00 MG 3,438 - 16168 Tablet 8 mg 100 16.00 MG 3,331 - R06AD02 PROMETHAZINE 1948 Injection 50 mg in 2 ml 25.00 MG 15,228 285,855 3488 Injection 50 mg in 2 ml 25.00 MG 18,087 298,422 4072 Tablet 10 mg 25.00 MG 56,007 713,270 4073 Tablet 25 mg 25.00 MG 84,581 1,254,627 10069 Tablet 25 mg 10 25.00 MG 566 - 11576 Ampoule 25 mg/ml 10 25.00 MG 503 - 12553 Elx 100 ml 1 25.00 MG 11,164 - 13089 Elx 5 mg/5 ml 1 25.00 MG 50,244 - 15089 Elx 5 mg/5 ml 25.00 MG 3,536 - 15810 Tablet 25 mg 30 25.00 MG 13,051 - R06AD52 PROMETHAZINE with PHOLCODINE 11574 Linct 200ml 1 - - 205 - 12066 Linct 100ml 1 - - 152 - R06AD01 TRIMEPRAZINE 12156 Syrup 7.5mg/5 1 30.00 MG 6,753 - 12157 Syrup 30mg/5 1 30.00 MG 2,375 - PIPERAZINE DERIVATIVES R06AE07 CETIRIZINE 4175 Tablet 10 mg, 30 10.00 MG 14,459 525,994 14363 Tablet 10 mg 10.00 MG 8,538 - 16121 Oral drops 10mg per mL 20mL 10.00 MG 266 - 16122 Oral solution 1mg/mL 75mL 10.00 MG 933 - 16123 Oral solution 1mg/mL 200mL 10.00 MG 164 -

160 R

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE

ANTIHISTAMINES FOR SYSTEMIC USE OTHER ANTIHISTAMINES FOR SYSTEMIC USE R06AX09 AZATADINE MALEATE 12505 Syrup 500ug 1 2.00 MG 191 - 12579 Tablet 1mg 20 2.00 MG 2,288 - 12814 Tablet 1 mg 50 2.00 MG 2,161 - R06AX02 CYPROHEPTADINE HYDROCHLORIDE 1798 Tablet 4 mg 12.00 MG 113,022 1,241,116 R06AX26 FEXOFENADINE 4237 Capsule 60mg 0.12 GM 6,939 293,300 4238 Tablet 120mg 0.12 GM 14,777 542,727 16141 Tablet 120mg 10 0.12 GM 5,010 - 16142 Tablet 180mg 10 0.12 GM 3,146 - 16266 Tablet 180mg 30 0.12 GM 1,224 - R06AX13 LORATADINE 4313 Tablet 10 mg 10.00 MG 49,811 2,034,866 13978 Tablet 10 mg 10.00 MG 9,345 - 14513 Syrup 100 mL 10.00 MG 2,074 - 16908 Syrup 200 mL 1 1mg/mL 10.00 MG 265 - R06AX13 LORATADINE with PSEUDOEPHEDRINE 15405 Tablet 10 10.00 MG 874 - 16281 Tablet 10 10.00 MG 291 -

161 S

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

SENSORY ORGANS OPHTHALMOLOGICALS

ANTIINFECTIVES ANTIBIOTICS S01AA01 CHLORAMPHENICOL 1171 Eye ointment 10 mg per g (1%), 4 g - - 422,187 3,028,219 2360 Eye drops 5 mg per ml (0.5%), 10 ml - - 868,752 6,503,148 14670 Minims 0.5% 20 - - 539 - S01AA11 GENTAMICIN SULPHATE 1441 Eye drops 3 mg (base) per ml (0.3%), 5 ml - - 13,978 226,595 S01AA30 POLYMYXIN B SULPHATE with BACITRACIN and NEOMYCIN SULPHATE 1910 Eye ointment 5,000 units-400 units-5 mg per g, 4 g - - 36,098 265,465 S01AA30 POLYMYXIN B SULPHATE with NEOMYCIN SULPHATE and GRAMICIDIN 1911 Eye drops 5,000 units-2.5 mg-25 ug per ml, - - 5,948 45,199 S01AA09 TETRACYCLINE HYDROCHLORIDE 2143 Eye ointment 10 mg per g (1%), 5 g - - 4,308 28,796 S01AA12 TOBRAMYCIN 2328 Eye drops 3 mg per ml (0.3%), 5 ml - - 62,747 1,011,697 2329 Eye ointment 3 mg per g (0.3%), 3.5 g - - 16,116 261,547 SULFONAMIDES S01AB04 SULPHACETAMIDE 2063 Eye drops 100 mg per ml (10%), 15 ml - - 60,189 532,111 ANTIVIRALS S01AD03 ACICLOVIR 1002 Eye ointment 30 mg per g (3%), 4.5 g - - 43,688 1,001,767 OTHER ANTIINFECTIVES S01AX13 CIPROFLOXACIN 1217 Eye drops 3 mg per ml (0.3%),5 ml - - 10,561 280,071 17303 Eye drops 3 mg per ml (0.3%),5 ml - - 326 - 17377 Eye drops 3 mg per ml (0.3%),2.5 ml - - 5,354 - S01AX11 OFLOXACIN 8383 Eye drops 3mg per ml (0.3%), 5 ml - - 10,738 268,484 17320 Eye drops 3mg per ml (0.3%), 5 ml - - 177 - ANTIINFLAMMATORY AGENTS CORTICOSTEROIDS, PLAIN S01BA01 DEXAMETHASONE 1288 Eye drops 1 mg per ml (0.1%), 5 ml - - 125,460 1,031,496 S01BA07 FLUOROMETHOLONE 1204 Eye drops 1 mg per ml (0.1%), 5 ml - - 201,616 1,655,738 1438 Eye drops 1 mg per ml (0.1%), 5 ml - - 27,017 222,075 S01BA02 HYDROCORTISONE 1489 Eye drops 5 mg per ml (0.5%), 10 ml - - 17,308 177,123 1492 Eye drops 10 mg per ml (1%), 10 ml - - 22,956 242,875 1497 Eye ointment 5 mg per g (0.5%), 5 g - - 22,433 225,215 2441 Eye ointment 10 mg per g (1%), 5 g - - 48,579 498,881 S01BA04 PREDNISOLONE 14678 Minims 0.5%, 20 - - 1,981 -

162 S

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

SENSORY ORGANS OPHTHALMOLOGICALS

ANTIINFLAMMATORY AGENTS CORTICOSTEROIDS AND SYMPATHOMIMETICS IN COMB S01BB02 PREDNISOLONE ACETATE with PHENYLEPHRINE HYDROCHLORIDE 3112 Eye drops 10 mg-1.2 mg per ml (1%-0.12%), 10 ml - - 202,521 3,502,548 ANTIINFLAMMATORY AGENTS, NON-STEROIDS S01BC03 DICLOFENAC 8329 Eye drops 0.1% 5 mL - - 19,699 240,130 15226 Eye drops 0.1% - - 641 - 17663 Eye drops 0.1% single dose units 0.3mL, 5 - - 206 - S01BC04 FLURBIPROFEN 8009 Eye drops 300 ug per mL (0.03%), 5 ml - - 14,258 173,785 S01BC05 KETOROLAC TROMETAMOL 16800 Eye drops 0.5% 5mL - - 20,539 - ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMB CORTICOSTER./ANTIINFECT./SYMPATHOMIMETICS IN COMB S01CB02 PREDNISOLONE with SULFACETAMIDE with PHENYLEPHRINE 10213 Eye drops .2%-10%-12%, 5ml - - 201 - ANTIGLAUCOMA PREPARATIONS AND MIOTICS SYMPATHOMIMETICS IN GLAUCOMA THERAPY S01EA03 APRACLONIDINE 8083 Eye drops 5 mg (base) per ml (0.5%), 10ml 1.50 MG 5,602 194,109 15211 Eye drops 0.5% 5 ml - - 198 - S01EA05 BRIMONIDINE 8351 Eye drops 2mg per mL (0.2%), 5mL 0.40 MG 235,614 4,410,906 S01EA02 DIPIVEFRINE 1351 Eye drops 1 mg per ml (0.1%), 10 ml 0.20 MG 23,028 410,535 PARASYMPATHOMIMETICS S01EB02 CARBACHOL 2535 Eye drops 15 mg per ml (1.5%), 15 ml 6.00 MG 1,113 23,539 2536 Eye drops 30 mg per ml (3%), 15 ml 12.00 MG 2,208 47,792 S01EB01 PILOCARPINE 2595 Eye drops 10 mg per ml (1%), 15 ml 4.00 MG 17,014 174,864 2596 Eye drops 20 mg per ml (2%), 15 ml 8.00 MG 28,092 320,932 2597 Eye drops 30 mg per ml (3%), 15 ml 12.00 MG 3,823 52,729 2598 Eye drops 40 mg per ml (4%), 15 ml 16.00 MG 24,142 339,472 2778 Eye drops 5 mg per ml (0.5%), 15 ml 2.00 MG 7,208 74,022 2779 Eye drops 60 mg per ml (6%), 15 ml 24.00 MG 6,932 122,238 CARBONIC ANHYDRASE INHIBITORS S01EC01 ACETAZOLAMIDE 1004 Tablet 250 mg 0.75 GM 34,563 671,210 1005 Injection 500 mg (solvent required) 0.75 GM 537 13,501 S01EC04 BRINZOLAMIDE 8483 Eye drops 10 mg per ml (1%), 5 ml 2.00 MG 80,958 1,514,992 S01EC03 DORZOLAMIDE 8488 Eye drops 20 mg per ml (2%), 5 ml 6.00 MG 64,969 1,217,216

163 S

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

SENSORY ORGANS OPHTHALMOLOGICALS

ANTIGLAUCOMA PREPARATIONS AND MIOTICS BETA BLOCKING AGENTS S01ED02 BETAXOLOL HYDROCHLORIDE 2811 Eye drops 2.5 mg (base) per ml(0.25%), 5 ml 0.50 MG 172,114 2,204,490 2825 Eye drops 5 mg (base) per ml (0.5%), 5 ml 1.00 MG 83,486 1,070,136 S01ED03 LEVOBUNOLOL 1819 Eye drops 2.5 mg per ml (0.25%), 5 ml 0.50 MG 43,818 513,347 S01ED51 TIMOLOL COMBINATIONS 4300 Eye drops 50ug 5mg per ml (0.005%-0.5%), 2.5 ml - - 10,624 475,199 S01ED01 TIMOLOL MALEATE 1278 Eye drops 2.5 mg (base) per ml (0.25%), 5 ml 0.50 MG 85,071 984,527 1279 Eye drops 5 mg (base) per ml (0.5%), 5 ml 1.00 MG 465,211 5,881,783 1925 Eye drops (gellan gum solution) 2.5 mg (base) per 0.50 MG 41,340 483,910 1926 Eye drops (gellan gum solution) 5 mg (base) per 1.00 MG 219,211 2,806,718 18141 Eye drops 5 mg (base) per ml (0.5%), 5 ml 1.00 MG 380 - S01ED51 TIMOLOL MALEATE with PILOCARPINE HYDROCHLORIDE 2664 Eye drops 5 mg 20 mg per ml (0.5%-2%), 5 ml - - 57,581 1,090,067 2665 Eye drops 5 mg 40 mg per ml (0.5%-4%), 5 ml - - 71,040 1,514,621 8567 Eye drops 5 mg 20 mg per ml (0.5%-2%), 5 ml - - 146,061 3,927,925 PROSTAGLANDIN ANALOGUES S01EE03 BIMATOPROST 8620 Eye drops 300 ug per mL (0.03%), 3 mL 30.00 UG 129,828 4,423,169 S01EE01 LATANOPROST 8243 Eye drops 50 ug per mL (0.005%), 2.5 mL 5.00 UG 1,405,837 47,934,423 OTHER ANTIGLAUCOMA PREPARATIONS S01EX04 TRAVOPROST 8597 Eye drops 0.040 mg per mL (0.004%) - - 107,393 3,659,407 MYDRIATICS AND CYCLOPLEGICS ANTICHOLINERGICS S01FA01 ATROPINE SULPHATE 1092 Eye drops 5 mg per ml (0.5%), 15 ml - - 2,342 21,859 1093 Eye drops 10 mg per ml (1%), 15 ml - - 15,020 137,004 S01FA04 CYCLOPENTOLATE 10596 Eye-drop 1%15ml 1 - - 148 - S01FA05 HOMATROPINE HYDROBROMIDE 2541 Eye drops 20 mg per ml (2%), 15 ml - - 9,908 136,725 2542 Eye drops 50 mg per ml (5%), 15 ml - - 2,123 38,664 S01FA06 TROPICAMIDE 11193 Eye-drop 1% 1 - - 297 - SYMPATHOMIMETICS EXCL. ANTIGLAUCOMA PREPARATIONS S01FB01 PHENYLEPHRINE 16103 Eye-drop 1 - - 270 -

164 S

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

SENSORY ORGANS OPHTHALMOLOGICALS

DECONGESTANTS AND ANTIALLERGICS SYMPATHOMIMETICS USED AS DECONGESTANTS S01GA51 ANTAZOLINE with NAPHAZOLINE 4031 Eye drops 5 mg (sulphate)-250 ug (nitrate) - - 6,164 69,713 4032 Eye drops 5 mg (phosphate)-500 ug - - 5,905 68,627 S01GA01 NAPHAZOLINE 4035 Eye drops 1 mg per ml (0.1%), 15 ml - - 3,830 44,297 11420 Eye-drop 15ml 1 - - 392 - S01GA51 NAPHAZOLINE COMBINATIONS 4355 Eye drops 250 ug-3 mg per ml (0.025%-0.3%), 15 ml - - 5,806 67,534 S01GA55 PHENYLEPHRINE HYDROCHLORIDE with ZINC SULPHATE 4034 Eye drops 2.5 mg-1.2 mg per ml (0.25%-0.12%),15ml - - 1,806 19,749 S01GA02 TETRAHYDROZOLINE 12179 Eye-drop 0.05%15m 1 - - 257 - 12197 Eye-drop plus15ml 1 - - 171 - OTHER ANTIALLERGICS S01GX02 LEVOCABASTINE 4310 Eye drops 500 ug per ml (0.05%), 4ml - - 6,498 91,912 S01GX05 LODOXAMIDE 8268 Eye drops 0.1% 10 mL - - 9,529 136,171 S01GX01 SODIUM CROMOGLYCATE 1127 Eye drops 20 mg per ml (2%), 10 ml - - 31,639 437,007 LOCAL ANAESTHETICS LOCAL ANAESTHETICS S01HA03 AMETHOCAINE 14667 Minims 0.5% 20 - - 139 -

165 S

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

SENSORY ORGANS OPHTHALMOLOGICALS

OTHER OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS S01XA20 ARTIFICIAL TEARS 8548 Eye drops 5 mg per mL (0.5%),15 mL - - 158,582 1,777,094 S01XA20 ARTIFICIAL TEARS and OTHER INDEFFERENT PREPARATIONS 8564 Ocular lubricating gel 2mg-3mg per g (0.2%-0.3%) - - 56,094 521,535 S01XA20 ARTIFICIAL TEARS and OTHER INDIFFERS 8676 Eye drops 4 mg-3 mg per ml (0.4%-0.3%), 15 mL - - 6,003 51,757 S01XA20 CARBOMER 940 8193 Ocular lubricating gel 2 mg per g (0.2%), 10 g - - 534 4,962 8384 Ocular lubricating gel 2 mg per g (0.2%), 10 g - - 233,184 2,173,790 8514 Ocular lubricating gel 3 mg per g (0.3%) 30 - - 17,346 593,930 17723 Ocular lubricating gel 2 mg per g (0.2%), 10 g - - 157 - S01XA20 CARBOMER 980 8578 Eye drops 2 mg per g (0.2%), single dose units - - 3,421 114,857 S01XA20 CARMELLOSE SODIUM 2324 Eye drops 10 mg per mL (1%), single dose units - - 13,760 491,104 2338 Eye drops 5 mg per mL (0.5%), single dose units - - 71,732 2,504,859 8593 Eye drops 10 mg per mL (1%), 15 mL - - 38,911 435,445 S01XA20 HYDROXYPROPYLCELLULOSE 1522 Ophthalmic inserts 5 mg, 60 - - 1,462 58,182 S01XA20 HYPROMELLOSE 1509 Eye drops 3 mg-1 mg per ml (0.3%-0.1%), 15 ml - - 743,769 8,346,577 2952 Eye drops 10 mg per ml (1%), 15 ml - - 10,082 93,503 2956 Eye drops 5 mg per ml (0.5%), 15 ml - - 33,358 292,372 8287 Eye drops 3 mg-1 mg per ml (0.3%), 15 mL - - 166,216 1,435,112 S01XA20 HYPROMELLOSE with DEXTRAN 8299 Eye drops (0.3%-0.1%) single dose 0.4 mL 28 - - 39,288 1,289,341 S01XA20 PARAFFIN 1750 Compound eye ointment 7 g - - 142,291 2,597,697 1754 Compound eye ointment 3.5 g - - 22,092 388,185 10757 Eye/o 3.5g 1 - - 386 - S01XA20 POLYVINYL ALCOHOL 2681 Eye drops 30 mg per ml (3%), 15 ml - - 44,262 591,139 2682 Eye drops 14 mg per ml (1.4%), 15 ml - - 191,512 1,776,365 S01XA20 POLYVINYL ALCOHOL with POVIDONE 2675 Eye drops 14 mg-6 mg per ml (1.4%-0.6%), 15 mL - - 192,364 1,820,123

166 S

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

SENSORY ORGANS OTOLOGICALS

ANTIINFECTIVES ANTIINFECTIVES S02AA10 ACETIC ACID 10103 Ear-drop 35ml 1 - - 297 - S02AA01 CHLORAMPHENICOL 1172 Ear drops (aqueous) 5 mg per ml (0.5%), 5 ml - - 16,170 149,312 S02AA30 NEOMYCIN UNDECENOATE with BACITRACIN ZINC 2296 Ear ointment 12 mg (3.5 mg base)-400 units per g, - - 115,733 792,450 CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION S02CA06 DEXAMETHASONE with FRAMYCETIN SULPHATE and GRAMICIDIN 2759 Ear ointment 500 ug-5 mg-50 ug per - - 28,596 181,081 2781 Ear drops 500 ug-5 mg-50 ug per - - 496,037 3,466,901 17782 Ear ointment 500 ug-5 mg-50 ug per - - 295 - S02CA02 FLUMETHASONE PIVALATE with CLIOQUINOL 15097 Ear drops 200 ug-10 mg per ml (0.02%-1%), - - 42,781 - S02CA03 HYDROCORTISONE with CIPROFLOXACIN 4528 Ear-drop 2mg/10mg per mL(0.2-1%) 10mL - - 70,175 1,896,805 S02CA04 TRIAMCINOLONE ACETONIDE with NEOMYCIN SULPHATE, GRAMICIDIN and NYSTATIN 2971 Ear drops 1 mg-2.5 mg (base)-250 ug- - - 157,222 1,099,179 2974 Ear ointment 1 mg-2.5 mg (base)-250 ug- - - 406,731 2,573,645 OTHER OTOLOGICALS ANALGESICS AND ANESTHETICS S02DA PHENAZONE with BENZOCAINE 10094 Ear-drop 10ml 1 - - 3,467 - INDIFFERENT PREPARATIONS S02DC 10803 Ear-drop non-nhs 15ml - - 201 - S02DC CARBAMIDE PEROXIDE 4176 Ear drops 65 mg per mL (6.5%), 10 mL - - 5,827 71,491 S02DC DICHLOROBENZENE, CHLORBUTOL and TURPENTINE OIL 4180 Ear drops 20 mg-50 mg-0.1 ml per ml (2%-5%-10%), - - 7,621 87,181 S02DC DOCUSATE SODIUM 4199 Ear drops 50 mg per mL (5%), 10 ml - - 11,508 141,574

167 S

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

SENSORY ORGANS OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS

ANTIINFECTIVES ANTIINFECTIVES S03AA FRAMYCETIN SULPHATE 1439 Eye/ear ointment 5 mg per ml (0.5%) - - 36,748 264,319 1440 Eye and ear drops 5 mg per ml (0.5%), 8 ml - - 90,546 680,933 CORTICOSTEROIDS CORTICOSTEROIDS S03BA02 PREDNISOLONE SODIUM PHOSPHATE 1922 Eye and ear drops 5 mg per ml (0.5%), 5 ml - - 84,903 694,030 18317 Eye and ear drops 5 mg per ml (0.5%), 5 ml - - 116 -

168 V

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

VARIOUS ALLERGENS

ALLERGENS ALLERGEN EXTRACTS V01AA07 INSECT ALLERGEN EXTRACT--HONEY BEE VENOM 2886 Injection set containing 550 ug - - 2,354 475,683 V01AA07 INSECT ALLERGEN EXTRACT--PAPER WASP VENOM 2918 Injection set containing 550 ug - - 328 66,234

169 V

2003 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($)

VARIOUS ALL OTHER THERAPEUTIC PRODUCTS

ALL OTHER THERAPEUTIC PRODUCTS ANTIDOTES V03AB15 NALOXONE HYDROCHLORIDE 3481 Injection 800 ug in 2 mL - - 250 22,333 3482 Injection 2 mg in 5 mL - - 14,181 835,853 IRON CHELATING AGENTS V03AC01 DESFERRIOXAMINE 6113 Powder for injection 500 mg vial - - 165 82,735 6270 Powder for injection 2 g vial - - 120 148,967 DRUGS FOR TREATMENT OF HYPERKALEMIA V03AE01 SODIUM POLYSTYRENE SULPHONATE 4470 Oral powder 454 g - - 1,804 119,106 DETOXIFYING AGENTS FOR CYTOSTATIC TREATMENT V03AF03 CALCIUM FOLINATE 2308 Tablet 15 mg 60.00 MG 4,211 462,106 V03AF01 MESNA 8078 Solution for I.V. injection 400 mg in 4 ml - - 167 10,772 8079 Solution for I.V. injection 1 g in 10 ml - - 1,216 185,714 17213 Tablet (film coated) 400mg 50 - - 502 - DRUGS FOR TREATMENT OF HYPERCALCEMIA V03AG SODIUM ACID PHOSPHATE 2946 Compound effervescent tablet containing elemental - - 2,484 198,323

170

TABLE 2

COMMUNITY PRESCRIPTION DRUG USE, IN DDDS/1000/DAY, FOR 2001 TO 2003

Table 2 lists most drugs on the Australian market by defined daily dose (DDD) per 1000 of the population per day from 2001 to 2003. To be listed in Table 2 the drugs need to have both an assigned DDD and an entry in Table 1 (i.e. more than 110 prescriptions dispensed in 2003). Items are arranged on the ATC code by generic name and the DDD/1000/day is given for both the subsidised ‘PBS/RPBS’ and the non-subsidised ‘survey’ components. Consult the index (Page 255) by generic drug name to obtain the appropriate ATC code.

Please note that items which have a level of usage low enough to result in an entry of 0.000 DDDs/1000 population/day (i.e. not registering at 3 decimal points) over each of the three years in the series are not included in Table 2.

An index by the 2nd level of the ATC classification follows:

ALIMENTARY TRACT AND METABOLISM PAGE NO

A01 STOMATOLOGICAL PREPARATIONS 175 A02 DRUGS FOR ACID RELATED DISORDERS 176 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 177 A04 ANTIEMETICS AND ANTINAUSEANTS 178 A05 BILE AND LIVER THERAPY 179 A06 LAXATIVES 180 A07 ANTIDIARRHOEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVES 181 A08 ANTIOBESITY PREPARATIONS, EXCLUDING DIET PRODUCTS 182 A10 ANTIDIABETIC THERAPY 183 A11 VITAMINS 185 A12 MINERAL SUPPLEMENTS 186 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 187

171

BLOOD AND BLOOD FORMING ORGANS

B01 ANTITHROMBOTIC AGENTS 188 B02 ANTIHAEMORRHAGICS 189 B03 ANTIANAEMIC PREPARATIONS 190 CARDIOVASCULAR SYSTEM

C01 CARDIAC THERAPY 191 C02 ANTIHYPERTENSIVES 193 C03 DIURETICS 194 C04 PERIPHERAL VASODILATORS 196 C07 BETA BLOCKING AGENTS 197 C08 CALCIUM CHANNEL BLOCKERS 198 C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 199 C10 SERUM LIPID REDUCING AGENTS 201 DERMATOLOGICALS

D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 202 D05 ANTIPSORIATICS 203 D10 ANTI-ACNE PREPARATIONS 204 GENITOURINARY SYSTEM AND SEX HORMONES

G01 GYNAECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 205 G02 OTHER GYNAECOLOGICALS 206 G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 207 G04 UROLOGICALS 210 SYSTEMIC HORMONAL PREPARATIONS, EXCLUDING SEX HORMONES

H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES 211 H02 CORTICOSTEROIDS FOR SYSTEMIC USE 212 H03 THYROID THERAPY 213 H04 PANCREATIC HORMONES 214 H05 CALCIUM HOMEOSTASIS 215 GENERAL ANTIINFECTIVES FOR SYSTEMIC USE

J01 ANTIBACTERIALS FOR SYSTEMIC USE 216 J02 ANTIMYCOTICS FOR SYSTEMIC USE 220 J04 ANTIMYCOBACTERIALS 221 J05 ANTIVIRALS FOR SYSTEMIC USE 222

172

ANTINEOPLASTIC AND IMMUNO-MODULATING AGENTS

L02 ENDOCRINE THERAPY 223 L03 IMMUNOSTIMULANTS 225 L04 IMMUNO-SUPPRESSIVE AGENTS 226 MUSCULO-SKELETAL SYSTEM

M01 ANTI-INFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS 227 M03 MUSCLE RELAXANTS 229 M04 ANTI-GOUT PREPARATIONS 230 M05 DRUGS FOR TREATMENT OF BONE DISEASES 231 NERVOUS SYSTEM

N02 ANALGESICS 232 N03 ANTI-EPILEPTICS 234 N04 ANTI-PARKINSON DRUGS 236 N05 PSYCHOLEPTICS 237 N06 PSYCHOANALEPTICS 240 N07 OTHER NERVOUS SYSTEM DRUGS 243 ANTI-PARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

P01 ANTI-PROTOZOALS 244 P02 ANTHELMINTICS 245 RESPIRATORY SYSTEM

R01 NASAL PREPARATIONS 246 R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 247 R05 COUGH AND COLD PREPARATIONS 249 R06 ANTI-HISTAMINES FOR SYSTEMIC USE 250 SENSORY ORGANS

S01 OPHTHALMOLOGICALS 251 VARIOUS

V03 ALL OTHER THERAPEUTIC PRODUCTS 253

173

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS

STOMATOLOGICAL PREPARATIONS ANTIINFECTIVES FOR LOCAL ORAL TREATMENT AMPHOTERICIN A01AB04 PBS/RPBS 0.102 0.100 0.094 SURVEY 0.026 0.023 0.020 CHLORHEXIDINE A01AB03 PBS/RPBS 0.004 0.005 0.004 SURVEY 0.003 0.005 0.005 MICONAZOLE A01AB09 SURVEY 0.008 0.008 0.007

NYSTATIN A01AB11 PBS/RPBS 0.028 0.028 0.027 SURVEY 0.009 0.009 0.008

175 A

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS

DRUGS FOR PEPTIC ULCER AND GORD H2-RECEPTOR ANTAGONISTS CIMETIDINE A02BA01 PBS/RPBS 0.612 0.433 0.321 SURVEY 0.007 0.003 0.005 FAMOTIDINE A02BA03 PBS/RPBS 3.143 1.876 1.268 SURVEY 0.625 0.333 0.231 NIZATIDINE A02BA04 PBS/RPBS 1.293 0.691 0.464 SURVEY 0.351 0.140 0.086 RANITIDINE HYDROCHLORIDE A02BA02 PBS/RPBS 14.622 10.419 8.056 SURVEY 2.136 1.635 1.157 PROSTAGLANDINS MISOPROSTOL A02BB01 PBS/RPBS 0.027 0.017 0.015 SURVEY 0.000 0.001 0.001 PROTON PUMP INHIBITORS ESOMEPRAZOLE A02BC05 PBS/RPBS 0.000 1.728 7.352 SURVEY 0.000 0.006 0.017 LANSOPRAZOLE A02BC03 PBS/RPBS 3.564 4.263 4.156 SURVEY 0.010 0.011 0.009 OMEPRAZOLE A02BC01 PBS/RPBS 17.560 23.310 21.665 SURVEY 0.080 0.056 0.052 PANTOPRAZOLE A02BC02 PBS/RPBS 5.491 8.651 9.041 SURVEY 0.009 0.014 0.011 RABEPRAZOLE A02BC04 PBS/RPBS 0.166 1.652 3.376 SURVEY 0.001 0.004 0.006 OTHER DRUGS FOR PEPTIC ULCER AND GORD BISMUTH SUBCITRATE A02BX05 PBS/RPBS 0.006 0.000 0.000 SURVEY 0.000 0.000 0.000 SUCRALFATE A02BX02 PBS/RPBS 0.065 0.055 0.045 SURVEY 0.000 0.000 0.008

176 A

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

DRUGS FOR FUNCTIONAL BOWEL DISORDERS SYNT ANTICHOLIN,ESTERS WITH TERTIARY AMINO GROUP MEBEVERINE HYDROCHLORIDE A03AA04 PBS/RPBS 0.066 0.065 0.061 SURVEY 0.407 0.365 0.359 SYNT ANTICHOLINERGICS,ESTERS,QUATER AMMONIUM COMP PROPANTHELINE A03AB05 PBS/RPBS 0.251 0.223 0.201 SURVEY 0.051 0.041 0.020 PAPAVERINE AND DERIVATIVES PAPAVERINE PAPAVERINE A03AD01 SURVEY 0.057 0.000 0.000

BELLADONNA AND DERIVATIVES, PLAIN BELLADONNA ALKALOIDS, TERTIARY AMINES ATROPINE A03BA01 PBS/RPBS 0.008 0.007 0.008 SURVEY 0.004 0.003 0.003 BELLADONNA ALKALOIDS SEMISYNT,QUATER AMMONIUM COMP HYOSCINE BUTYLBROMIDE A03BB01 PBS/RPBS 0.000 0.000 0.000 SURVEY 0.047 0.043 0.045

PROPULSIVES PROPULSIVES CISAPRIDE A03FA02 PBS/RPBS 0.660 0.370 0.221 SURVEY 0.025 0.019 0.015 DOMPERIDONE A03FA03 PBS/RPBS 0.264 0.299 0.333 SURVEY 0.091 0.084 0.105 METOCLOPRAMIDE HYDROCHLORIDE A03FA01 PBS/RPBS 0.589 0.600 0.603 SURVEY 0.343 0.310 0.288

177 A

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS

ANTIEMETICS AND ANTINAUSEANTS SEROTONIN (5HT3) ANTAGONISTS DOLASETRON MESYLATE A04AA04 PBS/RPBS 0.007 0.007 0.008 SURVEY 0.000 0.000 0.000 ONDANSETRON A04AA01 PBS/RPBS 0.017 0.018 0.022 SURVEY 0.000 0.000 0.000 TROPISETRON A04AA03 PBS/RPBS 0.009 0.011 0.015 SURVEY 0.001 0.001 0.000

178 A

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM BILE AND LIVER THERAPY

BILE THERAPY BILE ACID PREPARATIONS URSODEOXYCHOLIC ACID A05AA02 PBS/RPBS 0.055 0.080 0.095 SURVEY 0.001 0.001 0.001

179 A

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM LAXATIVES

LAXATIVES SOFTENERS, EMOLLIENTS DOCUSATE SODIUM A06AA02 PBS/RPBS 0.000 0.006 0.013 SURVEY 0.331 0.242 0.194 CONTACT LAXATIVES BISACODYL A06AB02 PBS/RPBS 0.973 0.933 0.865 SURVEY 0.038 0.034 0.036 DOCUSATE SODIUM with BISACODYL A06AB52 PBS/RPBS 0.022 0.021 0.015 SURVEY 0.000 0.001 0.000 PHENOLPHTHALEIN with LIQUID PARAFFIN A06AB04 SURVEY 0.098 0.109 0.105 BULK PRODUCERS PSYLLIUM HYDROPHILIC MUCILLOID A06AC01 PBS/RPBS 0.471 0.470 0.442 SURVEY 0.053 0.069 0.057 OSMOTICALLY ACTING LAXATIVES LACTULOSE A06AD11 PBS/RPBS 2.445 2.545 2.594 SURVEY 0.217 0.204 0.209 LACTULOSE with GALACTOSE with LACTOSE with EPILACTOSE A06AD11 SURVEY 0.002 0.002 0.003 MACROGAL A06AD15 PBS/RPBS 0.000 0.016 0.223 SURVEY 0.000 0.003 0.023

180 A

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM ANTIDIARR.,INTEST. ANTIINFL./ANTIINFECT. AGENTS

INTESTINAL ANTIINFECTIVES ANTIBIOTICS NEOMYCIN SULPHATE A07AA01 PBS/RPBS 0.000 0.000 0.001 SURVEY 0.000 0.000 0.000 NYSTATIN A07AA02 PBS/RPBS 0.113 0.114 0.110 SURVEY 0.087 0.071 0.071 VANCOMYCIN A07AA09 PBS/RPBS 0.001 0.001 0.000 SURVEY 0.000 0.000 0.000

INTESTINAL ADSORBENTS CHARCOAL PREPARATIONS CHARCOAL A07BA01 SURVEY 0.000 0.000 0.001

ANTIPROPULSIVES ANTIPROPULSIVES DIPHENOXYLATE HYDROCHLORIDE with ATROPINE SULPHATE A07DA01 PBS/RPBS 0.172 0.173 0.162 SURVEY 0.060 0.052 0.048 LOPERAMIDE HYDROCHLORIDE A07DA03 PBS/RPBS 0.235 0.249 0.257 SURVEY 0.057 0.053 0.053

INTESTINAL ANTIINFLAMMATORY AGENTS AMINOSALICYLIC ACID AND SIMILAR AGENTS MESALAZINE A07EC02 PBS/RPBS 0.471 0.533 0.664 SURVEY 0.004 0.005 0.002 OLSALAZINE SODIUM A07EC03 PBS/RPBS 0.242 0.249 0.235 SURVEY 0.000 0.000 0.000 SULPHASALAZINE A07EC01 PBS/RPBS 1.508 1.493 1.490 SURVEY 0.003 0.003 0.003

181 A

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL DIET PRODUCTS

ANTIOBESITY PREPARATIONS, EXCL DIET PRODUCTS CENTRALLY ACTING ANTIOBESITY PRODUCTS DIETHYLPROPION A08AA03 SURVEY 0.234 0.216 0.194 PHENTERMINE A08AA01 SURVEY 1.590 1.463 1.265 SIBUTRAMINE A08AA10 SURVEY 0.000 0.724 0.811 PERIPHERALLY ACTING ANTIOBESITY PRODUCTS ORLISTAT A08AB01 SURVEY 1.078 0.791 0.490

182 A

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM ANTIDIABETIC THERAPY

INSULINS AND ANALOGUES INSULINS AND ANALOGUES, FAST-ACTING INSULIN (BEEF) A10AB02 PBS/RPBS 0.022 0.022 0.017 INSULIN (HUMAN) A10AB01 PBS/RPBS 1.896 1.811 1.644 SURVEY 0.002 0.005 0.007 INSULIN ASPART A10AB05 PBS/RPBS 0.314 0.534 0.875 SURVEY 0.000 0.003 0.006 INSULIN LISPRO A10AB04 PBS/RPBS 1.106 1.135 1.062 SURVEY 0.004 0.006 0.003 INSULINS AND ANALOGUES, INTERMEDIATE-ACTING INSULIN (BEEF) A10AC02 PBS/RPBS 0.038 0.034 0.030 INSULIN (HUMAN) A10AC01 PBS/RPBS 3.514 3.587 3.626 SURVEY 0.045 0.044 0.060 INSULINS AND ANALOGUES, INTERMEDIATE ACTING COMBINED WITH FAST ACTING INSULIN (HUMAN) A10AD01 PBS/RPBS 4.202 4.373 4.252 SURVEY 0.026 0.041 0.041 INSULIN ASPART/PROTAMINE ASPART A10AD30 PBS/RPBS 0.000 0.106 0.601 SURVEY 0.000 0.000 0.000 INSULIN LISPRO A10AD04 PBS/RPBS 0.370 0.482 0.439 SURVEY 0.000 0.001 0.001 INSULINS AND ANALOGUES, LONG-ACTING INSULIN (HUMAN) A10AE01 PBS/RPBS 0.181 0.168 0.155 SURVEY 0.000 0.001 0.011

ORAL BLOOD GLUCOSE LOWERING DRUGS BIGUANIDES METFORMIN HYDROCHLORIDE A10BA02 PBS/RPBS 8.195 9.323 10.121 SURVEY 1.807 1.820 1.959

183 A

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM ANTIDIABETIC THERAPY

ORAL BLOOD GLUCOSE LOWERING DRUGS SULFONAMIDES, UREA DERIVATIVES GLIBENCLAMIDE A10BB01 PBS/RPBS 2.808 2.407 2.011 SURVEY 0.434 0.314 0.243 GLICLAZIDE A10BB09 PBS/RPBS 7.078 6.875 6.483 SURVEY 1.354 1.080 0.915 GLIMEPIRIDE A10BB12 PBS/RPBS 1.299 2.517 3.071 SURVEY 0.324 0.569 0.658 GLIPIZIDE A10BB07 PBS/RPBS 1.298 1.132 0.969 SURVEY 0.198 0.135 0.123 TOLBUTAMIDE A10BB03 PBS/RPBS 0.259 0.103 0.000 SURVEY 0.033 0.014 0.001 ALPHA GLUCOSIDASE INHIBITORS ACARBOSE A10BF01 PBS/RPBS 0.292 0.274 0.263 SURVEY 0.001 0.003 0.002 THIAZOLIDINEDIONES PIOGLITAZONE HYDROCHLORIDE A10BG03 PBS/RPBS 0.000 0.000 0.015 SURVEY 0.000 0.004 0.006 ROSIGLITAZONE A10BG02 PBS/RPBS 0.000 0.000 0.024 SURVEY 0.003 0.007 0.016 OTHER OTHER BLOOD GLUCOSE LOWERING DRUGS REPAGLINIDE A10BX02 SURVEY 0.022 0.013 0.010

184 A

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM VITAMINS

VIT A AND D, INCL COMBINATIONS OF THE TWO VITAMIN A, PLAIN VITAMIN A A11CA01 SURVEY 0.011 0.014 0.013 VITAMIN D AND ANALOGUES CALCITRIOL A11CC04 PBS/RPBS 1.368 1.045 0.817 SURVEY 0.021 0.020 0.013

VIT B1,PLAIN AND IN COMB WITH VITAMIN B6 AND B12 THIAMINE (VIT B1), PLAIN THIAMINE HYDROCHLORIDE A11DA01 PBS/RPBS 0.530 0.531 0.506 SURVEY 0.789 0.867 1.098

ASCORBIC ACID (VIT C), INCL COMBINATIONS ASCORBIC ACID (VIT C), PLAIN ASCORBIC ACID A11GA01 PBS/RPBS 0.005 0.004 0.005 SURVEY 0.000 0.002 0.006

OTHER PLAIN VITAMIN PREPARATIONS OTHER PLAIN VITAMIN PREPARATIONS PYRIDOXINE HYDROCHLORIDE A11HA02 PBS/RPBS 0.029 0.028 0.028 SURVEY 0.009 0.010 0.012

185 A

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM MINERAL SUPPLEMENTS

CALCIUM CALCIUM CALCIUM (DIFFERENT SALTS IN COMBINATION) A12AA20 SURVEY 0.010 0.010 0.011 CALCIUM CARBONATE A12AA04 PBS/RPBS 2.245 2.478 2.538 SURVEY 0.043 0.044 0.050 CALCIUM, COMBINATIONS WITH OTHER DRUGS CALCIUM CARBONATE with CHOLECALCIFEROL A12AX SURVEY 0.006 0.008 0.008

POTASSIUM POTASSIUM POTASSIUM CHLORIDE A12BA01 PBS/RPBS 2.408 2.202 1.992 SURVEY 0.103 0.098 0.078

OTHER MINERAL SUPPLEMENTS ZINC ZINC SULPHATE A12CB01 SURVEY 0.001 0.002 0.002 SELENIUM SELENIUM A12CE01 SURVEY 0.027 0.035 0.042

186 A

ATC SOURCE 2001 2002 2003

ALIMENTARY TRACT AND METABOLISM ANABOLIC AGENTS FOR SYSTEMIC USE

ANABOLIC STEROIDS ANDROSTAN DERIVATIVES METHENOLONE A14AA04 PBS/RPBS 0.003 0.002 0.000 SURVEY 0.006 0.003 0.000 ESTREN DERIVATIVES NANDROLONE DECANOATE A14AB01 PBS/RPBS 0.241 0.186 0.149 SURVEY 0.023 0.022 0.022

187 B

ATC SOURCE 2001 2002 2003

BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS

ANTITHROMBOTIC AGENTS VITAMIN K ANTAGONISTS PHENINDIONE B01AA02 SURVEY 0.001 0.001 0.000 WARFARIN B01AA03 PBS/RPBS 3.555 3.807 4.094 SURVEY 0.725 0.678 0.746 HEPARIN GROUP DALTEPARIN B01AB04 PBS/RPBS 0.034 0.048 0.058 SURVEY 0.002 0.000 0.000 ENOXAPARIN B01AB05 PBS/RPBS 0.246 0.470 0.608 SURVEY 0.017 0.005 0.004 HEPARIN CALCIUM B01AB01 PBS/RPBS 0.016 0.016 0.012 SURVEY 0.000 0.000 0.001 HEPARIN SODIUM B01AB01 PBS/RPBS 0.033 0.027 0.022 SURVEY 0.000 0.000 0.000 PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN ASPIRIN B01AC06 PBS/RPBS 13.065 14.542 16.199 SURVEY 1.010 1.096 1.070 CLOPIDOGREL B01AC04 PBS/RPBS 2.687 4.135 5.670 SURVEY 0.006 0.013 0.013 DIPYRIDAMOLE B01AC07 PBS/RPBS 0.615 0.487 0.395 SURVEY 0.007 0.006 0.008 DIPYRIDAMOLE with ASPRIN B01AC30 PBS/RPBS 0.999 1.440 1.644 SURVEY 0.001 0.002 0.003 TICLOPIDINE HYDROCHLORIDE B01AC05 PBS/RPBS 0.057 0.040 0.030 SURVEY 0.000 0.000 0.000

188 BA

ATC SOURCE 2001 2002 2003

BLOOD AND BLOOD FORMING ORGANS ANTIHAEMORRHAGICS

ANTIFIBRINOLYTICS AMINO ACIDS TRANEXAMIC ACID B02AA02 PBS/RPBS 0.069 0.071 0.079 SURVEY 0.001 0.000 0.001

VITAMIN K AND OTHER HAEMOSTATICS VITAMIN K MENAPHTHONE B02BA02 SURVEY 0.014 0.012 0.009 PHYTOMENADIONE B02BA01 SURVEY 0.004 0.003 0.004

189 B

ATC SOURCE 2001 2002 2003

BLOOD AND BLOOD FORMING ORGANS ANTIANAEMIC PREPARATIONS

IRON PREPARATIONS IRON BIVALENT, ORAL PREPARATIONS FERROUS GLUCONATE B03AA03 PBS/RPBS 0.029 0.031 0.017 SURVEY 0.002 0.002 0.002 FERROUS SULPHATE DRIED B03AA07 PBS/RPBS 0.070 0.000 0.000 SURVEY 0.883 0.778 0.710 IRON TRIVALENT, PARENTERAL PREPARATIONS IRON POLYMALTOSE COMPLEX B03AC03 PBS/RPBS 0.022 0.024 0.023 SURVEY 0.000 0.000 0.000

VITAMIN B12 AND FOLIC ACID VITAMIN B12 (CYANOCOBALAMIN AND DERIVATIVES) CYANOCOBALAMIN B03BA01 SURVEY 0.085 0.109 0.094 HYDROXOCOBALAMIN B03BA03 PBS/RPBS 3.826 4.103 4.370 SURVEY 0.415 0.354 0.351 FOLIC ACID AND DERIVATIVES FOLIC ACID B03BB01 SURVEY 0.000 0.000 0.014

OTHER ANTIANAEMIC PREPARATIONS OTHER ANTIANAEMIC PREPARATIONS DARBEPOETIN ALPHA B03XA02 PBS/RPBS 0.000 0.010 0.058 SURVEY 0.000 0.000 0.000 ERYTHROPOIETIN B03XA01 PBS/RPBS 0.037 0.047 0.036 SURVEY 0.001 0.002 0.000

190 C

ATC SOURCE 2001 2002 2003

CARDIOVASCULAR SYSTEM CARDIAC THERAPY

CARDIAC GLYCOSIDES DIGITALIS GLYCOSIDES DIGOXIN C01AA05 PBS/RPBS 5.857 5.525 5.119 SURVEY 0.669 0.538 0.480

ANTIARRHYTHMICS, CLASS I AND III ANTIARRHYTHMICS, CLASS IA DISOPYRAMIDE C01BA03 PBS/RPBS 0.080 0.070 0.062 SURVEY 0.000 0.000 0.000 QUINIDINE C01BA01 PBS/RPBS 0.065 0.054 0.048 SURVEY 0.000 0.002 0.000 ANTIARRHYTHMICS, CLASS IB LIGNOCAINE HYDROCHLORIDE C01BB01 PBS/RPBS 0.000 0.000 0.000 SURVEY 0.000 0.000 0.001 MEXILETINE HYDROCHLORIDE C01BB02 PBS/RPBS 0.024 0.022 0.019 SURVEY 0.000 0.001 0.000 ANTIARRHYTHMICS, CLASS IC FLECAINIDE ACETATE C01BC04 PBS/RPBS 0.391 0.413 0.422 SURVEY 0.000 0.000 0.001 ANTIARRHYTHMICS, CLASS III AMIODARONE HYDROCHLORIDE C01BD01 PBS/RPBS 1.604 1.686 1.616 SURVEY 0.012 0.016 0.014

CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES ADRENERGIC AGENTS ADRENALINE C01CA24 PBS/RPBS 0.038 0.037 0.035 SURVEY 0.009 0.005 0.003

191 C

ATC SOURCE 2001 2002 2003

CARDIOVASCULAR SYSTEM CARDIAC THERAPY

VASODILATORS USED IN CARDIC DISEASES ORGANIC NITRATES GLYCERYL TRINITRATE C01DA02 PBS/RPBS 6.345 6.101 5.920 SURVEY 0.173 0.124 0.116 ISOSORBIDE DINITRATE C01DA08 PBS/RPBS 0.364 0.314 0.261 SURVEY 0.014 0.017 0.012 ISOSORBIDE MONONITRATE C01DA14 PBS/RPBS 10.576 10.498 9.995 SURVEY 0.370 0.287 0.271 OTHER VASODILATORS USED IN CARDIAC DISEASES NICORANDIL C01DX16 PBS/RPBS 0.239 0.006 0.005 SURVEY 0.011 0.000 0.000

192 C

ATC SOURCE 2001 2002 2003

CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES

ANTIADRENERGIC AGENTS, CENTRALLY ACTING METHYLDOPA METHYLDOPA C02AB01 PBS/RPBS 0.609 0.561 0.521 SURVEY 0.108 0.091 0.086 IMIDAZOLINE RECEPTOR AGONISTS CLONIDINE C02AC01 PBS/RPBS 0.494 0.480 0.474 SURVEY 0.001 0.002 0.002

ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING ALPHA - ADRENOCEPTOR BLOCKING AGENTS PRAZOSIN HYDROCHLORIDE C02CA01 PBS/RPBS 3.770 3.625 3.461 SURVEY 0.308 0.232 0.226

ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON HYDRAZINOPHTHALAZINE DERIVATIVES HYDRALAZINE HYDROCHLORIDE C02DB02 PBS/RPBS 0.292 0.303 0.308 SURVEY 0.046 0.044 0.040 PYRIMIDINE DERIVATIVES MINOXIDIL C02DC01 PBS/RPBS 0.029 0.029 0.029 SURVEY 0.001 0.001 0.003

193 C

ATC SOURCE 2001 2002 2003

CARDIOVASCULAR SYSTEM DIURETICS

LOW-CEILING DIURETICS, THIAZIDES THIAZIDES, PLAIN BENDROFLUAZIDE C03AA01 PBS/RPBS 2.483 2.349 2.597 SURVEY 0.643 0.620 0.679 HYDROCHLOROTHIAZIDE C03AA03 PBS/RPBS 2.365 1.712 0.183 SURVEY 0.607 0.487 0.051

LOW-CEILING DIURETICS, EXCL THIAZIDES SULFONAMIDES, PLAIN CHLORTHALIDONE C03BA04 PBS/RPBS 0.419 0.377 0.473 SURVEY 0.092 0.067 0.097 INDAPAMIDE C03BA11 PBS/RPBS 7.486 6.611 6.148 SURVEY 1.851 1.431 1.387

HIGH-CEILING DIURETICS SULFONAMIDES, PLAIN BUMETANIDE C03CA02 PBS/RPBS 0.655 0.615 0.166 SURVEY 0.104 0.078 0.211 FRUSEMIDE C03CA01 PBS/RPBS 19.889 19.653 19.207 SURVEY 1.548 1.348 1.170 ARYLOXYACETIC ACID DERIVATIVES ETHACRYNIC ACID C03CC01 PBS/RPBS 0.054 0.053 0.048 SURVEY 0.000 0.000 0.002

POTASSIUM-SPARING AGENTS ALDOSTERONE ANTAGONISTS SPIRONOLACTONE C03DA01 PBS/RPBS 2.076 2.164 2.180 SURVEY 0.119 0.113 0.127 OTHER POTASSIUM-SPARING AGENTS AMILORIDE HYDROCHLORIDE C03DB01 PBS/RPBS 0.343 0.298 0.251 SURVEY 0.034 0.028 0.036

194 C

ATC SOURCE 2001 2002 2003

CARDIOVASCULAR SYSTEM DIURETICS

DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB LOW-CEILING DIURETICS AND POTASSIUM-SPARING AGENTS HYDROCHLOROTHIAZIDE with AMILORIDE HYDROCHLORIDE C03EA01 PBS/RPBS 6.292 5.574 5.153 SURVEY 1.827 1.396 1.336 HYDROCHLOROTHIAZIDE with TRIAMTERENE C03EA01 PBS/RPBS 1.274 1.076 0.921 SURVEY 0.303 0.223 0.214

195 C

ATC SOURCE 2001 2002 2003

CARDIOVASCULAR SYSTEM PERIPHERAL VASODILATORS

PERIPHERAL VASODILATORS PURINE DERIVATIVES OXPENTIFYLLINE C04AD03 SURVEY 0.027 0.020 0.009 OTHER PERIPHERAL VASODILATORS PHENOXYBENZAMINE HYDROCHLORIDE C04AX02 PBS/RPBS 0.016 0.014 0.015 SURVEY 0.000 0.001 0.001

196 C

ATC SOURCE 2001 2002 2003

CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS

BETA BLOCKING AGENTS, PLAIN BETA BLOCKING AGENTS, PLAIN, NON-SELECTIVE OXPRENOLOL HYDROCHLORIDE C07AA02 PBS/RPBS 0.058 0.052 0.045 SURVEY 0.020 0.011 0.011 PINDOLOL C07AA03 PBS/RPBS 0.509 0.459 0.404 SURVEY 0.067 0.055 0.046 PROPRANOLOL HYDROCHLORIDE C07AA05 PBS/RPBS 1.219 1.177 1.110 SURVEY 0.518 0.446 0.421 SOTALOL HYDROCHLORIDE C07AA07 PBS/RPBS 2.238 2.264 2.226 SURVEY 0.072 0.106 0.146 BETA BLOCKING AGENTS, PLAIN, SELECTIVE ATENOLOL C07AB03 PBS/RPBS 8.617 9.111 9.428 SURVEY 2.518 2.462 2.447 BISOPROLOL C07AB07 PBS/RPBS 0.000 0.001 0.053 SURVEY 0.000 0.000 0.000 METOPROLOL TARTRATE C07AB02 PBS/RPBS 4.977 5.185 5.292 SURVEY 1.110 1.055 1.016 ALPHA- AND BETA- ADRENOCEPTOR BLOCKING AGENTS CARVEDILOL C07AG02 PBS/RPBS 0.739 1.032 1.330 SURVEY 0.000 0.003 0.004 LABETALOL HYDROCHLORIDE C07AG01 PBS/RPBS 0.117 0.110 0.105 SURVEY 0.043 0.044 0.047

197 C

ATC SOURCE 2001 2002 2003

CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS

SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS DIHYDROPYRIDINE DERIVATIVES AMLODIPINE BESYLATE C08CA01 PBS/RPBS 14.891 15.209 15.173 SURVEY 1.280 1.125 1.022 FELODIPINE C08CA02 PBS/RPBS 10.547 9.987 9.406 SURVEY 0.700 0.543 0.502 LERCANIPIDINE C08CA13 PBS/RPBS 0.048 1.204 2.626 SURVEY 0.001 0.002 0.007 NIFEDIPINE C08CA05 PBS/RPBS 6.864 6.539 6.129 SURVEY 0.026 0.029 0.092

SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS PHENYLALKYLAMINE DERIVATIVES VERAPAMIL HYDROCHLORIDE C08DA01 PBS/RPBS 5.592 5.230 4.873 SURVEY 1.251 0.947 0.859 BENZOTHIAZEPINE DERIVATIVES DILTIAZEM HYDROCHLORIDE C08DB01 PBS/RPBS 52.513 44.157 38.171 SURVEY 0.055 0.172 0.196

NON-SELECTIVE CALCIUM CHANNEL BLOCKERS OTHER NON-SELECTIVE CALCIUM CHANNEL BLOCKERS PERHEXILINE MALEATE C08EX02 PBS/RPBS 0.246 0.248 0.243 SURVEY 0.000 0.002 0.002

198 C

ATC SOURCE 2001 2002 2003

CARDIOVASCULAR SYSTEM AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM

ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, PLAIN CONVERTING ENZYME BLOCKERS CAPTOPRIL C09AA01 PBS/RPBS 4.399 3.344 2.514 SURVEY 0.010 0.013 0.009 ENALAPRIL MALEATE C09AA02 PBS/RPBS 12.746 10.506 8.912 SURVEY 0.373 0.567 0.460 FOSINOPRIL C09AA09 PBS/RPBS 2.967 2.728 2.557 SURVEY 0.238 0.190 0.155 LISINOPRIL C09AA03 PBS/RPBS 8.899 8.251 7.499 SURVEY 0.161 0.144 0.136 PERINDOPRIL C09AA04 PBS/RPBS 8.865 9.194 9.579 SURVEY 0.378 0.391 0.450 QUINAPRIL C09AA06 PBS/RPBS 4.017 3.717 3.128 SURVEY 0.041 0.034 0.202 RAMIPRIL C09AA05 PBS/RPBS 16.369 23.380 29.038 SURVEY 0.257 0.554 0.558 TRANDOLAPRIL C09AA10 PBS/RPBS 3.167 2.448 2.236 SURVEY 0.066 0.603 0.540

ACE INHIBITORS, COMBINATIONS ANGIOTENSIN-CONVERTING ENZYME BLOCKERS AND DIURETICS ENALAPRIL and HYDROCHLOROTHIAZIDE C09BA02 PBS/RPBS 0.533 1.135 1.403 SURVEY 0.002 0.001 0.004 FOSINOPRIL with HYDROCHLOROTHIAZIDE C09BA09 PBS/RPBS 2.397 2.921 3.059 SURVEY 0.000 0.003 0.085 PERINDOPRIL and INDAPAMIDE C09BA04 PBS/RPBS 2.200 4.444 5.956 SURVEY 0.002 0.009 0.014

199 C

ATC SOURCE 2001 2002 2003

CARDIOVASCULAR SYSTEM AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM

ANGIOTENSIN II ANTAGONISTS ANGIOTENSIN II ANTAGONISTS, PLAIN CANDESARTAN C09CA06 PBS/RPBS 4.010 4.925 5.455 SURVEY 0.039 0.048 0.531 EPROSARTAN C09CA02 PBS/RPBS 0.302 0.422 0.492 SURVEY 0.000 0.003 0.003 IRBESARTAN C09CA04 PBS/RPBS 15.138 17.197 18.845 SURVEY 0.010 0.025 0.169 LOSARTAN C09CA01 SURVEY 0.020 0.023 0.020 TELMISARTAN C09CA07 PBS/RPBS 4.010 4.978 5.556 SURVEY 0.011 0.010 0.013

ANGIOTENSIN II ANTAGONISTS, COMBINATIONS ANGIOTENSIN II ANTAGONISTS AND DIURETICS CANDESARTAN with HYDROCHLOROTHIAZIDE C09DA06 PBS/RPBS 0.826 2.818 4.398 SURVEY 0.001 0.005 0.004 IRBESARTAN with HYDROCHLOROTHIAZIDE C09DA04 PBS/RPBS 11.435 15.945 19.243 SURVEY 0.006 0.034 0.036

200 C

ATC SOURCE 2001 2002 2003

CARDIOVASCULAR SYSTEM SERUM LIPID REDUCING AGENTS

CHOLESTEROL- AND TRIGLYCERIDE REDUCERS HMG COA REDUCTASE INHIBITORS ATORVASTATIN C10AA05 PBS/RPBS 49.794 61.004 72.101 SURVEY 0.078 0.081 0.114 CERIVASTATIN C10AA06 PBS/RPBS 1.964 0.000 0.000 SURVEY 0.000 0.000 0.000 FLUVASTATIN C10AA04 PBS/RPBS 0.637 0.555 0.486 SURVEY 0.002 0.001 0.002 PRAVASTATIN C10AA03 PBS/RPBS 9.675 11.894 13.298 SURVEY 0.008 0.022 0.024 SIMVASTATIN C10AA01 PBS/RPBS 35.335 40.832 46.945 SURVEY 0.030 0.048 0.044 FIBRATES GEMFIBROZIL C10AB04 PBS/RPBS 2.024 1.930 1.886 SURVEY 0.004 0.002 0.002 BILE ACID SEQUESTRANTS CHOLESTYRAMINE C10AC01 PBS/RPBS 0.185 0.197 0.199 SURVEY 0.000 0.000 0.001 COLESTIPOL HYDROCHLORIDE C10AC02 PBS/RPBS 0.009 0.009 0.010

NICOTINIC ACID AND DERIVATIVES NICOTINIC ACID C10AD02 PBS/RPBS 0.047 0.044 0.044 SURVEY 0.013 0.013 0.010 OTHER CHOLESTEROL- AND TRIGLYCERIDE REDUCERS EZETIMIBE C10AX09 SURVEY 0.000 0.000 0.003 PROBUCOL C10AX02 PBS/RPBS 0.027 0.002 0.000 SURVEY 0.000 0.000 0.000

201 D

ATC SOURCE 2001 2002 2003

DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE

ANTIFUNGALS FOR SYSTEMIC USE ANTIFUNGALS FOR SYSTEMIC USE GRISEOFULVIN D01BA01 PBS/RPBS 0.266 0.258 0.248 SURVEY 0.249 0.176 0.158 TERBINAFINE D01BA02 PBS/RPBS 0.574 0.610 0.580 SURVEY 0.034 0.024 0.026

202 D

ATC SOURCE 2001 2002 2003

DERMATOLOGICALS ANTIPSORIATICS

ANTIPSORIATICS FOR SYSTEMIC USE PSORALENS FOR SYSTEMIC USE METHOXSALEN D05BA02 SURVEY 0.003 0.004 0.001 RETINOIDS FOR TREATMENT OF PSORIASIS ACITRETIN D05BB02 PBS/RPBS 0.096 0.091 0.093 SURVEY 0.014 0.002 0.000

203 D

ATC SOURCE 2001 2002 2003

DERMATOLOGICALS ANTI-ACNE PREPARATIONS

ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE RETINOIDS FOR TREATMENT OF ACNE ISOTRETINOIN D10BA01 PBS/RPBS 1.112 0.876 0.732 SURVEY 0.010 0.011 0.008

204 G

ATC SOURCE 2001 2002 2003

GENITO URINARY SYSTEM AND SEX HORMONES GYNAECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS

ANTIINFECTIVES/ANTISEPT.,EXCL COMB WITH CORTICOST. ANTIBIOTICS CLINDAMYCIN G01AA10 SURVEY 0.013 0.012 0.013 NYSTATIN G01AA01 PBS/RPBS 0.001 0.002 0.002 SURVEY 0.072 0.070 0.062 IMIDAZOLE DERIVATIVES CLOTRIMAZOLE G01AF02 PBS/RPBS 0.001 0.001 0.001 SURVEY 0.114 0.115 0.111 ECONAZOLE NITRATE G01AF05 SURVEY 0.007 0.005 0.004 MICONAZOLE NITRATE G01AF04 PBS/RPBS 0.000 0.000 0.000 SURVEY 0.023 0.015 0.010

205 G

ATC SOURCE 2001 2002 2003

GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNAECOLOGICALS

OXYTOCICS PROSTAGLANDINS DINOPROSTONE G02AD02 SURVEY 0.001 0.001 0.000

OTHER GYNAECOLOGICALS PROLACTIN INHIBITORS BROMOCRIPTINE MESYLATE G02CB01 PBS/RPBS 0.007 0.006 0.004 SURVEY 0.006 0.006 0.005 CABERGOLINE G02CB03 PBS/RPBS 0.029 0.031 0.034 SURVEY 0.001 0.001 0.000

206 G

ATC SOURCE 2001 2002 2003

GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE PROGESTOGENS ETONOGESTREL G03AC08 PBS/RPBS 5.858 13.869 7.749 SURVEY 0.007 0.036 0.023 LEVONORGESTREL G03AC03 PBS/RPBS 0.827 0.761 0.651 SURVEY 1.736 1.452 1.232 MEDROXYPROGESTERONE G03AC06 PBS/RPBS 1.977 1.714 1.612 SURVEY 1.584 1.204 1.165

ANDROGENS 3-OXOANDROSTEN (4) DERIVATIVES FLUOXYMESTERONE G03BA01 SURVEY 0.002 0.000 0.000 TESTOSTERONE G03BA03 PBS/RPBS 0.405 0.435 0.461 SURVEY 0.108 0.108 0.100 5-ANDROSTANON (3) DERIVATIVES MESTEROLONE G03BB01 SURVEY 0.005 0.002 0.002

ESTROGENS NATURAL AND SEMISYNTHETIC ESTROGENS, PLAIN OESTRADIOL G03CA03 PBS/RPBS 3.616 3.155 2.558 SURVEY 2.695 2.178 1.789 OESTRADIOL VALERATE G03CA03 PBS/RPBS 0.851 0.722 0.552 SURVEY 0.599 0.437 0.349 OESTRIOL G03CA04 PBS/RPBS 2.326 2.377 2.340 SURVEY 0.781 0.743 0.750 OESTROGENS CONJUGATED G03CA57 PBS/RPBS 5.770 4.575 3.187 SURVEY 3.413 2.711 1.941 OESTRONE G03CA07 PBS/RPBS 1.714 1.361 0.936 SURVEY 1.204 0.911 0.610 SYNTHETIC ESTROGENS, PLAIN DIENOESTROL G03CB01 SURVEY 0.011 0.000 0.000

207 G

ATC SOURCE 2001 2002 2003

GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

PROGESTOGENS PREGNEN (4) DERIVATIVES MEDROXYPROGESTERONE G03DA02 PBS/RPBS 4.403 3.187 1.969 SURVEY 2.226 1.418 0.883 PREGNADIEN DERIVATIVES DYDROGESTERONE G03DB01 PBS/RPBS 0.048 0.036 0.030 SURVEY 0.096 0.068 0.051 ESTREN DERIVATIVES NORETHISTERONE G03DC02 PBS/RPBS 1.150 0.991 0.848 SURVEY 0.007 0.005 0.005 TIBOLONE G03DC05 SURVEY 0.577 0.934 1.206

PROGESTOGENS AND ESTROGENS IN COMBINATION PROGESTOGENS AND ESTROGENS, FIXED COMBINATIONS MEDROXYPROGESTERONE AND ESTROGEN G03FA12 PBS/RPBS 2.260 1.827 1.133 SURVEY 2.024 1.643 0.995 NORETHISTERONE AND ESTROGEN G03FA01 PBS/RPBS 0.512 0.424 0.297 SURVEY 0.614 0.486 0.342 PROGESTOGENS AND ESTROGENS,SEQUENTIAL PREPARATIONS DYDROGESTERONE AND ESTROGEN G03FB08 PBS/RPBS 0.013 0.012 0.009 SURVEY 0.027 0.026 0.020 MEDROXYPROGESTERONE AND ESTROGEN G03FB06 PBS/RPBS 0.259 0.195 0.110 SURVEY 0.396 0.298 0.190 OESTRADIOL with NORETHISTERONE ACETATE G03FB05 PBS/RPBS 1.173 0.963 0.681 SURVEY 1.694 1.243 0.930

208 G

ATC SOURCE 2001 2002 2003

GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

GONADOTROPHINS AND OTHER OVULATION STIMULANTS GONADOTROPHINS FOLLITROPIN ALFA G03GA05 PBS/RPBS 0.007 0.005 0.004 SURVEY 0.000 0.000 0.000 FOLLITROPIN BETA G03GA06 PBS/RPBS 0.004 0.004 0.006 SURVEY 0.000 0.000 0.000 HUMAN CHORIONIC GONADOTROPHIN G03GA01 PBS/RPBS 0.022 0.027 0.023 SURVEY 0.020 0.019 0.013 HUMAN MENOPAUSAL GONADOTROPHIN G03GA02 PBS/RPBS 0.001 0.000 0.000 OVULATION STIMULANTS, SYNTHETIC CLOMIPHENE CITRATE G03GB02 PBS/RPBS 0.306 0.297 0.298 SURVEY 0.001 0.003 0.009

ANTIANDROGENS ANTIANDROGENS, PLAIN PREPARATIONS CYPROTERONE ACETATE G03HA01 PBS/RPBS 0.552 0.548 0.540 SURVEY 0.025 0.006 0.007

OTHER SEX HORM. MODULATORS OF THE GENITAL SYSTEM ANTIGONADOTROPINS AND SIMILAR AGENTS DANAZOL G03XA01 PBS/RPBS 0.027 0.023 0.019 SURVEY 0.001 0.001 0.000 GESTRINONE G03XA02 PBS/RPBS 0.005 0.004 0.003

RALOXIFENE G03XC01 PBS/RPBS 1.102 1.305 1.381 SURVEY 0.055 0.061 0.059

209 G

ATC SOURCE 2001 2002 2003

GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS

OTHER UROLOGICALS, INCL ANTISPASMODICS ACIDIFIERS AMMONIUM CHLORIDE G04BA01 PBS/RPBS 0.004 0.004 0.004 SURVEY 0.000 0.000 0.000 URINARY ANTISPASMODICS OXYBUTYNIN G04BD04 PBS/RPBS 0.688 0.766 0.799 SURVEY 0.118 0.115 0.119 DRUGS USED IN ERECTILE DYSFUNCTION ALPROSTADIL G04BE01 PBS/RPBS 0.065 0.056 0.011 SURVEY 0.000 0.031 0.058 SILDENAFIL G04BE03 PBS/RPBS 0.022 0.026 0.028 SURVEY 0.375 0.407 0.333

DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY ALPHA-ADRENORECEPTOR ANTAGONISTS TAMSULOSIN G04CA02 PBS/RPBS 0.018 0.045 0.070 SURVEY 0.096 0.169 0.253 TERAZOSIN G04CA03 PBS/RPBS 0.010 0.009 0.007 SURVEY 0.037 0.022 0.023 TESTOSTERONE-5-ALPHA REDUCTASE INHIBITORS FINASTERIDE G04CB01 PBS/RPBS 0.044 0.048 0.049 SURVEY 0.082 0.069 0.076

210 H

ATC SOURCE 2001 2002 2003

SYSTEMIC HORMONAL PREP,EXCL SEX HORMONES PITUITARY, HYPOTHALAMIC HORMONES AND ANALOGUES

ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES ACTH TETRACOSACTRIN H01AA02 PBS/RPBS 0.001 0.001 0.001 SURVEY 0.000 0.000 0.000

POSTERIOR PITUITARY LOBE HORMONES VASOPRESSIN AND ANALOGUES DESMOPRESSIN H01BA02 PBS/RPBS 0.231 0.282 0.280 SURVEY 0.004 0.003 0.006

HYPOTHALAMIC HORMONES GONADOTROPHIN-RELEASING HORMONES NAFARELIN H01CA02 PBS/RPBS 0.010 0.010 0.011 SURVEY 0.007 0.014 0.007 ANTIGROWTH HORMONE OCTREOTIDE H01CB02 PBS/RPBS 0.000 0.000 0.000 SURVEY 0.001 0.000 0.000

211 H

ATC SOURCE 2001 2002 2003

SYSTEMIC HORMONAL PREP,EXCL SEX HORMONES CORTICOSTEROIDS FOR SYSTEMIC USE

CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN MINERALOCORTICOIDS FLUDROCORTISONE ACETATE H02AA02 PBS/RPBS 0.400 0.411 0.422 SURVEY 0.119 0.141 0.143 GLUCOCORTICOIDS BETAMETHASONE H02AB01 PBS/RPBS 0.166 0.164 0.167 SURVEY 0.005 0.005 0.005 BUDESONIDE H02AB16 SURVEY 0.008 0.004 0.007 CORTISONE H02AB10 PBS/RPBS 0.142 0.139 0.138 SURVEY 0.059 0.052 0.062 DEXAMETHASONE H02AB02 PBS/RPBS 0.662 0.681 0.736 SURVEY 0.151 0.164 0.208 HYDROCORTISONE H02AB09 PBS/RPBS 0.105 0.111 0.117 SURVEY 0.033 0.025 0.034 METHYLPREDNISOLONE H02AB04 PBS/RPBS 0.085 0.079 0.076 SURVEY 0.022 0.016 0.015 PREDNISOLONE H02AB06 PBS/RPBS 4.799 4.906 4.906 SURVEY 2.009 1.941 2.065 PREDNISONE H02AB07 PBS/RPBS 2.517 2.434 2.342 SURVEY 1.510 1.225 1.087 TRIAMCINOLONE ACETONIDE H02AB08 PBS/RPBS 0.029 0.027 0.029 SURVEY 0.003 0.006 0.003

212 H

ATC SOURCE 2001 2002 2003

SYSTEMIC HORMONAL PREP,EXCL SEX HORMONES THYROID THERAPY

THYROID PREPARATIONS THYROID HORMONES LIOTHYRONINE H03AA02 PBS/RPBS 0.033 0.040 0.042 SURVEY 0.005 0.003 0.004 THYROXINE SODIUM H03AA01 PBS/RPBS 8.989 9.535 9.812 SURVEY 4.619 4.850 4.889

ANTITHYROID PREPARATIONS THIOURACILS PROPYLTHIOURACIL H03BA02 PBS/RPBS 0.181 0.183 0.201 SURVEY 0.004 0.006 0.004 SULPHUR-CONTAINING IMIDAZOLE DERIVATIVES CARBIMAZOLE H03BB01 PBS/RPBS 0.452 0.488 0.532 SURVEY 0.032 0.026 0.028

213 H

ATC SOURCE 2001 2002 2003

SYSTEMIC HORMONAL PREP,EXCL SEX HORMONES PANCREATIC HORMONES

GLYCOGENOLYTIC HORMONES GLYCOGENOLYTIC HORMONES GLUCAGON HYDROCHLORIDE H04AA01 PBS/RPBS 0.004 0.005 0.005 SURVEY 0.000 0.000 0.000

214 H

ATC SOURCE 2001 2002 2003

SYSTEMIC HORMONAL PREP,EXCL SEX HORMONES CALCIUM HOMEOSTASIS

ANTI-PARATHYROID HORMONES CALCITONIN PREPARATIONS CALCITONIN (SALMON SYNTHETIC) H05BA01 PBS/RPBS 0.003 0.002 0.001 SURVEY 0.000 0.000 0.000

215 J

ATC SOURCE 2001 2002 2003

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE

TETRACYCLINES TETRACYCLINES DEMECLOCYCLINE HYDROCHLORIDE J01AA01 PBS/RPBS 0.006 0.007 0.009 SURVEY 0.000 0.000 0.000 DOXYCYCLINE J01AA02 PBS/RPBS 1.417 1.342 1.271 SURVEY 1.507 1.263 1.145 MINOCYCLINE J01AA08 PBS/RPBS 0.396 0.374 0.351 SURVEY 0.549 0.466 0.455 TETRACYCLINE J01AA07 PBS/RPBS 0.144 0.137 0.129 SURVEY 0.128 0.097 0.087 TETRACYCLINE with NYSTATIN J01AA20 SURVEY 0.001 0.000 0.000

BETA-LACTAM ANTIBACTERIALS,PENICILLINS PENICILLINS WITH EXTENDED SPECTRUM AMOXYCILLIN J01CA04 PBS/RPBS 2.510 2.479 2.557 SURVEY 2.288 2.127 2.147 AMPICILLIN J01CA01 PBS/RPBS 0.007 0.006 0.006 SURVEY 0.001 0.001 0.001 BETA-LACTAMASE SENSITIVE PENICILLINS BENZYLPENICILLIN J01CE01 PBS/RPBS 0.005 0.005 0.003 SURVEY 0.000 0.000 0.000 PHENOXYMETHYLPENICILLIN J01CE02 PBS/RPBS 0.286 0.268 0.242 SURVEY 0.417 0.368 0.325 PROCAINE PENICILLIN J01CE09 PBS/RPBS 0.014 0.011 0.010 SURVEY 0.001 0.000 0.000

216 J

ATC SOURCE 2001 2002 2003

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE

BETA-LACTAM ANTIBACTERIALS,PENICILLINS BETA-LACTAMASE RESISTANT PENICILLINS DICLOXACILLIN J01CF01 PBS/RPBS 0.209 0.210 0.199 SURVEY 0.201 0.169 0.145 FLUCLOXACILLIN J01CF05 PBS/RPBS 0.177 0.171 0.173 SURVEY 0.136 0.128 0.123 COMBINATIONS OF PENICILLINS, INCL.BETA-LACTAMASE INHIBITORS AMOXYCILLIN with CLAVULANIC ACID J01CR02 PBS/RPBS 1.487 1.479 1.489 SURVEY 1.387 1.283 1.231 TICARCILLIN with CLAVULANIC ACID J01CR03 PBS/RPBS 0.002 0.003 0.004 SURVEY 0.000 0.000 0.000

OTHER BETA-LACTAM ANTIBACTERIALS FIRST-GENERATION CEPHALOSPORINS CEFALEXIN J01DB01 PBS/RPBS 1.159 1.173 1.214 SURVEY 0.801 0.756 0.733 CEPHALOTHIN J01DB03 PBS/RPBS 0.019 0.019 0.018 SURVEY 0.001 0.001 0.000 CEPHAZOLIN J01DB04 PBS/RPBS 0.002 0.002 0.005 SURVEY 0.000 0.000 0.000 SECOND-GENERATION CEPHALOSPORINS CEFACLOR J01DC04 PBS/RPBS 0.470 0.391 0.328 SURVEY 0.406 0.305 0.269 CEFUROXIME J01DC02 PBS/RPBS 0.070 0.053 0.050 SURVEY 0.060 0.049 0.044 THIRD-GENERATION CEPHALOSPORINS CEFOTAXIME J01DD01 PBS/RPBS 0.002 0.002 0.001 SURVEY 0.000 0.000 0.000 CEFTRIAXONE J01DD04 PBS/RPBS 0.016 0.017 0.016

217 J

ATC SOURCE 2001 2002 2003

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE

SULFONAMIDES AND TRIMETHOPRIM TRIMETHOPRIM AND DERIVATIVES TRIMETHOPRIM J01EA01 PBS/RPBS 0.329 0.334 0.345 SURVEY 0.164 0.157 0.153 COMBINATIONS OF SULFONAMIDES AND TRIMETHOPRIM, INCL. DERIVAT TRIMETHOPRIM with SULPHAMETHOXAZOLE J01EE01 PBS/RPBS 0.288 0.269 0.260 SURVEY 0.209 0.182 0.158

MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS MACROLIDES AZITHROMYCIN J01FA10 PBS/RPBS 0.007 0.006 0.007 SURVEY 0.009 0.011 0.011 CLARITHROMYCIN J01FA09 PBS/RPBS 0.236 0.281 0.300 SURVEY 0.166 0.197 0.232 ERYTHROMYCIN J01FA01 PBS/RPBS 0.582 0.506 0.458 SURVEY 0.575 0.481 0.397 ROXITHROMYCIN J01FA06 PBS/RPBS 0.967 0.887 0.806 SURVEY 0.754 0.637 0.533 LINCOSAMIDES CLINDAMYCIN J01FF01 PBS/RPBS 0.023 0.027 0.032 SURVEY 0.017 0.013 0.013

AMINOGLYCOSIDE ANTIBACTERIALS OTHER AMINOGLYCOSIDES GENTAMICIN SULPHATE J01GB03 PBS/RPBS 0.011 0.011 0.011 SURVEY 0.001 0.001 0.001 TOBRAMYCIN J01GB01 PBS/RPBS 0.001 0.002 0.002 SURVEY 0.000 0.000 0.000

218 J

ATC SOURCE 2001 2002 2003

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE

QUINOLONE ANTIBACTERIALS FLUOROQUINOLONES CIPROFLOXACIN J01MA02 PBS/RPBS 0.215 0.209 0.204 SURVEY 0.013 0.010 0.015 MOXIFLOXACIN J01MA14 PBS/RPBS 0.000 0.000 0.000 SURVEY 0.000 0.001 0.004 NORFLOXACIN J01MA06 PBS/RPBS 0.145 0.142 0.147 SURVEY 0.069 0.066 0.065

OTHER ANTIBACTERIALS GLYCOPEPTIDE ANTIBACTERIALS VANCOMYCIN J01XA01 PBS/RPBS 0.004 0.006 0.005 SURVEY 0.000 0.000 0.000 STEROID ANTIBACTERIALS FUSIDIC ACID J01XC01 PBS/RPBS 0.024 0.027 0.030 SURVEY 0.000 0.000 0.000 IMIDAZOLE DERIVATIVES METRONIDAZOLE J01XD01 PBS/RPBS 0.007 0.007 0.007 SURVEY 0.000 0.000 0.000 NITROFURAN DERIVATIVES NITROFURANTOIN J01XE01 PBS/RPBS 0.233 0.222 0.213 SURVEY 0.069 0.053 0.051 OTHER ANTIBACTERIALS METHENAMINE J01XX05 PBS/RPBS 0.457 0.460 0.457 SURVEY 0.003 0.008 0.006

219 J

ATC SOURCE 2001 2002 2003

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE

ANTIMYCOTICS FOR SYSTEMIC USE IMIDAZOLE DERIVATIVES KETOCONAZOLE J02AB02 PBS/RPBS 0.140 0.128 0.116 SURVEY 0.058 0.046 0.045 TRIAZOLE DERIVATIVES FLUCONAZOLE J02AC01 PBS/RPBS 0.039 0.042 0.044 SURVEY 0.006 0.005 0.005 ITRACONAZOLE J02AC02 PBS/RPBS 0.022 0.023 0.022 SURVEY 0.007 0.004 0.003

220 J

ATC SOURCE 2001 2002 2003

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS

DRUGS FOR TREATMENT OF TUBERCULOSIS ANTIBIOTICS RIFABUTIN J04AB04 PBS/RPBS 0.000 0.000 0.000 SURVEY 0.000 0.001 0.009 RIFAMPICIN J04AB02 PBS/RPBS 0.008 0.007 0.007 SURVEY 0.005 0.007 0.006 HYDRAZIDES ISONIAZID J04AC01 PBS/RPBS 0.004 0.004 0.004 SURVEY 0.003 0.001 0.002 OTHER DRUGS FOR TREATMENT OF TUBERCULOSIS ETHAMBUTOL HYDROCHLORIDE J04AK02 SURVEY 0.001 0.000 0.001

DRUGS FOR TREATMENT OF LEPRA DRUGS FOR TREATMENT OF LEPRA CLOFAZIMINE J04BA01 SURVEY 0.000 0.001 0.004 DAPSONE J04BA02 SURVEY 0.080 0.032 0.001

221 J

ATC SOURCE 2001 2002 2003

GENERAL ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE

DIRECT ACTING ANTIVIRALS NUCLEOSIDES AND NUCLEOTIDES EXCL. REVERSE TRANSCRIPTASE INHIBITORS ACICLOVIR J05AB01 PBS/RPBS 0.049 0.042 0.035 SURVEY 0.001 0.001 0.001 FAMCICLOVIR J05AB09 PBS/RPBS 0.157 0.176 0.183 SURVEY 0.013 0.003 0.003 VALACICLOVIR J05AB11 PBS/RPBS 0.119 0.151 0.175 SURVEY 0.003 0.002 0.002 NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS LAMIVUDINE J05AF05 PBS/RPBS 0.003 0.007 0.009 SURVEY 0.001 0.000 0.000 NEURAMINIDASE INHIBITORS ZANAMIVIR J05AH01 SURVEY 0.005 0.002 0.002

222 L

ATC SOURCE 2001 2002 2003

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY

HORMONES AND RELATED AGENTS ESTROGENS FOSFESTROL L02AA04 PBS/RPBS 0.015 0.015 0.001 SURVEY 0.000 0.000 0.000 PROGESTOGENS MEDROXYPROGESTERONE L02AB02 PBS/RPBS 0.015 0.014 0.010 SURVEY 0.000 0.000 0.000 MEGESTROL L02AB01 PBS/RPBS 0.014 0.011 0.011 SURVEY 0.000 0.000 0.000 GONADOTROPHIN RELEASING HORMONE ANALOGUES GOSERELIN L02AE03 PBS/RPBS 0.522 0.540 0.554 SURVEY 0.085 0.006 0.002 LEUPRORELIN ACETATE L02AE02 PBS/RPBS 0.424 0.495 0.555 SURVEY 0.119 0.020 0.006

HORMONE ANTAGONISTS AND RELATED AGENTS ANTI-ESTROGENS TAMOXIFEN L02BA01 PBS/RPBS 1.768 1.763 1.693 SURVEY 0.003 0.016 0.014 TOREMIFENE L02BA02 PBS/RPBS 0.043 0.043 0.040 SURVEY 0.000 0.000 0.000 ANTI-ANDROGENS BICALUTAMIDE L02BB03 PBS/RPBS 0.098 0.125 0.140 SURVEY 0.002 0.001 0.001 FLUTAMIDE L02BB01 PBS/RPBS 0.056 0.045 0.037 SURVEY 0.000 0.000 0.000 NILUTAMIDE L02BB02 PBS/RPBS 0.083 0.071 0.071 SURVEY 0.001 0.001 0.000

223 L

ATC SOURCE 2001 2002 2003

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY

HORMONE ANTAGONISTS AND RELATED AGENTS ENZYME INHIBITORS AMINOGLUTETHIMIDE L02BG01 PBS/RPBS 0.002 0.002 0.001 SURVEY 0.000 0.000 0.000 ANASTROZOLE L02BG03 PBS/RPBS 0.077 0.107 0.135 SURVEY 0.000 0.001 0.000 EXEMESTANE L02BG06 PBS/RPBS 0.013 0.024 0.028 SURVEY 0.000 0.000 0.000 LETROZOLE L02BG04 PBS/RPBS 0.090 0.111 0.138 SURVEY 0.000 0.001 0.005

224 L

ATC SOURCE 2001 2002 2003

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS

CYTOKINES AND IMMUNOMODULATORS COLONY STIMULATING FACTORS FILGRASTIM L03AA02 PBS/RPBS 0.007 0.010 0.005 SURVEY 0.092 0.004 0.004 PEGFILGRASTIM L03AA13 PBS/RPBS 0.000 0.000 0.015 SURVEY 0.000 0.000 0.004 INTERFERONS INTERFERON BETA-1a L03AB07 PBS/RPBS 0.175 0.242 0.277 SURVEY 0.016 0.003 0.002 INTERFERON BETA-1b L03AB08 PBS/RPBS 0.121 0.134 0.137 SURVEY 0.018 0.002 0.003 INTERFERON-ALFA-2a L03AB04 PBS/RPBS 0.006 0.007 0.006 SURVEY 0.001 0.000 0.000 INTERFERON-ALFA-2b L03AB05 PBS/RPBS 0.009 0.009 0.008 SURVEY 0.000 0.000 0.000

OTHER CYTOKINES AND IMMUNOMODULATORS GLATIRAMER ACETATE L03AX13 PBS/RPBS 0.035 0.044 0.050 SURVEY 0.006 0.001 0.000

225 L

ATC SOURCE 2001 2002 2003

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSIVE AGENTS

IMMUNOSUPPRESSIVE AGENTS SELECTIVE IMMUNOSUPPRESSIVE AGENTS CYCLOSPORIN L04AA01 PBS/RPBS 0.010 0.014 0.013 SURVEY 0.000 0.000 0.002 ETANERCEPT L04AA11 PBS/RPBS 0.000 0.000 0.007 SURVEY 0.000 0.000 0.000 LEFLUNOMIDE L04AA13 PBS/RPBS 0.306 0.347 0.383 SURVEY 0.002 0.001 0.001 MYCOPHENOLIC ACID L04AA06 PBS/RPBS 0.001 0.003 0.004 SURVEY 0.000 0.000 0.000 TACROLIMUS L04AA05 PBS/RPBS 0.000 0.000 0.002 SURVEY 0.000 0.000 0.000 OTHER IMMUNOSUPPRESSIVE AGENTS AZATHIOPRINE L04AX01 PBS/RPBS 0.410 0.430 0.439 SURVEY 0.003 0.001 0.001

226 M

ATC SOURCE 2001 2002 2003

MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS ACETIC ACID DERIVATIVES AND RELATED SUBSTANCES DICLOFENAC M01AB05 PBS/RPBS 3.226 3.188 3.105 SURVEY 1.981 1.803 1.737 DICLOFENAC WITH MISOPROSTOL M01AB55 PBS/RPBS 0.018 0.014 0.011 SURVEY 0.011 0.007 0.007 INDOMETHACIN M01AB01 PBS/RPBS 0.881 0.875 0.855 SURVEY 0.528 0.529 0.528 KETOROLAC M01AB15 SURVEY 0.005 0.006 0.006 SULINDAC M01AB02 PBS/RPBS 0.140 0.119 0.097 SURVEY 0.019 0.018 0.020 OXICAMS MELOXICAM M01AC06 PBS/RPBS 0.000 1.497 3.202 SURVEY 0.000 0.008 0.022 PIROXICAM M01AC01 PBS/RPBS 1.282 1.121 0.973 SURVEY 0.625 0.479 0.444 TENOXICAM M01AC02 PBS/RPBS 0.144 0.092 0.000 SURVEY 0.028 0.018 0.000 PROPIONIC ACID DERIVATIVES IBUPROFEN M01AE01 PBS/RPBS 0.990 0.970 0.952 SURVEY 0.481 0.450 0.442 IBUPROFEN with CODEINE M01AE01 SURVEY 0.000 0.000 0.052 KETOPROFEN M01AE03 PBS/RPBS 1.563 1.342 1.112 SURVEY 0.576 0.440 0.392 NAPROXEN M01AE02 PBS/RPBS 3.376 3.135 2.853 SURVEY 2.019 1.734 1.672 TIAPROFENIC ACID M01AE11 PBS/RPBS 0.168 0.137 0.112 SURVEY 0.034 0.033 0.030

227 M

ATC SOURCE 2001 2002 2003

MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS FENAMATES MEFENAMIC ACID M01AG01 PBS/RPBS 0.060 0.054 0.051 SURVEY 0.033 0.027 0.025 COXIBS CELECOXIB M01AH01 PBS/RPBS 23.343 16.789 14.930 SURVEY 0.160 0.133 0.133 ROFECOXIB M01AH02 PBS/RPBS 6.375 9.638 10.762 SURVEY 0.034 0.070 0.071

SPECIFIC ANTIRHEUMATIC AGENTS GOLD PREPARATIONS AURANOFIN M01CB03 PBS/RPBS 0.028 0.025 0.023 SURVEY 0.000 0.000 0.000 AUROTHIOGLUCOSE M01CB04 PBS/RPBS 0.030 0.005 0.000 SODIUM AUROTHIOMALATE M01CB01 PBS/RPBS 0.116 0.126 0.114 SURVEY 0.000 0.000 0.000 PENICILLAMINE PENICILLAMINE M01CC01 PBS/RPBS 0.070 0.060 0.051 SURVEY 0.000 0.000 0.000

228 M

ATC SOURCE 2001 2002 2003

MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS

MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS ETHERS, CHEMICALLY CLOSE TO ANTIHISTAMINES ORPHENADRINE CITRATE M03BC01 SURVEY 0.077 0.066 0.059 ORPHENADRINE CITRATE with PARACETAMOL M03BC51 SURVEY 0.015 0.013 0.008 OTHER CENTRALLY ACTING AGENTS BACLOFEN M03BX01 PBS/RPBS 0.486 0.502 0.519 SURVEY 0.004 0.009 0.011

MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS DANTROLENE AND DERIVATIVES DANTROLENE SODIUM M03CA01 PBS/RPBS 0.031 0.030 0.030 SURVEY 0.001 0.000 0.001

229 M

ATC SOURCE 2001 2002 2003

MUSCULO-SKELETAL SYSTEM ANTIGOUT PREPARATIONS

ANTIGOUT PREPARATIONS PREPARATIONS INHIBITING URIC ACID PRODUCTION ALLOPURINOL M04AA01 PBS/RPBS 5.156 5.209 5.131 SURVEY 1.939 1.870 1.825 PREPARATIONS INCREASING URIC ACID EXCRETION PROBENECID M04AB01 PBS/RPBS 0.105 0.115 0.121 SURVEY 0.003 0.001 0.002 SULPHINPYRAZONE M04AB02 PBS/RPBS 0.035 0.010 0.000 SURVEY 0.000 0.006 0.000 PREPARATIONS WITH NO EFFECT ON URIC ACID METABOLISM COLCHICINE M04AC01 PBS/RPBS 1.078 1.103 1.112 SURVEY 0.455 0.455 0.415

230 M

ATC SOURCE 2001 2002 2003

MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES

DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION BISPHOSPHONATES ALENDRONIC ACID M05BA04 PBS/RPBS 3.617 5.974 7.430 SURVEY 0.150 0.223 0.299 CLODRONIC ACID M05BA02 PBS/RPBS 0.046 0.071 0.083 SURVEY 0.006 0.002 0.000 DISODIUM ETIDRONATE M05BA01 PBS/RPBS 0.007 0.005 0.003 SURVEY 0.002 0.001 0.001 DISODIUM PAMIDRONATE M05BA03 PBS/RPBS 0.002 0.002 0.002 SURVEY 0.000 0.003 0.000 RISEDRONIC ACID M05BA07 PBS/RPBS 0.290 0.569 1.319 SURVEY 0.007 0.015 0.040 TILUDRONIC ACID M05BA05 PBS/RPBS 0.012 0.007 0.006

231 N

ATC SOURCE 2001 2002 2003

NERVOUS SYSTEM ANALGESICS

OPIOIDS NATURAL OPIUM ALKALOIDS CODEINE with ASPIRIN N02AA59 SURVEY 0.006 0.009 0.003 CODEINE with PARACETAMOL N02AA59 PBS/RPBS 4.946 4.952 4.917 SURVEY 1.695 1.752 1.713 HYDROMORPHONE N02AA03 PBS/RPBS 0.058 0.087 0.070 SURVEY 0.015 0.003 0.000 MORPHINE N02AA01 PBS/RPBS 1.667 1.691 1.731 SURVEY 0.076 0.080 0.128 OXYCODONE N02AA05 PBS/RPBS 0.531 0.710 0.871 SURVEY 0.070 0.069 0.062 PHENYLPIPERIDINE DERIVATIVES FENTANYL N02AB03 PBS/RPBS 0.158 0.195 0.229 SURVEY 0.003 0.004 0.002 PETHIDINE HYDROCHLORIDE N02AB02 PBS/RPBS 0.015 0.013 0.012 SURVEY 0.011 0.011 0.008 DIPHENYLPROPYLAMINE DERIVATIVES DEXTROMORAMIDE N02AC01 SURVEY 0.002 0.002 0.001 DEXTROPROPOXYPHENE NAPSYLATE N02AC04 PBS/RPBS 0.049 0.044 0.040 SURVEY 0.097 0.070 0.064 DEXTROPROPOXYPHENE with PARACETAMOL N02AC54 SURVEY 0.350 0.315 0.293 BENZOMORPHAN DERIVATIVES PENTAZOCINE N02AD01 SURVEY 0.002 0.002 0.003 ORIPAVINE DERIVATIVES BUPRENORPHINE N02AE01 SURVEY 0.001 0.002 0.001 OTHER OPIOIDS TRAMADOL N02AX02 PBS/RPBS 0.460 1.569 2.252 SURVEY 0.106 0.297 0.356

232 N

ATC SOURCE 2001 2002 2003

NERVOUS SYSTEM ANALGESICS

OTHER ANALGESICS AND ANTIPYRETICS SALICYLIC ACID DERIVATIVES ASPIRIN N02BA01 PBS/RPBS 0.595 0.524 0.454 SURVEY 0.025 0.020 0.018 CODEINE with ASPIRIN N02BA51 PBS/RPBS 0.001 0.001 0.000 SURVEY 0.045 0.039 0.031 DIFLUNISAL N02BA11 PBS/RPBS 0.188 0.154 0.135 SURVEY 0.047 0.030 0.031 ANILIDES CODEINE with PARACETAMOL N02BE51 PBS/RPBS 0.027 0.025 0.023 SURVEY 0.122 0.107 0.097 PARACETAMOL N02BE01 PBS/RPBS 10.668 10.706 10.332 SURVEY 0.226 0.206 0.169

ANTIMIGRAINE PREPARATIONS ERGOT ALKALOIDS DIHYDROERGOTAMINE N02CA01 PBS/RPBS 0.002 0.002 0.001 SURVEY 0.002 0.001 0.001 ERGOTAMINE N02CA02 PBS/RPBS 0.060 0.025 0.000 SURVEY 0.042 0.016 0.000 METHYSERGIDE N02CA04 PBS/RPBS 0.052 0.049 0.045 SURVEY 0.000 0.000 0.000 SELECTIVE 5HT RECEPTOR AGONISTS NARATRIPTAN N02CC02 PBS/RPBS 0.019 0.021 0.024 SURVEY 0.013 0.013 0.017 SUMATRIPTAN N02CC01 PBS/RPBS 0.067 0.075 0.078 SURVEY 0.068 0.063 0.064 ZOLMITRIPTAN N02CC03 PBS/RPBS 0.033 0.035 0.037 SURVEY 0.020 0.017 0.020 OTHER ANTIMIGRAINE PREPARATIONS PIZOTIFEN MALATE N02CX01 PBS/RPBS 0.469 0.464 0.458 SURVEY 0.204 0.172 0.176

233 N

ATC SOURCE 2001 2002 2003

NERVOUS SYSTEM ANTIEPILEPTICS

ANTIEPILEPTICS BARBITURATES AND DERIVATIVES METHYLPHENOBARBITONE N03AA01 PBS/RPBS 0.043 0.028 0.001 SURVEY 0.000 0.000 0.007 PHENOBARBITONE N03AA02 PBS/RPBS 0.125 0.122 0.130 SURVEY 0.041 0.027 0.037 PRIMIDONE N03AA03 PBS/RPBS 0.091 0.095 0.104 SURVEY 0.034 0.018 0.002 HYDANTOIN DERIVATIVES PHENYTOIN N03AB02 PBS/RPBS 2.010 1.945 1.881 SURVEY 0.015 0.040 0.021 SUCCINIMIDE DERIVATIVES ETHOSUXIMIDE N03AD01 PBS/RPBS 0.022 0.021 0.019 SURVEY 0.000 0.000 0.000 BENZODIAZEPINE DERIVATIVES CLONAZEPAM N03AE01 PBS/RPBS 0.206 0.196 0.176 SURVEY 0.210 0.180 0.168 CARBOXAMIDE DERIVATIVES CARBAMAZEPINE N03AF01 PBS/RPBS 2.094 2.036 1.974 SURVEY 0.047 0.046 0.039 OXCARBAZEPINE N03AF02 PBS/RPBS 0.000 0.004 0.030 SURVEY 0.000 0.000 0.001 FATTY ACID DERIVATIVES SODIUM VALPROATE N03AG01 PBS/RPBS 2.844 3.039 3.214 SURVEY 0.031 0.035 0.029 TIAGABINE N03AG06 PBS/RPBS 0.022 0.022 0.020 SURVEY 0.000 0.000 0.000 VIGABATRIN N03AG04 PBS/RPBS 0.101 0.087 0.074 SURVEY 0.000 0.000 0.000

234 N

ATC SOURCE 2001 2002 2003

NERVOUS SYSTEM ANTIEPILEPTICS

ANTIEPILEPTICS OTHER ANTIEPILEPTICS GABAPENTIN N03AX12 PBS/RPBS 0.230 0.285 0.306 SURVEY 0.054 0.096 0.121 LAMOTRIGINE N03AX09 PBS/RPBS 0.561 0.625 0.679 SURVEY 0.018 0.008 0.011 LEVETIRACETAM N03AX14 PBS/RPBS 0.000 0.000 0.033 SULTHIAME N03AX03 PBS/RPBS 0.029 0.030 0.028 TOPIRAMATE N03AX11 PBS/RPBS 0.164 0.195 0.229 SURVEY 0.008 0.007 0.012

235 N

ATC SOURCE 2001 2002 2003

NERVOUS SYSTEM ANTI-PARKINSON DRUGS

ANTICHOLINERGIC AGENTS TERTIARY AMINES WITH CARBON CHAIN BENZHEXOL HYDROCHLORIDE N04AA01 PBS/RPBS 0.168 0.181 0.163 SURVEY 0.018 0.020 0.019 BIPERIDEN HYDROCHLORIDE N04AA02 PBS/RPBS 0.046 0.048 0.044 SURVEY 0.003 0.002 0.003 PROCYCLIDINE HYDROCHLORIDE N04AA04 SURVEY 0.003 0.000 0.000 ETHERS OF TROPINE OR TROPINE DERIVATIVES BENZTROPINE MESYLATE N04AC01 PBS/RPBS 0.632 0.457 0.505 SURVEY 0.072 0.053 0.038

DOPAMINERGIC AGENTS DOPA AND DOPA DERIVATIVES LEVODOPA with BENSERAZIDE N04BA02 PBS/RPBS 0.466 0.480 0.505 SURVEY 0.001 0.003 0.003 LEVODOPA with CARBIDOPA N04BA02 PBS/RPBS 0.864 0.873 0.873 SURVEY 0.003 0.007 0.005 ADAMANTANE DERIVATIVES AMANTADINE HYDROCHLORIDE N04BB01 PBS/RPBS 0.092 0.095 0.096 SURVEY 0.002 0.000 0.000 DOPAMINE AGONISTS BROMOCRIPTINE MESYLATE N04BC01 PBS/RPBS 0.043 0.038 0.030 SURVEY 0.000 0.000 0.000 CABERGOLINE N04BC06 PBS/RPBS 0.099 0.164 0.217 SURVEY 0.000 0.000 0.000 PERGOLIDE N04BC02 PBS/RPBS 0.038 0.036 0.032 SURVEY 0.000 0.000 0.000 MONOAMINE OXIDASE TYPE B INHIBITORS SELEGILINE HYDROCHLORIDE N04BD01 PBS/RPBS 0.172 0.150 0.134 SURVEY 0.001 0.000 0.002 OTHER DOPAMINERGIC AGENTS ENTACAPONE N04BX02 PBS/RPBS 0.099 0.102 0.107 SURVEY 0.000 0.001 0.001

236 N

ATC SOURCE 2001 2002 2003

NERVOUS SYSTEM PSYCHOLEPTICS

ANTIPSYCHOTICS PHENOTHIAZINE WITH DIMETHYLAMINOPROPYL GROUP CHLORPROMAZINE HYDROCHLORIDE N05AA01 PBS/RPBS 0.220 0.213 0.201 SURVEY 0.025 0.017 0.017 PHENOTHIAZINE WITH PIPERAZINE STRUCTURE FLUPHENAZINE DECANOATE N05AB02 PBS/RPBS 0.483 0.410 0.362 SURVEY 0.009 0.007 0.000 FLUPHENAZINE HYDROCHLORIDE N05AB02 SURVEY 0.001 0.002 0.001 PROCHLORPERAZINE N05AB04 PBS/RPBS 0.151 0.145 0.139 SURVEY 0.047 0.040 0.036 TRIFLUOPERAZINE HYDROCHLORIDE N05AB06 PBS/RPBS 0.161 0.136 0.117 SURVEY 0.021 0.017 0.013 PHENOTHIAZINE WITH PIPERIDINE STRUCTURE PERICYAZINE N05AC01 PBS/RPBS 0.089 0.086 0.083 SURVEY 0.017 0.016 0.011 THIORIDAZINE HYDROCHLORIDE N05AC02 PBS/RPBS 0.136 0.093 0.069 SURVEY 0.046 0.032 0.022 BUTYROPHENONE DERIVATIVES HALOPERIDOL N05AD01 PBS/RPBS 0.470 0.412 0.370 SURVEY 0.035 0.035 0.028 THIOXANTHENE DERIVATIVES FLUPENTHIXOL N05AF01 PBS/RPBS 0.150 0.145 0.147 SURVEY 0.004 0.002 0.001 THIOTHIXENE N05AF04 SURVEY 0.001 0.000 0.000 ZUCLOPENTHIXOL N05AF05 PBS/RPBS 0.176 0.201 0.220 SURVEY 0.004 0.003 0.003 DIPHENYLBUTYLPIPERIDINE DERIVATIVES PIMOZIDE N05AG02 SURVEY 0.016 0.016 0.013

237 N

ATC SOURCE 2001 2002 2003

NERVOUS SYSTEM PSYCHOLEPTICS

ANTIPSYCHOTICS DIAZEPINES, OXAZEPINES AND THIAZEPINES CLOZAPINE N05AH02 PBS/RPBS 0.036 0.039 0.042 SURVEY 0.408 0.231 0.098 OLANZAPINE N05AH03 PBS/RPBS 2.416 2.771 2.881 SURVEY 0.122 0.039 0.032 QUETIAPINE N05AH04 PBS/RPBS 0.238 0.395 0.531 SURVEY 0.009 0.009 0.013 NEUROLEPTICS, IN TARDIVE DYSKINESIA TETRABENAZINE N05AK01 PBS/RPBS 0.014 0.015 0.016 SURVEY 0.000 0.000 0.000 BENZAMIDES AMISULPRIDE N05AL05 PBS/RPBS 0.000 0.053 0.320 SURVEY 0.000 0.000 0.001 LITHIUM LITHIUM CARBONATE N05AN01 PBS/RPBS 0.886 0.885 0.872 SURVEY 0.303 0.208 0.197 OTHER ANTIPSYCHOTICS RISPERIDONE N05AX08 PBS/RPBS 0.702 0.757 0.777 SURVEY 0.013 0.017 0.017

ANXIOLYTICS BENZODIAZEPINE DERIVATIVES ALPRAZOLAM N05BA12 PBS/RPBS 2.702 2.914 3.072 SURVEY 0.794 0.708 0.815 BROMAZEPAM N05BA08 PBS/RPBS 0.015 0.013 0.013 SURVEY 0.174 0.168 0.163 CLOBAZAM N05BA09 SURVEY 0.078 0.075 0.078 DIAZEPAM N05BA01 PBS/RPBS 5.326 5.278 5.236 SURVEY 1.098 0.978 0.927 LORAZEPAM N05BA06 SURVEY 0.454 0.376 0.364 OXAZEPAM N05BA04 PBS/RPBS 2.818 2.711 2.621 SURVEY .0.484 0.426 0.389

238 N

ATC SOURCE 2001 2002 2003

NERVOUS SYSTEM PSYCHOLEPTICS

ANXIOLYTICS AZASPIRODECANEDIONE DERIVATIVES BUSPIRONE HYDROCHLORIDE N05BE01 PBS/RPBS 0.004 0.003 0.004 SURVEY 0.012 0.008 0.011

HYPNOTICS AND SEDATIVES BARBITURATES, PLAIN AMYLOBARBITONE SODIUM N05CA02 SURVEY 0.022 0.020 0.006 BENZODIAZEPINE DERIVATIVES FLUNITRAZEPAM N05CD03 PBS/RPBS 0.099 0.049 0.072 SURVEY 0.643 0.528 0.576 MIDAZOLAM N05CD08 SURVEY 0.003 0.003 0.003 NITRAZEPAM N05CD02 PBS/RPBS 2.619 2.512 2.383 SURVEY 0.403 0.364 0.316 TEMAZEPAM N05CD07 PBS/RPBS 5.010 4.538 4.214 SURVEY 1.262 1.249 1.139 TRIAZOLAM N05CD05 SURVEY 0.019 0.024 0.027 BENZODIAZEPINE RELATED DRUGS ZOLPIDEM N05CF02 SURVEY 0.489 0.964 1.138 ZOPICLONE N05CF01 PBS/RPBS 0.044 0.064 0.082 SURVEY 0.120 0.137 0.136 OTHER HYPNOTICS AND SEDATIVES CHLORMETHIAZOLE EDISYLATE N05CM02 SURVEY 0.002 0.002 0.001

239 N

ATC SOURCE 2001 2002 2003

NERVOUS SYSTEM PSYCHOANALEPTICS

ANTIDEPRESSANTS NON SELECTIVE MONOAMINE REUPTAKE INHIBITORS AMITRIPTYLINE HYDROCHLORIDE N06AA09 PBS/RPBS 2.490 2.549 2.606 SURVEY 0.594 0.589 0.659 CLOMIPRAMINE HYDROCHLORIDE N06AA04 PBS/RPBS 0.238 0.225 0.217 SURVEY 0.062 0.053 0.048 DESIPRAMINE HYDROCHLORIDE N06AA01 PBS/RPBS 0.005 0.000 0.000 SURVEY 0.007 0.000 0.000 DOTHIEPIN HYDROCHLORIDE N06AA16 PBS/RPBS 1.393 1.303 1.200 SURVEY 0.509 0.435 0.381 DOXEPIN HYDROCHLORIDE N06AA12 PBS/RPBS 1.217 1.149 1.065 SURVEY 0.216 0.187 0.155 IMIPRAMINE HYDROCHLORIDE N06AA02 PBS/RPBS 0.437 0.405 0.373 SURVEY 0.107 0.088 0.081 NORTRIPTYLINE HYDROCHLORIDE N06AA10 PBS/RPBS 0.185 0.195 0.151 SURVEY 0.059 0.046 0.038 TRIMIPRAMINE MALEATE N06AA06 SURVEY 0.052 0.039 0.033 SELECTIVE SEROTONIN REUPTAKE INHIBITORS CITALOPRAM N06AB04 PBS/RPBS 5.904 7.425 8.603 SURVEY 0.038 0.054 0.058 FLUOXETINE HYDROCHLORIDE N06AB03 PBS/RPBS 4.225 4.324 4.525 SURVEY 0.013 0.035 0.038 FLUVOXAMINE N06AB08 PBS/RPBS 1.354 1.533 1.687 SURVEY 0.007 0.008 0.044 PAROXETINE N06AB05 PBS/RPBS 6.789 6.928 6.732 SURVEY 0.033 0.040 0.033 SERTRALINE N06AB06 PBS/RPBS 14.684 15.300 16.251 SURVEY 0.067 0.096 0.087

240 N

ATC SOURCE 2001 2002 2003

NERVOUS SYSTEM PSYCHOANALEPTICS

ANTIDEPRESSANTS MONOAMINE OXIDASE INHIBITORS, NON-SELECTIVE PHENELZINE SULPHATE N06AF03 PBS/RPBS 0.037 0.018 0.009 SURVEY 0.007 0.007 0.000 TRANYLCYPROMINE SULPHATE N06AF04 PBS/RPBS 0.249 0.253 0.236 SURVEY 0.076 0.054 0.054 MONOAMINE OXIDASE TYPE A INHIBITORS MOCLOBEMIDE N06AG02 PBS/RPBS 3.206 2.668 2.230 SURVEY 0.014 0.008 0.008 OTHER ANTIDEPRESSANTS MIANSERIN HYDROCHLORIDE N06AX03 PBS/RPBS 0.306 0.265 0.239 SURVEY 0.007 0.004 0.004 MIRTAZAPINE N06AX11 PBS/RPBS 0.236 1.364 2.616 SURVEY 0.001 0.009 0.021 NEFAZODONE N06AX06 PBS/RPBS 0.443 0.368 0.300 SURVEY 0.035 0.024 0.020 REBOXETINE N06AX18 PBS/RPBS 0.000 0.024 0.099 SURVEY 0.000 0.000 0.003 VENLAFAXINE N06AX16 PBS/RPBS 6.137 7.225 8.531 SURVEY 0.035 0.066 0.078

PSYCHOSTIMULANTS AND NOOTROPICS CENTRALLY ACTING SYMPATHOMIMETICS DEXAMPHETAMINE SULPHATE N06BA02 PBS/RPBS 1.482 1.598 1.674 SURVEY 0.433 0.375 0.373 METHYLPHENIDATE N06BA04 SURVEY 0.538 0.472 0.728 MODAFINIL N06BA07 SURVEY 0.000 0.000 0.001

241 N

ATC SOURCE 2001 2002 2003

NERVOUS SYSTEM PSYCHOANALEPTICS

ANTI-DEMENTIA DRUGS ANTICHOLINESTERASES DONEPEZIL N06DA02 PBS/RPBS 0.496 0.703 0.798 SURVEY 0.010 0.017 0.018 GALANTAMINE N06DA04 PBS/RPBS 0.004 0.074 0.153 SURVEY 0.000 0.002 0.002 RIVASTIGMINE N06DA03 PBS/RPBS 0.067 0.089 0.079 SURVEY 0.002 0.004 0.000

242 N

ATC SOURCE 2001 2002 2003

NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS

PARASYMPATHOMIMETICS ANTICHOLINESTERASES PYRIDOSTIGMINE BROMIDE N07AA02 PBS/RPBS 0.108 0.086 0.096 SURVEY 0.000 0.002 0.002 CHOLINE ESTERS BETHANECHOL CHLORIDE N07AB02 PBS/RPBS 0.039 0.035 0.032 SURVEY 0.004 0.003 0.002

DRUGS USED IN ADDICTIVE DISORDERS DRUGS USED IN NICOTINE DEPENDENCE BUPROPION N07BA02 PBS/RPBS 3.018 0.788 0.551 SURVEY 0.103 0.017 0.011 NICOTINE N07BA01 PBS/RPBS 0.009 0.012 0.008 SURVEY 0.014 0.008 0.007 DRUGS USED IN ALCOHOL DEPENDENCE ACAMPROSATE N07BB03 PBS/RPBS 0.114 0.095 0.091 SURVEY 0.000 0.000 0.001 NALTREXONE N07BB04 PBS/RPBS 0.056 0.052 0.053 SURVEY 0.009 0.003 0.001 DRUGS USED IN OPIOID DEPENDENCE METHADONE HYDROCHLORIDE N07BC02 PBS/RPBS 0.301 0.308 0.311 SURVEY 1.384 1.627 0.803

ANTIVERTIGO PREPARATIONS ANTIVERTIGO PREPARATIONS BETAHISTINE N07CA01 SURVEY 0.309 0.326 0.319

OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS RILUZOLE N07XX02 PBS/RPBS 0.000 0.000 0.006 SURVEY 0.000 0.000 0.000

243 P

ATC SOURCE 2001 2002 2003

ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLANTS ANTIPROTOZOALS

AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES NITROIMIDAZOLE DERIVATIVES METRONIDAZOLE P01AB01 PBS/RPBS 0.121 0.123 0.125 SURVEY 0.123 0.111 0.105 TINIDAZOLE P01AB02 PBS/RPBS 0.010 0.008 0.008 SURVEY 0.014 0.012 0.010

ANTIMALARIALS QUINOLINE DERIVATIVES CHLOROQUINE P01BA01 SURVEY 0.041 0.033 0.020 HYDROXYCHLOROQUINE SULPHATE P01BA02 PBS/RPBS 0.368 0.391 0.424 SURVEY 0.001 0.002 0.001 PRIMAQUINE PHOSPHATE P01BA03 SURVEY 0.000 0.000 0.001 BIGUANIDES PROGUANIL P01BB01 SURVEY 0.033 0.024 0.009 METHANOLQUINOLINES MEFLOQUINE P01BC02 SURVEY 0.003 0.003 0.002 QUININE BISULPHATE P01BC01 PBS/RPBS 0.369 0.368 0.329 SURVEY 0.036 0.030 0.028 QUININE SULPHATE P01BC01 PBS/RPBS 0.568 0.569 0.562 SURVEY 0.053 0.042 0.041

244 P

ATC SOURCE 2001 2002 2003

ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLANTS ANTHELMINTICS ANTINEMATODAL AGENTS TETRAHYDROPYRIMIDINE DERIVATIVES PYRANTEL EMBONATE P02CC01 PBS/RPBS 0.001 0.001 0.001 SURVEY 0.000 0.000 0.000

245 R

ATC SOURCE 2001 2002 2003

RESPIRATORY SYSTEM NASAL PREPARATIONS

DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE SYMPATHOMIMETICS, PLAIN OXYMETAZOLINE R01AA05 PBS/RPBS 0.011 0.009 0.008 SURVEY 0.007 0.009 0.009 XYLOMETAZOLINE R01AA07 SURVEY 0.003 0.002 0.003 ANTIALLERGIC AGENTS, EXCL CORTICOSTEROIDS LEVOCABASTINE R01AC02 PBS/RPBS 0.003 0.003 0.004 SURVEY 0.006 0.002 0.002 SODIUM CROMOGLYCATE R01AC01 PBS/RPBS 0.001 0.001 0.002 SURVEY 0.001 0.001 0.001 CORTICOSTEROIDS BECLOMETHASONE DIPROPIONATE R01AD01 PBS/RPBS 0.146 0.205 0.100 SURVEY 0.733 0.515 0.314 BUDESONIDE R01AD05 PBS/RPBS 0.302 0.057 0.068 SURVEY 0.036 1.581 1.541 MOMETASONE FUROATE R01AD09 SURVEY 0.573 1.017 1.262 OTHER NASAL PREPARATIONS IPRATROPIUM BROMIDE R01AX03 PBS/RPBS 0.051 0.060 0.060 SURVEY 0.073 0.048 0.034

NASAL DECONGESTANTS FOR SYSTEMIC USE SYMPATHOMIMETICS PSEUDOEPHEDRINE R01BA02 PBS/RPBS 0.003 0.003 0.003 SURVEY 0.073 0.265 0.274

246 R

ATC SOURCE 2001 2002 2003

RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

ADRENERGICS, INHALANTS NON-SELECTIVE BETA-ADRENOCEPTOR AGONISTS ORCIPRENALINE R03AB03 SURVEY 0.011 0.010 0.007 SELECTIVE BETA-2-ADRENOCEPTOR AGONISTS EFORMOTEROL R03AC13 PBS/RPBS 1.481 1.374 1.029 SURVEY 0.001 0.002 0.002 FENOTEROL HYDROBROMIDE R03AC04 SURVEY 0.015 0.000 0.000 SALBUTAMOL R03AC02 PBS/RPBS 22.152 21.325 19.954 SURVEY 7.877 7.891 7.567 SALMETEROL R03AC12 PBS/RPBS 1.979 1.261 0.859 SURVEY 0.001 0.002 0.003 TERBUTALINE SULPHATE R03AC03 PBS/RPBS 3.303 2.865 2.483 SURVEY 1.828 1.433 1.132 ADRENERGICS AND OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES SALBUTAMOL with IPRATROPIUM BROMIDE R03AK04 PBS/RPBS 0.055 0.057 0.039 SURVEY 0.011 0.012 0.012

OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,INHALANTS GLUCOCORTICOIDS BECLOMETHASONE DIPROPIONATE R03BA01 PBS/RPBS 4.254 1.685 0.743 SURVEY 0.365 0.121 0.026 BUDESONIDE R03BA02 PBS/RPBS 10.009 8.319 6.094 SURVEY 0.095 0.078 0.053 FLUTICASONE R03BA05 PBS/RPBS 6.289 5.745 4.766 SURVEY 0.084 0.105 0.114 ANTICHOLINERGICS IPRATROPIUM BROMIDE R03BB01 PBS/RPBS 15.069 14.516 11.028 SURVEY 0.067 0.046 0.050 TIOTROPIUM BROMIDE R03BB04 PBS/RPBS 0.000 0.000 2.029 SURVEY 0.000 0.000 0.003

247 R

ATC SOURCE 2001 2002 2003

RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,INHALANTS ANTIALLERGIC AGENTS, EXCL CORTICOSTEROIDS NEDOCROMIL R03BC03 PBS/RPBS 0.567 0.441 0.359 SURVEY 0.002 0.002 0.003 SODIUM CROMOGLYCATE R03BC01 PBS/RPBS 0.484 0.353 0.263 SURVEY 0.001 0.001 0.001

ADRENERGICS FOR SYSTEMIC USE ALPHA- AND BETA-ADRENOCEPTOR AGONISTS EPHEDRINE R03CA02 SURVEY 0.007 0.005 0.007 SELECTIVE BETA-2-ADRENOCEPTOR AGONISTS SALBUTAMOL R03CC02 PBS/RPBS 0.031 0.038 0.054 SURVEY 0.010 0.009 0.016 TERBUTALINE SULPHATE R03CC03 PBS/RPBS 0.097 0.000 0.000 SURVEY 0.000 0.000 0.000

OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES XANTHINES CHOLINE THEOPHYLLINATE R03DA02 SURVEY 0.046 0.029 0.023 THEOPHYLLINE R03DA04 PBS/RPBS 1.160 0.929 0.812 SURVEY 0.231 0.223 0.145 LEUKOTRIENERECEPTOR ANTAGONISTS MONTELUKAST R03DC03 PBS/RPBS 0.000 0.000 0.087 SURVEY 0.185 0.163 0.137 ZAFIRLUKAST R03DC01 SURVEY 0.004 0.003 0.006

248 R

ATC SOURCE 2001 2002 2003

RESPIRATORY SYSTEM COUGH AND COLD PREPARATIONS

EXPECTORANTS,EXCL COMBINATIONS WITH ANTITUSSIVES MUCOLYTICS ACETYLCYSTEINE R05CB01 PBS/RPBS 0.005 0.005 0.005 SURVEY 0.000 0.000 0.000 BROMHEXINE HYDROCHLORIDE R05CB02 SURVEY 0.026 0.027 0.029

COUGH SUPPRESSANTS, EXCL.COMBINATIONS WITH EXPECTORANTS OPIUM ALKALOIDS AND DERIVATIVES CODEINE R05DA04 PBS/RPBS 0.181 0.169 0.157 SURVEY 0.050 0.039 0.036 PHOLCODINE R05DA08 PBS/RPBS 0.004 0.003 0.003 SURVEY 0.006 0.005 0.005 PHOLCODINE with PSEUDOEPHEDRINE R05DA20 SURVEY 0.001 0.000 0.000

249 R

ATC SOURCE 2001 2002 2003

RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE

ANTIHISTAMINES FOR SYSTEMIC USE AMINOALKYL ETHERS DIPHENHYDRAMINE R06AA02 SURVEY 0.002 0.003 0.002 SUBSTITUTED ALKYLAMINES BROMPHENIRAMINE COMBINATIONS R06AB51 SURVEY 0.015 0.011 0.011 DEXCHLORPHENIRAMINE R06AB02 SURVEY 0.380 0.372 0.355 PHENIRAMINE R06AB05 SURVEY 0.068 0.071 0.074 SUBSTITUTED ETHYLENE DIAMINES MEPYRAMINE R06AC01 SURVEY 0.001 0.001 0.001 PHENOTHIAZINE DERIVATIVES METHDILAZINE HYDROCHLORIDE R06AD04 SURVEY 0.054 0.038 0.035 PROMETHAZINE R06AD02 PBS/RPBS 0.176 0.165 0.157 SURVEY 0.741 0.771 0.764 TRIMEPRAZINE R06AD01 SURVEY 0.017 0.012 0.012 PIPERAZINE DERIVATIVES CETIRIZINE R06AE07 PBS/RPBS 0.035 0.045 0.049 SURVEY 0.029 0.021 0.025 OTHER ANTIHISTAMINES FOR SYSTEMIC USE AZATADINE MALEATE R06AX09 SURVEY 0.018 0.012 0.010 CYPROHEPTADINE HYDROCHLORIDE R06AX02 PBS/RPBS 0.482 0.457 0.428 SURVEY 0.081 0.067 0.063 FEXOFENADINE R06AX26 PBS/RPBS 0.733 0.747 0.735 SURVEY 0.181 0.233 0.181 LORATADINE R06AX13 PBS/RPBS 0.204 0.202 0.190 SURVEY 0.069 0.047 0.033 LORATADINE with PSEUDOEPHEDRINE R06AX13 SURVEY 0.003 0.001 0.001

250 S

ATC SOURCE 2001 2002 2003

SENSORY ORGANS OPHTHALMOLOGICALS

ANTIGLAUCOMA PREPARATIONS AND MIOTICS SYMPATHOMIMETICS IN GLAUCOMA THERAPY APRACLONIDINE S01EA03 PBS/RPBS 0.023 0.022 0.026 SURVEY 0.000 0.000 0.000 BRIMONIDINE S01EA05 PBS/RPBS 0.793 0.828 0.774 SURVEY 0.092 0.072 0.057 DIPIVEFRINE S01EA02 PBS/RPBS 0.317 0.221 0.154 SURVEY 0.020 0.009 0.007 PARASYMPATHOMIMETICS CARBACHOL S01EB02 PBS/RPBS 0.022 0.020 0.016 SURVEY 0.001 0.001 0.000 ECOTHIOPATE IODIDE S01EB03 PBS/RPBS 0.015 0.000 0.000 PILOCARPINE S01EB01 PBS/RPBS 0.673 0.545 0.432 SURVEY 0.058 0.031 0.024 CARBONIC ANHYDRASE INHIBITORS ACETAZOLAMIDE S01EC01 PBS/RPBS 0.129 0.121 0.112 SURVEY 0.028 0.027 0.025 BRINZOLAMIDE S01EC04 PBS/RPBS 0.122 0.237 0.258 SURVEY 0.013 0.021 0.025 DORZOLAMIDE S01EC03 PBS/RPBS 0.140 0.148 0.141 SURVEY 0.028 0.010 0.011 BETA BLOCKING AGENTS BETAXOLOL HYDROCHLORIDE S01ED02 PBS/RPBS 1.090 0.978 0.820 SURVEY 0.130 0.088 0.074 LEVOBUNOLOL S01ED03 PBS/RPBS 0.208 0.174 0.142 SURVEY 0.038 0.020 0.012 TIMOLOL MALEATE S01ED01 PBS/RPBS 2.547 2.375 2.136 SURVEY 0.354 0.300 0.258

251 S

ATC SOURCE 2001 2002 2003

SENSORY ORGANS OPHTHALMOLOGICALS

ANTIGLAUCOMA PREPARATIONS AND MIOTICS PROSTAGLANDIN ANALOGUES BIMATOPROST S01EE03 PBS/RPBS 0.000 0.000 0.553 SURVEY 0.000 0.000 0.002 LATANOPROST S01EE01 PBS/RPBS 4.213 4.935 4.942 SURVEY 0.002 0.008 0.010

252 V

ATC SOURCE 2001 2002 2003

VARIOUS ALL OTHER THERAPEUTIC PRODUCTS

ALL OTHER THERAPEUTIC PRODUCTS DETOXIFYING AGENTS FOR CYTOSTATIC TREATMENT CALCIUM FOLINATE V03AF03 PBS/RPBS 0.001 0.001 0.001 SURVEY 0.000 0.000 0.000

253

ATC INDEX

This ATC index is sorted alphabetically according to generic/substance name. It is an abbreviated version of the World Health Organization (WHO) ATC index and, as such, may contain some substances for which data are not available in the two tables. As well, there may be some differences in the spelling of the generic name.

J 05 A F 06 ABACAVIR R 03 A A ALPHA- AND BETA-ADRENOCEPTOR B 01 A C 13 ABCIXIMAB AGONISTS N 07 B B 03 ACAMPROSATE N 05 B A 12 ALPRAZOLAM A 10 B F 01 ACARBOSE C 07 A A 01 ALPRENOLOL C 07 A B 04 ACEBUTOLOL C 01 E A 01 ALPROSTADIL S 01 E C 01 ACETAZOLAMIDE G 04 B E 01 ALPROSTADIL S 02 A A 10 ACETIC ACID B 01 A D 02 ALTEPLASE (TISSUE PLASM. ACT.) G 01 A D 02 ACETIC ACID L 01 X X 03 ALTRETAMINE A 10 B B 31 ACETOHEXAMIDE A 02 A B 05 ALUMINIUM ACETATE S 01 E B 09 ACETYLCHOLINE S 02 A A 04 ALUMINIUM ACETATE R 05 C B 01 ACETYLCYSTEINE D 08 A B ALUMINIUM AGENTS V 03 A B 23 ACETYLCYSTEINE D 10 A X 01 ALUMINIUM CHLORIDE N 02 B A 01 ACETYLSALICYLIC ACID A 02 A B 02 ALUMINIUM HYDROXIDE B 01 A C 06 ACETYLSALICYLIC ACID D 11 A X ALUMINIUM OXIDE A 01 A D 05 ACETYLSALICYLIC ACID A 02 A B 03 ALUMINIUM PHOSPHATE M 01 B A 03 ACETYLSALICYLIC ACID AND C 05 A X 01 ALUMINIUM PREPARATIONS CORTICOSTEROIDS A 02 A B 05 ALUMINIUMACETOACETATE N 02 B A 51 ACETYLSALICYLIC ACID, COMB N 04 B B 01 AMANTADINE EXCL PSYCHOLEPTICS S 01 H A 03 AMETHOCAINE N 02 B A 71 ACETYLSALICYLIC ACID, COMB J 01 G B 06 AMIKACIN WITH PSYCHOLEPTICS C 03 D B 01 AMILORIDE J 05 A B 01 ACICLOVIR B 05 B A 01 AMINO ACIDS D 06 B B 03 ACICLOVIR B 02 A A AMINO ACIDS S 01 A D 03 ACICLOVIR B 05 X B AMINO ACIDS G 04 B A ACIDIFIERS V 06 D D AMINO ACIDS,INCL COMBINATIONS D 05 B B 02 ACITRETIN WITH POLYPEPTIDES H 01 A A ACTH V 06 D E AMINO ACIDS/CARBOHYDRATES/ D 10 A D 03 ADAPALENE MINERALS/VITAMINS, COMB C 01 C A 24 ADRENALINE B 02 A A 01 AMINOCAPROIC ACID S 01 E A 01 ADRENALINE L 02 B G 01 AMINOGLUTHETIMIDE C 01 C A ADRENERGIC AND DOPAMINERIC AGENTS R 03 D A 05 AMINOPHYLLINE R 03 A K ADRENERGICS AND OTHER DRUGS FOR P 01 B A AMINOQUINOLINES OBSTRUCTIVE AIRWAY DISEASES C 01 B D 01 AMIODARONE R 03 C K ADRENERGICS AND OTHER DRUGS FOR N 06 A A 09 AMITRIPTYLINE OBSTRUCTIVE AIRWAY DISEASES C 08 C A 01 AMLODIPINE A 07 X A 01 ALBUMIN TANNATE G 04 B A 01 AMMONIUM CHLORIDE D 07 A B 10 ALCLOMETASONE B 05 X A 04 AMMONIUM CHLORIDE S 01 B A 10 ALCLOMETASONE N 05 C A 02 AMOBARBITAL M 03 A A 01 ALCURONIUM D 01 A E 16 AMOROLFINE N 05 C C ALDEHYDES AND DERIVATIVES J 01 C A 04 AMOXYCILLIN H 02 A A 01 ALDOSTERONE J 01 C R 02 AMOXYCILLIN AND ENZYME C 03 D A ALDOSTERONE ANTAGONISTS INHIBITOR M 05 B A 04 ALENDRONIC ACID A 07 A A 07 AMPHOTERICIN A 02 B X 13 ALGINIC ACID A 01 A B 04 AMPHOTERICIN V 01 A A ALLERGEN EXTRACTS J 02 A A 01 AMPHOTERICIN M 04 A A 01 ALLOPURINOL G 01 A A 03 AMPHOTERICIN G 03 D C 01 ALLYLESTRENOL J 01 C A 01 AMPICILLIN N 02 B A 02 ALOXIPRIN J 01 C A AMPICILLIN AND SIMILAR C 02 C A ALPHA - ADRENOCEPTOR BLOCKING ANTIBIOTICS AGENTS V 03 A B 22 AMYL NITRITE C 07 A G ALPHA- AND BETA-ADRENOCEPTOR L 02 B G 03 ANASTROZOLE BLOCKING AGENTS G 03 E B ANDROGEN,PROGESTOGEN AND R 03 C A ALPHA- AND BETA-ADRENOCEPTOR ESTROGEN IN COMBINATION AGONISTS

255

G 03 E A ANDROGENS AND ESTROGENS S 02 A A 30 ANTIINFECTIVES, COMBINATIONS D 11 A E ANDROGENS FOR TOPICAL USE S 03 A A 30 ANTIINFECTIVES, COMBINATIONS G 03 E K ANDROGENS/FEMALE SEX M 02 A A ANTIINFL. PREP., NON-STEROIDS HORMONES IN COMB OTHER FOR TOPICAL USE DRUGS M 01 B A ANTIINFLAM AGENTS IN N 01 A A 01 ANESTHETIC ETHER COMB.W/CORTICOSTER (DIETHYL ETHER) S 01 B C ANTIINFLAMMATORY AGENTS, NON- D 04 A B ANESTHETICS FOR TOPICAL USE STEROIDS R 02 A D ANESTHETICS, LOCAL A 07 D A ANTIPROPULSIVES A 02 A F ANTACIDS WITH ANTIFLATULENTS A 02 E A ANTIREGURGITANTS A 02 A G ANTACIDS WITH ANTISPASMODICS R 02 A A ANTISEPTICS A 02 A H ANTACIDS WITH SODIUM G 01 B D ANTISEPTICS AND CORTICOSTEROIDS BICARBONATE A 03 E D ANTISPASMODICS IN COMBINATION WITH A 02 A X ANTACIDS, OTHER COMBINATIONS OTHER DRUGS R 01 A X 04 ANTAZOLINE A 03 E A ANTISPASMODICS, PSYCHOLEPTICS, R 06 A X 05 ANTAZOLINE ANALGESICS IN COMB L 01 D B ANTHRACYCLINES B 01 A B 02 ANTITHROMBIN L 02 B B ANTI-ANDROGENS R 05 F B 02 ANTITUSSIVES AND EXPECTORANTS C 01 D A ANTI-ANGINAL VASODILATORS R 05 F B 01 ANTITUSSIVES AND MUCOLYTICS J 06 B B 01 ANTI-D (RH) IMMUNOGLOBULIN R 05 D B ANTITUSSIVES CHEMICAL CLOSE TO L 02 B A ANTI-ESTROGENS LOCAL ANESTHETICS N 07 B A ANTI-SMOKING AGENTS S 01 A D ANTIVIRALS R 01 A C ANTIALLERGIC AGENTS, EXCL D 06 B B ANTIVIRALS CORTICOSTEROIDS D 05 A C ANTRACEN DERIVATIVES A 07 E B ANTIALLERGIC AGENTS, EXCL V 03 A B 07 APOMORPHINE CORTICOSTEROIDS S 01 E A 03 APRACLONIDINE R 03 B C ANTIALLERGIC AGENTS, EXCL B 02 A B 01 APROTININ CORTICOSTEROIDS B 05 X B 01 ARGININE CHLORIDE G 03 H B ANTIANDROGENS AND ESTROGENS A 05 B A 01 ARGININE GLUTAMATE G 03 H A ANTIANDROGENS, PLAIN S 01 X A 20 ARTIFICIAL TEARS AND OTHER PREPARATIONS INDIFFERENT PREP. C 01 B A ANTIARRHYTHMICS, CLASS IA A 11 G A 01 ASCORBIC ACID (VIT C) C 01 B B ANTIARRHYTHMICS, CLASS IB L 01 X X 02 ASPARAGINASE C 01 B C ANTIARRHYTHMICS, CLASS IC R 06 A X 11 ASTEMIZOLE C 01 B D ANTIARRHYTHMICS, CLASS III C 07 A B 03 ATENOLOL A 07 A A ANTIBIOTICS C 07 C B 03 ATENOLOL AND OTHER DIURETICS S 01 A A ANTIBIOTICS C 10 A A 05 ATORVASTATIN R 02 A B ANTIBIOTICS M 03 A C 04 ATRACURIUM J 04 A B ANTIBIOTICS S 01 F A 01 ATROPINE J 02 A A ANTIBIOTICS A 03 B A 01 ATROPINE G 01 A A ANTIBIOTICS M 01 C B 03 AURANOFIN D 01 B A ANTIBIOTICS M 01 C B 04 AUROTHIOGLUCOSE D 01 A A ANTIBIOTICS R 06 A X 09 AZATADINE G 01 B A ANTIBIOTICS AND L 04 A X 01 AZATHIOPRINE CORTICOSTEROIDS D 10 A X 03 AZELAIC ACID S 01 A A 20 ANTIBIOTICS IN COMBINATION WITH J 01 F A 10 AZITHROMYCIN OTHER DRUGS J 01 C A 09 AZLOCILLIN R 03 B B ANTICHOLINERGICS J 01 D F 01 AZTREONAM S 01 F A ANTICHOLINERGICS N 06 D A ANTICHOLINESTERASES D 06 A X 05 BACITRACIN H 02 C A ANTICORTICOSTEROIDS M 03 B X 01 BACLOFEN A 07 F A ANTIDIARRHEAL MICROORGANISMS N 03 A A BARBITURATES AND DERIVATIVES V 03 A B ANTIDOTES N 01 A F BARBITURATES, PLAIN A 02 D A ANTIFLATULENTS N 05 C A BARBITURATES, PLAIN G 03 X A ANTIGONADOTROPINS V 04 A A BARIUM SULPHATE H 01 C C ANTIGONADOTROPIN RELEASING V 04 A A 01 BARIUM SULPHATE WITH SUSPENDING HORMONES AGENTS H 01 C B ANTIGROWTH HORMONE V 04 A A 02 BARIUM SULPHATE WITHOUT D 11 A A ANTIHIDROTICS SUSPENDING AGENTS D 04 A A ANTIHISTAMINES FOR TOPICAL USE L 03 A X 03 BCG VACCINE B 05 C A ANTIINFECTIVES N 03 A X 30 BECLAMIDE S 03 A A ANTIINFECTIVES R 03 B A 01 BECLOMETHASONE S 02 A A ANTIINFECTIVES R 01 A D 01 BECLOMETHASONE A 01 A B ANTIINFECTIVES FOR LOCAL ORAL A 03 B A 04 BELLADONNA TOTAL ALKALOIDS TREATMENT C 03 A A 01 BENDROFLUAZIDE D 10 A F ANTIINFECTIVES FOR TREATMENT N 02 B A 10 BENORYLATE OF ACNE D 08 A J 01 BENZALKONIUM

256

J 01 C E 08 BENZATHINE PENICILLIN R 01 A D 05 BUDESONIDE N 04 A C 01 BENZATROPINE D 07 A C 09 BUDESONIDE N 04 A A 01 BENZHEXOL R 03 B A 02 BUDESONIDE D 04 A B 04 BENZOCAINE H 02 A B 16 BUDESONIDE C 05 A D 03 BENZOCAINE M 02 A A 09 BUFEXAMAC R 02 A D 01 BENZOCAINE C 03 C A 02 BUMETANIDE N 03 A E BENZODIAZEPINE DERIVATIVES C 03 C B 02 BUMETANIDE AND POTASSIUM N 05 C D BENZODIAZEPINE DERIVATIVES N 01 B B 01 BUPIVACAINE N 05 B A BENZODIAZEPINE DERIVATIVES N 02 A E 01 BUPRENORPHINE D 10 A E 01 BENZOYL PEROXIDE N 07 B C 01 BUPRENORPHINE A 01 A D 02 BENZYDAMINE N 07 B A 0 2 BUPROPION M 02 A A 05 BENZYDAMINE N 05 B E 01 BUSPIRONE M 01 A X 07 BENZYDAMINE L 01 A B 01 BUSULFAN P 03 A X 01 BENZYL BENZOATE A 03 D B 04 BUTYLSCOPOLAMINE AND ANALGESICS S 01 A A 14 BENZYLPENICILLIN N 05 A D BUTYROPHENONE DERIVATIVES J 01 C E 01 BENZYLPENICILLIN C 07 F B BETA BLOCK. SELECTIVE AND OTHER G 02 C B 03 CABERGOZINE ANTIHYPERTENSIVES N 06 B C 01 CAFFEINE S 01 E D BETA BLOCKING AGENTS D 05 A X 02 CALCIPOTRIOL C 07 A A BETA BLOCKING AGENTS, PLAIN, NON- H 05 B A 03 CALCITONIN (HUMAN SYNTHETIC) SELECTIVE H 05 B A 02 CALCITONIN (PORK NATURAL) C 07 A B BETA BLOCKING AGENTS, PLAIN, H 05 B A 01 CALCITONIN (SALMON SYNTHETIC) SELECTIVE H 05 B A CALCITONIN PREPARATIONS N 07 C A 01 BETAHISTINE A 11 C C 04 CALCITRIOL C 05 C A 02 BETA HYDROXYETHYLRUTOSIDES A 12 A A CALCIUM A 09 A B 02 BETAINE HYDROCHLORIDE A 12 A A 20 CALCIUM (DIFFERENT SALTS IN C 05 A A 05 BETAMETHASONE COMBINATION) A 07 E A 04 BETAMETHASONE N 07 B B 02 CALCIUM CARBIMIDE S 01 B A 06 BETAMETHASONE A 12 A A 04 CALCIUM CARBONATE R 03 B A 04 BETAMETHASONE A 02 A C 01 CALCIUM CARBONATE R 01 A D 06 BETAMETHASONE C 08 CALCIUM CHANNEL BLOCKERS H 02 A B 01 BETAMETHASONE G 04 B A 03 CALCIUM CHLORIDE D 07 X C 01 BETAMETHASONE B 05 X A 07 CALCIUM CHLORIDE D 07 A C 01 BETAMETHASONE A 12 A A 07 CALCIUM CHLORIDE D 07 C C 01 BETAMETHASONE AND ANTIBIOTICS A 07 X A 03 CALCIUM COMPOUNDS S 01 C A 05 BETAMETHASONE AND ANTIINFECTIVES A 02 A C CALCIUM COMPOUNDS D 07 B C 01 BETAMETHASONE AND ANTISEPTICS V 03 A F 03 CALCIUM FOLINATE S 01 E D 02 BETAXOLOL A 12 A A 02 CALCIUM GLUBIONATE N 07 A B 02 BETHANECHOL A 12 A A 10 CALCIUM GLUCOHEPTONATE B 04 A C 02 BEZAFIBRATE D 11 A X 03 CALCIUM GLUCONATE L 02 B B 03 BICALUTAMIDE A 12 A A 03 CALCIUM GLUCONATE D 01 A C 10 BIFONAZOLE A 12 A A 05 CALCIUM LACTATE P 01 B B BIGUANIDES A 12 A A 06 CALCIUM LACTATE GLUCONATE A 10 B A BIGUANIDES C 09 C A 06 CANDESARTAN A 05 A A BILE ACID PREPARATIONS L 01 B C 06 CAPECITABINE B 04 A D BILE ACID SEQUESTRANTS C 09 A A 01 CAPTOPRIL N 04 A A 02 BIPERIDEN S 01 E B 02 CARBACHOL A 06 A B 02 BISACODYL N 07 A B 01 CARBACHOL A 06 A G 02 BISACODYL N 05 B C CARBAMATES A 07 B B BISMUTH PREPARATIONS N 03 A F 01 CARBAMAZEPINE C 05 A X 02 BISMUTH PREPARATIONS, COMBINATIONS D 02 A E 01 CARBAMIDE A 02 B X 05 BISMUTH SUBCITRATE J 01 C A 03 CARBENICILLIN L 01 D C 01 BLEOMYCIN A 01 A D 11 CARBENOXOLONE C O1 BD 02 BRETYLIUM TOSILATE H 03 B B 01 CARBIMAZOLE S 01 E A 05 BRIMONIDINE B 05 B A 03 CARBOHYDRATES N 05 B A 08 BROMAZEPAM S 01 X A 20 CARBOMER R 05 C B 02 BROMHEXINE S 01 E C CARBONIC ANHYDRASE INHIBITORS N 05 C M 11 BROMIDES L 01 X A 02 CARBOPLATIN G 02 C B 01 BROMOCRIPTINE J 01 C A 05 CARINDACILLIN N 04 B C 01 BROMOCRIPTINE L 01 A D 01 CARMUSTINE N 05 A D 06 BROMPERIDOL C 07 A G 02 CARVEDILOL R 06 A B 01 BROMPHENIRAMINE V 04 C G 01 CATION EXCHANGE RESINS R 06 A B 51 BROMPHENIRAMINE, COMBINATIONS J 01 D A 08 CEFACLOR R 06 A E 01 BUCLIZINE J 01 D A 02 CEFALORIDINE R 06 A E 51 BUCLIZINE, COMBINATIONS J 01 D A 24 CEFEPIME

257

J 01 D A 32 CEFOPERAZONE M 01 A X 25 CHONDROTIN SULFATE J 01 D A 10 CEFOTAXIME G 03 G A 01 CHORIONIC GONADOTROPHIN J 01 D A 14 CEFOTETAN M 09 A B 01 CHYMOPAPAIN J 01 D A 05 CEFOXITIN S 01 K X 01 CHYMOTRYPSIN J 01 D A 11 CEFTAZIDIME B 06 A A 04 CHYMOTRYPSIN J 01 D A 13 CEFTRIAXONE C 09 A A 08 CILAZAPRIL J 01 D A 06 CEFUROXIME A 02 B A 01 CIMETIDINE M 01 A H 01 CELECOXIB C 05 A D 04 CINCHOCAINE A 08 A A CENTRALLY ACTING ANTIOBESITY N 01 B B 06 CINCHOCAINE PRODUCTS D 04 A B 02 CINCHOCAINE J 01 D A 01 CEPHALEXIN S 01 H A 06 CINCHOCAINE J 01 D A 03 CEPHALOTIN J 01 M B 06 CINOXACIN J 01 D A 07 CEPHAMANDOLE J 01 M A 02 CIPROFLOXACIN J 01 D A 04 CEPHAZOLIN S 01 A X 13 CIPROFLOXACIN J 01 D A CEPHALOSPORINS AND RELATED A 03 F A 02 CISAPRIDE SUBSTANCES L 01 X A 01 CISPLATIN J 01 D A 33 CEPODOXIME N 06 A B 04 CITALOPRAM C 10 A A 06 CERIVASTATIN A 09 A B 04 CITRIC ACID R 06 A E 07 CETIRIZINE L 01 B B 04 CLADRIBINE D 11 A C 01 CETRIMIDE J 01 F A 09 CLARITHROMYCIN D 08 A J 04 CETRIMIDE R 06 A A 04 CLEMASTINE B 05 C A 01 CETYLPYRIDINIUM R 06 A A 54 CLEMASTINE, COMBINATIONS D 08 A J 03 CETYLPYRIDINIUM A 03 C A 02 CLIDINIUM AND PSYCHOLEPTICS A 07 B A CHARCOAL PREPARATIONS D 10 A F 01 CLINDAMYCIN A 05 A A 01 CHENODEOXYCHOLIC ACID J 01 F F 01 CLINDAMYCIN N 05 C C 01 CHLORAL HYDRATE G 01 A A 10 CLINDAMYCIN L 01 A A 02 CHLORAMBUCIL D 08 A H 30 CLIOQUINOL D 06 A X 02 CHLORAMPHENICOL P 01 A A 02 CLIOQUINOL G 01 A A 05 CHLORAMPHENICOL G 01 A C 02 CLIOQUINOL D 10 A F 03 CHLORAMPHENICOL S 02 A A 05 CLIOQUINOL J 01 B A 01 CHLORAMPHENICOL P 01 A A 52 CLIOQUINOL, COMBINATIONS S 02 A A 01 CHLORAMPHENICOL N 05 B A 09 CLOBAZAM S 01 A A 01 CHLORAMPHENICOL D 07 A D 01 CLOBETASOL N 05 B A 02 CHLORDIAZEPOXIDE S 01 B A 09 CLOBETASONE B 05 C A 02 CHLORHEXIDINE D 07 A B 01 CLOBETASONE S 02 A A 09 CHLORHEXIDINE M 05 B A 02 CLODRONIC ACID S 01 A X 09 CHLORHEXIDINE J 04 B A 01 CLOFAZIMINE R 02 A A 05 CHLORHEXIDINE C 10 A B 01 CLOFIBRATE D 08 A C 02 CHLORHEXIDINE G 03 G B 02 CLOMIFENE S 03 A A 04 CHLORHEXIDINE N 06 A A 04 CLOMIPRAMINE A 01 A B 03 CHLORHEXIDINE N 03 A E 01 CLONAZEPAM P 03 A B CHLORINE CONTAINING PRODUCTS C 02 A C 01 CLONIDINE N 05 C M 02 CHLORMETHIAZOLE N 02 C X 02 CLONIDINE N 01 A B 02 CHLOROFORM C 02 A C CLONIDINE AND ANALOGUES P 01 B A 01 CHLOROQUINE C 02 L C CLONIDINE AND ANALOGUES IN COMB C 03 A A 04 CHLOROTHIAZIDE WITH DIURETICS D 08 A E 05 CHLOROXYLENOL C 02 L C 01 CLONIDINE AND DIURETICS D 01 A E 07 CHLORPHENESIN B 01 A C 04 CLOPIDOGREL R 06 A B 04 CHLORPHENIRAMINE C 03 B A 03 CLOPAMIDE R 06 A B 54 CHLORPHENIRAMINE, COMBINATIONS C 03 B B 03 CLOPAMIDE AND POTASSIUM N 05 A A 01 CHLORPROMAZINE N 05 B A 05 CLORAZEPATE POTASSIUM A 10 B B 02 CHLORPROPAMIDE G 01 A F 02 CLOTRIMAZOLE C 03 B A 04 CHLORTHALIDONE D 01 A C 01 CLOTRIMAZOLE D 06 A A 02 CHLORTETRACYCLINE J 01 C F 02 CLOXACILLIN J 01 A A 03 CHLORTETRACYCLINE N 05 A H 02 CLOZAPINE S 01 A A 02 CHLORTETRACYCLINE N 01 B C 01 COCAINE J 07 A E 01 CHOLERA S 01 H A 01 COCAINE C 10 A C 01 CHOLESTYRAMINE R 02 A D 03 COCAINE M 03 A B CHOLINE DERIVATIVES D 03 A A COD-LIVER OIL OINTMENTS N 07 A B CHOLINE ESTERS R 05 D A 04 CODEINE A 01 A D 11 CHOLINE SALICYLATE N 02 B A 51 CODEINE (<20mg) WITH ASPIRIN N 02 B A 03 CHOLINE SALICYLATE N 02 B E 51 CODEINE (<20mg) WITH PARACETAMOL R 03 D A 02 CHOLINE THEOPHYLLINATE N 02 A A 59 CODEINE COMBINATIONS EXCL. R 03 D B 02 CHOLINE THEOPHYLLINATE AND PSYCHOLEPTICS ADRENERGICS M 04 A C 01 COLCHICINE

258

L 01 C C COLCHICINE DERIVATIVES D 07 C C CORTICOSTEROIDS, POTENT, COMB WITH C 10 A C 02 COLESTIPOL ANTIBIOTICS A 07 A A 10 COLISTIN D 07 X C CORTICOSTEROIDS, POTENT, OTHER J 01 X B 01 COLISTIN COMBINATIONS L 03 A A COLONY STIMULATING FACTORS D 07 A D CORTICOSTEROIDS, VERY POTENT (GROUP IV) S 01 J A COLOURING AGENTS D 07 B D CORTICOSTEROIDS, VERY POTENT, COMB A 02 A D COMB OF ALUMINIUM,CALCIUM AND W/ANTISEPTICS MAGNESIUM COMPOUNDS D 07 C D CORTICOSTEROIDS, VERY POTENT, COMB H 03 A A 03 COMB OF LEVOTHYROXINE AND W/ANTIBIOTICS LIOTHYRONINE D 07 X D CORTICOSTEROIDS, VERY POTENT, J 01 L A COMB. OF DIFFERENT ANTIBIOTICS FOR OTHER COMBINATIONS SYTEMIC USER 03 A H COMBINATIONS OF ADRENERGICS D 07 A A CORTICOSTEROIDS, WEAK (GROUP I) R 06 A K COMBINATIONS OF ANTIHISTAMINES D 07 B A CORTICOSTEROIDS, WEAK, COMB WITH ANTISEPTICS N 05 C B 01 COMBINATIONS OF BARBITURATES D 07 C A CORTICOSTEROIDS, WEAK, COMB WITH D 07 A B 30 COMBINATIONS OF CORTICOSTEROIDS ANTIBIOTICS D 07 X B 30 COMBINATIONS OF CORTICOSTEROIDS D 07 X A CORTICOSTEROIDS, WEAK, OTHER L 01 X Y COMBINATIONS OF CYTOSTATICS COMBINATIONS S 01 A A 30 COMBINATIONS OF DIFFERENT H 01 A A 01 CORTICOTROPHIN ANTIBIOTICS S 01 B A 03 CORTISONE B 05 X A 30 COMBINATIONS OF ELECTROLYTES H 02 A B 10 CORTISONE C 02 A A 03 COMBINATIONS OF RAUWOLFIA M 01 A H COXIBS ALKALOIDS S 01 G X 01 CROMOGLYCATE SODIUM G 01 A E 10 COMBINATIONS OF SULFONAMIDES R 03 B C 01 CROMOGLYCATE SODIUM J 01 A A 20 COMBINATIONS OF TETRACYCLINES R 01 A C 01 CROMOGLYCATE SODIUM J 04 A L COMBINATIONS OF TUBERCULOSTATICS R 01 A C 51 CROMOGLYCATE SODIUM, COMBINATIONS A 11 J A COMBINATIONS OF VITAMINS D 04 A X CROTAMITON R 03 D A 20 COMBINATIONS OF XANTHINES M 03 A A CURARE ALKALOIDS G 03 C A 57 CONJUGATED ESTROGENS B 03 B A 01 CYANOCOBALAMIN A 06 A B CONTACT LAXATIVES B 03 B A 02 CYANOCOBALAMIN TANNIN COMPLEX A 06 A B 30 CONTACT LAXATIVES IN COMB W/ BELLADONNA ALKALOIDS B 03 B A 51 CYANOCOBALAMIN, COMBINATIONS A 06 A B 20 CONTACT LAXATIVES IN COMBINATION C 04 A X 01 CYCLANDELATE C 02 E A CONVERTING ENZYME BLOCKERS R 06 A E 03 CYCLIZINE C 02 L M CONVERTING ENZYME BLOCKERS AND R 06 A E 53 CYCLIZINE, COMBINATIONS DIURETICS R 01 A A 02 CYCLOPENTAMINE P 03 A X 02 COPPER OLEINATE C 03 A A 07 CYCLOPENTHIAZIDE V 03 A B 20 COPPER SULPHATE S 01 F A 04 CYCLOPENTOLATE C 01 D A 20 CORONARY VASODILATORS IN L 01 A A 01 CYCLOPHOSPHAMIDE COMBINATION J 04 A B 01 CYCLOSERINE S 01 C B CORTICOSTER./ANTIINFECT./ L 04 A A 01 CYCLOSPORIN SYMPATHOMIMETICS IN COMB R 06 A X 02 CYPROHEPTADINE N 02 C B CORTICOSTEROID DERIVATIVES G 03 H A 01 CYPROTERONE S 02 B A CORTICOSTEROIDS G 03 H B 01 CYPROTERONE AND ESTROGEN R 01 A D CORTICOSTEROIDS L 01 B C 01 CYTARABINE S 03 B A CORTICOSTEROIDS J 06 B B 09 CYTOMEGALOVIRUS INFECTION S 01 C A CORTICOSTEROIDS AND ANTIINFECTIVES IMMUNOGLOBULIN IN COMBINATION S 03 C A CORTICOSTEROIDS AND ANTIINFECTIVES L 01 A X 04 DACARBAZINE IN COMBINATION L 01 D A 01 DACTINOMYCIN S 02 C A CORTICOSTEROIDS AND ANTIINFECTIVES B 01 A B 04 DALTEPARIN SODIUM IN COMBINATION G 03 X A 01 DANAZOL S 01 B B CORTICOSTEROIDS AND MYDRIATICS IN M 03 C A 01 DANTROLENE COMB M 03 C A DANTROLENE AND DERIVATIVES A 01 A C CORTICOSTEROIDS FOR LOCAL ORAL J 04 B A 02 DAPSONE TREATMENT L 01 D B 02 DAUNORUBICIN A 07 E A CORTICOSTEROIDS FOR LOCAL USE C 02 C C 04 DEBRISOQUINE H 02 B X CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS S 01 E B 04 DEMECARIUM D 07 X B CORTICOSTEROIDS, MODERATELY D 06 A A 01 DEMECLOCYCLINE POTENT, OTHER COMB. J 01 A A 01 DEMECLOCYCLINE D 07 A B CORTICOSTEROIDS, MODERATELY R 02 A A 02 DEQUALINIUM POTENT (GROUP II) D 08 A H 01 DEQUALINIUM S 01 B A CORTICOSTEROIDS, PLAIN G 01 A C 05 DEQUALINIUM D 07 A C CORTICOSTEROIDS, POTENT (GROUP III) V 03 A C 01 DESFERRIOXAMINE D 07 B C CORTICOSTEROIDS, POTENT, COMB WITH N 06 A A 01 DESIPRAMINE ANTISEPTICS C 01 A A 07 DESLANOSIDE H 01 B A 02 DESMOPRESSIN

259

G 03 A A 09 DESOGESTREL AND ESTROGEN V 03 A B 09 DIMERCAPROL S 03 B A 01 DEXAMETHASONE N 06 A A 18 DIMETACRINE A 01 A C 02 DEXAMETHASONE G 02 A D 01 DINOPROST C 05 A A 09 DEXAMETHASONE G 02 A D 02 DINOPROSTONE R 01 A D 03 DEXAMETHASONE A 03 A B 15 DIPHEMANIL H 02 A B 02 DEXAMETHASONE A 03 C A 08 DIPHEMANIL AND PSYCHOLEPTICS D 10 A A 03 DEXAMETHASONE D 04 A A 32 DIPHENHYDRAMINE D 07 X B 05 DEXAMETHASONE R 06 A A 02 DIPHENHYDRAMINE S 02 B A 06 DEXAMETHASONE D 04 A A 33 DIPHENHYDRAMINE METHYLBROMIDE S 01 C B 01 DEXAMETHASONE R 06 A A 52 DIPHENHYDRAMINE, COMBINATIONS S 01 B A 01 DEXAMETHASONE A 07 D A 01 DIPHENOXYLATE D 07 C B 04 DEXAMETHASONE AND ANTIBIOTICS R 06 A A 07 DIPHENYLPYRALINE S 02 C A 06 DEXAMETHASONE AND ANTIINFECTIVES J 07 A F 01 DIPHTERIA S 01 C A 01 DEXAMETHASONE AND ANTIINFECTIVES J 06 A A 01 DIPHTERIA ANTITOXIN S 03 C A 01 DEXAMETHASONE AND ANTIINFECTIVES J 07 A M 51 DIPHTERIA-TETANUS N 06 B A 02 DEXAMPHETAMINE S 01 E A 02 DIPIVEFRINE R 06 A B 06 DEXBROMPHENIRAMINE B 01 A C 07 DIPYRIDAMOLE R 06 A B 56 DEXBROMPHENIRAMINE, COMBINATIONS C 01 B A 03 DISOPYRAMIDE R 06 A B 02 DEXCHLORPHENIRAMINE N 07 A A 03 DISTIGMINE R 06 A B 52 DEXCHLORPHENIRAMINE, COMBINATIONS N 07 B B 01 DISULFIRAM A 08 A A 04 DEXFENFLURAMINE P 03 A A 04 DISULFIRAM B 05 A A 05 DEXTRAN P 03 A A 54 DISULFIRAM, COMBINATIONS D 03 A X 02 DEXTRANOMER D 05 A C 01 DITHRANOL R 05 D A 09 DEXTROMETHORPHAN V 03 A B 26 DL-METHIONINE N 02 A C 01 DEXTROMORAMIDE C 01 C A 07 DOBUTAMINE N 02 A C 04 DEXTROPROPOXYPHENE L 01 C D 02 DOCETAXEL N 02 A C 74 DEXTROPROPOXYPHENE, COMB WITH A 06 A A 02 DOCUSATE SODIUM PSYCHOLEPTICS A 06 A G 10 DOCUSATE SODIUM, INCL COMBINATIONS N 02 A C 54 DEXTROPROPOXYPHENE,COMB EXCL A 04 A A 04 DOLASETRON PSYCHOLEPT A 03 F A 03 DOMPERIDONE B 04 A X 01 DEXTROTHYROXINE N 06 D A 02 DONEPEZIL P 01 B D DIAMINOPYRIMIDINES N 04 B A DOPA AND DOPA DERIVATIVES N 05 B A 01 DIAZEPAM C 01 C A 04 DOPAMINE V 03 A H 01 DIAZOXIDE N 04 B C DOPAMINE AGONISTS C 02 D A 01 DIAZOXIDE S 01 E C 03 DORZOLAMIDE N 05 C C 04 DICHLORALPHENAZONE N 06 A A 16 DOTHIEPIN R 02 A A 03 DICHLOROBENZYL ALCOHOL R 07 A B 01 DOXAPRAM S 01 E C 02 DICHLORPHENAMIDE C 02 C A 04 DOXAZOSIN P 02 X X 06 DICHLOROPHEN N 06 A A 12 DOXEPIN M 01 A B 05 DICLOFENAC L 01 D B 01 DOXORUBICIN M 02 A A 15 DICLOFENAC J 01 A A 02 DOXYCYCLINE S 01 B C 03 DICLOFENAC R 06 A A 09 DOXYLAMINE M 01 A B 55 DICLOFENAC COMBINATIONS N 01 A X 01 DROPERIDOL J 01 C F 01 DICLOXACILLIN M 05 B DRUGS AFFECTING BONE STRUCTURE J 05 A F 02 DIDANOSINE AND MINERALISATION G 03 C B 01 DIENESTROL A 02 DRUGS FOR ACID RELATED DISORDERS G 03 C C 02 DIENESTROL A 02 B DRUGS FOR PEPTIC ULCER P 02 C B 02 DIETHYLCARBAMAZINE A 03 DRUGS FOR FUNCTIONAL A 08 A A 03 DIETHYLPROPION GASTROINTESTINAL DISORDERS G 03 C B 02 DIETHYLSTILBESTROL A 03 A DRUGS FOR FUNCTIONAL BOWEL L 02 A A 01 DIETHYLSTILBESTROL DISORDERS G 03 C C 05 DIETHYLSTILBESTROL R 03 DRUGS FOR OBSTRUCTIVE AIRWAY N 02 B A 11 DIFLUNISAL DISEASES V 03 A B 24 DIGITALIS ANTITOXIN N 07 B DRUGS USED IN ADDICTIVE DISORDERS C 01 A A DIGITALIS GLYCOSIDES N 07 B A DRUGS USED IN NICOTINE DEPENDENCE C 01 A A 03 DIGITALIS LEAVES N 07 B B DRUGS USED FOR TREATMENT OF CHRONIC ALCOHOLISM C 01 A A 04 DIGITOXIN N 07 B C DRUGS USED IN OPIOD DEPENDENCE C 01 A A 05 DIGOXIN G 03 D B 01 DYDROGESTERONE N 02 A A 08 DIHYDROCODEINE G 03 F B 08 DYDROGESTERONE AND ESTROGEN N 02 C A 01 DIHYDROERGOTAMINE N 02 C A 51 DIHYDROERGOTAMINE, COMBINATIONS G 01 A F 05 ECONAZOLE A 11 C C 02 DIHYDROTACHYSTEROL D 01 A C 03 ECONAZOLE G 01 A C 01 DIIODOHYDROXYQUINOLINE S 01 E B 03 ECOTHIOPATE H 03 B X 01 DIIODOTYROSINE R 03 A C 13 EFORMOTERAL C 08 D B 01 DILTIAZEM B 05 B B 01 ELECTROLYTES

260

B 05 X A 31 ELECTROLYTES IN COMB WITH N 05 C M 08 ETHCHLORVYNOL OTHER DRUGS N 01 A A ETHERS B 05 B B 02 ELECTROLYTES WITH CARBOHYDRATES N 04 A B ETHERS CHEMICALLY CLOSE TO C 09 A A 02 ENALAPRIL ANTIHISTAMINES A 06 A G ENEMAS N 04 A C ETHERS OF TROPINE OR TROPINE N 01 A B 04 ENFLURANE DERIVATIVES J 01 M A 04 ENOXACIN M 03 B C ETHERS, CHEMICALLY CLOSE TO B 01 A B 05 ENOXAPARIN ANTIHISTAMINES A 09 A C ENZYME AND ACID PREPARATIONS, L 02 A A 03 ETHINYLESTRADIOL COMBINATIONS G 03 C A 01 ETHINYLESTRADIOL L 02 B G ENZYME INHIBITORS G 03 A A 10 ETHINYLESTRADIOL WITH GESTODENE A 09 A A ENZYME PREPARATIONS G 03 A B 06 ETHINYLESTRADIOL WITH GESTODENE B 01 A D ENZYMES J 04 A D 03 ETHIONAMIDE C 04 A F ENZYMES G 03 D C 04 ETHISTERONE B 06 A A ENZYMES G 03 F A 03 ETHISTERONE AND ESTROGEN M 09 A B ENZYMES N 03 A D 01 ETHOSUXIMIDE R 03 C A 02 EPHEDRINE N 01 B X 01 ETHYL CHLORIDE S 01 F B 02 EPHEDRINE D 01 A E 10 ETHYL HYDROXYBENZOATE R 01 A B 05 EPHEDRINE A 14 A B 02 ETHYLESTRENOL R 01 A A 03 EPHEDRINE N 01 B B 07 ETIDOCAINE A 08 A A 56 EPHEDRINE, COMBINATIONS M 05 B A 01 ETIDRONIC ACID J 01 C A 07 EPICILLIN M 05 B B 01 ETIDRONIC ACID AND CALCIUM A 01 A D 01 EPINEPHRINE M 01 A B 08 ETODOLAC R 03 C A 01 EPINEPHRINE N 01 A X 07 ETOMIDATE R 03 A A 01 EPINEPHRINE L 01 C B 01 ETOPOSIDE S 01 E A 01 EPINEPHRINE D 05 B B 01 ETRETINATE R 03 A K 01 EPINEPHRINE AND OTHER G 03 A A 01 ETYNODIOL AND ESTROGEN ANTI-ASTHMATICS L 02 B G 06 EXEMESTANE R 03 A K 01 EPINEPHRINE AND OTHER DRUGS FOR R 05 C A EXPECTORANTS OBSTRUCTIVE AIRWAY DISEASES S 01 E A 51 EPINEPHRINE, COMBINATIONS J 05 A B 09 FAMCICLOVIR L 01 D B 03 EPIRUBICIN A 02 B A 03 FAMOTIDINE C 09 C A 02 EPROSARTAN B 05 B A 02 FAT EMULSIONS A 11 C C 01 ERGOCALCIFEROL N 03 A G FATTY ACID DERIVATIVES G 02 A B 03 ERGOMETRINE C 08 C A 02 FELODIPINE G 02 A B 02 ERGOT ALKALOIDS M 01 A G FENAMATES G 02 A B ERGOT ALKALOIDS A 08 A A 02 FENFLURAMINE C 04 A E ERGOT ALKALOIDS R 03 A C 04 FENOTEROL N 02 C A ERGOT ALKALOIDS R 03 C C 04 FENOTEROL N 02 C A 02 ERGOTAMINE R 03 A K 03 FENOTEROL AND OTHER N 02 C A 52 ERGOTAMINE, COMBINATIONS ANTI-ASTHMATICS C 01 D A 13 ERYTHRITYL TETRANITRATE R 03 A K 03 FENOTEROL AND OTHER DRUGS C 01 D A 63 ERYTHRITYL TETRANITRATE, FOR OBSTRUCTIVE AIRWAY DISEASES COMBINATIONS N 02 A B 03 FENTANYL J 01 F A 01 ERYTHROMYCIN N 01 A H 01 FENTANYL D 10 A F 02 ERYTHROMYCIN N 01 A H 51 FENTANYL, COMBINATIONS S 01 A A 17 ERYTHROMYCIN B 03 A B 06 FERRIC CITRATE B 03 X A 01 ERYTHROPOIETIN B 03 A B 04 FERRIC HYDROXIDE A 02 B C 05 ESOMEPRAZOLE B 03 A B 05 FERRIC OXIDE POLYMALTOSE COMPLEX L 02 A A 02 ESTRADIOL B 03 A C 04 FERRIC OXIDE POLYMALTOSE COMPLEX G 03 C A 03 ESTRADIOL B 03 A B 01 FERRIC SODIUM CITRATE G 03 C A 53 ESTRADIOL, COMBINATIONS B 03 A C 05 FERRIC SORBITOL GLUCONIC ACID G 03 D C ESTREN DERIVATIVES COMPLEX A 14 A B ESTREN DERIVATIVES B 03 A D 01 FERROUS AMINO ACID COMPLEX G 03 C A 04 ESTRIOL B 03 A A 10 FERROUS ASCORBATE L 02 A A ESTROGENS B 03 A A 09 FERROUS ASPARTATE G 03 C C ESTROGENS, COMBINATIONS B 03 A A 04 FERROUS CARBONATE WITH OTHER DRUGS B 03 A A 05 FERROUS CHLORIDE G 03 C A 07 ESTRONE B 03 A A 02 FERROUS FUMARATE G 03 C C 04 ESTRONE B 03 A D 02 FERROUS FUMARATE B 02 B X 01 ETAMSYLATE B 03 A A 03 FERROUS GLUCONATE C 03 C C 01 ETHACRYNIC ACID B 03 A A 01 FERROUS GLYCINE SULPHATE J 04 A K 02 ETHAMBUTOL B 03 A A 11 FERROUS IODINE V 03 A Z 01 ETHANOL B 03 A A 06 FERROUS SUCCINATE V 03 A B 16 ETHANOL B 03 A A 07 FERROUS SULPHATE C 05 B B 01 ETHANOLAMINE OLEATE B 03 A D 03 FERROUS SULPHATE

261

B 03 A A 08 FERROUS TARTRATE B 03 B B 01 FOLIC ACID R 06 A X 26 FEXOFENADINE L 01 B A FOLIC ACID ANALOGUES B 04 A C FIBRATES B 03 B B FOLIC ACID AND DERIVATIVES B 02 B B FIBRINOGEN B 03 B B 51 FOLIC ACID, COMBINATIONS B 01 A D 05 FIBRINOLYSIN G 03 G A 05 FOLLITROPIN ALFA B 06 A A 02 FIBRINOLYSIN AND G 03 G A 06 FOLLITROPIN BETA DESOXYRIBONUCLEASE J 05 A D 01 FOSCARNET L 03 A A 02 FILGRASTIM L 02 A A 04 FOSFESTROL G 04 C B 01 FINASTERIDE J 05 A D 02 FOSFONET G 04 B D 02 FLAVOXATE C 09 A A 09 FOSINOPRIL C 01 B C 04 FLECAINIDE S 01 A A 07 FRAMYCETIN J 01 C F 05 FLUCLOXACILLIN D 09 A A 01 FRAMYCETIN J 02 A C 01 FLUCONAZOLE S 03 A A FRAMYCETIN D 01 A A 05 FLUCYTOSINE C 01 E B 07 FRUCTOSE 1,6-DIPHOSPHATE J 02 A X 01 FLUCYTOSINE C 03 C A 01 FRUSEMIDE H 02 A A 02 FLUDROCORTISONE D 05 A X 01 FUMARIC ACID S 01 C A 06 FLUDROCORTISONE AND ANTIINFECTIVES D 08 A F FURAN DERIVATIVES S 03 C A 05 FLUDROCORTISONE AND ANTIINFECTIVES G 01 A X 06 FURAZOLIDONE S 02 C A 07 FLUDROCORTISONE AND ANTIINFECTIVES S 01 A A 13 FUSIDIC ACID D 07 A C 07 FLUDROXYCORTIDE D 06 A X 01 FUSIDIC ACID D 07 C C 03 FLUDROXYCORTIDE AND ANTIBIOTICS J 01 X C 01 FUSIDIC ACID M 01 A G 03 FLUFENAMIC ACID D 09 A A 02 FUSIDIC ACID V 03 A B 25 FLUMAZENIL D 07 X B 01 FLUMETASONE C 01 A C 01 G-STROPHANTHIN D 07 A B 03 FLUMETASONE N 03 A X 12 GABAPENTIN D 07 C B 05 FLUMETASONE AND ANTIBIOTICS V 04 C E 01 GALACTOSE S 02 C A 02 FLUMETASONE AND ANTIINFECTIVES M 03 A C 02 GALLAMINE D 07 B B 01 FLUMETASONE AND ANTISEPTICS D 11 A X 02 GAMOLENIC ACID R 03 B A 03 FLUNISOLIDE J 05 A B 06 GANCICLOVIR R 01 A D 04 FLUNISOLIDE S 01 A D 09 GANCICLOVIR N 05 C D 03 FLUNITRAZEPAM N 07 X A GANGLIOSIDES AND GANGLIOSIDE D 07 A C 04 FLUOCINOLONE DERIVATIVES S 02 C A 05 FLUOCINOLONE ACETONIDE AND J 06 A A 05 GAS-GANGRENE SERA ANTIINFECTIVES J 01 M A 16 GATIFLOXACIN D 07 C C 02 FLUOCINOLONE AND ANTIBIOTICS B 05 A A 06 GELATIN AGENTS D 07 B C 02 FLUOCINOLONE AND ANTISEPTICS L 01 B C 05 GEMCITABINE D 07 A C 08 FLUOCINONIDE G 02 A D 03 GEMEPROST C 05 A A 08 FLUOCORTOLONE C 10 A B 04 GEMFIBROZIL H 02 A B 03 FLUOCORTOLONE D 06 A X 07 GENTAMICIN D 07 A C 05 FLUOCORTOLONE S 01 A A 11 GENTAMICIN S 01 C A 04 FLUOCORTOLONE AND ANTIINFECTIVES J 01 G B 03 GENTAMICIN D 07 B C 03 FLUOCORTOLONE AND ANTISEPTICS G 03 X A 02 GESTRINONE S 01 J A 01 FLUORESCEIN N 06 D X 02 GINKGO BILOBA S 01 J A 51 FLUORESCEIN, COMBINATIONS L 03 A X 13 GLATIRAMER ACETATE A 12 C D FLUORIDE A 10 B B 01 GLIBENCLAMIDE D 10 A A 01 FLUOROMETHOLONE A 10 B B 09 GLICLAZIDE D 07 X B 04 FLUOROMETHOLONE A 10 B B 07 GLIPIZIDE D 07 A B 06 FLUOROMETHOLONE H 04 A A 01 GLUCAGON C 05 A A 06 FLUOROMETHOLONE H 02 A B GLUCOCORTICOIDS S 01 B A 07 FLUOROMETHOLONE R 03 B A GLUCOCORTICOIDS D 07 C B 03 FLUOROMETHOLONE AND ANTIBIOTICS B 05 C X 01 GLUCOSE S 01 C A 07 FLUOROMETHOLONE AND A 09 A B 01 GLUTAMIC ACID ANTIINFECTIVES N 05 C E 01 GLUTETHIMIDE L 01 B C 02 FLUOROURACIL A 06 A X 01 GLYCEROL N 06 A B 03 FLUOXETINE A 06 A G 04 GLYCEROL G 03 B A 01 FLUOXYMESTERONE C 01 D A 02 GLYCERYL TRINITRATE N 05 A F 01 FLUPENTIXOL C 01 D A 52 GLYCERYL TRINITRATE, COMBINATIONS D 07 A B 05 FLUPEROLONE B 05 C X 03 GLYCINE N 05 A B 02 FLUPHENAZINE A 03 A B 02 GLYCOPYRROLATE N 05 C D 01 FLURAZEPAM A 10 B C 01 GLYMIDINE S 01 B C 04 FLURBIPROFEN M 01 C B GOLD PREPARATIONS L 02 B B 01 FLUTAMIDE H 01 C A 01 GONADORELIN R 03 B A 05 FLUTICASONE V 04 C M 01 GONADORELIN C 10 A A 04 FLUVASTATIN L 02 A E GONADOTROPHIN RELEASING HORMONE N 06 A B 08 FLUVOXAMINE ANALOGUES

262

H 01 C A GONADOTROPHIN-RELEASING C 04 A E 51 HYDROGENATED ERGOT ALKALOIDS, HORMONES COMBINATIONS G 03 G A GONADOTROPINS A 01 A B 02 HYDROGEN PEROXIDE L 02 A E 03 GOSERELIN D 08 A X 01 HYDROGEN PEROXIDE R 02 A B 30 GRAMICIDIN M 09 A A 01 HYDROQUININE D 01 B A 01 GRISEOFULVIN B 03 B A 03 HYDROXOCOBALAMIN R 05 C A 03 GUAIFENESIN N 01 A X 11 HYDROXYBUTYRIC ACID S 01 E X 01 GUANETHIDINE L 01 X X 05 HYDROXYCARBAMIDE C 02 C C 02 GUANETHIDINE P 01 B A 02 HYDROXYCHLOROQUINE C 02 L F 01 GUANETHIDINE AND DIURETICS B 05 A A 07 HYDROXYETHYL STARCH C 02 D G GUANIDINE DERIVATIVES G 03 D A 03 HYDROXYPROGESTERONE C 02 C C GUANIDINE DERIVATIVES G 03 F A 02 HYDROXYPROGESTERONE AND C 02 L F GUANIDINE DERIVATIVES AND DIURETICS ESTROGEN P 01 A A HYDROXYQUINOLINE DERIVATIVES A 02 B A H2-RECEPTOR ANTAGONISTS N 05 B B 01 HYDROXYZINE D 07 A D 02 HALCINONIDE N 05 B B 51 HYDROXYZINE, COMBINATIONS N 01 A B HALOGENATED HYDROCARBONS A 03 B B 01 HYOSCINE BUTYLBROMIDE N 05 A D 01 HALOPERIDOL A 03 B A 03 HYOSCYAMINE N 01 A B 01 HALOTHANE A 03 C B 31 HYOSCYAMINE AND PSYCHOLEPTICS B 05 Z A HEMODIALYTICS, CONCENTRATES B 05 D B HYPERTONIC SOLUTIONS B 05 Z B HEMOFILTRATES N 05 C X HYPNOTICS & SEDATIVES COMB., B 01 A B 01 HEPARIN EXCL BARBITURATES B 01 A B HEPARIN GROUP B 01 A B 51 HEPARIN, COMBINATIONS R 03 D C 04 IBUDILAST J 07 B C 02 HEPATITIS A M 01 A E 01 IBUPROFEN J 07 B C 01 HEPATITIS B D 06 B B 01 IDOXURIDINE J 06 B B 04 HEPATITIS B IMMUNOGLOBULIN S 01 A D 01 IDOXURIDINE C 01 D A 24 HEPTAMINOL J 05 A B 02 IDOXURIDINE V 04 C G 03 HISTAMINE L 01 A A 06 IFOSFAMIDE B 04 A B HMG COA REDUCTASE INHIBITORS A 07 A C IMIDAZOLE DERIVATIVES S 01 F A 05 HOMATROPINE G 01 A F IMIDAZOLE DERIVATIVES B 02 B B 01 HUMAN FIBRINOGEN D 01 A C IMIDAZOLE AND TRIAZOLE DERIVATIVES G 03 G A 02 HUMAN MENOPAUSAL GONADOTROPHIN J 01 X D IMIDAZOLE DERIVATIVES S 01 K A 01 HYALURONIC ACID J 02 A B IMIDAZOLE DERIVATIVES S 01 K A 51 HYALURONIC ACID, COMBINATIONS G 01 B F IMIDAZOLE DERIVATIVES AND CORTICOSTEROIDS B 06 A A 03 HYALURONIDASE C 04 A B IMIDAZOLINE DERIVATIVES N 03 A B HYDANTOIN DERIVATIVES J 01 D H 51 IMIPENEM AND ENZYME INHIBITOR C 02 D B 02 HYDRALAZINE N 06 A A 02 IMIPRAMINE C 02 L G 02 HYDRALAZINE AND DIURETICS D 06 B B 10 IMIQUIMOD J 04 A C HYDRAZIDES J 06 A A IMMUNE SERA A 09 A B 03 HYDROCHLORIC ACID C 03 B A 11 INDAPAMIDE C 03 A A 03 HYDROCHLOROTHIAZIDE S 02 D C INDIFFERENT PREPARATIONS C 03 A B 03 HYDROCHLOROTHIAZIDE AND POTASSIUM N 05 A E INDOLE DERIVATIVES C 03 E A 01 HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS M 02 A A 23 INDOMETHACIN R 05 D A 03 HYDROCODONE M 01 A B 01 INDOMETHACIN D 07 A A 02 HYDROCORTISONE S 01 B C 01 INDOMETHACIN A 01 A C 03 HYDROCORTISONE M 01 A B 51 INDOMETHACIN,COMBINATIONS D 07 X A 01 HYDROCORTISONE C 02 C A 02 INDORAMIN S 01 B A 02 HYDROCORTISONE J 07 B B INFLUENZA H 02 A B 09 HYDROCORTISONE A 11 H A 07 INOSITOL S 02 B A 01 HYDROCORTISONE C 04 A C 03 INOSITOL NICOTINATE A 07 E A 02 HYDROCORTISONE A 10 A B 05 INSULIN ASPART C 05 A A 01 HYDROCORTISONE A 10 A B 04 INSULIN LISPRO D 07 C A 01 HYDROCORTISONE AND ANTIBIOTICS A 10 A C 04 INSULIN LISPRO S 01 C A 03 HYDROCORTISONE AND ANTIINFECTIVES A 10 A D 04 INSULIN LISPRO S 02 C A 03 HYDROCORTISONE AND ANTIINFECTIVES A 10 A B 01 INSULINS FAST ACTING (HUMAN) S 03 C A 04 HYDROCORTISONE AND ANTIINFECTIVES A 10 A E 01 INSULINS FAST ACTING (HUMAN) D 07 B A 04 HYDROCORTISONE AND ANTISEPTICS A 10 A B 02 INSULINS FAST ACTING (BEEF) S 01 B B 01 HYDROCORTISONE AND MYDRIATICS A 10 A B 03 INSULINS FAST ACTING (PORK) D 07 A B 02 HYDROCORTISONE BUTYRATE A 10 A C 01 INSULINS INTERMEDIATE ACTING (HUMAN) D 07 B B 04 HYDROCORTISONE BUTYRATE AND A 10 A C 02 INSULINS INTERMEDIATE ACTING (BEEF) ANTISEPTICS A 10 A C 03 INSULINS INTERMEDIATE ACTING (PORK) S 02 A A 06 HYDROGEN PEROXIDE A 10 A D 01 INSULINS INTERMEDIATE ACTING + FAST C 04 A E 01 HYDROGENATED ERGOT ALKALOIDS ACTING(HUMAN)

263

A 10 A D 02 INSULINS INTERMEDIATE ACTING + FAST B 05 X A 06 K-PHOSPHATE, INCL COMB WITH OTHER ACTING(BEEF) K-SALTS A 10 A D 03 INSULINS INTERMEDIATE ACTING + FAST A 07 A A 08 KANAMYCIN ACTING(PORK) J 01 G B 04 KANAMYCIN S 01 A D 05 INTERFERON A 07 B C 02 KAOLIN COMBINATIONS L 03 A B INTERFERONS N 01 A X 03 KETAMINE L 03 A B 01 INTERFERON-ALFA-NATURAL J 02 A B 02 KETOCONAZOLE L 03 A B 02 INTERFERON-BETA-NATURAL G 01 A F 11 KETOCONAZOLE L 03 A B 03 INTERFERON-GAMMA D 01 A C 08 KETOCONAZOLE L 03 A B 04 INTERFERON-ALFA-2a M 01 A E 03 KETOPROFEN L 03 A B 05 INTERFERON-ALFA-2b M 02 A A 10 KETOPROFEN L 03 A B 06 INTERFERON-ALFA-N1 M 01 A B 15 KETOROLAC L 03 A B 07 INTERFERON-BETA-1a S 01 B C 05 KETOROLAC L 03 A B 08 INTERFERON-BETA-1b R 06 A X 17 KETOTIFEN L 03 A C INTERLEUKINS J 01 E C INTERMEDIATE-ACTING SULFONAMIDES C 07 A G 01 LABETALOL G 02 B A INTRAUTERINE CONTRACEPTIVES G 01 A D 01 LACTIC ACID G 02 B B INTRAVAGINAL CONTRACEPTIVES A 07 F A 51 LACTIC ACID PRODUCING ORGANISMS, D 08 A G 03 IODINE COMBINATIONS D 08 A G IODINE PRODUCTS A 07 F A 01 LACTIC ACID PRODUCING ORGANISMS H 03 C A IODINE THERAPY A 06 A D 11 LACTULOSE R 05 C A 04 IPECACUANHA A 06 A D 61 LACTULOSE, COMBINATIONS V 03 A B 01 IPECACUANHA J 05 A F 05 LAMIVUDINE R 01 A X 03 IPRATROPIUM BROMIDE N 03 A X 09 LAMOTRIGINE R 03 B B 01 IPRATROPIUM BROMIDE C 01 A A 06 LANATOSIDE C N 06 A A 13 IPRINDOLE A 02 B C 03 LANSOPRAZOLE C 09 C A 04 IRBESARTAN J 01 D A 18 LATAMOXEF C 09 D A 04 IRBESARTAN AND DIURETICS S 01 E X 03 LATANOPROST B 03 A E 03 IRON AND MULTIVITAMINS L 04 A A 13 LEFLUNOMIDE B 03 A A IRON BIVALENT, ORAL PREPARATIONS J 04 B A LEPROSTATICS V 03 A C IRON CHELATING AGENTS L 02 B G 04 LETROZOLE B 03 A C 01 IRON DEXTRAN L 02 A E 02 LEUPRORELIN B 03 A D IRON IN COMBINATION WITH FOLIC ACID P 02 C E 01 LEVAMISOLE B 03 A E IRON IN OTHER COMBINATIONS S 01 E D 03 LEVOBUNOLOL B 03 A B IRON TRIVALENT, ORAL PREPARATIONS R 01 A C 02 LEVOCABASTIN B 03 A C IRON TRIVALENT, PARENTERAL S 01 G X 02 LEVOCABASTIN PREPARATIONS A 16 A A 01 LEVOCARNITINE B 03 A E 02 IRON, MULTIVITAMINS AND FOLIC ACID R 06 A E 09 LEVOCETIRIZINE B 03 A E 04 IRON, MULTIVITAMINS AND MINERALS N 04 B A 01 LEVODOPA B 03 A E 01 IRON, VITAMIN B12 AND FOLIC ACID N 04 B A 02 LEVODOPA AND DECARBOXYLASE B 03 A C 03 IRON-SORBITOL-CITRIC ACID COMPLEX INHIBITOR N 06 A F 01 ISOCARBOXAZID G 03 A C 03 LEVONORGESTREL G 01 A F 07 ISOCONAZOLE G 03 F A 11 LEVONORGESTREL AND ESTROGEN D 01 A C 05 ISOCONAZOLE G 03 A A 07 LEVONORGESTREL AND ESTROGEN N 01 A B 06 ISOFLURANE G 03 A B 03 LEVONORGESTREL AND ESTROGEN J 04 A C 01 ISONIAZID H 03 A A 01 LEVOTHYROXINE SODIUM C 01 C A 02 ISOPRENALINE A 01 A D 11 LIGNOCAINE R 03 C B 01 ISOPRENALINE C 05 A D 01 LIGNOCAINE R 03 A B 02 ISOPRENALINE N 01 B B 02 LIGNOCAINE R 03 A K 02 ISOPRENALINE AND OTHER ANTI- D 04 A B 01 LIGNOCAINE ASTHMATICS S 02 D A 01 LIGNOCAINE A 03 A B 09 ISOPROPAMIDE S 01 H A 07 LIGNOCAINE A 03 C A 01 ISOPROPAMIDE AND PSYCHOLEPTICS R 02 A D 02 LIGNOCAINE C 01 D A 08 ISOSORBIDE DINITRATE C 01 B B 01 LIGNOCAINE C 01 D A 58 ISOSORBIDE DINITRATE, COMBINATIONS J 01 F F 02 LINCOMYCIN C 01 D A 14 ISOSORBIDE MONONITRATE P 03 A B 02 LINDANE B 05 D A ISOTONIC SOLUTIONS A 06 A C 05 LINSEED D 10 B A 01 ISOTRETINOIN A 06 A C 55 LINSEED, COMBINATIONS D 10 A D 04 ISOTRETINOIN H 03 A A 02 LIOTHYRONINE SODIUM D 10 A D 54 ISOTRETINOIN, COMBINATIONS A 06 A A 01 LIQUID PARAFFIN C 04 A A 01 ISOXSUPRINE A 06 A A 51 LIQUID PARAFFIN, COMBINATIONS A 06 A C 01 ISPAGHULA (PSYLLA SEEDS) D 02 A D LIQUID PLASTERS A 06 A C 51 ISPAGHULA, COMBINATIONS C 09 A A 03 LISINOPRIL J 02 A C 02 ITRACONAZOLE G 02 C B 02 LISURIDE P 02 C F 01 IVERMECTIN N 05 A N 01 LITHIUM N 05 A N LITHIUM

264

A 05 B A LIVER THERAPY M 01 A G 01 MEFENAMIC ACID S 01 H A LOCAL ANESTHETICS P 01 B C 02 MEFLOQUINE B 02 B C LOCAL HEMOSTATICS C 03 B A 05 MEFRUSIDE S 01 GX 05 LODOXAMIDE L 02 A B 01 MEGESTROL N 06 A A 07 LOFEPRAMINE L 01 A A 03 MELPHALAN L 01 A D 02 LOMUSTINE B 02 B A 02 MENADIONE J 01 E D LONG-ACTING SULFONAMIDES J 07 A H MENINGOCOCCAL VACCINES A 07 D A 03 LOPERAMIDE N 01 B B 03 MEPIVACAINE R 06 A X 13 LORATADINE N 05 B C 01 MEPROBAMATE N 05 B A 06 LORAZEPAM R 06 A C 01 MEPYRAMINE C 09 C A 01 LOSARTAN L 01 B B 02 MERCAPTOPURINE B 04 A B 02 LOVASTATIN D 08 A K MERCURIAL PRODUCTS N 05 A H 01 LOXAPINE D 08 A K 04 MERCUROCHROME H 01 B A 03 LYPRESSIN A 07 E C 02 MESALAZINE V 03 A F 01 MESNA A 06 A D 15 MACROGOL R 05 C B 05 MESNA J 01 F MACROLIDES, LINCOSAMIDES AND G 03 B B 01 MESTEROLONE STREPTOGRAMINS P 03 A A 03 MESULFEN J 01 F A MACROLIDES D 10 A B 05 MESULFEN A 12 C C MAGNESIUM C 01 C A 09 METARAMINOL A 12 C C 05 MAGNESIUM ASPARTATE A 10 B A 02 METFORMIN A 06 A D 01 MAGNESIUM CARBONATE J 01 A A 05 METHACYCLINE A 02 A A 01 MAGNESIUM CARBONATE N 07 B C 02 METHADONE A 12 C C 01 MAGNESIUM CHLORIDE P 01 B C METHANOLQUINOLINES B 05 X A 11 MAGNESIUM CHLORIDE R 06 A D 04 METHDILAZINE A 12 C C 04 MAGNESIUM CITRATE J 01 X X 05 METHENAMINE B 05 C B 03 MAGNESIUM CITRATE J 01 R A 02 METHENAMINE AND SULFONAMIDES A 02 A A MAGNESIUM COMPOUNDS A 14 A A 04 METHENOLONE A 12 C C 03 MAGNESIUM GLUCONATE J 01 H B 03 METHICILLIN G 04 B X 01 MAGNESIUM HYDROXIDE M 03 B A 03 METHOCARBAMOL A 02 A A 04 MAGNESIUM HYDROXIDE L 01 B A 01 METHOTREXATE A 06 A D 02 MAGNESIUM OXIDE D 05 B A 02 METHOXALEN, SYSTEMIC A 02 A A 02 MAGNESIUM OXIDE D 05 A D 02 METHOXALEN, TOPICAL A 06 A D 03 MAGNESIUM PEROXIDE C 01 C A 10 METHOXAMINE A 02 A A 03 MAGNESIUM PEROXIDE N 01 A B 03 METHOXYFLURANE B 05 X A 10 MAGNESIUM PHOSPHATE R 03 C B 02 METHOXYPHENAMINE A 02 A A 05 MAGNESIUM SILICATE N 03 A D 03 METHSUXIMIDE A 12 C C 02 MAGNESIUM SULPHATE C 03 A A 08 METHYCLOTHIAZIDE A 06 A D 04 MAGNESIUM SULPHATE C 03 A B 08 METHYCLOTHIAZIDE AND POTASSIUM V 04 C C 02 MAGNESIUM SULPHATE A 03 B B 02 METHYLATROPINE B 05 X A 05 MAGNESIUM SULPHATE A 06 A C 06 METHYLCELLULOSE P 03 A X 03 MALATHION C 02 A B METHYLDOPA J 01 Z Z 07 MANDELIC ACID C 02 A B 01 METHYLDOPA (LEVOROTATORY) J 01 X X 06 MANDELIC ACID G 03 D C 31 METHYLESTRENOLONE B 05 C X 04 MANNITOL L 01 X B METHYLHYDRAZINES B 05 B C 01 MANNITOL G 03 F A 05 METHYLNORTESTOSTERONE AND L 01 A B 03 MANNOSULFAN ESTROGEN C 02 K C MAO INHIBITORS N 05 C X 03 METHYLPENTYNOL, COMBINATIONS A 08 A A 05 MAZINDOL N 06 B A 04 METHYLPHENIDATE P 02 C A 01 MEBENDAZOLE N 03 A A 01 METHYLPHENOBARBITONE A 03 A A 04 MEBEVERINE D 07 A A 01 METHYLPREDNISOLONE R 06 A X 15 MEBHYDROLIN D 10 A A 02 METHYLPREDNISOLONE R 06 A E 05 MECLOZINE H 02 A B 04 METHYLPREDNISOLONE R 06 A E 55 MECLOZINE, COMBINATIONS D 07 A C 14 METHYLPREDNISOLONE ACEPONATE D 11 A C MEDICATED SHAMPOOS D 07 C A 02 METHYLPREDNISOLONE AND ANTIBIOTICS A 07 B A 01 MEDICINAL CHARCOAL S 01 C A 08 METHYLPREDNISOLONE AND G 03 A C 06 MEDROXYPROGESTERONE ANTIINFECTIVES G 03 D A 02 MEDROXYPROGESTERONE G 03 E K 01 METHYLTESTOSTERONE L 02 A B 02 MEDROXYPROGESTERONE G 03 B A 02 METHYLTESTOSTERONE G 03 A A 08 MEDROXYPROGESTERONE AND G 03 E A 01 METHYLTESTOSTERONE AND ESTROGEN ESTROGEN V 03 A B 17 METHYLTHIONINE G 03 F B 06 MEDROXYPROGESTERONE AND V 04 C G 05 METHYLTHIONINE ESTROGEN H 03 B A 01 METHYLTHIOURACIL G 03 F A 12 MEDROXYPROGESTERONE AND N 02 C A 04 METHYSERGIDE ESTROGEN A 03 F A 01 METOCLOPRAMIDE S 01 B A 08 MEDRYSONE

265

C 03 B A 08 METOLAZONE S 01 G A 51 NAPHAZOLINE, COMBINATIONS C 07 A B 02 METOPROLOL M 01 A E 02 NAPROXEN D 06 B X 01 METRONIDAZOLE N 02 C C 02 NARATRIPTAN J 01 X D 01 METRONIDAZOLE A 01 A B 10 NATAMYCIN G 01 A F 01 METRONIDAZOLE D 01 A A 02 NATAMYCIN P 01 A B 01 METRONIDAZOLE A 07 A A 03 NATAMYCIN V 04 C D 01 METYRAPONE S 01 A A 10 NATAMYCIN C 01 B B 02 MEXILETINE G 01 A A 02 NATAMYCIN J 01 C A 10 MEZLOCILLIN G 03 C A NATURAL AND SEMISYNTHETIC N 06 A X 03 MIANSERIN ESTROGENS, PLAIN C 08 C X 01 MIBEFRADIL N 02 A A NATURAL OPIUM ALKALOIDS A 01 A B 09 MICONAZOLE R 03 B C 03 NEDOCROMIL D 01 A C 02 MICONAZOLE N 06 A X 06 NEFAZODONE A 07 A C 01 MICONAZOLE D 06 A X 04 NEOMYCIN J 02 A B 01 MICONAZOLE A 07 A A 01 NEOMYCIN G 01 A F 04 MICONAZOLE A 01 A B 08 NEOMYCIN N 05 C D 08 MIDAZOLAM S 03 A A 01 NEOMYCIN A 06 A D 10 MINERAL SALTS IN COMBINATION J 01 G B 05 NEOMYCIN H 02 A A MINERALOCORTICOIDS S 01 A A 03 NEOMYCIN J 01 A A 08 MINOCYCLINE R 02 A B 01 NEOMYCIN C 02 D C 01 MINOXIDIL A 07 A A 51 NEOMYCIN, COMBINATIONS D 11 A X 01 MINOXIDIL, TOPICAL N 07 A A 01 NEOSTIGMINE A 02 B B 01 MISOPROSTOL S 01 E B 06 NEOSTIGMINE L 01 D C 03 MITOMYCIN N 07 A A 51 NEOSTIGMINE, COMBINATIONS L 01 D B 07 MITOZANTRONE V 03 A Z NERVE DEPRESSANTS N 06 A G 02 MOCLOBEMIDE J 01 G B 07 NETILMICIN N 06 A D MODIFIED CYCLIC DERIVATIVES J 05 A H NEURAMINIDASE INHIBITORS D 07 A C 13 MOMETASONE N 05 A K NEUROLEPTICS, IN TARDIVE DYSKINESIA D 07 X C 03 MOMETASONE J 05 A G 01 NEVIRAPINE R 03 B A 07 MOMETASONE P 02 D A 01 NICLOSAMIDE N 06 A F MONOAMINE OXIDASE INHIBITORS, C 01 D X 16 NICORANDIL NON-SELECTIVE A 11 H A 01 NICOTINAMIDE N 06 A G MONOAMINE OXIDASE TYPE A INHIBITORS N 07 B A 01 NICOTINE J 01 D F MONOBACTAMS C 10 A D 02 NICOTINIC ACID L 01 X C MONOCLONAL ANTIBODIES C 04 A C 01 NICOTINIC ACID N 06 A E MONOCYCLIC DERIVATIVES C 04 A C NICOTINIC ACID AND DERIVATIVES R 03 D C 03 MONTELUKAST B 04 A E NICOTINIC ACID AND DERIVATIVES A 14 A A 04 METHENOLONE C 08 C A 05 NIFEDIPINE J 07 B D MORBILLI VACCINES R 07 A B 02 NIKETHAMIDE N 02 A A 01 MORPHINE R 07 A B 52 NIKETHAMIDE, COMBINATIONS N 02 A G 01 MORPHINE AND ANTISPASMODICS L 02 B B 02 NILUTAMIDE N 02 A A 51 MORPHINE, COMB. EXCL. C 08 C A 06 NIMODIPINE PSYCHOLEPTICS C 02 D E 14 NISOLDIPINE A 07 D A 52 MORPHINE, COMBINATIONS N 05 C D 02 NITRAZEPAM R 05 C B MUCOLYTICS C 02 D E 05 NITRENDIPINE A 09 A A 02 MULTIENZYMES (LIPASE, PROTEASE ETC) C 02 D D NITROFERRICYANIDE DERIVATIVES A 11 A A 03 MULTIVIT AND OTHER MINERALS, INCL J 01 X E NITROFURANTOIN DERIVATIVES COMBINATIONS J 01 X E 01 NITROFURANTOIN A 11 A A 02 MULTIVITAMINS AND CALCIUM D 08 A F 01 NITROFURAZONE A 11 A A 01 MULTIVITAMINS AND IRON S 01 A X 04 NITROFURAZONE A 11 A A 04 MULTIVITAMINS AND TRACE ELEMENTS D 09 A A 03 NITROFURAZONE A 11 A A MULTIVITAMINS WITH MINERALS S 02 A A 02 NITROFURAZONE A 11 A B MULTIVITAMINS, OTHER COMBINATIONS B 05 C A 03 NITROFURAZONE A 11 B A MULTIVITAMINS, PLAIN L 01 A A NITROGEN MUSTARD ANALOGUES D 06 A X 09 MUPIROCIN P 01 A B NITROIMIDAZOLE DERIVATIVES C 02 D D 01 NITROPRUSSIDE B 01 A B 06 NADROPARIN L 01 A D NITROSOUREAS H 01 C A 02 NAFARELIN ACETATE J 01 X X 07 NITROXOLINE J 01 M B 02 NALIDIXIC ACID A 02 B A 04 NIZATIDINE V 03 A B 02 NALORPHINE N 06 A D 01 NOMIFENSINE V 03 A B 15 NALOXONE J 05 A G NON-NUCLEOSIDE REVERSE N 07 B B 04 NALTREXONE TRANSCRIPTASE INHIBITORS A 14 A B 01 NANDROLONE R 03 A B NON-SELECTIVE BETA-ADRENOCEPTOR S 01 G A 01 NAPHAZOLINE AGONISTS R 01 A A 08 NAPHAZOLINE R 03 C B NON-SELECTIVE BETA-ADRENOCEPTOR R 01 A B 02 NAPHAZOLINE AGONISTS

266

C 01 C A 03 NORADRENALINE N 03 A C OXAZOLIDINE DERIVATIVES N 05 B A 16 NORDAZEPAM M 01 A C OXICAMS G 03 A C 01 NORETHISTERONE B 02 B C 02 OXIDIZED CELLULOSE G 03 D C 02 NORETHISTERONE R 05 D B 07 OXOLAMINE G 03 A A 05 NORETHISTERONE AND ESTROGEN J 01 M B 05 OXOLINIC ACID G 03 F A 01 NORETHISTERONE AND ESTROGEN C 04 A D 03 OXPENTIFYLLINE G 03 F B 05 NORETHISTERONE AND ESTROGEN C 07 A A 02 OXPRENOLOL G 03 A B 04 NORETHISTERONE AND ESTROGEN G 04 B D 04 OXYBUTYNIN J 01 M A 06 NORFLOXACIN N 02 A A 05 OXYCODONE G 03 F A 10 NORGESTREL AND ESTROGEN R 01 A A 05 OXYMETAZOLINE G 03 F B 01 NORGESTREL AND ESTROGEN S 01 G A 04 OXYMETAZOLINE G 03 A A 06 NORGESTREL AND ESTROGEN R 01 A B 07 OXYMETAZOLINE J 06 B A NORMAL HUMAN IMMUNOGLOBULIN A 14 A A 05 OXYMETHOLONE R 05 D A 06 NORMETHADONE M 01 A A 03 OXYPHENBUTAZONE N 06 A A 10 NORTRIPTYLINE S 01 B C 02 OXYPHENBUTAZONE R 05 D A 07 NOSCAPINE M 02 A A 04 OXYPHENBUTAZONE J 05 A F NUCLEOSIDE REVERSE TRANSCRIPTASE A 03 A A 01 OXYPHENCYCLIMINE INHIBITORS A 03 C A 03 OXYPHENCYCLIMINE AND J 05 A B NUCLEOSIDES WITH NUCLEOTIDES PSYCHOLEPTICS J 05 A F NUCLEOSIDE AND NUCLEOTIDE REVERSE A 03 A B 03 OXYPHENONIUM TRANSCRIPTASE INHIBITORS A 03 A B 53 OXYPHENONIUM, COMBINATIONS V 06 C A NUTRIENTS WITHOUT PHENYLALANINE G 01 A A 07 OXYTETRACYCLINE D 01 A A 01 NYSTATIN D 06 A A 03 OXYTETRACYCLINE G 01 A A 01 NYSTATIN S 01 A A 04 OXYTETRACYCLINE A 07 A A 02 NYSTATIN J 01 A A 06 OXYTETRACYCLINE A 01 A B 11 NYSTATIN J 01 A A 56 OXYTETRACYCLINE, COMBINATIONS H 01 B B 02 OXYTOCIN H 01 C B 02 OCTREOTIDE H 01 B B OXYTOCIN AND DERIVATIVES S 01 A X 11 OFLOXACIN A 06 A G 06 OIL L 01 C D 01 PACLITAXEL D 09 A A OINTMENT DRESSINGS WITH M 05 B A 03 PAMIDRONIC ACID ANTIINFECTIVES M 03 A C 01 PANCURONIUM N 05 A H 03 OLANZAPINE A 02 B C 02 PANTOPRAZOLE A 07 E C 03 OLSALAZINE A 03 A D 01 PAPAVERINE A 02 B C 01 OMEPRAZOLE A 03 A D PAPAVERINE AND DERIVATIVES A 04 A A 01 ONDANSETRON A 03 A D 51 PAPAVERINE, COMBINATIONS N 06 D X OTHER ANTI-DEMENTIA DRUGS N 02 B E 01 PARACETAMOL N 01 A H OPIOID ANESTHETICS N 02 B E 51 PARACETAMOL, COMBINATIONS EXCL N 02 A G OPIOIDES IN COMB WITH PSYCHOLEPTICS ANTISPASMODICS N 05 C C 05 PARALDEHYDE R 05 D A OPIUM ALKALOIDS AND DERIVATIVES S 01 E B PARASYMPATHOMIMETICS A 07 C A ORAL REHYDRATION SALT FORMULATIONS H 05 A PARATHYROID HORMONES AND R 03 C B 03 ORCIPRENALINE ANALOGUES R 03 A B 03 ORCIPRENALINE H 05 A A PARATHYROID HOMONES AND G 01 A D ORGANIC ACIDS ANALOGUES C 05 B A 01 ORGANO-HEPARINOID N 06 A B 05 PAROXETINE N 02 A E ORIPAVINE DERIVATIVES L 03 A B 10 PEGINTERFERON ALFA-2B H 01 B A 05 ORNIPRESSIN C 07 A A 23 PENBUTOLOL N 04 A B 02 ORPHENADRINE M 01 C C 01 PENICILLAMINE M 03 B C 01 ORPHENADRINE M 01 C C PENICILLAMINE M 03 B C 51 ORPHENADRINE, COMBINATIONS J 01 C F PENICILLINASE RESISTANT PENICILLINS A 06 A D OSMOTICALLY ACTING LAXATIVES J 01 C E PENICILLINASE SENSITIVE PENICILLINS J 01 G B OTHER AMINOGLYCOSIDES C 01 D A 05 PENTAERYTHRITOL TETRANITRATE N 06 D X OTHER ANTI-DEMENTIA DRUGS C 01 D A 55 PENTAERYTHRITOL TETRANITRATE, A 02 X OTHER DRUGS FOR ACID RELATED COMBINATIONS DISORDERS N 02 A D 01 PENTAZOCINE A 03 A X OTHER DRUGS FOR FUNCTIONAL BOWEL A 03 A B 04 PENTHIENATE DISORDERS N 05 C A 01 PENTOBARBITONE R 03 B OTHER DRUGS FOR OBSTRUCTIVE R 05 D B 05 PENTOXYVERINE AIRWAY DISEASES, INHALANTS A 09 A A 03 PEPSIN R 03 B X OTHER DRUGS FOR OBSTRUCTIVE A 09 A C 01 PEPSIN AND ACID PREPARATIONS AIRWAY DISEASES, INHALANTS H 03 B C PERCHLORATES A 02 B X OTHER DRUGS FOR PEPTIC ULCER N 04 B C 02 PERGOLIDE G 03 G B OVULATION STIMULANTS, SYNTHETIC C 08 E X 02 PERHEXILINE A 14 A A 08 OXANDROLONE N 05 A C 01 PERICYAZINE N 05 B A 04 OXAZEPAM C 09 A A 04 PERINDOPRIL

267

C 09 B A 04 PERINDOPRIL AND DIURETICS J 01 C A 12 PIPERACILLIN P 03 A C 04 PERMETHRIN P 02 C B 01 PIPERAZINE D 10 A E PEROXIDES R 06 A E PIPERAZINE DERIVATIVES N 05 A B 03 PERPHENAZINE P 02 C B PIPERAZINE DERIVATIVES J 07 A J PERTUSSIS N 06 B X 15 PIPRADROL J 07 A K 01 PEST (PLAGUE) J 01 M B 03 PIROMIDIC ACID N 02 A B 02 PETHIDINE M 01 A C 01 PIROXICAM N 02 B B 01 PHENAZONE M 02 A A 07 PIROXICAM G 04 B X 06 PHENAZOPYRIDINE N 02 C X 01 PIZOTIFEN J 01 E B 20 PHENAZOPYRIDINE AND SULFONAMIDES B 05 A A PLASMA SUBSTITUTES AND PLASMA N 06 A F 03 PHENELZINE PROTEIN FRACTIONS J 01 C E 05 PHENETHICILLIN B 01 A C PLATELET AGGREGATION INHIBITORS R 06 A X 04 PHENINDAMINE EXCL. HEPARIN B 01 A A 02 PHENINDIONE L 01 X A PLATINUM COMPOUNDS R 06 A B 05 PHENIRAMINE J 07 A L PNEUMOCOCCAL VACCINES N 03 A A 02 PHENOBARBITONE D 06 B B 04 PODOPHYLLOTOXIN C 05 B B 05 PHENOL J 07 B F POLIOMYELITIS VACCINES D 08 A E 03 PHENOL S 02 A A 11 POLYMYXIN B D 08 A E PHENOL AND DERIVATIVES S 03 A A 03 POLYMYXIN B A 06 A B 04 PHENOLPHTHALEIN J 01 X B POLYMYXINS V 04 C H 03 PHENOLSULPHONPHTHALEIN D 01 A E 05 POLYNOXYLIN N 01 A H 04 PHENOPERIDINE A 01 A B 05 POLYNOXYLIN R 06 A D PHENOTHIAZINE DERIVATIVES V 03 A E 01 POLYSTYRENE SULPHONATE N 05 A A PHENOTHIAZINE WITH L 01 X D 01 PORFIMER SODIUM DIMETHYLAMINOPROPYL GROUP A 12 B A POTASSIUM N 05 A B PHENOTHIAZINE WITH PIPERAZINE B 05 X A 01 POTASSIUM CHLORIDE STRUCTURE A 12 B A 01 POTASSIUM CHLORIDE N 05 A C PHENOTHIAZINE WITH PIPERIDINE A 12 B A 51 POTASSIUM CHLORIDE,COMBINATIONS STRUCTURE A 12 B A 02 POTASSIUM CITRATE C 04 A X 02 PHENOXYBENZAMINE A 12 B A 04 POTASSIUM HYDROGENCARBONATE J 01 C E 02 PHENOXYMETHYLPENICILLIN A 12 B A 03 POTASSIUM HYDROGENTARTRATE N 03 A D 02 PHENSUXIMIDE R 05 C A 02 POTASSIUM IODIDE A 08 A A 01 PHENTERMINE V 03 A B 21 POTASSIUM IODIDE C 04 A B 01 PHENTOLAMINE S 01 X A 04 POTASSIUM IODIDE G 04 B X 12 PHENYL SALICYLATE H 03 B C 01 POTASSIUM PERCHLORATE M 01 A A 01 PHENYLBUTAZONE V 03 A B 18 POTASSIUM PERMANGANATE M 02 A A 01 PHENYLBUTAZONE P 03 A A 02 POTASSIUM POLYSULPHIDE R 01 A A 04 PHENYLEPHRINE N 02 B A 12 POTASSIUM SALICYLATE C 01 C A 06 PHENYLEPHRINE D 11 A C 06 POVIDONE-IODINE R 01 A B 01 PHENYLEPHRINE D 08 A G 02 POVIDONE-IODINE S 01 F B 01 PHENYLEPHRINE G 01 A X 11 POVIDONE-IODINE R 01 B A 03 PHENYLEPHRINE C 07 A B 01 PRACTOLOL S 01 G A 05 PHENYLEPHRINE V 03 A B 04 PRALIDOXIME S 01 G A 55 PHENYLEPHRINE, COMBINATIONS C 10 A A 03 PRAVASTATIN N 06 B A PHENYLETHYLAMINE DERIVATIVES P 02 B A 01 PRAZIQUANTEL D 08 A K 02 PHENYLMERCURIC BORATE C 02 C A 01 PRAZOSIN D 09 A A 04 PHENYLMERCURIC NITRATE A 07 E A 01 PREDNISOLONE N 02 A B PHENYLPIPERIDINE DERIVATIVES H 02 A B 06 PREDNISOLONE R 01 B A 01 PHENYLPROPANOLAMINE D 07 A A 03 PREDNISOLONE R 01 B A 51 PHENYLPROPANOLAMINE, COMBINATIONS S 03 B A 02 PREDNISOLONE N 03 A B 02 PHENYTOIN S 02 B A 03 PREDNISOLONE R 05 D A 08 PHOLCODINE R 01 A D 02 PREDNISOLONE C 01 C E PHOSPHODIESTERASE INHIBITORS D 07 X A 02 PREDNISOLONE J 05 A D PHOSPHONIC ACID DERIVATIVES C 05 A A 04 PREDNISOLONE A 07 A B 02 PHTHALYLSULFATHIAZOLE S 01 C B 02 PREDNISOLONE V 03 A B 19 PHYSOSTIGMINE S 01 B A 04 PREDNISOLONE S 01 E B 05 PHYSOSTIGMINE D 07 C A 03 PREDNISOLONE AND ANITBIOTICS B 02 B A 01 PHYTOMENADIONE S 02 C A 01 PREDNISOLONE AND ANTIINFECTIVES N 07 A X 01 PILOCARPINE S 01 C A 02 PREDNISOLONE AND ANTIINFECTIVES S 01 E B 01 PILOCARPINE S 03 C A 02 PREDNISOLONE AND ANTIINFECTIVES S 01 E B 51 PILOCARPINE, COMBINATIONS S 01 B B 02 PREDNISOLONE AND MYDRIATICS N 05 A G 02 PIMOZIDE H 02 A B 07 PREDNISONE C 07 A A 03 PINDOLOL A 07 E A 03 PREDNISONE J 01 M B 04 PIPEMIDIC ACID G 03 D B PREGNADIEN DERIVATIVES A 03 A B 14 PIPENZOLATE G 03 D A PREGNEN (4) DERIVATIVES

268

N 01 B B 04 PRILOCAINE J 04 A K 01 PYRAZINAMIDE P 01 B A 03 PRIMAQUINE C 03 C D PYRAZOLONE DERIVATIVES N 03 A A 03 PRIMIDONE N 02 B B PYRAZOLONES J 01 F G 01 PRISTINAMYCIN P 03 A C PYRETHRINES, INCL SYNTHETIC M 04 A B 01 PROBENECID COMPOUNDS C 10 A X 02 PROBUCOL P 03 A C 01 PYRETHRUM C 01 B A 02 PROCAINAMIDE P 03 A C 51 PYRETHRUM, COMBINATIONS S 01 H A 05 PROCAINE N 07 A A 02 PYRIDOSTIGMINE C 05 A D 05 PROCAINE A 11 H A 02 PYRIDOXINE (VIT B6) N 01 B A 02 PROCAINE P 01 B D 01 PYRIMETHAMINE J 01 C E 09 PROCAINE PENICILLIN P 01 B D 51 PYRIMETHAMINE, COMBINATIONS L 01 X B 01 PROCARBAZINE L 01 B C PYRIMIDINE ANALOGUES N 05 A B 04 PROCHLORPERAZINE C 02 D C PYRIMIDINE DERIVATIVES N 04 A A 04 PROCYCLIDINE G 03 D A 04 PROGESTERONE D 08 A J QUATERNARY AMMONIUM COMPOUNDS G 03 F A 04 PROGESTERONE AND ESTROGEN C 09 A A 06 QUINAPRIL L 02 A B PROGESTOGENS C 03 B A 02 QUINETHAZONE G 03 A C PROGESTOGENS C 01 B A 01 QUINIDINE G 03 F A PROGESTOGENS AND ESTROGENS, FIXED P 01 B C 01 QUININE COMBINATIONS P 01 B C QUININE ALKALOIDS G 03 A A PROGESTOGENS AND ESTROGENS, FIXED M 09 A A QUININE AND DERIVATIVES COMBINATIONS M 05 A A 51 QUININE, COMBINATIONS G 03 F B PROGESTOGENS AND D 08 A H QUINOLINE DERIVATIVES ESTROGENS,SEQUENTIAL PREPS G 01 A C QUINOLINE DERIVATIVES G 03 A B PROGESTOGENS AND P 02 B A QUINOLINE DERIVATIVES ESTROGENS,SEQUENTIAL PREPS G 01 B C QUINOLINE DERIVATIVES AND P 01 B B 01 PROGUANIL CORTICOSTEROIDS G 02 C B PROLACTIN INHIBITORS M 01 C A QUINOLINES N 06 B X 14 PROLINTANE J 01 M QUINOLONE ANTIBACTERIALS N 05 A A 03 PROMAZINE G 04 A B QUINOLONE DERIVATIVES (excl. J01M) R 06 A D 02 PROMETHAZINE D 04 A A 10 PROMETHAZINE J 05 A B 54 RIBAVIRIN, COMBINATIONS R 06 A D 52 PROMETHAZINE, COMBINATIONS J 07 B G RABIES VACCINES D 08 A C 03 PROPAMIDINE J 06 A A 06 RABIES SERUM N 01 A X 04 PROPANIDID J 06 B B 05 RABIES IMMUNOGLOBULIN A 03 A B 05 PROPANTHELINE G 03 X C 01 RALOXIFENE A 03 C A 34 PROPANTHELINE AND PSYCHOLEPTICS L 01 B A 03 RALTITREXED M 01 A E PROPIONIC ACID DERIVATIVES C 09 A A 05 RAMIPRIL N 01 A X 10 PROPOFOL A 02 B A 02 RANITIDINE C 07 A A 05 PROPRANOLOL C 02 A A RAUWOLFIA ALKALOIDS C 07 F A 05 PROPRANOLOL AND OTHER N 05 A L 04 REMOXIPRIDE ANTIHYPERTENSIVES C 02 A A 02 RESERPINE A 03 F A PROPULSIVES D 10 A X 02 RESORCINOL H 03 B A 02 PROPYLTHIOURACIL S 01 A X 06 RESORCINOL C 01 A B 01 PROSCILLARIDIN R 07 A B RESPIRATORY STIMULANTS A 02 B B PROSTAGLANDINS B 01 A D 07 RETEPLASE G 02 A D PROSTAGLANDINS D 10 A D RETINOIDS FOR TOPICAL USE IN ACNE C 01 E A PROSTAGLANDINS D 10 B A RETINOIDS FOR TREATMENT OF ACNE V 03 A B 14 PROTAMINE D 05 B B RETINOIDS FOR TREATMENT OF J 05 A E PROTEASE INHIBITORS PSORIASIS B 05 B A 04 PROTEIN HYDROLYSATES A 11 C A 01 RETINOL (VITAMIN A) B 02 A B PROTEINASE INHIBITORS A 11 H A 04 RIBOFLAVIN (VITAMIN B2) D 03 B A PROTEOLYTIC ENZYMES J 04 A B 02 RIFAMPICIN V 04 C J 02 PROTIRELIN M 05 B A 07 RISEDRONIC ACID A 02 B C PROTON PUMP INHIBITORS N 05 A X 08 RISPERIDONE N 06 A A 11 PROTRIPTYLINE G 02 C A 01 RITODRINE A 01 A B 11 PROVIDINE IODINE L 01 X C 02 RITUXIMAB D 09 A A 09 PROVIDINE IODINE N 06 D A 03 RIVASTIGMINE S 01 H A 04 PROXYMETACAINE M 01 A H 02 ROFECOXIB R 01 B A 02 PSEUDOEPHEDRINE J 01 A A 09 ROLITETRACYCLINE R 01 B A 52 PSEUDOEPHEDRINE, COMBINATIONS J 01 F A 06 ROXITHROMYCIN D 05 B A PSORALENS FOR SYSTEMIC USE J 06 B B 06 RUBELLA IMMUNOGLOBULIN D 05 A D PSORALENS FOR TOPICAL USE C 05 C A 01 RUTOSIDE L 01 B B PURINE ANALOGUES C 05 C A 51 RUTOSIDE, COMBINATIONS C 04 A D PURINE DERIVATIVES P 02 C C 01 PYRANTEL R 03 A C 02 SALBUTAMOL

269

R 03 C C 02 SALBUTAMOL S 01 A X 10 SODIUM PROPIONATE N 02 B A 55 SALICYLAMIDE, COMBINATIONS EXCL N 02 B A 04 SODIUM SALICYLATE PSYCHOLEPTICS A 06 A D 13 SODIUM SULPHATE G 04 A D SALICYLATES A 12 C A 02 SODIUM SULPHATE D 01 A E 12 SALICYLIC ACID C 05 B B 04 SODIUM TETRADECYL SULPHATE P 02 D A SALICYLIC ACID DERIVATIVES D 02 A C SOFT PARAFFIN AND FAT PRODUCTS N 02 B A SALICYLIC ACID DERIVATIVES D 09 A X SOFT PARAFFIN DRESSINGS D 02 A F SALICYLIC ACID PREPARATIONS A 06 A A SOFTENERS, EMOLLIENTS R 03 A C 12 SALMETEROL B 05 B B SOLUTIONS AFFECTING THE B 05 C B SALT SOLUTIONS ELECTROLYTE BALANCE C 01 A B SCILLA GLYCOSIDES B 05 B A SOLUTIONS FOR PARENTERAL NUTRITION C 05 B B SCLEROSING AGENTS FOR LOCAL B 05 B C SOLUTIONS PRODUCING OSMOTIC INJECTION DIURESIS A 04 A D 01 SCOPOLAMINE V 07 A B SOLVENTS AND DILUTING AGENTS,INCL S 01 F A 02 SCOPOLAMINE IRRIGAT SOLUT N 05 C M 05 SCOPOLAMINE H 01 C B 01 SOMATOSTATIN A 04 A D 51 SCOPOLAMINE, COMBINATIONS B 05 C X 02 SORBITOL R 03 A C SELECTIVE BETA-2-ADRENOCEPTOR V 04 C C 01 SORBITOL AGONISTS A 06 A G 07 SORBITOL R 03 C C SELECTIVE BETA-2-ADRENOCEPTOR A 06 A D 18 SORBITOL AGONISTS C 07 A A 07 SOTALOL G 03 X C SELECTIVE ESTROGEN RECEPTOR J 06 B B SPECIFIC IMMUNOGLOBULINS MODULATORS J 01 X X 04 SPECTINOMYCIN L 04 A A SELECTIVE IMMUNOSUPPRESSIVE J 01 F A 02 SPIRAMYCIN AGENTS C 03 D A 01 SPIRONOLACTONE N 04 B D 01 SELEGILINE J 05 A F 04 STAVUDINE A 12 C E SELENIUM A 06 A C 03 STERCULIA D 11 A C 03 SELENIUM COMPOUNDS A 06 A C 53 STERCULIA, COMBINATIONS D 01 A E 13 SELENIUM SULFIDE J 01 K C STEROID ANTIBIOTICS R 05 C A 06 SENEGA B 01 A D 01 STREPTOKINASE A 06 A B 06 SENNA GLYCOSIDES J 01 G A 01 STREPTOMYCIN A 06 A B 56 SENNA GLYCOSIDES, COMBINATIONS J 01 G A STREPTOMYCINS C 02 K D SEROTONIN ANTAGONISTS R 06 A B SUBSTITUTED ALKYLAMINES N 06 A B 06 SERTRALINE R 06 A C SUBSTITUTED ETHYLENE DIAMINES G 03 G A 03 SERUM GONADOTROPHIN N 03 A D SUCCINIMIDE DERIVATIVES J 01 E B SHORT-ACTING SULPHONAMIDES A 02 B X 02 SUCRALFATE G 04 B E 03 SILDENAFIL S 01 A B 04 SULFACETAMIDE D 02 A A SILICONE PRODUCTS J 01 E C 02 SULFADIAZINE A 03 A X 13 SILICONES J 01 E B 03 SULFADIMIDINE D 08 A L 30 SILVER S 01 A B 02 SULFAFURAZOLE S 01 A X 02 SILVER COMPOUNDS J 01 E B 05 SULFAFURAZOLE D 08 A L SILVER COMPOUNDS J 01 E B 02 SULFAMETHIZOLE D 08 A L 01 SILVER NITRATE J 01 E E 01 SULFAMETHOXAZOLE AND D 06 B A 01 SILVER SULFADIAZINE TRIMETHOPRIM D 06 B A 51 SILVER SULFADIAZINE, COMBINATIONS J 01 E B 04 SULFAPYRIDINE A 02 D A 01 SIMETHICONE A 07 E C 01 SULFASALAZINE C 10 A A 01 SIMVASTATIN D 06 B A 02 SULFATHIAZOLE V 04 C C 03 SINCALIDE M 04 A B 02 SULFINPYRAZONE A 12 C A SODIUM A 07 A B SULFONAMIDES B 05 X A 08 SODIUM ACETATE G 01 A E SULFONAMIDES C 05 B A 02 SODIUM APOLATE D 06 B A SULFONAMIDES M 01 C B 01 SODIUM AUROTHIOMALATE C 03 B K SULFONAMIDES, COMB. WITH OTHER B 05 C B 04 SODIUM BICARBONATE DRUGS B 05 X A 02 SODIUM BICARBONATE C 03 B A SULFONAMIDES, PLAIN V 03 A G 01 SODIUM CELLULOSE PHOSPHATE C 03 C A SULFONAMIDES, PLAIN B 05 X A 03 SODIUM CHLORIDE A 10 B B SULFONAMIDES, UREA DERIVATIVES A 12 C A 01 SODIUM CHLORIDE M 01 A B 02 SULINDAC B 05 C B 01 SODIUM CHLORIDE D 10 A B 02 SULPHUR S 01 X A 03 SODIUM CHLORIDE, HYPERTONIC D 11 A C 08 SULPHUR COMPOUNDS B 05 C B 02 SODIUM CITRATE P 03 A A SULPHUR CONTAINING PRODUCTS S 01 X A 05 SODIUM EDETATE H 03 B B SULPHUR-CONTAINING IMIDAZOLE A 12 C D 01 SODIUM FLUORIDE DERIVATIVES A 01 A A 01 SODIUM FLUORIDE N 03 A X 03 SULTHIAME V 03 A B 08 SODIUM NITRITE N 02 C C 01 SUMATRIPTAN B 05 X A 09 SODIUM PHOSPHATE M 03 A B 01 SUXAMETHONIUM A 06 A G 01 SODIUM PHOSPHATE R 01 B A SYMPATHOMIMETICS

270

S 01 F B SYMPATHOMIMETICS EXCL. B 02 B D 30 THROMBIN ANTIGLAUCOMA PREPARATIONS B 02 B C 06 THROMBIN S 01 E A SYMPATHOMIMETICS IN GLAUCOMA A 01 A B 11 THYMOL THERAPY H 03 A A 05 THYROID GLAND PREPARATIONS S 01 G A SYMPATHOMIMETICS USED AS H 03 A A THYROID HORMONES DECONGESTANTS H 01 A B THYROTROPHIN G 02 C A SYMPATHOMIMETICS, LABOUR REPRESSANTS H 01 A B 01 THYROTROPHIN R 01 A A SYMPATHOMIMETICS, PLAIN H 03 A A 01 THYROXINE A 03 A A SYNT ANTICHOLIN,ESTERS WITH N 03 A G 06 TIAGABINE TERTIARY AMINO GROUP M 01 A E 11 TIAPROFENIC ACID A 03 A B SYNT ANTICHOLINERGICS,QUATERNARY J 01 C A 13 TICARCILLIN AMMONIUM COMP J 01 C R 03 TICARCILLIN AND ENZYME INHIBITOR A 03 A C SYNT ANTISPASMODICS, AMIDES WITH B 01 A C 05 TICLOPIDINE TERTIARY AMINES M 05 B A 05 TILUDRONIC ACID G 03 C B SYNTHETIC ESTROGENS, PLAIN S 01 E D 01 TIMOLOL C 07 A A 06 TIMOLOL N 06 D A 01 TACRINE J 01 X D 02 TINIDAZOLE L 02 B A 01 TAMOXIFEN P 01 A B 02 TINIDAZOLE D 05 A A TARS B 01 A B 10 TINZAPARIN C 09 C A 07 TELMISARTAN B 01 A C 17 TIROFIBAN N 05 C D 07 TEMAZEPAM J 01 G B 01 TOBRAMYCIN L 01 C B 02 TENIPOSIDE S 01 A A 12 TOBRAMYCIN M 01 A C 02 TENOXICAM C 01 B B 03 TOCAINIDE G 04 C A 03 TERAZOSIN A 11 H A 03 TOCOPHEROL (VIT E) D 01 A E 15 TERBINAFINE A 10 B B 05 TOLAZAMIDE D 01 B A 02 TERBINAFINE M 02 A X 02 TOLAZOLINE R 03 A C 03 TERBUTALINE C 04 A B 02 TOLAZOLINE R 03 C C 03 TERBUTALINE V 04 C A 01 TOLBUTAMIDE R 06 A X 12 TERFENADINE A 10 B B 03 TOLBUTAMIDE G 03 B A 03 TESTOSTERONE M 01 A G 02 TOLFENAMIC ACID J 07 A M 01 TETANUS M 01 A B 03 TOLMETIN J 06 A A 02 TETANUS ANTITOXIN D 01 A E 18 TOLNAFTATE J 06 B B 02 TETANUS IMMUNOGLOBULIN N 03 A X 11 TOPIRAMATE N 05 A K 01 TETRABENAZINE L 01 X X 17 TOPOTECAN H 01 A A 02 TETRACOSACTRIN L 02 B A 02 TOREMIFENE N 06 A C TETRACYCLIC DERIVATIVES N 02 A X 02 TRAMADOL D 06 A A 04 TETRACYCLINE R 01 A A 09 TRAMAZOLINE S 01 A A 09 TETRACYCLINE C 09 A A 10 TRANDOLAPRIL J 01 A A 07 TETRACYCLINE B 02 A A 02 TRANEXAMIC ACID S 03 A A 02 TETRACYCLINE N 06 A F 04 TRANYLCYPROMINE S 02 A A 08 TETRACYCLINE N 06 A D 02 TRAZODONE D 06 A A TETRACYCLINE AND DERIVATIVES D 10 A D 01 TRETINOIN J 01 A A TETRACYCLINES H 02 A B 08 TRIAMCINOLONE R 03 D A 04 THEOPHYLLINE D 07 X B 02 TRIAMCINOLONE D 01 A C 06 THIABENDAZOLE D 07 A B 09 TRIAMCINOLONE P 02 C A 02 THIABENDAZOLE A 01 A C 01 TRIAMCINOLONE D 07 C B 01 TRIAMCINOLONE AND ANTIBIOTICS S 01 B A 05 TRIAMCINOLONE A 11 D A 01 THIAMINE (VIT B1) S 02 C A 04 TRIAMCINOLONE AND ANTIINFECTIVES A 11 D A THIAMINE (VIT B1), PLAIN C 03 D B 02 TRIAMTERENE C 02 D A THIAZIDE DERIVATIVES N 05 C D 05 TRIAZOLAM C 03 A A THIAZIDES, PLAIN N 01 A B 05 TRICHLOROETHYLENE R 06 A D 03 THIETHYLPERAZINE N 05 C M 07 TRICLOFOS J 04 A D THIOCARBAMIDE DERIVATIVES D 08 A E 04 TRICLOSAN L 01 B B 03 THIOGUANINE N 06 B D TRICYCLIC COMPOUNDS D 08 A K 06 THIOMERSAL N 06 A A TRICYCLIC DERIVATIVES N 05 C A 19 THIOPENTONE N 05 A B 06 TRIFLUOPERAZINE N 01 A F 03 THIOPENTONE N 04 A A 01 TRIHEXYPHENIDYL N 05 A B 05 THIOPROPAZATE R 06 A D 01 TRIMEPRAZINE N 05 A B 08 THIOPROPERAZINE C 02 B A 01 TRIMETAPHAN N 05 A C 02 THIORIDAZINE N 03 A C 02 TRIMETHADIONE V 03 A B 06 THIOSULPHATE J 01 E A 01 TRIMETHOPRIM L 01 A C 01 THIOTEPA J 01 E A TRIMETHOPRIM N 05 A F 04 THIOTIXENE N 06 A A 06 TRIMIPRAMINE H 03 B A THIOURACILS D 05 B A 01 TRIOXYSALEN, SYSTEMIC N 05 A F THIOXANTHENE DERIVATIVES D 05 A D 01 TRIOXYSALEN, TOPICAL

271

R 06 A X 07 TRIPROLIDINE R 01 A B 06 XYLOMETAZOLINE B 05 B B 03 TROMETAMOL S 01 G A 03 XYLOMETAZOLINE B 05 X X 02 TROMETAMOL R 01 A A 07 XYLOMETAZOLINE S 01 F A 06 TROPICAMIDE A 04 A A 03 TROPISETRON J 07 A A 16 YELLOW FEVER D 03 B A 01 TRYPSIN R 03 D C 01 ZAFIRLUKAST B 06 A A 07 TRYPSIN J 05 A F 03 ZALCITABINE V 04 C F TUBERCULOSIS DIAGNOSTICS J 05 A H 01 ZANAMIVIR M 03 A A 02 TUBOCURARINE J 05 A F 01 ZIDOVUDINE R 05 C A 01 TYLOXAPOL N 02 C C 03 ZOLMITRIPTAN J 07 A P TYPHOID VACCINES A 12 C B ZINC J 07 A P 10 TYPHOID-PARATYPHOID A AND B B 05 X A 12 ZINC CHLORIDE J 01 R A URINARY ANTISEPTICS AND ANTI- S 01 A X 03 ZINC COMPOUNDS INFECTIVES D 02 A B ZINC OXIDE PRODUCTS G 04 B D URINARY ANTISPASMODICS C 05 A X 04 ZINC PREPARATIONS G 03 G A 04 UROFOLLITROPHIN A 12 C B 01 ZINC SULPHATE B 01 A D 04 UROKINASE N 05 C F 01 ZOPICLONE N 02 C C 03 ZOLMITRIPTAN J 06 B B 07 VACCINIA IMMUNOGLOBULIN N 05 A F 05 ZUCLOPENTHIXOL J 05 A B 11 VALACICLOVIR N 03 A G 01 VALPROIC ACID A 07 A A 09 VANCOMYCIN J 01 X A 01 VANCOMYCIN J 06 B B 03 VARICELLA/ZOSTER IMMUNOGLOBULIN J 07 A A 13 VARIOLA (SMALLPOX) H 01 B A 01 VASOPRESSIN H 01 B A VASOPRESSIN AND ANALOGUES M 03 A C 03 VECURONIUM N 06 A X 16 VENLAFAXINE C 08 D A 01 VERAPAMIL L 01 X D 02 VERTEPORFIN S 01 A D 06 VIDARABINE J 05 A B 03 VIDARABINE N 03 A G 04 VIGABATRIN L 01 C A 01 VINBLASTINE L 01 C A VINCA ALKALOIDS AND ANALOGUES L 01 C A 02 VINCRISTINE L 01 C A 03 VINDESINE L 01 C A 04 VINORELBINE A 11 D B VIT B1 IN COMB WITH VITAMIN B6 AND/OR VITAMIN B12 A 11 C B VITAMIN A AND D IN COMBINATION V 04 C B 01 VITAMIN A CONCENTRATES A 11 C A VITAMIN A, PLAIN A 11 E C VITAMIN B-COMPLEX WITH MINERALS A 11 E B VITAMIN B-COMPLEX WITH VITAMIN C A 11 E X VITAMIN B-COMPLEX, OTHER COMBINATIONS A 11 E A VITAMIN B-COMPLEX, PLAIN B 03 B A VITAMIN B12 (CYANOCOBALAMIN AND DERIVATIVES) A 11 C C VITAMIN D AND ANALOGUES A 11 H A 03 VITAMIN E B 02 B A VITAMIN K B 01 A A VITAMIN K ANTAGONISTS B 05 X C VITAMINS A 11 J B VITAMINS WITH MINERALS A 11 J C VITAMINS, OTHER COMBINATIONS

B 01 A A 03 WARFARIN D 11 A F WART AND ANTI-CORN PREPARATIONS

C 03 B D XANTHINE DERIVATIVES N 06 B C XANTHINE DERIVATIVES R 03 D A XANTHINES

272